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Abstract
Dendritic cells (DCs) provide a vital link between the innate and adaptive immune systems, 
allowing for detection of invading pathogens and the rapid initiation of an appropriate 
response. Until recently, research on type-I interferons (IFN-I) has focused on their function 
as viral inhibitors. However, it is now evident that IFN-I also has multiple roles in immune 
regulation, including the alteration of DC function. IFN-I has been shown to enhance T and 
B cell responses in vivo through stimulation of DCs, but the mechanisms by which IFN-I acts 
on DCs to produce these effects are unclear. We have investigated how gene expression is 
altered in IFN-I treated DCs, with the aim of identifying IFN induced genes which enhance 
the ability of DCs to initiate and sustain an effective immune response. Murine splenic 
CD1 lc+ DCs or bone marrow-derived DCs were isolated and cultured either alone or in the 
presence of IFN-I, and two techniques were employed for discovery of differentially 
expressed genes: representational difference analysis (RDA) and microarray analysis. We 
identified IFN-I induced genes involved in diverse aspects of cell function, including 
transcription factors, signaling molecules, co-stimulatory molecules, cytokines and 
chemokines. For further study, we selected genes which encode putative cell surface 
proteins or which share homology with proteins involved in adaptive immune functions. 
Investigation of a putative chemoattractant receptor, Gpr33, showed that expression of this 
molecule was upregulated in DCs in response to IFN-I both in vitro and in vivo. We 
attempted to generate antibodies against Gpr33 and have studied mRNA expression by real­
time PCR. Gpr33 mRNA expression was shown to be upregulated by IFN-I in all splenic 
DC subsets, but was expressed in the CD8 + subset at levels more than 40 fold higher than the 
CD4+ subset, indicating that it may specifically be involved in the migration of this subset.
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Chapter 1: Introduction
1.1 Overview
Dendritic cells (DCs) are key components of the immune system. In the peripheral organs, 
DCs are deployed at potential sites of infection, where they are able to capture both self and 
foreign antigens. DCs directly detect pathogens through specialised receptors but can also 
detect the presence of an infection indirectly, through receptors for inflammatory cytokines 
released by neighbouring cells. One such group of cytokines is type I interferon (IFN-I). 
IFN-I plays an important role in anti-viral defence and can modulate both the innate and 
adaptive arms of the immune system. In fact, DCs themselves are a major source of IFN-I 
during infections and its expression can be induced by the detection of pathogens.
Both pathogen-derived signals and inflammatory cytokines can induce DC maturation. This 
triggers their migration to the lymph node, where they can contact circulating T cells. 
Before leaving the periphery, DCs release inflammatory cytokines, allowing the recruitment 
and activation of innate effector cells important for early control of the infection. DC 
maturation is also essential for prolonged presentation of antigens and delivery of co­
stimulatory molecules necessary for naive T cell activation and proliferation. However, DCs 
presenting antigen in the absence of co-stimulation are important in promoting tolerance to 
peripheral antigens. Importantly, DCs are not simply messengers alerting T cells to the 
presence an infection, but translate information regarding the nature of an infection, through 
expression of cell surface molecules and release of cytokines. These act as a third signal to 
T cells and determine the type of T cell response initiated, necessary for effective elimination 
of the pathogen. DCs also interact with B cells in the lymph node and can enhance their 
proliferation, as well as enhancing antibody production and isotype switching.
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DC maturation is a complex and closely regulated process and consists of many different 
facets which could effect the outcome of an immune response. We now review this process 
and focus on the relationship between DCs and IFN-I.
1.2 Dendritic Cells
1.2.1 Identification of dendritic cells as potent antigen presenting cells
Characterisation of dendritic cells (DCs) began just over 30 years ago with the identification 
of a morphologically distinct splenic cell type featuring long dynamic cytoplasmic 
projections (Steinman et al., 1973). These cells were subsequently identified as the essential 
accessories for the initiation of a primary antibody response by T and B cells (Inaba et a l , 
1983), and were established as potent stimulators of the mixed leukocyte reaction 
(MLR)(Steinman et al., 1985). Following this, it was shown that antigen-pulsed DCs 
injected into naive mice were able to initiate CD4+ T cell response in the draining lymph 
node (Inaba et al., 1990). DCs are present in various forms and are found in non-lymphoid 
organs such as the skin, gut, liver and lungs, as well as in the lymphoid organs and in the 
circulation (Steinman, 1991). DCs are highly specialised antigen presenting cells, 
expressing abundant major histocompatability complex (MHC) class I and class II molecules 
on their cell surface, in addition to adhesion molecules which promote homing and 
interactions with T cells (Steinman, 1991).
DC function can be divided into three separate phases: 1) they act as sentinels of the immune 
system capturing antigen in the peripheral tissues and, in the context of an infection, receive 
signals which initiate their activation, 2 ) on activation they undergo a process of maturation, 
during which time they migrate to the lymph nodes and 3) on reaching the lymph node they 
carry out their unique function of inducing a primary immune response.
1.2.2 Antigen capture, processing and presentation
1.2,2.1 Antigen capture
After differentiation from bone marrow progenitors DC precursors migrate to the non­
lymphoid tissues where they reside as immature DCs awaiting the arrival of foreign antigen 
(Banchereau et al., 2000). These immature DCs are highly efficient at capturing antigens 
and employ several mechanisms for this. Particles, microbes and fragments of apoptotic and 
necrotic cells can be taken up by phagocytosis (Reis e Sousa et a l , 1993; Albert et a l , 
1998b; Inaba et a l , 1998). DCs also use macropinocytosis, a process involving uptake of 
extracellular fluids by membrane ruffling, which leads to the concentration of solutes in the 
MHC class II compartment (Sallusto et a l , 1995). Receptor-mediated endocytosis is 
enabled by the expression of C-type lectin receptors, such as the mannose receptor (Sallusto 
et a l , 1995; Engering et a l , 1997) and DEC-205 (Jiang et a l , 1995), in addition to FcyR 
(Sallusto et a l, 1994) and FceRl (Maurer et a l, 1995). Using these different mechanisms 
the amount of antigen available for presentation by DCs is greatly increased. For example 
uptake via the mannose receptor leads to a 1 0 0 -fold increase in the presentation of soluble 
antigen (Engering et a l, 1997). Phagocytosed particles from necrotic or apoptotic cells are 
presented more than 1000 times more effectively than pre-processed peptide (Reis e Sousa et 
a l, 1993; Albert et a l, 1998b; Inaba et a l, 1998). When DCs are exposed to maturation 
stimuli antigen macropinocytosis is transiently stimulated, enhancing presentation by MHC 
class I and class II molecules (West et a l, 2004). Following this, DCs down-regulate 
receptors involved in antigen uptake and lose their phagocytic ability (Reis e Sousa et a l, 
1993; Sallusto et a l, 1994; Sallusto et a l, 1995; Albert et a l, 1998a).
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1.2.2.2 MHC class IIpresentation pathway
DCs contain specialized machinery necessary for antigen processing (Figure 1.1). MHC 
class II-rich compartments (MIICs), to which exogenously acquired antigens are targeted, are 
lysosome-related intracellular compartments where MHC class II molecules are constantly 
accumulated (Kleijmeer et al., 1995). The class II molecules are associated with the 
invariant chain which targets them to the endosomal-lysosomal pathway but prevents binding 
of peptides. The MIICs contain HLA-DM or H-2M molecules which promote the removal 
of the invariant chain and enhance peptide binding to MHC class II molecules (Cresswell,
1996). On DC maturation the invariant chain is degraded by the cysteine protease cathepsin 
S, allowing loading of the antigen onto MHC class II and export to the cell surface. The 
regulation of this process is regulated by a cathepsin S inhibitor, cystatin C, which in mature 
DCs is expressed at lower levels and is no longer localised in the MIICs (Pierre et a l, 1998). 
During DC maturation there is a period of rapid class II synthesis. Unlike in immature DCs, 
where class II molecules are rapidly internalised and recycled, the MHC II-peptide 
complexes are stably expressed on the surface for days, providing a window for prolonged 
CD4+ T cell stimulation (Celia et a l, 1997; Pierre et a l, 1997; Winzler et a l, 1997). DC- 
LAMP, a marker of mature human DCs is expressed transiently in the MIIC and was 
suggested to have a role in MHC class II-restricted antigen presentation (de Saint-Vis et a l, 
1998). However, more recently it was found that the mouse homologue of DC-LAMP is not 
expressed in activated DCs (Salaun et a l, 2003).
1.2.2.3 MHC class I  presentation pathway
DCs also present MHC class I-restricted antigens to CD8 + T cells. The majority of antigens 
are loaded onto MHC class I molecules through an endogenous pathway, a process which has 
been extensively reviewed (Pamer et a l, 1998; Rock et a l, 1999). The class I molecules are
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Figure 1.1 Processing of antigens for presentation to CD4+ and CD8+ T cells Antigens entering the cell through exogenous pathways are 
contained in phagosomes or endosomes which then fuse with the MIICs. After removal o f the invariant chain and proteolysis o f  the antigen, peptides 
are loaded onto the MHC II molecules and transportated to the cell surface for presentation to CD4+ T cells. Antigens present in the cytosol such as the 
products o f  replicating viruses are degraded by the proteosome and transported into the endoplasmic reticulum (ER) via TAP. The peptides are loaded 
onto MHC I molecules and exported to the cell surface for presentation to CD8+ T cells. Exogenously aquired antigens can also gain access to the 
class I pathway possibly through fusion with ER-derived vesicles and transport to the cytosol by Sec61.
assembled in the endoplasmic reticulum (ER) and are retained there through interactions with 
various chaperone proteins and other associated proteins including tapasin. Cytosolic 
proteins derived from the host or intracellularly replicating pathogens are ubiquitin- 
conjugated, which targets them to proteosomes for degradation. The peptides generated are 
then transported to the ER via TAP 1/2 transmembrane transporters where they are trimmed 
into 8-10 mers and loaded onto MHC class I molecules. In the absence of infection a large 
proportion of the host peptides presented on MHC I molecules are thought to be derived from 
defective ribosomal initiation products (DRiPs). These proteins are relatively unstable for 
several reasons such as errors in translation and mis-folding and are rapidly targeted for 
degradation (Yewdell et al., 2001).
1.2.2.4 Cross-presentation
An important property of DCs is their ability to present exogenous antigens on MHC class I 
molecules, a process known as cross-presentation (Heath et al., 2004). Several types of 
antigen may be cross-presented, including soluble proteins, immune complexes, intracellular 
bacteria and parasites. Importantly, DCs can cross-present cellular antigens acquired 
through uptake of apoptotic cells, virally-infected cells and tumour cells (Heath et al., 2004). 
This mechanism is vital for generation of cytotoxic lymphocyte (CTL) responses against 
tumour antigens and against viruses which do not directly infect DCs. Cross-presentation 
does not occur in most cell types where expression of antigen on class I molecules is 
restricted to antigens present in the cytoplasm, ensuring that only infected cells are 
recognised and destroyed by CTLs. The mechanism by which antigens present in the 
phagosomes or endosomes gain access to the cytosol for proteolysis and consequently into 
the ER for loading onto class I molecules is still unclear. The current model is based on the 
discovery that phagosomes can fuse with ER-derived vesicles (Figure 1.1) (Ackerman et al.,
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2003; Guermonprez et al., 2003; Houde et al., 2003). The resulting compartment contains 
MHC class I molecules in addition to the machinery required for peptide loading. It is 
thought that antigens can be transported into the cytosol via a mechanism which involves the 
Sec61 complex, which is known to ‘translocate’ proteins into the cytosol from the ER 
(Wiertz et al., 1996). Proteosomes closely associated with the phagosome would then 
degrade the antigens before transport of peptides back into the phagosome via TAP 
(Ackerman et al., 2004; Heath et al., 2004). In agreement with this model, it was shown that 
class I molecules contain a residue in their cytoplasmic tail which is necessary for their 
trafficking to the phagosome (Lizee et al., 2003). This residue is essential for cross­
presentation but dispensable in the endogenous pathway. Cross-presentation will be 
discussed again, in the context of DC subsets (section 1.2.7.3.3) and type I IFNs (section 
1.3.8.4).
1.2.3 Innate activation of DCs
1.2.3.1 Activation by Toll-like receptors
1.1.3.1.1 Toll-like receptor recognition o f pathogen components
In addition to presenting pathogen-derived peptides in association with MHC molecules, DCs 
can migrate to the lymph node (LN) and express co-stimulatory molecules in order to 
stimulate naive T cells. This maturation process must be tightly regulated to avoid the 
generation of self-reactive T-cells. Therefore a system has evolved whereby DCs only 
become activated in the presence of signals associated with tissue damage or infection. DCs 
respond directly to pathogens through pathogen recognition receptors (PRRs) which 
recognize a conserved set of microbial molecular patterns known as pathogen-associated 
molecular patterns (PAMPs) (Janeway, 1989). The largest group of PRRs identified to date 
are the Toll-like receptors (TLRs) with at least 10 members in most mammalian species
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(Iwasaki et al., 2004). TLRs 1-9 are conserved between the human and mouse, however 
TLR 10 appears to be non-functional in mice, while in humans the presence of a stop codon 
in the TLR11 gene results in a lack of its production (Zhang et al., 2004; Takeda et a l, 
2005). Various components of infectious agents are recognized by TLRs, and these 
interactions are summarised in Table 1.1 (Takeda et al., 2005; Yarovinsky et al., 2005). 
TLR2 recognises a wide range of microbial components, which can be explained by its 
ability to associate with either TLR1, TLR6  and dectin-1. Many of the TLRs (TLR3, 7, 8  
and 9) are not expressed on the cell surface, but instead are present in phagosomal or 
endosomal compartments and contact their ligands after ingestion and degradation of the 
microbe by phagocytosis or receptor-mediated endocytosis (Takeda et al., 2005).
Table 1.1. Recognition of pathogen components by TLRs
TLR fam ily member Organism Ligand
TLR2 Gram+ bacteria Peptidoglycan
Lipotecheicoic acids
Staphylococcus Modulin
Mycobacteria Lipoarabinomannan
Yeast Zymosan
Trypanosoma cruzi GPI anchors
Treponema maltoplilum Glycolipids
Non-entero-bacteria Lipopolysaccaride (LPS)
TLR3 Viruses Double-stranded RNA
TLR4 Gram' bacteria LPS
Gram+ bacteria Lipotecheicoic acids
TLR5 Bacteria (with flagella) Flagellin
TLR7 Viruses Single-stranded RNA
(synthetic) Imidazoquinoline compounds
TLR8 Viruses Single-stranded RNA
(synthetic) Imidazoquinoline compounds
TLR9 Bacteria Unmethylated CpG DNA
TLR11 Uropathogenic bacteria Unknown
Toxoplasma gondii Profilin
1.2.3.1.2 TLR signaling pathways
Toll-like receptors (TLRs) signal through a pathway that leads to activation of NF-kB and 
the induction of an inflammatory response (Medzhitov, 2001). Activation of DCs through 
TLRs triggers fundamental changes necessary for stimulation of adaptive immune responses,
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firstly, the alteration of chemokine receptor expression (Dieu et a l , 1998; Sallusto et al., 
1998c) allowing migration to the draining LN. Secondly, they induce DC maturation, 
resulting in increased expression of co-stimulatory molecules (Medzhitov, 2001). TLR 
ligation also influences cytokine secretion, and induces Thl-polarising cytokines such as IL- 
12 or if appropriate, cytokines leading to Th2 development (Pulendran, 2005). The 
signaling pathways of the TLRs have distinct components which lead to divergent responses. 
For instance, signaling through TLR3 and TLR4 leads to the induction of type I interferons 
(IFN-I) whereas signaling through TLR2 does not (Doyle et al., 2002; Hoshino et al., 2002; 
Toshchakov et al., 2002). Signaling through TLR7 and TLR9 also leads to the induction of 
IFN-I, but occurs through a distinct mechanism to TLR3/4 induction (Hemmi et al., 2002; 
Hoshino et al., 2002). Interestingly, ligation of the same TLR on different types of DC can 
induce expression of different cytokines. Ligation of TLR7 and TLR9 triggers production of 
IFN-a by plasmacytoid DCs and production of IL-12 by CD1 lc+ DCs, whilst co-stimulatory 
molecule expression is enhanced in both DC subsets (Ito et al., 2002; Hemmi et al., 2003).
TLRs share a common signaling pathway which utilizes the adaptor protein MyD8 8  and 
leads to the activation of the AP-1 transcription factors and NF-kB (Figure 1.2). The 
production of inflammatory cytokines such as TNF-a and IL-12p40 in response to all TLR 
ligands is dependent on MyD8 8  (Takeda et al., 2005). A second adaptor TIRAP/Mal is 
essential for MyD8 8 -dependent signaling through TLR4 and TLR2, but not TLR3, TLR5, 
TLR7 or TLR9 (Homg et al., 2002; Yamamoto et al., 2002a). In addition to the MyD8 8 - 
dependent pathway, TLR4 and TLR3 utilize a second pathway which acts through an adaptor 
known as the Toll/IL-1 receptor (TIR)-domain-containing adaptor inducing IFN-p (TRIF) 
which associates with IRF3 and can induce IFN-P expression (Diebold et a l, 2003; Oshiumi 
et al., 2003).
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Figure 1.2 Pathogen recognition receptor signaling pathways (Adapted from Takeda 2003) 
Pathogen components are recognised by TLRs on the cell surface or within endosomal compartments 
or by non-TLR receptors in the cytosol. Signaling through TLRs occurs via two distinct pathways, 
which utilise different adaptor molecules and lead to the activation o f  either NF-kB or IRF3 and the 
induction o f  inflammatory cytokines.
1.2.3.2 Non-TLR recognition o f pathogens
DCs can recognise PAMPs through receptors other than TLRs. C-type lectins are also 
thought to act as PRRs, including DC-SIGN which captures and internalizes mycobacterium 
tuberculosis through the cell wall component ManLAM (Geijtenbeek et a l , 2003). In 
contrast to TLR ligation, ManLAM inhibits DC maturation in response to lipopolysaccaride 
(LPS), and induces the production of the anti-inflammatory cytokine IL-10. A second C- 
type lectin, dectin-1 , is a phagocytic receptor for P-glucan containing particles including the 
yeast cell wall component zymosan. Dectin-1 acts in a synergistic manner with TLR2 to 
induce the production of IL-12p40 and TNF-a in response to zymosan (Brown et al., 2003; 
Gantner et a l, 2003).
Induction of IFN-I by DCs in response to the synthetic double stranded RNA (dsRNA) 
polyriboinosinic polyribocytidylic acid (poly(I:C)) can occur through TLR-independent 
mechanisms (Diebold et a l, 2003). In these experiments, the production of IFN-I, but not 
IL-12, was found to be partly dependent on Protein kinase R (PKR), which is present in the 
cytoplasm and is activated on binding to dsRNA. Recently a molecule encoded by the gene 
Retinoic acid-inducible-1 (RIG-1) was found to mediate TLR3-independent dsRNA 
recognition. RIG-1 is a cytoplasmic protein which can interact with dsRNA and induces 
expression of IFN-I through interaction with the adaptor molecule CARDIF (also named IPS- 
I and MAVS) (Yoneyama et a l, 2004; Kawai et a l, 2005; Meylan et a l, 2005; Seth et a l, 
2005). CARDIF recruits IKK kinases, leading to the activation of IRF3 and NF-kB (Meylan 
et a l, 2005). In addition, an intracellular mechanism for TLR-independent detection of 
bacteria has been described, in which the nucleotide-binding oligomerisation domain (NOD) 
family of proteins appear to play an important role (Chamaillard et a l, 2003; Girardin et a l, 
2003a; Girardin et a l, 2003b).
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1.2.3.3 DC activation by endogenous signals
DCs can also be activated indirectly, through inflammatory cytokines produced locally by 
infected cells. For example virally-infected cells produce IFN-a, a potent DC activating 
factor (discussed in detail in section 1.3.8). IFN-I induces the production of IL-15 from DCs 
and increases expression of the IL-15 receptor, resulting in an autocrine loop where IL-15 
itself can activate DCs (Mattei et a l , 2001). DC maturation can also be induced in vitro by 
TNF-a, granulocyte macrophage-colony stimulating factor (GM-CSF) and IL-1 (Heufler et 
a l, 1988; Caux et a l, 1992; Sallusto et a l, 1994; Winzler et a l, 1997). In addition, ligation 
of chemokine receptors appears to mediate aspects of DC activation, since stimulation of the 
CCR5 receptor results in the production of IL-12 (Aliberti et a l, 2000). It has recently been 
shown, that although indirect activation of DCs by inflammatory mediators can induce their 
maturation in the context of antigen presentation and ability to enhance T cell expansion, 
direct stimulation through TLRs is necessary for IL-12 production and T helper cell 
polarisation (Sporri et a l, 2005). However, the TLR ligands used in this model were LPS 
and CpG which do not induce high levels of type I IFNs compared to the TLR3 ligand 
poly(I:C) (Vanessa Durand, personal communication).
In the absence of infection, DCs can be activated by endogenous signals such as mechanical 
stress and signals from stressed, viral ly-infected or necrotic cells (Gallucci et a l, 1999) as 
was originally proposed by Matzinger’s ‘danger model’ (Matzinger, 1994). This activation 
of DCs is due to components which are released by necrotic cells such as heat shock proteins, 
ATP and UTP which all act by triggering receptors on the DC cell surface (Coutinho-Silva et 
al, 1999; Basu et a l, 2000; Schnurr et a l, 2000). Finally, crystalline uric acid, which is an 
end production of RNA and DNA degradation, induces DC maturation and enhances the 
generation of CD8 + T cell responses in vivo. Removal of uric acid severely reduced the
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CD8 + T cell response elicited by damaged cells in vivo, indicating that it is the major 
stimulant of immunity released by necrotic cells (Shi et al., 2003).
1.2.4 Induction of innate effector cells by DCs
When immature DCs encounter pathogens such as viruses they secrete cytokines at the site of 
infection and in this way they can activate other cells of the innate immune system such as 
natural killer (NK) cells (Degli-Esposti et al., 2005). DCs secrete IL-12 (Reis e Sousa et al.,
1997), which is known to promote IFN-y production by NK cells (Orange et al., 1996a; 
Orange et al., 1996b), and IFN-I, which is necessary for NK cell cytotoxity and contributes 
to but is not essential for IFN-y production (Orange et al., 1996b; Kamath et al., 2005). In 
addition, IL-2, which is also produced by DCs, has recently been shown to be necessary for 
the efficient production of IFN-y by NK cells (Granucci et al., 2004). Moreover, DCs 
induce the expansion of NK cells, which in one model of murine viral infection was shown to 
be dependent on IL-12 and IL-18 (Andrews et al., 2003). In addition to cytokine secretion, 
direct cell-cell contact has been shown to be necessary for DC induction of NK cell cytolytic 
activity and maximal IFN-y production (Fernandez et al., 1999; Fernandez et al., 2002; Borg 
et al., 2004; Kamath et al., 2005). Notably the NK:DC interaction is reciprocal; NK cells 
promote the maturation of DCs and secretion of IL-12 (Gerosa et a l, 2002).
1.2.5 DC migration
1.2.5.1 Chemokines and their receptors
The migration of leukocytes from the bloodstream and lymphatics to peripheral tissues and
lymphoid organs, and their localisation to compartments within the tissues, is regulated by
chemokines, chemokine receptors and adhesion molecules. Chemokines are low molecular
weight cytokines, which, in the large majority of cases, are secreted from cells and so can
exert their effects in an autocrine or paracrine manner. Chemokines can be divided into four
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sub-families according to the organisation of a cysteine-containing motif in their amino acid 
sequence and are known as the CC, CXC, C and CX3C subfamilies. CXCL16 and CX3 C can 
adopt both secreted and cell bound forms, in which case they are thought to act as adhesion 
molecules (McColl, 2002). Chemokines act by binding to seven transmembrane domain G- 
protein coupled receptors (GPCRs) on the cell surface. This initiates a signaling cascade, 
triggering changes in cell morphology and adhesion molecule expression, culminating in 
their migration. Both chemokines and their receptors can be described as constitutive or 
inflammatory, reflecting their involvement in leukocyte trafficking under resting conditions 
or during an inflammatory response. Distinct patterns of chemokine receptor expression are 
associated with stages of DC maturation, allowing them to respond to different chemokines 
which direct their movement during an inflammatory response. Expression of chemokine 
receptors is regulated by both gene expression and desensitization (Sallusto et al., 1998c). 
The chemokine receptors expressed by DCs are shown in Table 1.2.
Table 1.2 Chemokine receptor expression by DCs
Receptor Ligands Original name
CCR1 CCL3 M IP-la
CCL5 RANTES
CCL7 MCP-3 (MARC)
CCR2 CCL2 MCP-1 (JE)
CCL8 MCP-2
CCL13 MCP-4
CCR4 CCL17 TARC
CCL22 MDC (ABCD-1)
CCR5 CCL3 M IP-la
CCL4 M IP-ip
CCL5 RANTES
CCR6 CCL20 MIP-3a/LARC/Exodus-l
CCR7 CCL19 MIP-3 p/ELC/Exodus-3
CCL21 6Ckine/SLC/Exodus-2
CCR8 CCL1 1-309
CXCR1 CXCL8 IL-8
CXCL6 GCP-2
CXCR3 CXCL9 Mig
CXCL10 IP-10 (Crg-2)
CXCL11 I-TAC
CXCR4 CXCL12 SDF-1
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1.2.5.2 Migration o f immature DCs
Circulating DC precursors express high levels of CCR2, and are thought to be targeted to the 
epithelium by the ligand CCL13, produced by basal epithelial cells at the contact of blood 
vessels (Vanbervliet et al., 2002). Likewise, the expression of CCR6  by Langerhans cells 
(LCs), the resident population of skin DCs, enables their migration to the epidermis in 
response to MIP-3a/CCL20 (Charbonnier et al., 1999). In the mouse, CCR6  is necessary for 
DC localisation in the Peyer’s patches and the maximal induction of humoral immunity in the 
mucosal tissues (Cook et al., 2000). In addition to its role in DC homeostasis in the 
peripheral tissues, CCR6  also directs DCs to sites of inflammation. Although epithelial cell 
lines constitutively produce low levels of the CCR6  ligand CCL20, primary cultures do not, 
and keratinocytes produce high levels of CCL20 only after stimulation by inflammatory 
cytokines (Dieu-Nosjean et al., 2000). Likewise, the importance of CCR2 in the recruitment 
of skin DC precursors into inflamed skin has been demonstrated in the mouse using CCR2'A 
bone marrow chimeras. Recruitment of LCs into the skin in the steady-state was unaffected, 
indicating that other chemoattractants are involved in this process (Merad et al., 2002). In 
vitro, mouse and human immature DC express receptors for CCR1, CCR2 and CCR5, and 
respond to their ligands which include CCL3, CCL4, CCL5, CCL7 and CCL13, which are 
expressed in inflamed tissues (Sozzani, ; Sozzani et al., 1997; Sallusto et al., 1998c; Vecchi 
et al., 1999). The importance of CCR1 and CCR5 in recruitment of DCs to airway 
epithelium has been demonstrated in the rat, where administration of a CCR1 and CCR5 
antagonist resulted in a reduction of DC numbers in resting airway epithelium and prevented 
DC influx after inhalation of heat-killed bacteria (Stumbles et al., 2001). Immature DCs 
also express functional CXCR4, the receptor for CXCL12 which is constitutively produced 
in both lymphoid and non-lymphoid tissues (Sozzani et al., 1997).
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Some of the first molecules identified as inducers of DC migration were classical 
chemotactic agonists including formylated peptides and complement cleavage products 
(Sozzani et a l, 1995; McWilliam et a l, 1996). Formylated peptides originate from 
endogenous sources, such as mitochondrial proteins of ruptured cells, as well as from the 
proteins of invading pathogens (Le et a l, 2002), and so are involved in targeting DCs to sites 
of tissue damage or infection.
1.2.5.3 Migration o f mature DCs
1.2.5.3.1 Chemokine receptor expression
At the site of infection in the peripheral tissues DCs are exposed to both microbes and 
inflammatory cytokines, triggering their maturation. Part of this program of maturation 
includes a complete switch in chemokine receptor expression, resulting in migration to the 
secondary lymphoid organs where they localize in the T-cell areas (Banchereau et al., 2000). 
Firstly, DCs downregulate CCR1 and CCR5 from the cell surface, which occurs within one 
to two hours of initial stimulation (Sallusto et al., 1998c). This rapid downregulation is not 
due to changes in mRNA levels which remain unaffected, but is mediated by chemokines 
released by the DC after exposure to maturation stimuli. These bind to their cognate 
receptors and trigger their internalization (Sallusto et al., 1998c). Maturing DCs also lose 
responsiveness to formylated peptides (Sozzani et al., 1998). Next, after three to four hours, 
DC upregulate CCR7 and acquire responsiveness to its ligands (Dieu et a l, 1998; Sallusto et 
a l, 1998c; Vecchi et al., 1999), a feature essential for their migration to the LN. The ligands 
for CCR7, CCL19 and CCL21, are expressed constitutively in the high endothelial venules 
(HEVs) lining the draining lymphatics (Saeki et al., 1999; Baekkevold et al., 2001) and in 
the T cell zones of the lymph nodes (Willimann et al., 1998; Luther et al., 2000), and so can 
direct migration both out of the tissues and into specific regions of the LN. This is possible
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because CCR7 is not susceptible to ligand-induced downregulation and its expression is 
maintained on mature DCs for extended periods (Sallusto et al., 199%). By in situ 
hybridisation, it was shown that the majority of CCL19 and CCL21 in the T cell zones of 
lymphoid organs is produced by stromal cells, with DCs contributing to the production of 
CCL19 (Ngo et al., 1998; Luther et al., 2000). The requirement for CCR7 expression for 
migration of activated skin DCs into the draining LN has been shown in CCR7 deficient 
mice (Forster et al., 1999) and by injection of CCR7 deficient DCs into wild-type mice 
(Martin-Fontecha et al., 2003). Pre-injection with DCs or with the inflammatory mediators 
TNF or IL-lp, known to be released by maturing DCs, increased their migration, and was 
due to increased expression of CCL21 by lymphatic endothelial cells (Martin-Fontecha et al., 
2003). In mice with defects in the production of CCL19 and CCL21, DCs fail to accumulate 
in the spleen and LN (Gunn et al., 1999). Since CCR7 is also expressed on naive and central 
memory T cells (Sallusto et al., 1999a), this receptor co-ordinates the convergence of mature 
antigen-loaded DCs and circulating T cells.
Recently a second chemokine receptor, CCR8, has been implicated in the migration of DCs 
to the lymph node. In CCR8 deficient mice, recruitment of monocyte-derived DCs to the 
lymph nodes was reduced by fifty percent, although this was not as severe as the reduction 
seen in CCL19/21 deficient mice (Qu et al., 2004). In addition, HCR (human chemokine 
receptor)/CCRL2 is an orphan chemokine receptor whose expression is induced in maturing 
DCs (Migeotte et al., 2002). This receptor is reportedly induced in maturing DCs prior to 
CCR7, suggesting a role in the early phase of DC departure from the peripheral tissues 
(Sozzani). The role of CXCR4 in DC migration is unclear, since both immature and mature 
DC have been shown to respond to its ligand, CXCL12, in vitro (Delgado et al., 1998; 
Vecchi et al., 1999; Penna et a l , 2002).
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1.2.5.3.2 Regulation o f migration by adhesion molecules
In addition to changes in chemokine receptor expression during DC maturation, there is a 
loss of adhesive structures, accompanied by cytoskeleton reorganisation, which confers high 
motility (Winzler et al., 1997). Adhesion molecule expression also changes. For example, 
LCs express E-cadherin, which retains them in the epidermis. On maturation E-cadherin 
expression is lost, allowing migration out of the skin (Tang et al., 1993). Also involved in 
DC migration from the skin to the lymph nodes are the a6 integrins, which are involved in 
the initial migration from the epidermis (Price et al., 1997). Although ICAM-1 expression is 
induced during DC maturation, it appears that ICAM-1 expressed on lymphatic endothelium 
is more important for DC migration into the draining LN (Xu et al., 2001). DCs 
differentially regulate CD44 isoforms during their migration and blocking of specific CD44 
isoforms prevents their migration to T cell zones and ability to induce a delayed type 
hypersensitivity reaction (Weiss et al., 1997). In contrast, the adhesion molecule JAM-A, 
expressed on DCs and intercellular junctions of endothelium, appears to negatively regulate 
DC migration. In JAM-A deficient mice there was increased migration to the lymph nodes 
in a contact sensitisation assay. This effect was DC-specific, since injection of JAM-A 
deficient DCs into wild-type mice also resulted in enhanced contact hypersensitivity (Cera et 
al., 2004). Similarly, in vivo migration of DCs is increased in SPARC (secreted protein, 
acidic and rich in cysteine) deficient mice, in this case as a result of secretion from the tissue 
environment which altered the structure of the extracellular matrix (Sangaletti et al., 2005). 
Finally, Langerhans cells produce digestive enzymes such as metalloprotease-2 and -9, which 
facilitate their movement through the basement membrane and extracellular matrix 
(Ratzinger et a l, 2002).
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1.2.6 DCs and the control of adaptive immunity
1.2.6.1 Deregulation ofT cell responses
1.2.6.1.1 Initiation o fT  cell responses
A critical function of DCs is their ability to prime antigen-specific naive T cells. It has been 
shown that DCs pulsed with a soluble antigen and administered to naive mice can induce the 
formation of antigen responsive CD4+ T cells in the draining LN (Inaba et al., 1990). 
Importantly it was demonstrated that it was the injected DCs, and not host DCs that presented 
the antigen. In contrast, antigen-pulsed spleen cells, of which sixty percent are B cells, were 
found to be extremely inefficient in their ability to prime naive T cells. Further evidence 
showing that DCs are the main antigen presenting cells (APC) in vivo comes from studies 
showing direct interactions between antigen-bearing DCs and antigen specific T cells in situ. 
In these experiments, fluorescently labeled ovalbumin was taken up by DCs either in vitro or 
in vivo and ovalbumin-specific T cells were found clustered around the fluorescent DCs in 
the LN (Ingulli et al., 1997; Byersdorfer et al., 2001). As well as being able to prime naive 
CD4+ T cells DCs also appear to function in regulating their homeostasis (Brocker, 1997).
DCs have also been shown to be the essential APC capable of stimulating the proliferation of 
naive CD8+ T cells in the MLR (Inaba et al., 1987). A number of studies have shown that 
DCs can generate CTL responses in vivo, where the injected DCs expressed viral antigens or 
had been pre-loaded with viral or tumour antigens (Banchereau et al., 2000). Often CD4+ 
help is required for CD8+ T cell activation, although it has been shown that DCs can also 
generate a CTL response directly, without CD4+ help (Young et al., 1990). Presentation of 
antigens by DCs also seems to be necessary for the maintenance of CTL-mediated immunity 
against viruses (Ludewig et al., 1999).
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1.2.6.1.2 Antigen presentation
During their migration, DCs undergo a process of maturation, developing the machinery 
necessary for presentation of antigen to nai've T lymphocytes and their efficient activation. 
Naive T lymphocytes continuously recirculate through the LNs where they can contact DCs 
and survey for specific antigen. As discussed earlier, DCs acquire and process antigens for 
presentation on class I and class II MHC molecules. During maturation DCs increase the 
synthesis of class II molecules and decrease their degradation, leading to rapid accumulation 
of MHC-peptide complexes on the cell surface (Celia et al., 1997). DCs also increase the 
rate of synthesis of class I molecules by approximately 10 fold after exposure to a maturation 
stimulus (Celia et al., 1999b). The level of peptide-MHC complexes available for 
interaction with the T cell-receptor on antigen-specific T cells, known as signal one, is a 
crucial factor in determining the intensity of the signal delivered to the T cell. Another 
factor determining the amount of signal received by the T cells is the length of contact time 
between the peptide-MHC and the T cell receptor (TCR) (Lanzavecchia et al., 2001). This 
contact occurs in molecular structures known as the immunological synapse which are 
formed by interactions between adhesion molecules such as CD58 (LFA-3) and CD54 
(ICAM-1).
1.2.6.1.3 DC co-stimulatory molecules
Mature DCs express high levels of the co-stimulatory molecules CD40, CD80 and CD86 
which deliver a second signal to the T cell, an essential requirement for activation of naive T 
cells (Banchereau et al., 2000). DCs also express several other cell surface receptors which 
mediate DC-T cell interactions. These include RANK (receptor activator of NF-kappaB), 
whose expression on DCs can be induced by CD40 signaling (Anderson et al., 1997). Like 
CD40L the ligand for RANK, named TRANCE (TNF-related activation-induced cytokine),
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is expressed on activated T cells (Josien et a l, 1999) and can enhance DC survival and their 
ability to stimulate T cell proliferation, although unlike CD40L, it does not appear to induce 
CD80/86 expression (Anderson et al., 1997; Wong et a l, 1997; Josien et al., 1999). CD40, 
TNF receptor (TNFR) and RANK are related molecules belonging to the family of TNFRs 
and all signal through TRAF2 which results in the activation of NF-kB pathway (Rothe et 
al., 1995; Wong et al., 1997). NF-kB regulates the transcription of many genes involved in 
immune and inflammatory responses and can inhibit cell death (Baeuerle et al., 1994). In 
fact, TRANCE has been shown to act cooperatively with CD40L and TNF-a in promoting 
DC survival (Josien et a l, 1999).
Several other TNFRs expressed by DCs are involved in T cell co-stimulation (Table 1.3) 
(Watts, 2005). After CD40 ligation, but not LPS stimulation, DCs upregulate 0X40 ligand 
(OX40L) which signals activated T cells expressing 0X40 and ultimately leads to 
accumulation of CD4+ T cells in the B cell follicles (Brocker et al., 1999). OX40L on DCs 
can contribute to T cell expansion, and expression of 0X40 on T cells is associated with their 
long term survival in vivo, consistent with a role in T cell memory (Watts, 2005). Another 
DC cell surface molecule, 4-1BBL, can act on both CD4+ and CD8+ T cells, although its 
prominent role appears to be in directing CD8+ T cell responses, since anti-4-IBB antibodies 
preferentially activate CD8+ T cells in vivo (Shuford et al., 1997) and 4-lBBL-deficient mice 
have reduced CD8+ T cell proliferation and impaired CTL responses in certain viral 
infections (DeBenedette et al., 1999; Tan et al., 1999). Finally, members of the C-type 
lectin family of receptors appear to have dual roles in the immune system, and have been 
implicated in both pathogen recognition and cell-cell interactions. For instance the DC- 
associated lectin-1 (DCAL-1), which has a putative carbohydrate recognition domain, was
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shown to act as a co-stimulatory molecule, enhancing the production of IL-4 by CD4+ T cells 
(Ryan et al., 2002).
Table 1.3 Expression of co-stimulatory molecules on DCs (Watts 05)
Receptor Expression Ligand Expression
CD80
CD86
DC (enhanced on maturation), 
activated monocytes and B cells
CD28
CD28
T cells
TNF/TNFR family members
CD40 B cells, DCs, activated T cells CD40L Activated T and B cells
RANK Maure DCs TRANCE Memory T cells
OX40L Activated T cells, B cells and DCs 0X 40 Activated T cells
4-1BBL Activated macrophages, DCs and B 
cells
4 -IBB Activated T cells 
DC subsets, NK cells
LIGHT Activated T cells, immature DCs HVEM Resting T cells monocytes and 
immature DCs
GITRL B cells, macrophages and BMDC GITR T cells -  enhanced by activation, 
Tregs
1.2.6.1.4 Activation o f DCs by CD40 ligation
The interaction between DCs and T cells is a reciprocal one, that is, T cells also provide 
signals to the DCs which enhance their maturation and function. DCs express receptors 
which allow them to respond to T cells, the most well characterised of which being CD40. 
CD40 ligand (CD40L/CD154) is expressed by activated, but not resting, T cells as well as 
activated B cells (Quezada et al., 2004). Ligation of CD40 promotes DC survival and 
increases their expression of MHC and co-stimulatory molecules (Caux et al., 1994; Sallusto 
et al., 1994). CD4+ T cell help was originally thought to be mediated via IL-2 secretion. 
However this would require the close proximity of two antigen specific T cells in association 
with the APC, likely to be a rare event. The maturation signal provided by CD40 ligation 
enables the DC to stimulate CD8+ killer T cells, and provides a mechanism whereby CD4+ T 
helper cells can mediate help during CTL generation (Bennett et al., 1998; Ridge et al., 1998;
Schoenberger et al., 1998). These studies showed that stimulation of CD40 could 
reconstitute CTL responses in mice lacking CD4+ T cells. However the requirement for 
activation through CD40 was not absolute, since generation of CTL responses could also be 
initiated by DCs stimulated by other activation signals such as influenza infection (Ridge et 
al., 1998). Ligation of CD40L by human monocyte-derived DCs was shown to be the most 
effective stimulus for induction of IL-12. LPS {Salmonella), TNF-a and other pathogens 
tested had little or no effect on IL-12 production (Celia et a l, 1996). In contrast to these 
findings Sousa et al. demonstrated that mouse splenic DCs can produce IL-12p40 after 
exposure to a Toxoplasma gondii antigen (STAg) in vivo, and that the production of IL-12 
was unaffected in CD40L deficient mice (Reis e Sousa et al., 1997). They subsequently 
showed that CD40 stimulation alone did not lead to the production of IL-12 in vivo and that 
for maximal levels of production both microbial stimulation and CD40 signaling were 
required. Microbial stimulation led to increased expression of CD40, suggesting that the 
inability of the DCs to produce IL-12 in response to a CD40 agonist was due its absence 
(Schulz et al., 2000). Studies carried out on human monocyte-derived DCs in vitro have 
shown that both IFN-y and CD40 ligation are required for IL-12 production, and that LPS 
requires a second signal from either IFN-y or CD40 ligation for maximal IL-12 production 
(Hilkens et al., 1997; Snijders et al., 1998).
1.2.6.1.5 DC control ofThl/Th2 balance
The delivery of co-stimulatory signals allows T cells to differentiate between antigens which
are associated with danger from those which are host-derived, against which it would be
detrimental to mount a response. DCs can also provide T cells with information concerning
the nature of the pathogen they have encountered and thereby aid in determining the Thl/Th2
polarisation of the response (Kalinski et al., 1999a). The polarisation of CD4+ T cells
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towards a Thl or Th2 phenotype is critical in the control of pathogens. Thl cells are 
characterised by secretion of IFN-y and are important in the cell-mediated control of viral 
infection, while Th2 cells produce IL-4 and are responsible for the control of extracellular 
parasites. Soluble factors released by the DCs are the most well characterised influencers of 
the Thl/Th2 balance, of which IL-12 appears to be the most important in inducing a Thl 
response (Trinchieri, 2003). IL-12 produced by DCs was first shown to be necessary for
development of Thl cells in vitro (Macatonia et al., 1995). Subsequently it was shown that 
in vivo, DCs in the spleen were the main cell type responsible for IL-12 production in 
response to microbial stimulation (Reis e Sousa et al., 1997). IL-12 acts synergistically with 
CD86/CD28 interactions in the stimulation of T cell proliferation and production of IFN-y 
(Kubin et al., 1994; Murphy et al., 1994). Further Thl-inducing molecules expressed by 
DCs include IFN-I (discussed in section 1.3.2), the IL-12 family members IL-23 and IL-27 
and intercellular adhesion molecule 1 (ICAM-1) (Trinchieri, 2003). In addition to Thl- 
biasing molecules, DCs produce the chemokine CCL2 which acts on both Thl and Th2 cells 
(Sallusto et al., 2000), and express the co-stimulatory molecule OX40L which induces the 
differentiation of naive CD4+ T cells into high IL-4 producing effector cells (Ohshima et al., 
1998).
The major contributing factor determining the Thl/Th2 polarising potential of DCs is thought
to be the environment in which they are first activated, which conditions the DCs to express
molecules promoting either Thl, Th2 or regulatory T cell development. As discussed
previously a large array of both pathogen and host-derived factors can influence DC
maturation, and these can also influence the phenotype of the mature DC. Endogenous
inflammatory mediators can instruct DCs to become Thl or Th2 cell-promoting effector
DCs. IFN-y at can augment the production of IL-12 on re-stimulation of LPS-matured DCs,
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and is most effective if added at the initiation of activation (Vieira et al., 2000). Conversely, 
the addition of prostaglandin E2 has the opposite effect, inhibiting IL-12 production and 
conferring a Th2 polarising function on the DCs (Kalinski et al., 1998; Vieira et al., 2000). 
Since this study showed that the IL-12 producing capacity of the matured DCs could not be 
altered it appears that stimuli received by immature DCs are the most potent at inducing DC 
polarisation. An alternative model is that it is the DC subset which influences the Thl/Th2 
balance since the DC subsets differ in their capacity to produce Th polarising cytokines 
(discussed in section 1.2.7.3).
Signaling through TLRs has so far mainly been shown to lead to the development of a Thl 
response. For example, signaling through TLR7 or TLR9 by the ligands R-848 and CpG 
DNA respectively, results in production of either IL-12, IFN-a or both (Hemmi et a l, 2000; 
Krug et al., 2001; Ito et al., 2002). Maturation of DCs by dsRNA, which is the major ligand 
for TLR3, results in DCs with the capacity to polarize naive T cells towards a Thl phenotype 
(Celia et al., 1999b; de Jong et al., 2002). Surprisingly however, this induction of a Thl 
response has been shown in the absence of IL-12 production and was not significantly 
inhibited by anti-IL-18 or IFN-a antibodies (de Jong et al., 2002). Stimulation by the TLR4 
agonist, LPS, does induce IL-12 production and thereby also conditions DCs to bias towards 
a Thl response (Celia et al., 1999b). However the kinetics of DC activation also influence 
the response in this case, since after longer periods of LPS stimulation DCs lose their ability 
to produce IL-12 and preferentially induce Th2 polarisation (Langenkamp et al., 2000). In 
addition, the amount of antigen presented by DCs may influence the outcome, since 
stimulation in the presence of high doses of antigen preferentially induces a Thl, and lower 
doses a Th2 response (Boonstra et al., 2003). Finally, the dose and source of LPS have been
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demonstrated to have an effect on the Thl/Th2 bias (Pulendran et al., 2001; Eisenbarth et al., 
2002).
Several pathogen components induce Th2 cell-promoting effector DCs, including ES-62 
glycoprotein {Acanthocheilonema viteae), soluble egg antigens {Schistosoma mansoni), and 
cholera toxin (Gagliardi et al., 2000; Whelan et al., 2000; de Jong et al., 2002), although it is 
still unclear which PRRs mediate this effect. Finally, pathogens can initiate the development 
of T regulatory cells, which could be beneficial to both the pathogen and the host, in 
preventing chronic inflammation (Kapsenberg, 2003).
Another important concept in the initiation of Thl and Th2 responses by DCs is the apparent 
ability of different subsets of DCs to preferentially induce one or other of the responses. This 
will be discussed in section 1.2.7.3.1.
1.2.6.1.6 DC induction o f Tcell tolerance
As well as their fundamental role in inducing immunity to pathogens, DCs can also induce 
tolerance to self and to non-infectious commensals. The original concept of tolerance 
induction was that in the absence of inflammation immature DCs presenting antigen to T 
cells would not deliver the necessary co-stimulatory signals, resulting in the generation of 
anergic T cells. Mature DCs, on the other hand, would be able to deliver the co-stimulatory 
“signal 2” and induce T cell proliferation and differentiation (Gad et al., 2003). However 
this model does not explain how DCs would make contact with the T cells, since immature 
DCs require an activation signal to migrate from the peripheral tissues to the LN (Banchereau 
et al., 2000). It has been shown that mice exposed to ovalbumin in the absence of infection 
are able to present ovalbumin in the draining LN, leading to tolerance (Brimnes et al., 2003).
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Since the ovalbumin was transported to the LN in levels comparable to that in virally 
infected mice, a system must exist enabling the trafficking of DCs to the LN in the steady 
state. Mature DCs can induce CD4+ T cell tolerance (Gad et al., 2003), further illustrating 
that tolerance induction by DCs is not restricted to immature DCs.
It is likely that cells in the local environment can deliver a tolerizing signal to DCs. For 
example, keratinocytes in the skin produce TGF-p which can prevent LC maturation. In 
addition, immature LCs could be found in the LN suggesting that full maturation is not 
necessary for their migration (Geissmann et a l , 1999). Production of IL-10 in the Peyer’s 
patch and respiratory tract may skew the T cell response towards a Th2 response, thereby 
limiting an inflammatory T cell response (Iwasaki et al., 1999). There also appears to exist a 
population of DCs which are loaded with tissue antigens and can migrate to the LN under 
steady state conditions (Huang et al., 2000; Hemmi et al., 2001). Although these DCs 
express co-stimulatory molecules at a level similar to mature DCs, they are unlikely to 
produce IL-12 or other pro-inflammatory cytokines. It is possible that self-antigens 
transported to the LN in this way can be delivered to tolerizing DCs within the LN (Carbone 
et al., 2004). Certain maturation stimuli can induce tolerogenic DCs which upregulate MHC 
class II and co-stimulatory molecules but lack production of inflammatory cytokines. These 
include lactobacilli from gut flora, apoptotic cells and TNF-a (Gad et a l, 2003).
DCs can induce tolerance by a number of mechanisms. Firstly, they can induce the 
apoptosis of T cells via ligation of Fas ligand or TRAIL (TNF-related apoptosis inducing 
ligand) (Suss et a l, 1996; Fanger et a l, 1999). Secondly, DCs can induce T cell anergy, 
likely as a result of their incomplete maturation or by negative regulation, for example 
through CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and PD-1 (programmed cell
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death 1) (Perez et al., 1997; Latchman et a l, 2001). These anergic T cells show a lack of 
antigen-specific proliferation and reduced production of IL-2 and IFN-y (Schwartz, 2003). 
Finally, DCs may be able to induce the differentiation of regulatory T cells (Tregs) (Smits et 
al, 2005). These T cells are also anergic and fail to secrete IL-2 on TCR ligation . Tregs 
can suppress both CD4+ and CD8+ T cell responses by an antigen specific mechanism, 
probably explained by their ability to inhibit DC function and mediate anti-proliferative 
effects on T cells. The induction of tolerogenic DCs is linked to the activation of NF-kB. 
TLR and CD40 ligation result in sustained NF-kB activation, whilst culturing with Tregs 
does not (Chang et a l, 2002).
To demonstrate the capability of DCs to induce tolerance in the steady state, Steinman et al., 
used a system where antigen could be targeted to DCs in vivo via the endocytic receptor 
DEC-205 (Hawiger et a l, 2001). Adoptively transferred TCR transgenic CD4+ and CD8+ T 
cells went through an initial stage of proliferation which was followed by their deletion. The 
remaining T cells were unresponsive to subsequent challenge (Hawiger et a l, 2001; Bonifaz 
et a l, 2002). Finally, Probst et al. used the cre/lox system where expression and 
presentation of a lymphochoriomeningitis virus (LCMV)-derived CTL epitope was induced 
in C D llc+ DCs by injection of tamoxifen. Presentation of the epitope by resting DCs 
resulted in tolerance which could not be broken by subsequent viral infection (Probst et al, 
2003).
1.2.6.2 DC regulation o f B cell responses
DCs are also important regulators of B cell responses. The critical role of DCs in initiating
T cell-dependent antibody responses has been demonstrated in vitro and in vivo (Inaba et a l,
1983; Somasse et a l, 1992). DCs have been shown to enhance the proliferation and Ig
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production of CD40L-activated B cells as well as inducing an IgA isotype switch (Dubois et 
al, 1997; Fayette et a l, 1997). These studies suggested that DCs could act directly on B 
cells and that this effect was mediated by soluble factors, in part by TGF-p. IL-12 was 
found to be an essential DC-derived factor involved in the differentiation of naive B cells 
into IgM plasma cells, and synergised with IL-6/soluble IL-6Ra in driving naive B cell 
proliferation (Dubois et al., 1998). IL-2 is also known to augment B cell proliferation in 
vitro (Arpin et al., 1995).
Recently the involvement of two DC secreted factors in T cell independent antibody 
responses has come to light. These are known as BAFF (B cell activating factor of the TNF 
family) and APRIL (a proliferation-inducing ligand), which bind to three receptors expressed 
on B cells and activate a CD40-like pathway (Litinskiy et al., 2002). BAFF binds to BAFF- 
R, TACI (transmembrane activator and CAML interactor) and with lower affinity to BCMA 
(B cell maturation antigen), whilst APRIL binds with high affinity to BCMA and lower 
affinity to TACI but not to BAFF-R (Schneider, 2005). BAFF plays an essential role in B 
cell survival (Schneider, 2005). Whilst the presence of APRIL does not appear to be critical 
for B cell survival, it does support the survival of plasma cells (O'Connor et a l, 2004). 
BAFF-R knockout mice, like BAFF-deficient mice, display a dramatically reduced 
population of mature B cells, although they are capable of T cell independent antibody 
responses (Shulga-Morskaya et a l, 2004). In contrast, TACI knockout mice have increased 
splenic B cell numbers while antibody responses to T cell independent antigens were almost 
completely abolished (von Bulow et a l, 2001). Both BAFF and APRIL have been shown to 
induce isotype switching in a CD40-independent manner, and APRIL seems to be especially 
important in mediating IgA class switching (Litinskiy et a l, 2002; Castigli et a l, 2004). 
Therefore signaling through the BAFF and APRIL receptors initiates distinct components of
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B cell function. BAFF has also been identified as a T cell co-stimulatory factor, inducing 
IFN-y and IL-2 secretion from responding T cells and increasing their proliferation (Huard et 
al., 2001; Huard et al., 2004).
CD38, which is expressed on both T and B cells, is important in modulating T cell dependent 
antibody responses (Cockayne et al., 1998), and recently a novel ligand (CD38L) was 
identified on DCs (Wykes et al., 2004). Stimulation with CD38 enhanced maturation in 
vitro and led to diminished IgG2a responses in vivo.
Activated B cells expand and differentiate into plasma cells and memory B cells in a 
microenvironment known as the germinal centre (GC). It is in the GC where mature B cells 
undergo Ig gene somatic hypermutation, which increases the antibody affinity for antigen, 
and Ig heavy chain class switching, which modulates the antibody effector functions by 
substituting the constant region of IgM with that of IgG, IgA or IgE. A distinct set of DCs, 
follicular DCs (FDCs) are responsible for sustaining activated B cell viability, growth and 
differentiation in the germinal centres (Park et al., 2005). These cells appear to belong to a 
different cell lineage from the DCs typically associated with the initiation ofT  cell responses 
since they are not derived from bone marrow progenitors and have a unique pattern of cell 
surface receptors (Banchereau et al., 1998). FDCs do not internalise and process antigen. 
Instead they retain antigens on the cell surface bound to Fc and complement receptors (Park 
et al., 2005). Two cytokines produced in the germinal centres by DCs and T cells, IL-15 and 
IL-2 respectively, augment B cell proliferation and antibody production (Armitage et al., 
1995; Arpin et a l, 1995). IL-15, along with B cell receptor ligation, is necessary for class 
switching induced by BAFF/APRIL (Litinskiy et al., 2002) and acts in a cell bound form 
since it can be detected in a biologically active form on the cell surface of FDCs where it is
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likely to be captured by IL-15Ra (Park et al., 2004a). Also produced by FDCs, the molecule 
8D6 appears to be important for plasma cell formation but not memory B cell expansion 
(Zhang et al., 2001). Another population of DCs present in the GC, termed the germinal 
centre DC (GCDC), has been identified and are clearly distinct from FDCs (Grouard et al., 
1996). GCDCs can induce B cell proliferation and induce isotype switching of naive B cells 
preferentially towards IgGl (Dubois et al., 1999).
1.2.6.3 Expression o f chemokines by DCs
As well as responding to chemokines, DCs are capable of producing many chemokines 
which assist in the migration of leukocytes to the site of infection and to the secondary 
lymphoid organs. Several studies on human in vitro derived DCs have characterised the 
expression of chemokines during different stages of maturation. Activated DCs transiently 
express several inflammatory chemokines; CCL3 (MIP-la), CCL4 (MIP-lp) and IL-8 are 
rapidly produced at high levels after DC activation but only remain for a few hours, whilst 
CCL5 (RANTES) is expressed in a more sustained fashion (Sallusto et al., 1999b). Similar 
results were seen in mouse LC, where CCL3 and CCL4 levels were elevated 6h after 
stimulation, whereas CCL5 production increased dramatically after 48h (Fujita et al., 2004). 
In addition, maturation of mouse BM-derived DCs resulted in the upregulation of mRNA 
encoding CCL2, CCL3, CCL4, CCL5, CXCL1 and CXCL2 (Chen et al., 2002).
The chemokines CCL17 (TARC), CCL18 (PARC/DC-CK1) and CCL19 (ELC) are 
expressed by immature DCs and are upregulated by maturation stimuli, but only at later time 
points (Sallusto et al., 1999b; Vissers et al., 2001). This indicates that these chemokines are 
important under resting conditions in attracting cells to peripheral tissues, and also at later 
time points during an inflammatory response, by which time the DCs are likely to have
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migrated to the LN. In addition, CCL19 but not CCL18 expression was further enhanced 
by CD40 ligation (Vissers et a l, 2001), consistent with its role for maximising DC-T cell 
interactions. More recently, CCL20 was shown to be induced during DC maturation 
whereas expression of CCL18, a chemokine active on naive T and B cells and immature 
DCs, was suppressed (Adema et al., 1997; Vulcano et a l, 2003). CCL22 (MDC) has also 
been shown to be induced by maturation stimuli in both humans and mice (Sallusto et al., 
1999b), although a later study reported constant levels of CCL22 during maturation (Vissers 
et al., 2001). Mice do not express the same repertoire of chemokines as humans. For 
example, there appears to be no functional IL-8 or CCL18 in mice (Rollins, 1997).
CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 (I-TAC), which all act on the receptor 
CXCR3, are produced by DCs and are induced by stimulation with IFN-y or LPS (Meyer et 
al., 2001). These chemokines assist in the attraction of resting memory and activated T cells 
and their retention in secondary lymphoid organs (Cole et al., 1998; Rabin et al., 1999; 
Yoneyama et a l, 2002). CXCL9 has also been shown to attract B cells and so would act to 
maximise interactions between DCs, T and B cells (Park et a l, 2002). Therefore the 
expression of chemokines is also regulated during DC maturation. This makes physiological 
sense, since on initial DC activation release of inflammatory cytokines would mediate the 
recruitment of monocytes and immature DCs into the site of infection. The delay in 
expression of chemokines such as CCL19 would allow for the time taken to migrate to 
draining LN where they would then have the capacity to attract T cells.
DCs can also influence the homing patterns of T cells. For example, stimulation of T cells 
with DCs from gut-associated lymphoid tissues imprints an ability to migrate back to the gut. 
This was recently shown to be mediated by the vitamin A metabolite, retinoic acid, which is
produced by mesenteric LN and Peyer’s patch DCs and enhances expression of the gut- 
homing receptors a4p7 and CCR9 by responding T cells (Iwata et al., 2004).
1.2.7 DC subsets
1.2.7.1 Murine DC subsets and their origins
Murine lymphoid tissue resident DCs can be segregated into five subsets depending on 
expression of CD4, CD8, C D llb (the integrin <Xm chain of Mac-1) and CD205 (DEC205, 
originally NLDC-145). Three of these subsets are present in the spleen, with an additional 
two DC subsets existing in the LN (Shortman et al., 2002)(Table 1.4). These additional LN 
DC subsets are the CD4'CD8a'CD205+CDl lb+ DCs which are found in all LNs and are 
thought to be a mature form of tissue interstitial DCs, while the CD4'CD8aloCD205hlCDl lb+ 
DCs are only found in the skin-draining LN and express langerin, a characteristic LC marker 
(Henri et al., 2001). These DCs also express high levels of MHC II, CD40, CD80 and 
CD86, and therefore it is likely that these are mature LCs which have arrived at the LN after 
activation at the periphery. The majority of work examining DC subset function has been on 
DCs divided on the basis of CD8a expression only, and so will be referred to simply as the 
CD8+ and CD8‘ subsets.
Table 1.4 DC subsets (adapted from Anjuere et al., 1999; Shortman et al., 2002)
CD4"CD8ahl 
CD205hi 
CD1 lb-
CD4+CD8a"
CD205"
CD1 lb +
CD4"CD8a" 
CD205' 
CD1 lb +
C D 4C D 8a  
CD205+ 
CD1 lb +
CD4"CD8a'° 
CD205hi 
CD1 lb +
% total DCs in:
Spleen 23 56 19 <4 <1
Thymus 70
Mesenteric LN 19 4 37 26 <4
Skin-draining LM 17 4 17 20 33
Peyer’s Patch 70 10 20
DCs were originally thought to be derived from myeloid precursors, and it was shown that 
human DCs could be derived in vitro from monocytes (Sallusto et al., 1994). However, DC
development is more complex than this, since it has also been shown that DCs can develop 
from CD4l0 thymic precursors which are devoid of myeloid reconstitution potential, leading 
to the idea that some DCs could be of lymphoid origin (Ardavin et al., 1993). One of the 
questions concerning DC subsets was whether they represent different stages of a single 
developmental lineage or whether they are derived from entirely separate lineages. After 
showing that thymic precursors only developed into CD8+ DCs (Wu et a l , 1996), it was 
thought that the CD8+ DC subset was derived from lymphoid-restricted precursors and the 
CD8' DCs from myeloid-restricted precursors. However, it is now clear that both CD8' and 
CD8+ DCs can be produced from either lymphoid or myeloid-restricted precursors (Martin et 
al., 2000; Traver et al., 2000). Nevertheless, there is some evidence from studies on 
knockout mice that the DC subsets are products of separate developmental pathways. In 
mice lacking the transcription factors RelB (a subunit of NF-kB) or PU.l, there is a defect in 
the differentiation of CD8' DCs but normal CD8+ DC development (Wu et a l, 1998; 
Guerriero et a l, 2000). Conversely, in mice deficient in the IFN consensus sequence 
binding protein (ICSBP) or Id2, differentiation of the CD8+ DCs is affected while maturation 
of both CD8' and CD8+ DCs is defective (Schiavoni et a l, 2002; Aliberti et a l, 2003; 
Hacker et a l, 2003). Therefore it appears that RelB and PU.l play a role in development of 
CD8' DCs while ICSBP and Id2 are important for CD8+ DC development. Although CD8+ 
DCs were suggested to originate from CD8* DCs in experiments where CD8' DCs injected 
into mice appeared to differentiate into CD8 expressing DCs (del Hoyo et a l, 2002), this was 
subsequently ruled out in subsequent experiments by Naik et a l  (Naik et a l , 2003).
In 1999 the plasmacytoid DCs (pDCs) of human peripheral blood were definitively 
characterised as the main producers of type I IFNs after microbial stimulation (Celia et a l, 
1999a; Siegal et a l, 1999). Mouse pDCs were subsequently identified, and share the
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phenotype and functional characteristics of human pDCs (Asselin-Paturel et al., 2001; 
Bjorck, 2001; Nakano et a l, 2001). However, unlike human pDCs they express B220, 
Ly6C and intermediate levels of CD1 lc. Freshly isolated pDCs are poor inducers ofT  cell 
proliferation, which can be explained by their low expression of MHC class II and co­
stimulatory molecules (Grouard et a l , 1997; Asselin-Paturel et al., 2001). On activation, 
pDCs upregulate MHC class II and co-stimulatory molecule expression, and are able to 
stimulate CD4+ and CD8+ T cell proliferation, although not as efficiently as C D llc+ DCs 
(Grouard et a l, 1996; Celia et a l, 2000; Asselin-Paturel et a l, 2001; Fonteneau et a l, 2003). 
pDCs were initially thought to be inducers of Th2 differentiation, however this is not 
consistent with their IFN-I producing ability, and they are now known to be potent Thl 
inducers (Celia et a l, 2000; Boonstra et a l, 2003; Krug et a l, 2003).
1.2. 7.2 DC subset localization
DC subsets reside in distinct anatomical locations within the lymphoid organs. In the 
spleen, CD8+ DCs are concentrated in the T cell-rich periarteriolar lymphatic sheaths 
(PALS), whereas the CD8' DCs are found mainly in the marginal zones but can migrate to 
the PALS after stimulation by microbial products, for example LPS (De Smedt et a l, 1996) 
or a Toxoplasma gondii extract (STag)(Reis e Sousa et a l, 1997). Corresponding subsets 
exist in the Peyer’s patch. Again, the CD8+ subset is localised in the T-cell rich areas and 
the CD8' subset in the subepithelial dome where they would be positioned for antigen uptake 
(Kelsall et a l, 1996). As seen in the spleen CD8‘ DCs have been shown to migrate into the 
T-cell rich areas of the Peyer's patch in response to microbial stimuli (Iwasaki et a l, 2000). 
The subsets also have different trafficking properties in vivo; when injected into the skin of 
mice, the CD8+ subset is not able to migrate to the LN, whilst the CD8' subset can (Ruedl et 
a l, 1999; Smith et a l, 1999). Similarly, Colvin et al. demonstrated that although both DC
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subsets, when matured overnight in the presence of GM-CSF, are detected in the draining LN 
24 hours after sub-cutaneous injection, the CD8‘ DCs are found in much lower numbers and 
disappear at an earlier time point (Colvin et al., 2004b). The reason for this inefficient 
migration may be that the CD8+ DC subset is normally resident in the lymphoid tissues and 
absent from peripheral tissues, since several studies implicate the existence of a system 
where antigen is transferred from migratory CD8* DCs arriving from peripheral tissues, to 
CD8+ DCs in the LN for presentation to T cells (Vermaelen et al., 2000; Scheinecker et a l , 
2002; Allan et a l , 2003).
1.2.7.3 Subset specialisation
1.2.7.3.1 Induction o fT  helper responses
Both the CD8+ and CD8' DC subsets share the ability to prime CD4+ and CD8+ T cell 
responses in vivo (Maldonado-Lopez et al., 1999; Pulendran et al., 1999; Ruedl et al., 1999; 
Smith et al., 1999). However it appears that the CD8+ DC subset preferentially induces CTL 
responses, while the CD8' subset preferentially induces CD4+ T cell responses (Yoneyama et 
al., 2005). As discussed earlier, DCs can adopt a Thl or Th2 polarizing function depending 
on environmental factors encountered during their immature stage. This was further 
complicated by observations suggesting that the DC subsets can differentially regulate Thl 
and Th2 development. The DC subsets appear to differ in their ability to respond to 
pathogen components and in their subsequent cytokine production, thereby promoting 
different types of responses. Pulendran et al. made use of Flt-3 ligand-treated mice, in 
which numbers of both CD8+ and CD8' subsets are substantially increased. Injection of the 
C D llb+ subset (which corresponds to the CD8' subset) resulted in T cells which produced 
higher levels of Th2 cytokines than after injection of the CD1 lb‘ (CD8+) subset, whilst levels 
of IFN-y and IL-2 induced by the two subsets were similar (Pulendran et al., 1999). In a
47
similar set of experiments using normal mice, antigen pulsed CD8' DCs promoted the 
production of IL-4, IL-5 and IL-10 while CD8+ DCs promoted the production of IL-2 and 
IFN-y (Maldonado-Lopez et al., 1999). The ability to promote Thl cytokine production was 
attributed to IL-12 p70 production, which has been shown to be produced mainly by the 
CD8+ DC subset (Reis e Sousa et a l , 1997; Maldonado-Lopez et al., 1999). By injecting 
CD8+ DCs from IL-12 deficient mice, it was shown that the production of IFN-y was 
severely diminished. Likewise, CD8' DCs from IL-10 deficient mice have a reduced 
capacity to elicit a Th2 response (Maldonado-Lopez et al., 1999; Maldonado-Lopez et al., 
2001).
1.2.7.3.2 Responses to TLR agonists
As discussed earlier, DCs express TLRs which recognize specific conserved motifs on 
pathogens, and stimulation through TLRs can influence the type of response elicited. 
Although DCs do exhibit a considerable amount of plasticity, there does appear to be 
restraints on this flexibility. Stimulation with zymosan inhibits the production of IFN-y from 
responding T cells by both DC subsets, although IL-4 production was only induced by the 
CD8' subset. In contrast, stimulation with STag induced a dramatic Thl profile by CD8+ 
DCs but not by CD8' DCs (Manickasingham et al., 2003). Again, this can be explained by 
the preferential induction of IL-12 by the CD8+ subset in response to STag (Reis e Sousa et 
al., 1997; Aliberti et al., 2000; Schulz et al., 2000). In addition, IL-12 has been shown to be 
preferentially expressed by the CD8+ subset in response to E.coli LPS, whilst IL-10 is 
preferentially produced by the CD8' subset in response to Pam-3-Cys (a TLR2 stimulus) 
(Pulendran et al., 2001; Dillon et al., 2004). This responsiveness can not clearly be 
attributed to TLR2 and TLR4 expression (Table 1.5 (Boonstra et al., 2003; Edwards et al., 
2003b)). In addition, both E.coli LPS and Pam-3-Cys induced expression of co-stimulatory
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molecules on both DC subsets, indicating that although both subsets can respond to these 
ligands they differ in the intracellular signaling pathways which regulate cytokine 
production. These results are consistent with the expression of TLR4 on both subsets, which 
has been demonstrated by semi-quantitative PCR (Edwards et a l , 2003b). However in a 
separate study, TLR4 was only found to be expressed on CD1 lb+ BM-derived DC (BM-DC), 
and only these DCs produced IL-12 in response to LPS (Boonstra et al., 2003). In contrast 
to CD8' DCs, CD8+ DCs do not express TLR5 or TLR7 and fail to produce IL-12 or 
upregulate co-stimulatory molecules in response to TLR7 agonists (Edwards et al., 2003b).
Human DC subsets also express different combinations of TLRs; myeloid DCs express TLR4 
but not TLR9 and correspondingly they respond to LPS but not CpG by expressing IFN-a. 
This is in contrast to pDCs which express TLR9 and produce IFN-a in response to CpG 
(Jarrossay et a l, 2001; Kadowaki et a l, 2001). Interestingly, two different forms of CpG 
induced the production of different cytokines from pDCs; CpG 2006 induced IL-12 whereas 
CpG 2216 induced IFN-a production, although both induced upregulation of CCR7 
(Jarrossay et a l, 2001). Therefore it appears that different ligands for the same TLR 
activate different signaling pathways and consequently induce different responses. Overall, 
it seems that several mechanisms can determine the response of DCs to pathogens, including 
the nature of the pathogen itself and the expression of TLRs by the DC subsets. Although 
DC subsets appear to have an intrinsic bias in the type of response they initiate, they also 
retain a degree of functional plasticity and can respond rapidly to environmental signals. In 
this way, an appropriate immune response can be mounted.
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Table 1.5 Expression of TLRs on DC subsets (adapted from Iwasaki et al., 2004)
CD8CD4* CD8+CD4' DN PDC
TLR1 ++ ++ ++ ++
TLR2 ++ ++ ++ ++
TLR3 - ++ ++ -
TLR4 ++/- ++/- ++/- ++/-
TLR5 ++ - ++ +
TLR6 ++ ++ ++ +
TLR7 ++ - ++ ++
TLR8 ++ ++ ++ ++
TLR9 ++ ++ ++ ++
1.2.7.3.3 CTL responses, cross-priming and cross-tolerance
CD8+ DCs have been shown to be the principal DC subset involved in priming MHC class I- 
restricted CTL immunity against a number of cytolytic viruses including herpes simplex 
virus-1 (Smith et al., 2003), as well as a non-cytolytic virus (LCMV), and an intracellular 
bacterium (Listeria monocytogenes) (Belz et al., 2005). The CD8+ and CD8' DC subsets 
also differ in their ability to cross-present exogenous antigen in association with MHC class I 
(den Haan et al., 2000). Although cross-presentation was originally thought to be restricted 
to the CD8+ subset, it was subsequently shown that the CD8' subset could cross-present an 
ovalbumin-immune complex, although this was dependent on their activation via the Fey 
receptor (den Haan et al., 2002). The efficiency of the CD8+ DCs cross-presenting capacity 
is enabled by their ability to capture apoptotic cells (Iyoda et al., 2002; Schulz et al., 2002)
Several studies have highlighted the importance of CD8+ DCs in tolerance. Work by Suss et 
al. showed that CD8+ DCs induced a weak CD4+ T cell response compared to CD8' DCs, 
which was associated with T cell apoptosis (Suss et al., 1996). CD8+ DCs also prevented 
proliferation of CD8+ T cells by inhibiting their IL-2 production (Kronin et al., 1996). The 
ability of CD8+ DCs to capture cell-associated antigens (Iyoda et al., 2002), and to induce the 
deletion of reactive CD8+ T cells (Belz et al., 2002) is consistent with a capacity for inducing
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cross-tolerance. The decision by CD8+ DCs to induce T cell immunity or tolerance is 
dictated by the licensing signal delivered by CD4+ T helpers or microbial stimuli (Bennett et 
al, 1997).
1.3 Type I Interferons
1.3.1 IFN-I subtypes
Interferon (IFN) was first identified more than 50 years ago as an “inhibitory factor” of viral 
replication (Isaacs et al., 1957). IFNs are split into the acid-resistant type I IFNs and the 
acid-labile type II IFNs (now known as IFN-y). The type I IFNs (IFN-I) belong to a family 
of closely related cytokines and consist of the products of numerous IFN-a genes, a single 
IFN-P gene (in mice and humans) and several other genes that are expressed variably in 
different species (IFN-co, -x, - k , -e, -8 and limitin) (De Maeyer et al., 1998). In mice, 14 
IFN-a genes have been identified (van Pesch et al., 2004), in addition to IF N -k  (Vassileva et 
al., 2003), limitin (Oritani et a l, 2001) and IFN- el (Hardy et al., 2004) and are clustered on 
chromosome 4.
All of the type I IFNs tested act on a common cell surface receptor, the IFN-I receptor (IFN- 
IR) (Uze et a l, 1995; Oritani et a l, 2001), which has brought into question whether they are 
able to mediate distinct biological effects. Varying anti-viral activities of human IFN-I 
subtypes have been reported (Foster et a l, 1996) and recently the murine IFN-a subtypes 
were found to vary widely in their anti-viral and anti-proliferative effects. IFN-a 11, -a  12 
and -p were 9-18 fold more active as anti-viral factors, and 44-197 more effective as anti­
proliferative factors than IFN-a 1 (van Pesch et a l, 2004). The correlation between anti-
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viral and anti-proliferative effects suggests a lack of functional specialisation for the subsets 
at least in this respect. Studies using global gene expression analysis have identified 
additional genes induced by IFN-P compared to IFN-a2. Again, however, these differences 
could be due to the specific activity of the IFNs, i.e. quantitative rather than qualitative 
differences (Der et al., 1998; da Silva et al., 2002). There is evidence that IFN subtypes 
differ in their ability to activate other cells of the immune system, since human IFN-a7 has 
anti-viral activity but is unable to activate NK cells (Ortaldo et al., 1984). In addition, 
human IFN-a8 was shown to induce B cell proliferation at concentrations up to 100-fold 
lower than other IFN subtypes. IFN-a8 appeared to be able to activate proliferation via a 
distinct pathway from that leading to transcription of IFN stimulated genes (ISGs), since no 
difference in subtype induction of ISGs was detected (Hibbert et al., 1999). Similarly 
CXCL10 expression by DCs is differentially regulated by IFN-a subtypes, since even at 10- 
fold lower concentrations, IFN-a2 induced both CXCL10 mRNA and protein to significantly 
higher levels than IFN-a 1, in contrast to other ISGs which were induced to comparable 
levels (Hilkens et al., 2003). Recently, the migration of T cells was shown to be induced by 
IFN-a2 but not IFN-a8. This was reflected in the regulation of ISGs, since certain ISGs 
were induced by IFN-a2 but not IFN-a8 (Foster et al., 2004).
1.3.2 IFN-I expression
1.3.2.1 The IFN-I producing cells
Although many cell types can produce IFN-I in response to viral infection, a type of cell 
originally known as the “natural IFN-producing cell” is considered to be the major source of 
IFN-I. As discussed in section 1.2.7.1 the plasmacytoid DCs (pDCs) are the natural IFN-
producing cells which have been identified in both human and mouse (Siegal et al., 1999;
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Asselin-Paturel et al., 2001). In humans, pDCs produced 200 -1000 times more IFN-I than 
peripheral blood mononuclear cells after challenge with UV-inactivated herpes simplex virus 
(Siegal et al., 1999). Similarly, murine pDCs were shown to be the main source of IFN-I, 
since in vivo depletion of cells expressing the pDC marker Ly6G/C resulted in the dramatic 
inhibition of IFN-a production from spleen cells stimulated with influenza and in the serum 
of cytomegalovirus-infected mice (Asselin-Paturel et al., 2001).
pDCs express a number of TLRs which allow them to sense pathogens and initiate the 
production of IFN-I (Table 1.5), including TLR7 and TLR9 which account for their ability to 
respond to ssRNA viruses and bacterial DNA (Diebold et al., 2004; Heil et al., 2004; Iwasaki 
et al., 2004; Lund et al., 2004). After activation by CD40 or virus infection pDCs develop 
into cells with the properties of mature DCs; they develop long dendrites, lose their 
phagocytic capacity, express mature DC cell surface markers and have increased T cell 
stimulatory activity (Grouard et al., 1997; Celia et al., 2000; Asselin-Paturel et al., 2001). 
CpG also activates pDCs; stimulation with CpG 2216 induces high levels of IFN-a but has 
minimal effect on MHC II and co-stimulatory molecule expression, whilst for CpG 2006 the 
opposite is true (Kerkmann et al., 2003). C D llc+ DCs are also able to produce IFN-I in 
response to viruses, but the levels of IFN-I produced were initially shown to be considerably 
lower than that from pDCs (Celia et al., 1999a; Kadowaki et al., 2000; Asselin-Paturel et al., 
2001). However, during LCMV infection of mice, IFN-I production is not dependent on 
pDCs (Dalod et al., 2002), and in fact C D llc+ DCs can produce high levels of IFN-a in 
response to an LCMV strain which infects the C D llc+ DCs themselves (Diebold et al., 
2003). Indeed classical CD1 lc+ DCs could produce IFN-I to the same magnitude as pDCs 
when poly(I:C) was delivered intracellularly.
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1.3.2.2 Induction o f  IFN-I expression
One pathway of IFN-I induction is through TLRs, as discussed in section 1.2.3.1.2. TLRs 
are known to signal through both MyD88-dependent and independent pathways (Figure 1.2). 
TLR3 and TLR4 utilise an alternative pathway which is dependent on the adaptor molecule 
TRIF, and blocking its function using a dominant negative TRIF inhibits the TLR3 
dependent activation of the IFN-p promoter (Yamamoto et al., 2002b). TRIF is essential 
for the activation of IFN regulatory factor 3 (IRF-3), a key transcription factor in regulating 
IFN-I expression (Takeda et a l, 2005) and this activation is now known to be mediated by 
two kinases, IkB kinase e (IKKe) and TANK binding kinase 1 (TBK1). IKKs and TBK1 
were shown to be essential for the phosphorylation of IRF3, and the equally important IFN- 
gene transcription factor, IRF7 (Fitzgerald et al., 2003; Sharma et al., 2003).
In addition, dsRNA can induce IFN-I through a TLR3-independent mechanism; in the case of 
BM-derived C D llc+ DCs, PKR appears to be more important for IFN-I induction (Diebold 
et al., 2003). Cellular lectin receptors, especially the mannose receptor are also able to 
induce IFN-I expression (Milone et al., 1998), for which the activating ligands are likely to 
be viral glycoproteins present on the surface of enveloped viruses (Malmgaard, 2004). 
Finally, it should be noted that signals from the host can also induce IFN-I production: 
CD40L on activated T cells interacts with CD40 on DCs inducing them to produce high 
levels of IFN-I (Foster et al., 2000).
These observations therefore provide a mechanism for induction of IFN-I by TLR3 or TLR4
ligation. However other TLR ligands such as those binding TLR7 and TLR9 which do not
utilise the TRIF pathway are capable of inducing IFN-I expression. Indeed there is no
evidence for a TRIF pathway of IFN-I induction in pDCs, and induction of IFN-a through
TLR7 and TLR9 occurs through an MyD88-dependent pathway (Colonna et al., 2004).
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Recently, IRF7 was shown to interact with MyD88 and tumour necrosis factor receptor- 
associated factor 6 (TRAF6). Furthermore IRF7 activation and translocation to the nucleus 
by TLR9 ligand was dependent on both MyD88 and TRAF6 (Kawai et a l, 2004). Unlike 
most cells, which inducibly express IRF7 after IFN-I stimulation, pDCs constitutively 
express IRF7 (Izaguirre et al., 2003), and so this mechanism may enable pDCs to rapidly 
produce IFN-a in response to microbes. In agreement with this, it has recently been shown 
that pDCs from IRF7 knockout mice are unable to produce IFN-I and that this results in 
impaired CD8+ T cell responses when CpG was used as an adjuvant (Honda et a l, 2005). In 
addition, IRF5 appears to be a critical mediator of IFN-I induction by TLR7 signaling, and its 
activation is also dependent on MyD88 and TRAF6 (Schoenemeyer et a l, 2005).
IFN regulatory factors (IRFs) are a family transcription factors which regulate the 
transcription of both the IFN genes and IFN-stimulated genes. Nine mammalian IRFs have 
so far been identified, of which two closely related IRFs, IRF3 and IRF7, play a key role in 
IFN-I gene induction (Taniguchi et a l, 2001). Their importance in IFN-I induction has been 
demonstrated in knock-out mice: in IRF3 deficient mice virally induced IFN-I is severely 
disrupted, whilst in IRF3 and IRF9 double knockouts, in which IRF7 cannot be induced, 
IFN-I mRNA induction is completely abolished (Sato et a l, 2000). IRF3 is constitutively 
expressed in the cytoplasm and is not induced by viral infection or IFN treatment (Au et a l, 
1995). However, during a viral infection, phosphorylation of IRF3 allows its translocation 
to the nucleus where it initiates transcription of IFN-p and IFN-a4 (Sato et a l, 1998b). In 
contrast to IRF3, which is constitutively present in the cytoplasm, expression of IRF7 is 
dependent on IFN-I signaling in most cells (Marie et a l, 1998; Sato et a l, 1998a) but like 
IRF3, translocation of IRF7 to the nucleus is dependent on virally induced phosphorylation
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(Sato et al., 1998a). Once in the nucleus IRF7 then maximizes IFN-I production through 
transcription of IFN-p and further IFN-a subtypes (Marie et al., 1998).
IRF3 and IRF7 are therefore essential components controlling a positive feedback loop which 
amplifies the expression of IFN-I only in the continued presence of infection (Figure 1.3). 
However pDCs appear to able to bypass the need for IRF3 activation and the initial stage of 
low IFN-I production by their constitutive IRF7 expression, which allows them to rapidly 
produce high levels of IFN-I. In addition, IFN-P and IFN-a4, which are induced early after 
viral infection and released by the infected cell, can then act on neighbouring cells and 
induce the expression of other IFN-a subtypes. This amplification mechanism also provides 
a reason for the large number of IFN-a genes, that is, the levels of IFN-I could be more 
easily controlled by having a number of genes which respond to different transcription 
factors (Levy et al., 2002).
1.3.3 IFN-I signaling pathways
1.3.3.1 Signaling through the JAK/STATpathway
The IFN-IR is a hetereodimer composed of IFNAR1 and IFNAR2 subunits, which interact
with the Janus family member tyrosine kinases (JAK), JAK1 and tyrosine kinase 2 (TYK2),
respectively. Several signaling pathways are initiated through binding of IFN-I, consistent
with their pleiotropic biological effects, and their ability to induce transcription of hundreds
of genes (Der et al., 1998). The first IFN-I signaling pathway to be identified was the JAK-
STAT signaling pathway (Figure 1.4). Once IFN-I binds to its receptor a tyrosine
phosphorylation cascade is initiated, involving autophosphorylation and activation of JAK 1
and TYK2 (Velazquez et al., 1992; Silvennoinen et al., 1993), and leads to the
phosphorylation of STAT1 and STAT2 (signal transducers and activators of transcription 1
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Figure 1.3 Induction of IFN-I expression In pDCs IRF7 is constitutively expressed and can 
be activated via TLR signaling (1). Phoshorylated IRF-7 can then tranlocate the nucleus (2) 
and induce the production o f  high levels o f  IFN-I (3). This can then act on neighbouring cells 
to induce the expression o f  IRF-7 (4), which in the presence o f  infection will be phoshorylated 
and induce IFN-I expression (5). In the absence o f  pDCs, m ost cell types require virally 
activated IRF3 for the initial stage o f  IFN-I production which induces production o f  IFN-P and 
IFN -a4 (A) and acts in a positive feedback loop (B) in the induction o f  IRF-7 expression and 
consequently high levels o f  IFN-I production.
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Figure 1.4 IFN-I signaling pathways Binding o f  IFN-I to the IFN-I receptor results in the 
autophosphorylation o f  JAKI and TYK2, in turn leading to phosphorylation o f  the STATS which can homo- 
or hetero-dimerise and bind to GAS elements in the promoters o f  ISGs. In the case o f  STATI and STAT2, a 
complex with IRF9 is formed, ISGF3, which can bind a second element in ISG promoters, the ISRE. 
Several other molecules are activated downstream o f  the IFN-I receptor, including STAT5/CRKL which 
when dimerised also bind to a GAS element. In addition PI3K and MAPK pathways are activated which 
mediate anti-viral and growth supressive properties o f  IFN-I.
and 2) (Stark et al., 1998). The phosphorylated STATs can then homo- or heterodimerize 
and translocate to the nucleus where they bind to specific DNA sequences and stimulate 
transcription. The major transcription factor formed in response to IFN-I is known as 
interferon-stimulated gene factor 3 (ISGF3), a heterodimer of STAT1 and STAT2 combined 
with a third factor, IRF9. ISGF3 is the only complex which binds to interferon regulated 
response elements (ISREs), contained in the promoters of ISGs (Platanias, 2005). All other 
STAT complexes, for example STAT1-STAT1 homodimers, which are also formed after 
signaling through the type II receptor, bind the IFN-y-activated site (GAS) element that is 
also present in the promoter of some ISGs. Since some ISGs contain only GAS or ISRE 
elements in their promoters, whilst others contain both, the combinations of activated STAT 
dimers present will determine which ISGs are expressed and influence their optimal 
expression. Engagement of the type II receptor does not however result in the formation of 
ISGF3 and therefore cannot induce ISGs which contain only ISRE in their promoter 
(Platanias, 2005).
Another member of the STAT family, STAT4, also plays a role in signaling through the IFN- 
IR. STAT4 is necessary for the differentiation of naive T cells into polarized Thl cells and 
was initially shown to be activated by IFN-a in human but not mouse CD4+ T cells (Rogge et 
al., 1998). STAT2 is required for STAT4 recruitment to the IFN-IR (Farrar et al., 2000b) 
and murine STAT2 carries a disruption which prevents this association (Farrar et al., 2000a). 
However, more recent studies have demonstrated that IFN-I can activate STAT4 in mouse 
cells, which presumably occurs through a different pathway from that in humans 
(Freudenberg et al., 2002; Nguyen et al., 2002). The delicate balance of STAT activation 
can influence the cellular response, since IFN-a and IFN-p mediated induction of STAT4 is
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required for IFN-y production during viral infections, whereas STAT1 negatively regulates 
IFN-y production (Nguyen et al., 2000; Nguyen et al., 2002).
1.3.3.2 CRK protein mediated IFN-I signaling
A second IFN-signaling pathway acts through the CRK family of adaptor proteins, which has 
three members, CRKL, CRKI and CRKII (Platanias, 2005). These adaptors also interact 
with TYK2 and can be activated by both IFN-I and IFN-y (Ahmad et al., 1997; Alsayed et 
al., 2000). The SH3 domain of CRKs interacts with guanine-nucleotide-exchange factors 
(GEFs) through which RAP1, a small GTPase, is activated (Feller, 2001). RAP1 has several 
biological functions, including growth inhibition (Platanias et al., 1999) and regulation of 
mitogen-activated protein kinase (MAPK) signaling cascades (Bos et al., 2001). In addition, 
during IFN-I signaling CRKL forms a complex with activated STAT5 which can translocate 
to the nucleus and bind a GAS element (Fish et al., 1999). The STAT-CRKL complex 
seems to be critical for transcription from promoters containing GAS elements, since defects 
in either STAT5 or CRKL results in the loss of IFN-I dependent transcription via GAS 
elements (Lekmine et al., 2002; Uddin et al., 2003).
1.3.3.3 MAPK mediated IFN-I signaling
Of the MAPK pathways, those involving p38 appear to be the most important in mediating
IFN-mediated signals (Platanias, 2005). One pathway for p38 activation is believed to occur
through VAV phosphorylation by TYK2, which mediates guanine nucleotide exchange in
RAC1 leading to the activation of MAPK kinases that phosphorylate p38 (Platanias, 2005).
Inhibition of p38 blocks IFN-a-dependent transcription from ISREs, but ISGF3 formation
and its binding to ISREs was not prevented, suggesting that p38 acts independently from
STATs (Uddin et al., 1999). p38 is also required for IFN-I driven gene transcription through
GAS elements, and again this was not the result of a lack of STAT phosphorylation or their
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dimerisation (Uddin et al., 2000). In contrast, IFN-y driven transcription from GAS 
elements is not p38 dependent (Li et al., 2004). Several kinases are activated by p38, 
including MAPK-activated protein kinase 2 and 3 (MAPKAPK2 and 3) (Uddin et a l, 1999). 
The activation of MAPKAPK2 is required for transcription of ISGs, including Isgl5 (IFN 
stimulated gene 15) (Li et al., 2005) and for anti-viral properties of IFN-I (Li et al., 2004). 
p38 has also been shown to be necessary for maximal IFN-I anti-viral activity, as inhibition 
of p38 results in the loss of protection by IFN-a against encephalomyocarditis virus (Goh et 
al., 1999) and hepatitis C virus (Ishida et al., 2004). Finally, the p38 signaling pathway is 
involved in the growth suppressive effects of IFN-I (Mayer et al., 2001).
1.3.3.4 PI3K in IFN-I signaling
The phophatidyl-inositol 3-kinase (PI3K) signaling pathway is induced by both IFN-I and 
IFN-y, in addition to various other cytokines, hormones and growth factors (Platanias, 2005). 
IFN-I induces the phosphorylation of PI3K via the insulin receptor substrate (IRS) family of 
multi-site docking proteins (Uddin et al., 1995), a distinct mechanism from that of IFN-y. 
Phosphorylated PI3K can activate various downstream effectors, including protein kinase C 
(PKC) isoforms, of which PKC-8 is important in IFN-signaling as it acts as a serine kinase 
for STAT1 (Uddin et al., 2002). Another downstream effector of PI3K, AKT, mediates anti- 
apoptotic and pro-survival signals (Vivanco et al., 2002).
1.3.3.5 IFN induction o f mRNA translation
Finally, IFN-signaling can regulate the translation of ISG mRNAs. One regulator of this 
translation is mammalian target of rapamycin (MTOR), whose activation is dependent on 
IFN-signaling through PI3K (Lekmine et a l, 2003). In turn, MTOR is necessary for the de­
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activation of the repressor of translation EIF4E- binding protein (EIF4EBP), allowing its 
dissociation from EIF4E, and the initiation of translation (Hay et a l, 2004).
1.3.4 IFN-I induces anti-microbial immunity
1.3,4.1 IFN-I and the anti-viral state
As mentioned earlier, interferons were first identified because of their ability to impart an 
anti-viral state on cells (Isaacs et a l, 1957). They are able to block viral replication at any 
stage, from entry and uncoating (eg simian virus 40) through to assembly and release of the 
mature virion (retroviruses and vesicular stomatitis virus)(Stark et a l, 1998). The 
importance of IFN-I in anti-viral responses has been illustrated in mice with deletions in the 
IFN-I receptor genes (Muller et a l, 1994). IFN-IR knockout mice are extremely susceptible 
to a number of viruses including LCMV, vaccinia virus (VV) and vesicular stomatitis virus 
(VSV), which is largely due to their inability to inhibit viral replication (Muller et a l, 1994). 
In contrast, loss of the IFN- II receptor signaling pathway did not affect the susceptibility to 
VSV, and LCMV titers were maintained at much lower levels compared to that found in 
IFN-IR knockout mice whereas susceptibility to VV was equally profound in both types of 
knockout mice (Muller et a l, 1994). Therefore IFN-y only appears to be necessary for the 
control of certain viral infections. Cells can respond to IFNs by the initiation of several 
mechanisms which give rise to an anti-viral state and are discussed next.
One of the proteins induced by IFNs is the protein kinase R (PKR), which, when activated by 
dsRNA, leads to the phosphorylation of eIF2 (elongation initiation factor 2). eIF2 is 
required for protein translation and its phosphorylation renders it inactive, thereby halting all 
translation in the virally infected cell (Stark et a l, 1998). Experiments in PKR-deficient 
mice highlighted the importance of PKR in viral infection, since poly(I:C) or IFN-y treatment
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extended the survival of wild-type but not PKR-deficient mice after encephalomyocarditis 
virus (ECMV) infection. However, IFN-a also utilises separate anti-viral mechanisms since 
the IFN-a-induced anti-viral response against ECMV was the same in wild-type and PKR- 
deficient mice (Yang et al., 1995). The IFN-inducible 2-5A synthetases constitute a multi­
enzyme family, which like PKR, is stimulated by dsRNA and produces short 2’,5’- 
oligoadenylates (2-5A) that activate RNaseL (Kerr et al., 1978). This results in the 
extensive cleavage of single-stranded RNA (ssRNA) (Wreschner et al., 1981) and therefore 
also prevents translation. Studies using RNaseL deficient mice have shown the importance 
of the 2-5 A system in the anti-viral properties of IFN-a against ECMV (Zhou et al., 1997).
Another important group of IFN induced proteins are the Mx proteins, high abundance 
GTPases which restrict RNA virus replication (Stark et al., 1998). Although their mode of 
action is not completely understood, they act primarily at the level of transcription and are 
thought to interfere with the viral polymerases (Stranden et al., 1993). However, they also 
act at other stages of viral replication. In mice, Mxl associates with distinct nuclear 
domains, known as PML bodies, and interferes with the transcription of RNA viruses having 
a nuclear replication phase, such as influenza (Staeheli et al., 1986b; Engelhardt et al., 2004). 
The human Mx protein, MxA, operates via a different mechanism, since it is located in the 
cytoplasm and inhibits a step of influenza replication that follows primary transcription 
(Pavlovic et al., 1992). In contrast to other ISGs, Mxl expression is not constitutive and can 
only be induced by IFN-I via the JAK-STAT signaling pathway and not directly by viruses 
or dsRNA (Simon et al., 1991; Bazzigher et al., 1992; Dupuis et al., 2003).
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Table 1.6 Mechanisms of IFN-induced viral inhibition (Weber et al., 2004)
Protein M echanism Viruses known to inhibit
ISG20 3 ’-5’ exonuclease that degrades ssRNA Vesicular stomatitis virus
P56 Inhibits translation via eukaryotic 
translation initiation factor 3e (eIF3e)
Hepatitus C virus
RNA-specific adenosine 
deaminase (ADAR 1)
dsRNA-editing enzyme: destabilizes 
dsRNA structure
Unknown
Promyelocytic protein 
(PML)
Organizer and main component o f  PML 
nuclear bodies, which contain various IFN- 
induced protein involved in apoptosis and 
the anti-viral state (ISG20, Daxx and p53)
Vesicular stomatitis virus 
Influenza A virus 
LCMV
Human foamy retrovirus
Guanylate binding protein-1 
(GBP-1)
GTPase -  unknown mechanism Vesicular stomatitis virus
The three pathways discussed above are the best characterised anti-viral mechanisms induced 
by IFNs. However, it is certain that other pathways do exist. In one study, mice were 
generated which were deficient in all three pathways, carrying no functional RNaseL, PKR 
or Mxl genes. These mice showed increased survival times after EMCV infection when 
treated with IFN (Zhou et al, 1999). Additional IFN-induced anti-viral proteins have been 
identified, and their properties are summarised in table 1.6.
1.3.4.2 Role o f  IFN-I in non-viral infections
Although IFN-I is known primarily for its anti-viral properties, it has many effects on the 
immune system including defence against bacterial and protozoan infections. Bacteria can 
induce the expression of IFN-I through TLR4 (LPS of gram-positive bacteria) and TLR9 
(non-methylated bacterial CpG DNA). In addition there appears to be an alternative 
mechanism for IFN-I induction by bacterial components, since IFN-(3 production during 
Listeria monocytogenes (L. monocytogenes) infection is dependent on IRF3 but not TLRs or 
the TRIF adaptor (Stockinger et al., 2004). A large number of non-viral pathogens induce 
IFN-I expression including bacteria such as L. monocytogenes, protozoa, such as Leishmania
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major and Toxoplasma gondii, and the eggs of the helminth Schistosoma mansoni, indicating 
the importance if IFN-I in controlling these infections (Bogdan et a l, 2004). Although IFN- 
I does have a protective effect against many of these pathogens, it can be detrimental during 
certain infections. For example increased resistance against L. monocytogenes has been seen 
in mice deficient in IRF3 or signaling through the IFN-IR (O'Connell et al., 2004). IFN-I 
does contribute to a direct anti-microbial effects as it is necessary for nitric oxide synthesis 
induced by TLR signaling (Decker et al., 2005). Several members of the IFN-y inducible 
family of p47 GTPases, which have microbicidal properties, are also induced by IFN-I 
(Taylor et al., 2004). However to a large extent, the anti-bacterial properties of IFN-I are 
likely to be indirect, that is by inducing the production of IFN-y or by inducing DC 
maturation (Decker et al., 2005).
1.3.S IFN-I, cell cycle control and apoptosis
IFN-I also controls microbial infections by growth suppression and apoptosis of infected
cells, which is also important for the elimination of cancer cells. IFN-a treatment inhibits
the cell cycle kinases, which results in loss of phosphorylation of the retinoblastoma protein
that is necessary for the release of transcription factors such as E2F and cell cycle
progression (Chawla-Sarkar et al., 2003). IFN-I mediated apoptosis involves TRAIL and
Fas, which on binding to their respective receptors induce signaling through the Fas
associated death domain (FADD) and caspase-8 (Chawla-Sarkar et al., 2003). The
regulators of IFN-I expression have been linked to apoptosis: IRF1 is a mediator of both cell
cycle arrest and DNA-damage-induced apoptosis (Tanaka et al., 1994), whilst over
expression of IRF3 is a potent inducer of apoptosis (Heylbroeck et a l , 2000). In addition to
TRAIL, Fas, caspase-4 and caspase-8, several other ISGs involved in apoptosis and growth
inhibition have been identified by gene microarray studies (Der et al., 1998; de Veer et al.,
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2001). These include the anti-viral factors PKR, PML and 2-5A oligoadenylate/RNase L, as 
well as several more recently identified genes known as the regulators of IFN-induced death 
(RIDs) (Chawla-Sarkar et a l, 2003). Over expression of the ISG galectin-9, an eosinophil 
chemoattractant involved in cell-cell attraction and adhesion, sensitizes to Fas-induced 
apoptosis (Saita et a l, 2002). Finally, IFN-I inducible phospholipid scramblase inhibits 
tumour growth (Silverman et al., 2002).
1.3.6 IFN-I control of innate immunity
1.3.6.1 Macrophages
IFN-I has been shown to augment the effector function of macrophages in several ways. For 
instance, IFN-I stimulates antibody-dependent cytotoxicity (Ralph et al., 1988), is necessary 
for complement receptor mediated phagocytosis (Sampson et al., 1991) and regulates the 
production of cytokines by macrophages (Taylor et al., 1998). IFN-I can also induce the 
expression of the enzyme inducible nitric oxide synthase (iNOS) by macrophages, which 
catalyzes the production of nitric oxide and helps to mediate their cytotoxic function (Gao et 
al., 1998). Finally, an IFN-I dependent, IL-12 independent mechanism of IFN-y production 
has been found in Chlamidia-infected macrophages (Gigliotti Rothfuchs et al., 2001).
1.3.6.2 NK cells
IFN-I and IL-12 appear to have complementary roles in NK cell activation; whereas IFN-I is 
necessary for NK cell blastogenesis and cytotoxicity but not IFN-y production, IL-12 is 
required for IFN-y production but not cytotoxicity or blastogenesis (Biron et al., 1984; Biron 
et al., 1996; Orange et al., 1996a). Induction of NK cell cytotoxicity by IFN-I has been 
shown to be dependent on STAT1 (Lee et al., 2000). In addition, IFN-I has been shown to 
negatively regulate IFN-y production by NK and T cells in response to virus infection, an
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effect which is again mediated by STAT1 (Nguyen et al., 2000); STAT1 activation renders 
the NK and T cells unresponsive to IL-12 and TCR stimulation. However, in the absence of 
STAT1 IFN-I can stimulate IFN-y production. Therefore, STAT1 may function to inhibit 
IFN-y production early on in the innate response to viral infection. Later, STAT1 activation 
appears to be regulated to allow IFN-I induction of IFN-y in T cells at the peak of the 
adaptive response. Indeed, after 8 days of LCMV infection when adaptive immune 
responses would be initiated, production of IFN-y could be induced (Nguyen et al., 2002). 
This IFN-y production was dependent on STAT4, whose phosphorylation could not be 
induced by IFN-I at the early stages of infection. Both IL-12 and IFN-I induce STAT4 
phosphorylation and binding to the IFN-y gene (Nguyen et al., 2002).
1.3.7 IFN-I control of adaptive immunity
1.3.7.1 T cell responses
In recent years, it has been revealed that IFN-I plays a crucial role in the development of 
adaptive immune responses. All IFNs have the ability to enhance expression of MHC class I 
proteins and so can promote the development of CD8+ T cell responses (Boehm et al., 1997). 
The transcription factor IRF1 is known to drive this expression and mutations in either the 
IFN receptors, STAT1, PKR or IRF1 results in the cells being unable to upregulate MHC 
class I in response to IFN-I (Chang et al., 1992; Reis et al., 1992). Although both type I and 
type II IFNs can upregulate MHC I expression, IFN-I was shown to inhibit IFN-y 
upregulation of class II expression in macrophages (Boehm et al., 1997).
Live viruses are more effective than killed virus or virus components at generating long term 
immune memory. One explanation for this is the production of IFN-I following viral 
infection. IFN-I has been shown to trigger bystander CD8+ T cell proliferation and has also
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been implicated in the maintenance of CD44hl CD8+ memory cells (Tough et a l, 1996). In 
these experiments, mice were injected with either LCMV or poly(I:C), an inducer of IFN-I, 
after which 70-90% of CD44+ CD8+ T cells went through cell division. This is a much 
higher proportion than that which could be accounted for by antigen-specific T cells and 
therefore could represent a mechanism by which the memory T cell pool is maintained. 
Injection of LPS or CpG DNA has also been shown to induce T cell activation and 
proliferation of CD44+ CD8+ T cells, an effect which is abolished in IFN-IR-deficient mice 
(Tough et al., 1997; Sun et al., 1998). This is likely to be mediated by DCs, which produce 
IFN-I after stimulation by LPS or CpG DNA. The IFN-I was acting directly on the T cells, 
since IFN-RI-deficient T cells could not be activated by IFN-I in the presence of normal 
APCs, and purified T cells could be activated by IFN-I itself. IFN-I is also important in T 
cell survival during an infection, and is able to prevent the death of antigen-activated, but not 
resting T cells (Marrack et al., 1999). In support of observations by Sun et al., IFN-I was 
shown to act directly on the T cells, as shown by increased survival of normal but not IFN- 
IR-deficient T cells in response to IFN-I in vitro.
In humans, IFN-I can induce the expression of the IL-12 receptor (32 chain on CD4+ T cells, 
thereby enabling them to respond to IL-12 and differentiate into Thl cells (Rogge et a l,
1997). Studies in mice had shown that IFN-a could not substitute for IFN-y in inducing 
IFN-y production by CD4+ T cells in response to IL-12, but could inhibit their IL-4 
production (Wenner et a l, 1996). Indeed, IFN-I does not induce Thl differentiation as 
strongly as IL-12. Whereas IL-12 induces sustained STAT4 phosphorylation (>48h), IFN-a 
induction of STAT4 was only transient (<4h) and could be explained by the loss of cell 
surface IFN-I receptors (Athie-Morales et a l, 2004). Although it was initially thought that 
IFN-I could act directly on human, but not mouse T cells to drive Thl development via the
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activation of STAT4 (Rogge et al., 1998), it was subsequently shown that IFN-I, in synergy 
with IL-18, could induce IFN-y via a STAT4 dependent mechanism in mice (Freudenberg et 
al., 2002; Nguyen et al., 2002).
IL-12 is important in promoting NK and Thl cell IFN-y responses in parasite and bacterial 
infections. However, IL-12 is not induced in all viral infections, for example LCMV, 
whereas IFN-I levels are highly elevated 2-3 days after infection (Orange et al., 1996b). In 
addition, IFN-I can negatively regulate IL-12 expression (Cousens et al., 1997). In fact both 
IFN-I and IL-12 dependent pathways were shown to be important for the induction of IFN-y 
from CD8+ T cells, and in the control of LCMV infection (Cousens et al., 1999). Therefore 
the balance between IFN-I and IL-12 seems to be important for the control of different 
infections.
IFN-I can also inhibit T cell function since it can reduce T cell proliferation (Sun et al.,
1998). However IFN-I is only able to exert its anti-proliferative effect on naive and not 
activated T cells (Dondi et al., 2003). Inhibition of naive T cell proliferation may be 
overruled in the presence of DCs, on which IFN-I has a strong adjuvant effect (Tough, 2004).
1.3.7.2 Humoral immune response
Studies on the role of IFNs in the humoral immune response have mainly been focused on 
IFN-y. It now appears though, that IFN-I may induce many of the same effects. IFNs are 
known to affect three aspects of B cell function; development and proliferation, Ig secretion 
and Ig heavy chain switching (Stark et al., 1998). Ig heavy chain switching is important in 
tailoring the immune response to different pathogens as the different isotypes promote 
distinct effector functions in the host. Injection of IFN-a into mice enhances IgG2a 
secretion whilst suppressing IgE secretion (Finkelman et al., 1991). In addition, in mice
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deficient for both type I and type II receptors IgG2a is not produced in response to LCMV 
infection. This contrasts with normal IgG2a levels in single knockout mice suggesting that 
IFN-I and IFN-y share a redundant role in Ig class switching (van den Broek et al., 1995). 
IFN-I has been shown to upregulate the B cell activation markers CD69, CD86 and CD25 
and to enhance responses to B cell receptor ligation (Braun et a l, 2002). In addition, IFN-I 
promoted survival of mature B cells and resistance to Fas-mediated apoptosis in vitro. In 
another study, co-injection of soluble antigen and IFN-I resulted in long lasting antigen- 
specific antibodies and the generation of memory B cells (Le Bon et a l, 2001). Finally, 
IFN-I and IL-6 secreted by pDCs induces the generation of plasma cells and their 
differentiation into Ig-secreting plasma cells, respectively (Jego et a l, 2003).
1.3.8 The immunomodulatory effect of IFN-I on DCs
1.3.8.1 IFN-I induces DC differentiation and maturation
DCs are highly dynamic cells and can rapidly transform themselves in response to
environmental factors in order to carry out the distinct functions required of them. As
already discussed, the factors that regulate these transformations include cytokines,
chemokines and danger signals from pathogens or distressed cells. Several groups have
demonstrated the ability of IFN-I to accelerate the differentiation and maturation of human in
v/Vro-derived DCs. In one system, immature human DCs generated from CD34+ progenitors
in the presence of GM-CSF, TNF-a and IL-4 spontaneously matured into activated DCs in
14 days (Luft et a l, 1998). When IFN-I was added the DCs matured into activated DCs in
only 3 days, an effect which could not be duplicated with any other cytokine tested. These
DCs had upregulated MHC I and the co-stimulatory molecules CD80 and CD86. In
addition, DCs matured in the presence of IFN-a2a upregulated class II expression and
expressed the human DC lineage-associated antigens CD83 and CMRF44. The DCs were
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functionally mature as they had high stimulatory capacity in the MLR. Likewise, maturation 
of DCs directly isolated from human blood can be induced by IFN-I (Ito et a l, 2001).
The development of phenotypically and functionally mature DCs from peripheral blood 
monocytes after culture with IFN-a and GM-CSF has also been reported (Paquette et al., 
1998; Radvanyi et a l, 1999; Santini et al., 2000). This effect could be enhanced by the 
addition of IL-4 (Paquette et a l, 1998) and is superior to treatment with IL-4/GM-CSF alone 
(Santini et a l, 2000). In contrast to the experiments by Luft and Radvanyi (Luft et a l, 1998; 
Radvanyi et a l, 1999), this DC maturation appeared to be independent of TNF-a. IL-4/GM- 
CSF treated DCs could revert back to cells of macrophage-like morphology after cytokine 
removal. In contrast, the monocytes matured in the presence of IFN-a had reached a more 
advanced stage of maturation and expressed CD83, which was irreversible after removal of 
the cytokines (Santini et a l, 2000). Overproduction of IFN-a in vivo as seen in patients 
with systemic lupus erythematosus (SLE), appears to affect DC development since 
monocytes from these patients could function as APCs. Serum from these patients could 
also be used to induce the differentiation of monocytes into cells with mature DC 
characteristics able to induce CD4+ T cell proliferation, which was inhibited by neutralising 
antibodies against IFN-a. Therefore IFN-a-maturation of DCs presentating antigens from 
captured apoptotic cells could drive the production of auto-reactive T and B cells as seen in 
SLE (Blanco et a l, 2001). Finally, DCs able to initiate proliferation of naive CD4+ T cells 
can be generated from human monocytes in the absence of GM-CSF using a combination of 
IL-3 and IFN-P (Buelens et a l, 2002).
Some studies have reported the inhibition of DC development from monocytes in the 
presence of IFN-I (Bartholome et a l, 1999; McRae et a l, 2000; Wiesemann et a l, 2002).
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This may be due to differences in culture conditions, since IL-4, which can suppress 
transcription of ISGs in monocytes (Lamer et al., 1993), was also present in the monocyte 
cultures. The stage of differentiation or maturation at which DCs are exposed to IFN-I may 
also determine how they respond. Indeed, when IFN-p was added at the initial stage of 
monocyte-derived DC (MoDC) differentiation it had an inhibitory effect on DC function, 
whilst addition at a later stage (at 7-10 days of culture) had the opposite effect and enhanced 
their T cell stimulatory capacity (Wiesemann et al., 2002).
In mice, IFN-a can activate resting BM-derived DCs in the absence of any other stimulating 
factors (Gallucci et al., 1999). Recently, splenic DCs have also been shown to mature in 
response to IFN-I both in vitro and in vivo (Montoya et al., 2002). In this study it was also 
shown that both BM-derived DCs and splenic DCs secrete IFN-I, which could activate DCs 
in an autocrine manner. Another study highlighted the importance of IFN-I during the 
maturation of mouse DCs stimulated by CpG DNA in vitro (Cho et al., 2002). Stimulation 
of mouse BM-derived DCs with CpG DNA resulted in upregulation of MHC class I and co­
stimulatory molecules. However, among BM-derived DCs from IFN-IR'7' mice only a 
subset of DCs up-regulated co-stimulatory molecules, and no upregulation of MHC I 
molecules could be detected in response to CpG DNA.
Although IFN-I is necessary for the full maturation of DCs by CpG or dsRNA, it does not
appear to be sufficient, since maturation of DCs induced by IFN-p was not as complete as
that seen with poly(I:C) (Honda et al., 2003). Due to the kinetics of co-stimulatory molecule
and inflammatory cytokine induction seen in wild-type and IFN-IR'7' mice, these authors
suggested that stimulation of DC maturation by dsRNA occurs in two phases; dsRNA
induces expression of IFN-I, inflammatory cytokines and CCR7, and IFN-I augments
cytokine expression and induces effective DC maturation in the late phase. A recent report
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has shown that although IFN-I produced by HSV infected MoDCs could activate uninfected 
DCs, it was not necessary for the maturation of the infected DCs themselves (Pollara et al., 
2004). Similarly, in IFN-IR7' mice lower levels of costimulatory and MHC molecules are 
induced following LCMV infection compared to wild-type mice. DCs isolated from IFN-IR7' 
mice after LCMV infection could stimulate proliferation of naive T cells but not as 
efficiently as wild-type controls (Montoya et al., 2005). Therefore a degree of maturation 
had occurred by an independent IFN-I pathway.
There appears to be a differential requirement for IFN-I signaling for maturation in response 
to TLR ligands. Defects in maturation caused by loss of IFN-I signaling are less severe 
when the initial stimulus is LPS or CpG compared to poly(I:C) (Honda et a l , 2003). 
Likewise, maturation of DCs in vivo after viral infection or injection of R848 or CpG is 
suppressed in IFN-IR7' mice, although maturation in response to LPS remains intact (Honda 
et a l , 2003; Asselin-Paturel et a l , 2005b). This is consistent with earlier reports showing 
the varying dependence on IFN-I signaling for induction of CD40 expression through TLR4 
and TLR9 stimulation (Hoshino et a l, 2002).
DCs also regulate their own responsiveness to IFN-I during maturation. This has been 
demonstrated in human MoDCs, which after LPS-induced maturation down-regulated the 
expression of both type I IFN receptor chains (Gauzzi et a l, 2002). Likewise, regulation of 
genes involved in IFN-I signaling and production appears to be essential for the correct 
development of DCs. Recent studies revealed that development of CD1 lc+ CD8+ DCs and 
pDCs is dependent on an IRF family member which regulates expression of IFN-responsive 
genes, the IFN consensus sequence binding protein (ICSBP)/IRF-8 (Schiavoni et a l, 2002; 
Aliberti et a l, 2003; Tsujimura et a l, 2003). The few CD8+ DCs that develop in ICSBP- 
deficient mice are unable to mature in response to LPS or poly IC (Schiavoni et a l, 2002).
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In addition, the CD8' subset of DCs in these mice also have impaired function and are unable 
to mature after TLR signaling (Aliberti et a l , 2003). ICSBP'A DCs are also unable to 
produce IFN-a, IL-12p40 or IL-15 (Schiavoni et al., 2002; Tsujimura et a l, 2003). In 
contrast, IRF2-deficient mice display a loss of the CD8' DC subset (Honda et a l, 2004). 
This defect has been attributed to excessive IFN-I signaling which in normal mice is 
regulated by IRF2 via the inhibition of ISGF3. These studies highlight the importance of 
IFN-regulated genes for the development and function of DCs. However, in IFN-IR 
knockout mice there is no apparent deficiency in DC development, so IFN-I may not be 
required for DC development in vivo.
Finally, treatment of pDCs with IFN-I can maintain their survival, although unlike 
stimulation with viruses, does not induce their differentiation (Kadowaki et al., 2000; Ito et 
al., 2001). It was subsequently shown that IFN-I is necessary for dsRNA induced 
differentiation of bone marrow pDCs into CD1 lc+ CD1 lb+ DCs (Zuniga et al., 2004).
It is clear therefore, that the effect of IFN-I on DC maturation is dependent on a complex set 
of factors, including the stage of maturation, the maturation stimulus, the DC subset and the 
influence of other cytokines present during their differentiation and maturation.
1.3.8.2 IFN-I enhances chemokine and cytokine secretion by DCs
IFN-I induces the upregulation of MHC and co-stimulatory molecules by DCs which results 
in an increased ability to stimulate antigen-specific T cell proliferation (Luft et al., 1998; 
Paquette et al., 1998; Wang et al., 1999). In addition, IFN-I can enhance the ability of DCs 
to attract T cells. IFN-a2a-treatment of MoDCs induces the secretion of the chemokines 
CXCL9 (MIG) and CXCL10 (IP-10) as well as the upregulation of CXCL11 (I-TAC) mRNA 
(Padovan et al., 2002). Furthermore, memory and activated CD8+ T cells show increased
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chemotaxis in response to medium from IFN-I treated DCs which is inhibited by blocking the 
CXCR3 receptor. In addition, expression of the chemokine DC-CK-1, involved in the 
recruitment of naive T cells, has been shown to be expressed in MoDCs derived in vitro with 
GM-CSF combined with IFN-I but not IL-4 (Parlato et al., 2001).
MoDCs derived in the presence of IFN-I produce elevated levels of IL-15 compared to 
MoDCs generated in GM-CSF and IL-4 (Santini et al., 2000). In addition IFN-I has been 
shown to induce expression of IL-15 by mouse splenic DCs after treatment with IFN-I either 
in vivo or in vitro (Mattei et al., 2001). Interestingly, IFN-I also induced the expression of 
the IL-15 receptor (IL-15R) by splenic DCs, which were shown to respond to IL-15 by 
upregulating co-stimulatory molecules. Furthermore DCs from IL-15-treated mice were 
better stimulators of CD8+ T cell proliferation, an effect which was reduced in DCs from 
IFN-IR'a mice suggesting that IFN-I could enhance the response of DCs to IL-15. The 
importance of DC stimulation by IL-15 in the initiation of CD8+ T cell responses in vivo has 
subsequently been demonstrated (Ruckert et al., 2003), and has also recently been shown to 
regulate DC production of IL-2 (Feau et al., 2005). IL-15 shares an overlapping yet distinct 
set of biological functions with IL-2, explained in part by the composition of the IL-15 
receptor, which contains the p and y subunits of the IL-2 receptor but has a unique a  subunit 
(Fehniger et al., 2001). IL-15 also acts directly on T cells, and has been shown to act as a 
survival factor for both naive and memory CD8+ T cells (Berard et al., 2003) as well as being 
an inducer of memory CD8+ T cell proliferation (Zhang et al., 1998).
There is conflicting evidence on the effect on IFN-I on IL-12 production by DCs. IFN-I
regulates the production of IL-12 during viral infections, as shown by elevated IL-12 levels
after in vivo neutralisation of IFN-I during murine cytomegalovirus (MCMV) infection and
in IFN-IR'a mice during LCMV infection (Cousens et al., 1997). Several reports have
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indicated that monocyte-derived DCs generated in the presence of IFN-I secrete reduced 
levels of IL-12 compared to monocyte-derived DCs generated with GM-CSF/IL-4 alone 
(Bartholome et al., 1999; McRae et al., 2000; Huang et al., 2001b). In these cases the DCs 
showed an inability to support CD4+ T cell production of IFN-y. Ito et al. also reported that 
IFN-a did not induce IL-12p70 production by human blood DCs, and instead augmented IL- 
10 production (Ito et al., 2001). However treatment of immature MoDCs with IFN-a2a 
augments the production of IL-12 by CD40 ligation or LPS stimulation (Luft et al., 2002; 
Pollara et al., 2004). Furthermore, addition of IFN-I during LPS or CD40L stimulation of 
immature MoDCs increases IL-12 production, but inhibits CD40L-induced IL-12 production 
by mature DCs (Heystek et al., 2003). In fact production of IL-12 appears to be strictly 
controlled during DC maturation since it had previously been demonstrated that mature DCs 
were limited in their ability to produce IL-12, and were unresponsive to IFN-y or bacterial 
stimulation (Kalinski et al., 1999b). There appears to be a tight cross-regulation between 
IFN-I and IL-12 production, which may be important for limiting overproduction of either of 
the cytokines. For example during infection of mice with MCMV, pDC production of IFN-I 
limits IL-12 production by CD1 lc+ DCs whilst enhancing IFN-I levels (Dalod et al., 2002). 
In addition, IFN-I can interfere with the ability of IFN-y to induce IL-12 even under 
conditions where IFN-I would normally enhance IL-12 (Heystek et al., 2003).
A recent study has demonstrated the key role of IFN-I in IL-12 production by DCs in 
response to TLR stimulation (Gautier et al., 2005). The TLR7 ligand R848 was shown to 
synergise with poly(I:C) and LPS in IL-12 p70 and p40 production by mouse BM-derived 
DCs. The amount of IL-12p70 but not p40 was dramatically reduced in IFN-IR deficient 
DCs, in addition to reduced levels of IL-12p35 mRNA. Likewise addition of a neutralizing 
anti-human IFN-IR antibody partially blocked IL-12p70 but not p40 secretion from MoDCs
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in response to TLR stimulation. These results suggest that IFN-I increases IL-12p70 
secretion through regulation of p35 production. However in other studies, the production of 
IL-12p40 was severely impaired in IFN-IR'7* mice after viral infection (Honda et al., 2003).
The Thl inducing ability of IFN-I may result from the induction of cytokines other than IL- 
12 from DCs. Nagai et al. showed that maturation of MoDCs with TNF-a and IFN-p 
augmented IL-18 production and increased levels of the IL-23 pl9 subunit. In addition, DCs 
matured in the presence of IFN-P but not with TNF-a alone were partially dependent on IL- 
18 for inducing IFN-y production by responding T cells (Nagai et al., 2003). The ability of 
pDCs to induce Thl polarisation has also been shown to be independent of IL-12 and only 
partially dependent on IFN-p and IL-18; addition of a combination of anti-IFN-p, anti-IL-18 
receptor and anti-IL-12 did not abrogate T cell IFN-y production during stimulation with 
pDCs (Krug et a l, 2003).
1.3.8.3 IFN-I induces DC migration
The migration of DCs is dependent on their ability to respond to chemokines released by 
cells in the surrounding environment and by the DCs themselves. Early experiments 
indicated that IFN-I could induce the migration of DCs from the skin (Luft et a l, 1998). 
Expression of certain chemokines and their receptors by DCs are enhanced by stimulation 
with IFN-I; CCR5 expression is elevated on MoDCs derived in the presence of IFN-I and 
correspondingly they respond more strongly to CCL5 (RANTES), CCL3 (MIP-la) and 
especially CCL4 (MIP-ip) compared to MoDCs generated with IL-4 (Parlato et a l, 2001). 
Mature DCs are known to lose their responsiveness to inflammatory cytokines and become 
responsive to CCL19 (MIP-3p) and CCL21 (6Ckine) due to upregulation of their receptor 
CCR7. Both the expression of CCR7 and its ligand CCL19 were induced in IFN-generated
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DCs (Parlato et al., 2001). Consequently these DCs migrated in response to CCL19 whereas 
IL-4 derived DCs did not. Since CCL 19 is thought to play a key role in homing of mature 
DCs to the LN, this suggests a role for IFN-I in DC trafficking. In contrast, treatment of 
immature MoDCs with IFN-I did not result in expression of functional CCR7 even though 
gene expression was induced (Parlato et al., 2001; Luft et al., 2002), implying that IFN-I is 
not an influencing factor in the migration of mature DCs. In support of this, lack of IFN-I 
signaling in the mouse did not effect the expression of CCR7 or migration of CD1 lc+ DCs 
into the T cell zone of the spleen after viral infection or injection of CpG (Honda et al., 2003; 
Asselin-Paturel et al., 2005b). However, migration of pDCs does appear to be dependent on 
IFN-I. In resting conditions, pDCs are scattered through the T cell area and red pulp of the 
spleen. After injection of TLR7 or TLR9 ligands (but not TLR4 ligands), pDCs form 
clusters within the marginal zone and T cell area. However in IFN-IR'7' mice, this clustering 
does not occur, and ex vivo pDCs from CpG-treated mice were impaired in their migration in 
response to CCL21 (Asselin-Paturel et al., 2005a).
1.3.8.4 IFN-I enhances immunity in vivo
Finally, IFN-I has also been shown to enhance the immunostimulatory capacity of DCs in 
vivo (Figure 1.5). MoDCs generated in the presence of IFN-I can induce a strong primary 
antibody response against HIV-1 antigens when inoculated into severe combined 
immunodeficiency (SCID) mice reconstituted with human peripheral blood leukocytes 
(Santini et al., 2000; Parlato et al., 2001). Similarly, Le Bon et al. showed that co-injection 
of poly(I:C) and antigen resulted in highly elevated antigen-specific antibody titres of all IgG 
subclasses, an effect which was severely diminished in IFN-IR knockout mice (Le Bon et al.,
2001). Injection of IFN-I also enhanced levels of antigen-specific antibodies, and its activity 
was comparable to that of the potent adjuvant, complete Freund’s adjuvant (CFA). In fact,
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Figure 1.5 IFN-I enhances the im m unostimulatory capacity o f DCs IFN-I 
produced by pDCs or C D llc + DCs induces the production o f  cytokines by DCs 
which regulate T and B cell function. These include IL-12, which prom otes IFN-y 
production by CD4 T cells and differentiation o f  naive B cells into plasm a cells 
(in co-operation with IL-6 also produced by DCs). BAFF and APRIL prom ote 
isotype switching, which is also dependent on IL-15. In addition, IL-15 induces 
CD8+ T cell proliferation. IFN-I also enhances the production o f  chem okines 
which aid in the attraction o f  T cells.
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the ability of CFA to induce high titers of IgM, IgG2 and IgG3 antibodies was dependent on 
IFN-I. Six months after immunisation with antigen and IFN-I, antigen-specific antibodies 
could be detected in the sera, and the mice could mount a secondary response when 
challenged, showing that IFN-I could promote the generation of memory B cells. Wild-type 
DCs treated with IFN-I and injected into IFN-IR7' mice also induced enhanced antibody 
responses and isotype switching, and since DCs were the only cells capable of responding to 
IFN in this system, the results clearly demonstrated that DCs were direct targets of IFN-I in 
stimulating B cell responses. The mechanism by which DCs can induce class-switching was 
explained by the discovery that IFN-a treatment of DCs induces expression of BAFF and 
APRIL, two factors which promote B cell and plasma cell survival in addition to promoting 
class switching (Litinskiy et al., 2002). The ability of DCs to induce the secretion of class- 
switched antibodies was also dependent on IL-15.
In vz/ro-derived DCs differentiated or activated with IFN-I have an increased ability to 
stimulate T cell proliferation, IFN-y production and cytotoxic function (Luft et al., 1998; 
Paquette et al., 1998; Santini et al., 2000; Ito et al., 2001; Buelens et al., 2002; Luft et al., 
2002; Padovan et al., 2002; Nagai et al., 2003), although there have been reports to the 
contrary (Bartholome et a l, 1999; McRae et al., 2000). In addition, DCs from IFN-IR7' 
mice are less efficient stimulators of CD4+ and CD8+ T cell proliferation (Montoya et al.,
2002). The ability of CpG DNA to induce cross-priming and IFN-y production against a 
soluble antigen in vivo was found to be partially dependent on IFN-I (Van Uden et al., 2001; 
Cho et al., 2002). In addition, cross-priming induced by LCMV infection was abolished in 
IFN-IR7' mice (Le Bon et al., 2003), while co-injection of IFN-a and ovalbumin resulted in 
antigen-specific CD8+ T cell proliferation, IFN-y production and cytotoxicity through a 
mechanism that was independent of CD4+ T cells and CD40 licensing. Notably, the CD8+ T
80
cells primed in the presence of IFN-I are functional in vivo, since co-injection of IFN-a and 
ovalbumin was shown to result in protection against a recombinant vaccinia virus expressing 
ovalbumin. Similar to findings on the induction of antibodies by IFN-I, IFN-I could act 
directly on DCs to induce cross-priming, since wild-type DCs treated with IFN-I and injected 
into IFN-IR7' resulted in antigen-specific IFN-y production.
1.3.8.5 Conclusions
The relationship between IFN-I and DCs acts as a bridge between the innate and adaptive 
immune systems. Pathogen-associated molecules can induce large amounts of IFN-I which 
is essential for the full maturation of DCs during certain infections. In addition, DCs 
themselves are a major source of IFN-I. The presence of IFN-I during DC maturation may 
affect the outcome of the immune response by conditioning the DCs to become Thl inducers. 
Alternatively IFN-I could simply act to augment DC maturation thereby promoting a stronger 
immune response. It is apparent that IFN-I influences many facets of DC biology: 
regulation of cell surface molecules which mediate migration or interactions with T cells, 
chemokines which attract T cells, and the release of cytokines which act on T and B cells. 
Altogether, these result in promotion of the adaptive immune response. Further knowledge 
of these mechanisms may be applied in the development of vaccines and therefore the DC- 
IFN-I relationship is worthy of detailed investigation.
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1.4 Objectives
Our interest in the effect of IFN-I on DCs stemmed from experiments in which in vivo 
administration of either poly(I:C) or IFN-I itself were shown to enhance both antibody 
production and isotype switching in response to antigen (Le Bon et al., 2001). IFN-I was 
shown to be acting directly on DCs in stimulating the increase in titers of all four IgG 
subclasses specific for co-injected antigen. As discussed, IFN-I also enhances the ability of 
DCs to stimulate CD4+ and CD8+ T cell proliferation, as well as promoting cross-priming in 
vivo (Le Bon et al., 2003).
It is clear that IFN-I plays an important role in modulating several aspects of DC function. 
In order to investigate this further, we decided to study how gene expression in DCs is 
affected by treatment with IFN-I. We hoped to identify genes involved in the adaptive 
immune response, specifically, genes encoding co-stimulatory molecules, cytokines, 
chemokines or their receptors.
The aims of this study were to;
1) identify genes regulated by IFN-I in murine DCs
2) verify regulation of genes by IFN-I using methods such as quantitative-PCR
3) functionally characterise novel genes with potential roles in DC biology by 
examining protein expression and test functional properties using assays appropriate 
for their predicted function
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Chapter 2: Materials and Methods
2.1 Materials
2.1.1 Type-I IFN
2.1.1.1 IFN-a/p
IFN-a/p was obtained from Filippo Belardelli (Istituto Superiore di Sanita, Rome) and had 
been prepared in the C243-3 cell line following a method adapted from Tovey et al. (Tovey 
et a l , 1974). Briefly, confluent cells were primed by the addition of lOU/ml IFN in Eagle 
minimum essential medium (MEM) containing 10% FCS and ImM sodium butyrate. After 
16 hours of culture at 37°C, C243-3 cells were infected by Newcastle disease virus in MEM 
plus 0.5% FCS plus 5mM theophylline. At 18 hours after infection, culture supernatant was 
collected and centrifuged at 1500 rpm for 10 minutes. The supernatant was adjusted to pH 
2.0 and kept at 0°C for six days. IFN was concentrated and partially purified by ammonium 
sulphate precipitations and dialysis against PBS, followed by further dialysis for 24 hours at 
4°C against 0.01 M percloric acid and then against PBS, before being tested for any possible 
residual toxicity on a line of L1210 cells resistant to IFN. These partially purified IFN 
preparations had a titer of at least 2 x 107 U/mg protein and were endotoxin free, as assessed 
by the Limulus amebocyte assay. The IFN was constituted of 75% IFN-p and 25% IFN-a as 
evaluated by neutralisation assays using mouse antibodies to IFNs (Belardelli et a l, 1987).
2.1.1.2 IFN-a4
IFN-a4 was obtained from Cornelia Rossmann (Acambis, Cambridge, UK) and Dirk Gewert
(Biolauncher, Cambridge, UK). Briefly, the mouse gene encoding IFN-a4 was cloned into
the pEE12 plasmid (Celltech, Slough, UK). After amplification in E.coli, pEE12 encoding
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IFN-a4 DNA was used to transfect NSO mouse myeloma cells. A single colony of cells 
expressing high levels of IFN-a4 was selected, and grown for 10-15 days in serum-free 
medium supplemented with Cholesterol Lipid Concentrate (Invitrogen, Paisley, UK). IFN- 
a4 content of the supernatant was assayed by inhibition of the cytopathic effect of vesicular 
stomatitis virus on L cells. The IFN-a4 had an activity of 2 x 106 U/ml.
2.1.2 Equipment
Item Supplier
Eppendorf 5417R centrifuge 
Allegra 6R centrifuge 
Storm 860 phosphorimager 
MoFlo MLS
FACSCaliber flow cytometer 
MiniMACS, MidiMACS Cell Separation Units 
ABI prism 377 DNA sequencer 
ABI prism 7700 sequence detector 
GeneAmp 9700 PCR thermal cycler
Eppendorf
Beckman
Molecular Dynamics 
DakoCytomation, Colorado 
Becton Dickenson, UK 
Miltenyi Biotech, UK 
Perkin-Elmer 
Perkin-Elmer 
Perkin-Elmer
SpectraMAX 340, 96-well plate spectrophotometer 
UV Stratalinker 2400 
Gene Pulser II
Dynabead magnetic particle concentrator 
Agilent 2100 Bioanalyser 
GeneChip fluidics station 450 
GeneChip scanner 2000
Molecular Devices, UK
Stratagene
Biorad
Dynal
Agilent
Affymetrix
Affymetrix
2.1.3 Chemicals
Chemical Supplier Chemical Supplier
Acetonitrile Sigma Milk powder Tesco
Ammonium acetate BDH AnalaR Mineral oil Sigma
Ammonium sulphate Sigma NP40 (RIPA buffer) Sigma
B-mercapto ethanol Sigma Paraformaldehyde Sigma
Bromophenol blue Sigma Phenol/chloroform/isoamyl
alcohol(25:24:l)
Sigma
Chloroform Sigma Potasium chloride Sigma
Chloroform/isoamyl alcohol 
(24:1)
Sigma Tris HCl/base Sigma
Dithiothreitol (DTT) Invitrogen Tween-20 Sigma
Ethanol Sigma Saponin Sigma
Ethanolamine sigma Sodium acetate Sigma
Glacial acetic acid Sigma Sodium carbonate Sigma
Glycerol BDH AnalaR Sodium (H) carbonate Sigma
Glycine Sigma Sodium chloride Sigma
Isopropanol Sigma Sodium Dodocyl sulphate Gibco
Magnesium chloride Sigma Sodium deoxycholate Sigma
Methanol BDH AnalaR Sodium hydroxide Sigma
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2.1.4 Tissue culture and cell isolation reagents
Reagent Supplier
Antibiotic-antimycotic solution Gibco
Dimethyl sulphoxide Sigma
Phosphate buffered saline Gibco
Feotal Bovine Serum (FBS) Gibco
Feotal Bovine Serum (endotoxin-free) Harlan
Iscoves MOD.DMEM medium Gibco
RPMI 1640 Gibco
Glasgow MEM Gibco
Dulbecco’s MEM Gibco
Hanks buffered salt solution Gibco
Bovine serum albumin Sigma
Tryptose phosphate broth Media services, IAH, Compton
Guinea Pig Complement Cedarlane Laboratories
Collagenase type III, 117U/mg Lome Laboratories, UK
Dnase, 200-400 Kunitz U/mg) Sigma
Nycoprep 1.077 A Nycomed
P-mercaptoethanol Gibco
Accutase PA A labs
Red blood cell lysing buffer Sigma
Recombinant mouse GM-CSF R&D Systems
DMSO Sigma
Dynabeads M-450 Sheep anti-Rat IgG Dynal
FITC microbeads Miltenyi Biotech
CD4 microbeads Miltenyi Biotech
CD8a microbeads Miltenyi Biotech
CD 19 microbeads Miltenyi Biotech
DX5 microbeads Miltenyi Biotech
Plasmacytoid DC isolation kit Miltenyi Biotech
MACS LS columns Miltenyi Biotech
MACS MS columns Miltenyi Biotech
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2.1.5 Molecular Biology reagents
2.1.5.1 General reagents
Reagent Supplier
Isolation and quantification o f RNA
Trizol reagent Life Technologies Ltd
Glycogen Boehringer Mannheim
RNAse-free water Ambion
Oligotex mRNA isolation kit Qiagen Ltd
RNase-free DNase kit Qiagen Ltd
Ribogreen RNA quantification kit Molecular probes
Agarose Gel Electrophoresis
Agarose BioRad
Ethidium bromide Gibco
10 x Tris-Acetate-EDTA buffer Invitrogen
6x Gel Loading Dye Abgene
Low DNA mass ladder Invitrogen
1 kb plus Ladder Invitrogen
PCR/RT-PCR/qPCR
10 x PCR buffer Invitrogen
dNTPs Invitrogen
50mM MgCl2 Invitrogen
Taq DNA polymerase Invitrogen
Reverse transcriptase qPCR kit Oswel Research Products, UK
Reverse-iT 1st strand synthesis kit Abgene
Sequencing
Big dye terminator kit PE Applied Biosystems, UK
Long Ranger Singel Gels Flowgen, UK
Loading buffer PE Applied Biosystems, UK
2.1.5.2 Representational Difference Analysis
2.1.5.2.1 Buffers
5 X RT2 Second Strand Buffer: 100 mM trisHCl (pH 7.5), 500 mM potassium chloride, 25 
mM magnesium chloride, 50 mM ammonium sulphate , 50 mM DTT, 250 ng/ml BSA (non- 
acetylated, Ambion) and 225 pi of water
5 x PCR buffer: 335 mM trisHCl, pH 8.9, 20 mM MgCl2, 80 mM (NH4)2SC>4, 166 pg/ml 
BSA
EE x 3 buffer: 30 mM EPPS (Sigma), pH 8.0 at 20°C; 3 mM EDTA
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2.1.5.2.2 Additional reagents
OligodT primer, 50 ng/pl (Promega) pNAD (Boehringer Mannheim), ATP (Invitrogen), 
EPPS, (Sigma)
2.1.5.3 Cloning and transfections
Reagent Supplier
Cloning
QIAquick PCR purification kit Qiagen Ltd
Qiagen gel extraction kit Qiagen Ltd
QIAgen plasmid mini/midi/maxi kits Qiagen Ltd
QIAgen plasmid endo-free maxi kit Qiagen Ltd
pBluescript II KS Stratagene
pcDNA6/V5-His (C) Stratagene
Luria broth agar plates, 100|ig/ml ampicillin Media services, IAH, Compton
Luria broth Media services, IAH, Compton
Ampicillin Media services, IAH, Compton
XLl-Blue-M RF’ competent cells Stratagene
One shot TOP 10 competent cells Invitrogen
Isopropylthio-P-galactoside (IPTG) Invitrogen
X-gal Invitrogen
FLAG mammalian N-terminal expression system Sigma
Transfections
Effectene QIAgen
Blasticidin Invitrogen
G418 Invitrogen
M ammalian cell lines
BHK-21
BAF/3 Gift from Mike Hubank, ICH, UK
WEHI Gift from Mike Hubank, ICH, UK
2.1.5.4 Microarray analysis
Reagent Supplier
RNeasy mini kit Qiagen Ltd
cDNA synthesis system Roche Lewes
Genechip Sample Cleanup Module Affymetrix, UK
Enzo BioArray high yield RNA transcript labeling kit Affymetrix, UK
Murine genome U74Av2 array Affymetrix, UK
Murine genome 430 2.0 array Affymetrix, UK
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2.1.5.6 Southern/Western Blotting
Reagent Supplier
Southern blotting
20 x Sodium chloride-Sodium citrate buffer Invitrogen
Rapid-Hyb buffer Amersham
Hybond N+ membrane Amersham
PCR DIG probe synthesis kit Roche
DIG wash and block buffer set Roche
Hyperfilm ECL Amersham
M icroarray analysis
RNeasy mini kit Qiagen Ltd
cDNA synthesis system Roche Lewes
Genechip Sample Cleanup Module Affymetrix, UK
Enzo BioArray high yield RNA transcript labeling kit Affymetrix, UK
SDS-PAGEAVestern Blot
Biorad ready gel, 10% Tris-HCl Biorad
Protease Inhibitor cocktail Sigma
Phenylmethylsulphonyl flouride (PMSF) Sigma
Tris/Glycine/SDS Buffer Biorad
Wide range colour marker Sigma
Hybond C Super nitrocellulose membrane Amersham
ECL western blotting detection reagent Amersham
Anti FLAG M2 Sigma
Anti FLAG M2 Sigma
Mouse IgGl Amersham
ECL donkey anti-rabbit HRP linked F(ab’)2 fragment Amersham
2.1.5.7 Enzymes
Enzyme Concentration Supplier
RNase Inhibitor 40 U/pl Promega
DNase I (RNase-free) lOU/pl Roche
Superscript II 200 U/pl Invitrogen
E. coli DNA ligase lOU/pl N ew  England Biosciences
RNase H 2 U/pl Invitrogen
E. coli DNA polymerase lOU/pl New  England Biosciences
T4 DNA ligase 400U/pl New  England Biosciences
T4 DNA ligase 20U/pl Promega
Taq DNA polymerase 5 U/pl Invitrogen
PfuTurbo® DNA polymerase 2.5U/pl Stratagene
Mung Bean Nuclease lOU/pl New  England Biosciences
Calf Intestinal Alkaline Phosphatase lU /pl Promega
Dpnll lOU/pl N ew  England Biosciences
BamHl lOU/pl Invitrogen
EcoRl lOU/pl Invitrogen
Hindlll lOU/pl Invitrogen
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2.1.6 Oligos
2.1.6.1 Representational Difference Analysis
All primers were synthesised by MWG-biotech, Germany
Oligo Sequence 5’- 3 ’
R-12 GATCTGCGGTGA
R-24 AGCACTCTCCAGCCTCTCACCGCA
J-12 GATCTGTTCATG
J-24 ACCGACGTCGACTATCCATGAACA
N-12 GATCTTCCCTCG
N-24 AGGCAACTGTGCTATCCGAGGGAA
2.1.6.2 Sequencing
Primers were synthesised by MWG-biotech, Germany or by Sigma-genosys, UK.
Oligo Sequence 5 ’- 3 ’
M 13-20 GTAAAACGACGGCCAGT
M13 rev GGAAACAGCTATGACCATG
T3 AATTAACCCTCACTAAAGGG
I? GTAATACGACTCACTATAGGGC
N-CMV-30 forward AATGTCGTAATAACCCCGCCCCGT
C-CMV-24 reverse TATTAGGACAAGGCTGGTGGGCAC
Gpr33 forward CTGACTGGGAGAGCA AAGAGC
Gpr33 reverse CCATTGCCCTAGTGTTTGATGC
CCR7 forward CGGGATGCTGCTGCTCCTATGC
CCR7 reverse GCATAGGAGCAGCAGCATCC
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2.1.6.3 Real time PCR
Probes were obtained from Sigma-genosys, Cambridge, UK. Primers were synthesised by 
MWG-biotech, Germany
Name Sequence 5’ -  3 ’
28S Forward CGC CGC TAG AGG TGA AAT TCT
Reverse CAT TCT TGG CAA ATG CTT TCG
Probe ACC GGC GCA AGA CGC ACC AG
M xl Forward GGA ATT ACC AGG GTG GCT GTA G
Reverse TGG ATG TAT GTC TTG ATA AGT CTC TTG A
Probe ACC AGC CTG CAG ACA TAG GAC GCC
9130002C22Rik Forward CAC CAA AAC CCA TGT TCT TCA A
Reverse AAG AGG AAT ACA CAA TCA ATA CTC CTG TT
Probe AAC AGA ATC AAG CCA TCA CAC AAC AGG AAA TT
AI448571 Forward GCT AGA ACT TAG CAA AGA GAG GAC AAC
Reverse GGC ATG AAT ACT TAT CTG TTA GAA AGA GAA
Probe CCC GCC CCC ACC CCA AAT T
M xl Intron Forward GCA GAG TGA AGA ATC AAC TCT GTT GT
Reverse CAG TGA TGC CCC CTC TAT CAG
Probe ACC TCT CCA TGG CCA CCA CCC A
Slfn5 Forward AAC ACG ACG TGA CTA CCC AGA CT
Reverse CGC TGA GGA GCC CAG TTT AC
Probe TCC AAC CCC TCC CTG ACC TGC A
Slfn4 Forward GAG CAG AAC ATG GCT AAG GAT AAT G
Reverse GCC CAT CAC GAC AGT TCT GA
Probe CTG TGA ACA CCC AAC TCA TAG CCC CC
Gpr33 Forward CAT CAA ACA CTA GGG CAA TGG A
Reverse CAG AAG GAA ACC CAG CAA GAA
Probe TCA TGC AGC CTG TTT CGT CGG C
M s4a4c Forward CAG GAT CCC TGT CAA TTG CA
Reverse CAC AGA GGT GAT AGT GTT CAG AGT TAG A
Probe AGT GAA ACC TAC AAA AAG CCT GAT CAT CAG CA
Ms4a6B Forward CCC CAC TAC AAT GGC CTG AA
Reverse GCC AAA GCC CAG ACC TAC AA
Probe CAT TCT GTT TGG TTT TCT AAG AAA GGC CAC CA
IMAGE 4168084 Forward TTA AGG GTG TCT CCT CCA ACC TT
Reverse GTG ACT TTT GCC TTC TTG GAT CTC
Probe TCT TTG TGG AGC ACA ACT TTC CTG AGC A
Ppicap Forward CGT CAT CAT GAG AGT GGA TGC T
Reverse CGA TTC TTC GGG AGT AAA AGT ACC T
Probe TGC ATG CCT GTC GTC AGA GAC TTC CT
CCR7 Forward CCCAAAACGACAGCCAAAA
Reverse GGCCCCACATCCCTCACT
Probe AAAGTGAGAGGCTGCCACACTTTCCG
2.1.7 Antibodies and FACS reagents
2.1.7.7 Antibodies for FACS staining and sorting
Antibody Flourochrome Supplier
FACS sorting
C D llc FITC BD Pharmingen
C D llb PE BD Pharmingen
CD4 Cy5 Made in house
CD4 PE BD Pharmingen
CD8 Cy5 Made in house
CD19 PE BD Pharmingen
F4/80 FITC Serotec
NK1.1 PE BD Pharmingen
M ACS sort
CD4 FITC BD Pharmingen
C D llc FITC BD Pharmingen
FACS analysis
CD3 PE BD Pharmingen
CD4 PE BD Pharmingen
CD8 Cy5 Made in house
C D llb PE BD Pharmingen
C D llc FITC/PE/APC BD Pharmingen
CD14 PE BD Pharmingen
CD 16/32 (Fc) Purified BD Pharmingen
CD19 PE BD Pharmingen
CD40 Biotinylated BD Pharmingen
CD45R (B220) PE BD Pharmingen
CD80 Biotinylated BD Pharmingen
CD86 Biotinylated BD Pharmingen
CD86 Purified BD Pharmingen
DX5 PE BD Pharmingen
F4/80 PE Serotec
GR-1 FITC BD Pharmingen
H-2Db Biotinylated BD Pharmingen
I-Ab Biotinylated BD Pharmingen
NK1.1 PE BD Pharmingen
Propidium Iodide Sigma
Rat IgG (rabbit) FITC vector
Rat Ig PE BD Pharmingen
Rabbit IgG FITC Jackson Immunoresearch
Mouse IgG Biotin BD Pharmingen
Streptavidin APC BD Pharmingen
FLAG M2 None Sigma
Isotype controls
Rabbit Ig Gift from Rob Carter
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2.1.7.2 Antibodies for Dynabead Depletions
Antibody specificity Clone name/supplier
CD2 BD Pharmingen
CD3 KT3
CD4 GK1.5
CD45R (B220) RA36B2
CD90 T24.1
Gr-1 RB68C5
MAC-1 M l/70
MHC II TIB 120
2.1.8 Immunisations for monoclonal antibody production
Titermax Gold adjuvant, Sigma
Peptides were synthesised by Alta Bioscience, University of Birmingham
Peptide Sequence
A l CQNNYIV STDWESKEB
A2 V STD WESKEHQTLGQB
A3 ESKEHQTLGQWIHAAB
2.1.9 ELISAs
Reagent Supplier
IL-ip Immunoassay kit Biosource
IL-6 Immunoassay kit Biosource
CCL2 Immunoassay kit Biosource
CCL4 Quantikine ELISA kit R&D
CCL5 Immunoassay kit Biosource
CCL 12 Quantikine ELISA kit R&D
CXCL9 Quantikine ELISA kit R&D
CXCL10 Detection antibody R&D
CXCL10 Capture antibody R&D
CXCL10 Protein R&D
Anti Rat IgG - peroxidase Jackson Immunoresearch
Anti Rat IgG -  alkaline phosphatase Jackson Immunoresearch
p-Nitrophenyl phosphate (pNPP) SIGMA FAST tablets Sigma
o-Phenylenediamine dihydrochloride (OPD) SIGMA FAST tablets Sigma
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2.1.10 Calcium Flux Assay
Ionomycin (Sigma), Indo-1 AM (Molecular Probes, Netherlands)
Peptide Sequence Supplier
A5 SLLWLTCRPWEAM
Annexin 1 (Acl-25) Ac-AMVSEFLKQAWFIEN EEQEYVQTVK
HIV-derived F EGSDTITLPCRIKQFINMWQE
HIV-derived T20 Ac-YTSLIHSLIEESQNQQEKN
EQELLELDKWASLWNWF-NH2
HIV-derived V3 RIHIGPGRAFYTTKN
Humanin MAPRGFSCLLLLTSEIDLPVKRRA Open Biosystems
I4G10-C FLPIIASLLGKLL-NH2
I4S10-C FLPIIASLLSKLL-NH2
MMK-1 LESIFRSLLFRVM
Rana-6 FISAIASMLGKFL-NH2
TIP FLPIVGKLLSGLL-NH2
TA FLPLIGRVLSGIL-NH2
W WKYMVm
Amyloid P protein DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIG
LMVGGVVIA
Bachem AG
Prion protein (106- 
126)
KTNMKHMAGAAAAGAVVGGLG Bachem AG
Chemerin (human) NCBI: Y14838 R&D systems
Chemerin (mouse) NCBI: NP 082128 R&D systems
fMLF Formyl-MLF Sigma
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2.2 Methods
2.2.1 Animals and immunisations
22.7.7 Mice
C57/B16 mice were obtained from the specific pathogen-free unit at the Institute for Animal 
Health (Compton, UK) or from Harlan UK Ltd (Blackthorn, UK). 200pl of phosphate 
buffered saline (PBS) or PBS containing 105 units IFN-a4 was injected intravenously. Mice 
were kept under humane conditions at all times and the number of mice used was kept to the 
minimum necessary for each experiment. Mice were sacrificed by asphyxiation by rising 
concentrations of carbon dioxide.
2.2.7.2 Rats
Female Lewis rats obtained from Charles River-UK were immunized intraperitoneally or 
subcutaneously and sacrificed by asphyxiation by rising concentrations of carbon dioxide.
2.2.2 Isolation and purification of murine cell types
2.2.2.1 Splenic Dendritic Cell Isolation
2.2.2.1.1 Digestion and release o f DCs
C57/B16 spleens were injected with 1ml 1 mg/ml collagenase, 0.5mg/ml DNase in RPMI- 
2.5% FCS and incubated at 37°C for 25 minutes. The digested spleens were then pushed 
through a 70p cell strainer and washed with RPMI-2.5% FCS-2mM EDTA.
2.2.2.1.2 Selection o f low density cells
Cells resuspended in 3ml ofNycoprep were layered onto 3ml of Nycoprep. 1ml of FCS was 
then layered on top and the samples centrifuged at 2800rpm for 25 minutes at room
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temperature. The low density fraction was collected and the cells washed with RPMI-2.5% 
FCS-2mM EDTA.
2.2.2.1.3 C D llc+ DC Isolation
The cells were stained with CD1 lc-FITC, washed with RPMI-2.5% FCS -2mM EDTA and 
incubated with anti-FITC MACS beads, washed again and resuspended in 500ul medium/100 
million cells. C D llc+ cells were then selected by running through a MACS column and 
further purified either through a second MACS column or by FACS sorting. Cells purities 
were routinely >99% CD1 lc+.
2.2.2.2 Isolation o f dendritic cell subsets
Dendritic cells subsets were isolated by one of two methods:
2.2.2.2.1 Depletion/MACS sorting
Spleens were digested with collagenase/DNase and the low density cells enriched as 
described for the C D llc+ DC isolation. The cells were incubated with a cocktail of rat 
antibodies specific for cell types to be depleted. This included antibodies specific for T cells 
(CD90, CD3), NK cells (CD2), B cells (CD45R), granulocytes (GR-1) and macrophages 
(F4/80). For isolation of the CD4'CD8+ and CD4+CD8' subsets, anti-CD4 and anti CD8- 
antibodies were added respectively. The cells were then incubated with sheep anti-rat 
magnetic beads (Dynal) for 30 minutes at 4°C with rotation. Unwanted cells were then 
removed by two rounds of contact with a magnetic particle concentrator (Dynal). The cells 
then went through two rounds of positive selection by MACS, using either CD4 or CD8 
MACS beads, following the manufacturers instructions (Miltenyi Biotech). To purify the 
CD4CD8' DC subset, cells which eluted in the negative fractions were positively selected for 
C D llc expression by MACS sorting. Cell purities were as follows CD1 lc+CD8+CD4', 
88%, CD1 lc+CD8'CD4+, >82%, CD1 lc+CD8CD4+, >87%
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2.2.2.2.2 MoFlo sorting
RDA: MACS sorted CD1 lc+ DCs were stained with CD1 lb-PE and sorted on expression of 
CD 11 b and CD 11c. Isolated cells were >99% CD 11 c+ and >92% CD 11 b+/'.
Taqman analysis: C D llc+ DCs were stained with CD4-PE and CD8-Cy5 and sorted by 
FACS on a MoFlo cytometer. The cells were sorted on C D llc expression as well as on 
CD4 and CD8 expression. Cell purities were as follows CD1 lc+CD8+CD4’, >90%, 
CD1 lc+CD8CD4+, >93%, CD1 lc+CD8CD4\ >96%.
2.2.2.3 Isolation o f plasmacytoid DCs
Spleens were digested with collagenase/DNase I and the low density cells isolated. The 
plasmacytoid DCs were then isolated using a MACS plasmacytoid DC isolation kit (Miltenyi 
Biotech). This involves a depletion step, where T, B, NK cells and macrophages were 
labeled and removed by separation on a MACS depletion column. The CD45R positive 
cells in the remaining population were then labeled and purified by separation on an MS 
column. To achieve high purity (>90%) the separation on an MS column was repeated.
2.2.2.4 Generation o f Bone Marrow-Derived DCs
Bone marrow-derived DCs (BMDCs) were isolated using method based on that of Lutz et. al. 
(Lutz et a l, 1999), and adapted by Brandt et al (Brandt et al., 2003).
2.2.2.4.1 Bone marrow preparation
The femurs and tibiae of C57BL/6 mice were removed and as much flesh as possible cleaned 
using a scalpel. The ends of the bone were then cut and the marrow flushed out with BMDC 
media (RPMI containing 10% low-endotoxin FCS, 100 units/ml penicillin, 100pg/ml 
streptomycin and 0.5mM p-mercaptoethanol) using a 25 gauge needle. The cells were 
pipetted to obtain a homogenous cell suspension, then filtered through a 70p strainer and
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washed. The red blood cells were lysed for 2 minutes on ice with red blood cell lysis buffer 
(Sigma) and remaining cells filtered through a 40p strainer.
2.2.2.4.2 Bone Marrow Cell Culture
Cells were plated into petri dishes (Falcon 1029) at 2 x 106 cells/dish in 10ml BMDC media 
containing 20ng/ml recombinant mouse granulocyte macrophage colony stimulating factor 
(rm-GM-CSF)(R&D systems). At day three, 10ml BMDC media plus 20ng rm-GM-CSF 
was added to the dishes. At day six, 10ml of medium was removed from the dishes, 
centrifuged, and resuspended in 10ml BMDC media plus lOng/ml rm-GM-CSF before 
returning to the dish. At day 8 the non-adherent cells were removed. 2ml of accutase (PAA 
labs) was added to the adherent cells and incubated for 15 minutes at 37°C. Cells were 
collected by thorough pipetting.
2.2.2.4.3 Bone marrow DC purification
Adherant bone marrow culture cells were depleted of granulocytes, T and B cells. They 
were first incubated with rat anti-Gr-1, -B220 and -CD3, washed and incubated with sheep 
anti-rat magnetic beads (Dynal). Unwanted cells were then removed by two rounds of 
contact with a magnetic particle concentrator (Dynal). After depletion cells were >95% 
CD1 lc+.
2.2.2.5 Isolation o fT  cells and B cells
Cell suspensions were made in RPMI containing 2.5% FBS by disrupting lymph nodes and 
spleens from C57BL/6 mice using glass slides. The cell suspensions were incubated with 
antibodies specific for cell types to be depleted (Table 2.1), followed by incubation with 
sheep anti-rat magnetic beads (Dynal) at 4°C with rotation. Unwanted cells were then 
removed by two rounds of contact with a magnetic particle concentrator (Dynal). The cells
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were then either stained with the appropriate antibodies or MACS microbeads and sorted by 
FACS on a MoFlo cytometer or by MACS sorting respectively. Cell purities of cells 
isolated from the spleen were as follows: CD4+ T cells, >90%, CD8+ T cells >97% ,B cells, 
>98%, and from the lymph nodes: CD4+ T cells, >92%, CD8+ T cells >99%, B cells, >99%.
Table 2.1 Staining of cells for negative depletion and sorting
Negative Depletion Sorting
Cell Type Specificity Ab Clone Staining for MoFlo sort
Staining for 
MACS sort
MHC II TIB 120
CD8 T cells B220 RA36B2 CD8-Cy5 CD8a
MAC-1 Ml/70 microbeads
CD4 GK1.5
MHC II TIB 120
CD4-FITC,
FITC
microbeads
CD4 Tcells B220 RA36B2 CD4-Cy5
MAC-1
CD8
Ml/70
B cells
MAC-1
CD4
CD8
Ml/70
GK1.5 CD19-PE CD19microbeads
2.2.2.6 Isolation o f macrophages
Peritoneal lavages from C57BL/6 mice resuspended in RPMI/2.5% FCS were plated in petri 
dishes (Falcon 1029) for 3 hours at 37°C. After this time, cells still in suspension were 
discarded and adherant cells harvested using a cell scraper. The cells were then stained with 
F4/80-FITC and sorted on a MoFlo cytometer. Cell purities were greater than 99%.
2.2.2.7 Isolation o f natural killer cells
Spleens were digested by DNase/collagenase (as in 2.2.2.1.1) followed by incubation in red 
blood cell lysis buffer (Sigma) for two minutes at room temperature. The cells were then 
incubated with DX5 MACS beads and positively selected on a MACS LS column according
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to the manufacturers instructions (Miltenyi Biotech). The cells were then stained with 
NK1.1 PE and sorted on a MoFlo cytometer. Cell purities were greater than 96%.
2.2.3 Treatment of ex vivo isolated cells with type-I IFN
2.2.3.1 Splenic DCs
3-5 x 106 cells/ml of purified DCs were cultured in 12ml Sterilin tubes in RPMI-10% low 
endotoxin FBS, either alone or with 20,000 U/ml IFN-a/p or IFN-a4 at 37°C in tissue for 2- 
24 hours.
2.2.3.2 BM DCs
4 x 106 cells/ml of purified DCs were cultured in 12ml Sterilin tubes in RPMI-10% low 
endotoxin FBS, either alone or with 20,000 U/ml IFN-a4 at 37°C in tissue culture tubes for 
2-24 hours.
2.2.3.3 T, B cells
5- 10 x 106 cells/ml were cultured in RPMI-10% FCS alone or with 20,000 U IFN-a4/ml in 
tissue culture tubes (Sterilin), for two hours at 37°C.
2.2.4 FACS staining
2.2.4.1 Cell surface staining
FACS staining was carried out in 96-well U-bottomed plates. 2 x 105 cells were washed in 
FACS buffer (PBS, 2.5% FCS) and vortexed gently to resuspend the cell pellet. Fc 
receptors were blocked for 10 minutes on ice, then the cells were washed with FACS buffer. 
15pl of diluted antibodies were added before incubating on ice in the dark for 15 minutes.
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Cells were again washed before addition of any secondary antibodies which were incubated 
on ice for 15 minutes. Cells were washed and resuspended in PBS before FACS acquisition. 
1 x 104 cells were acquired and analysed using CellQuest Pro software (BD Pharmingen).
2.2.4.2 Propidium Iodide staining
Propidium iodide was added to the cells at a final concentration of 2.5pg/ml immediately 
before FACS acquisition.
2.2.4.3 Intracellular staining
After blocking the Fc receptors cells were washed with PBS and fixed in 2% 
paraformaldehyde diluted in PBS for 20 minutes on ice. The cells were washed with FACS 
buffer and made permeable in FACS buffer containing 0.1% saponin for 10 minutes at room 
temperature. The cells were pelleted and resuspended in antibody diluted in FACS buffer 
containing 0.1% saponin and incubated for a further 10 minutes at room temperature. The 
cells were washed in FACS buffer before FACS aquisition.
2.2.4.4 Rat Gpr33 antibody FACS staining
Gpr33 transfected cell lines or DCs (pre-blocked with mouse sera) were incubated with 
supernatants from the poly- or monoclonal hybridomas. The anti-Gpr33 antibodies were 
then detected using anti-rat IgG antibodies.
2.2.4.5 Rabbit Gpr33 antibody FACS staining
After blocking the Fc receptors Gpr33 transfected cell lines or DCs were incubated with the 
purified antibodies raised against the Gpr33 N-terminus (Pacific Immunology). The anti- 
Gpr33 antibodies were then detected using anti-rabbit IgG-FITC.
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2.2.5 Molecular biology techniques
2.2.5.1RNA isolation
Total RNA was isolated from up to 107 cells using Trizol reagent (Invitrogen) following the 
manufacturers instructions. During the precipitation step, 1 pi of 10 mg/ml glycogen was 
added as a co-precipitant. The dried pellets were resuspended in RNase-free water. In 
some cases, RNA was further purified using the RNeasy mini kit (QIAgen), residual DNA 
was digested on column using the RNase-free DNase kit (QIAgen). The integrity of total 
RNA was determined by agarose gel electrophoresis and was quantified using the Ribogreen 
RNA quantification kit (Molecular probes).
2.2.5.2 Representational Difference Analysis (RDA)
RDA was carried out as previously described (Hubank et al., 1999) with minor 
modifications.
2.2.5.2.1 Isolation o f mRNA and preparation o f double stranded cDNA
Residual genomic DNA was removed by digestion of total RNA with DNase I before 
isolation of polyA+ RNA using the Oligotex mRNA isolation kit (QIAgen). The mRNA 
was reverse transcribed using Superscript II and oligo dT primers, followed by second strand 
synthesis by E. coli DNA polymerase.
2.2.5.2.2 Generation o f Representations
Double stranded cDNA was digested with DpnW and ligated to R-adaptors using T4 DNA 
ligase overnight at 14 °C. Pilot reactions were performed with the R-24 primer under the 
following cycle conditions: 72°C for 3 min, Taq DNA polymerase added, 72°C for 5 min, 
then 26 cycles: 95°C for 1 min and 72°C for 3 min with final extension at 72°C for 10 min.
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After 20, 22, 24 and 26 cycles the reactions were paused and 10 pi aliquots of the product 
were removed for analysis on a 1.5 % agarose gel. A cycle number that produced a smear 
ranging in size from 0.2 -  1.5 kb, and containing approximately 0.5 pg of DNA in the 10 pi 
aliquot was selected for subsequent reactions. For each sample sixteen 100 pi reactions 
were set up, and the PCR run using the appropriate number of cycles. The reactions were 
extracted with twice with phenol/chloroform/isoamyl alcohol (P/C/I) and once with 
chloroform/isoamyl alcohol (C/I). Samples were then precipitated on ice for 20 minutes 
with one tenth volume 3M sodium acetate (pH 5.3) and one volume of isopropanol. DNA 
was pelleted, washed with 70% ethanol and resuspended in TE buffer (lOmM Tris, ImM 
EDTA, pH 8) at a concentration of 0.5mg/ml.
2.2.5.2.3 Generation o f Tester and Driver
90 pg (180 pi) of each representation was digested with DpnW, extracted with P/C/I and C/I, 
precipitated and resuspended in TE at 0.5 mg/ml, to form the driver. The R-adaptors were 
removed from the final digested product using QIAquick spin columns (QIAgen). 1 pg of 
spin column-purified DNA was ligated to J-adaptors overnight using a ligation temperature 
of 12°C. The ligation was then diluted to 10 ng/pl to generate the J-ligated tester.
2.2.5.2.4 Subtractive hybridisation
20 pi (10 pg) of digested driver representation was mixed with 10 pi of diluted, J-ligated 
tester representation (0.1 pg), a driver:tester ratio of 100:1. The samples were P/C/I and C/I 
extracted, and precipitated with 10 M ammonium acetate and 100% ethanol at -70 °C for 10 
min. The pellets were washed twice with 70% ethanol and resuspended very thoroughly in 4 
pi of EE x 3 buffer and the solution overlaid with 35 pi of mineral oil. The DNA was then 
denatured for 5 min at 98°C, cooled to 67°C, and immediately 1 pi of 5 M sodium chloride
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was added directly into the DNA. The samples were hybridised at 67°C for 20 hours, after 
which they were diluted to lOOpl with TE.
2.2.5.2.5 Generation o f  the first difference product (DPI)
The subtractions were then amplified by PCR using the following cycle: 72 °C for 3 min, 
Taq DNA polymerase added, 72 °C for 5 min, J-24 primer added, then 11 cycles: 95 °C for 1 
min and 70 °C for 3 min, final extension at 72 °C for 10 min. After extraction and 
precipitation, the PCR products were resuspended in 20pl of TE and digested with Mung 
Bean Nuclease (MBN) (NEB) to eliminate single stranded DNA.
Amplification to DPI: PCR reactions were set up, using the MBN treated DNA as a 
template, this time the J-24 primer was added to the master mix. PCR cycle; 95°C for 1 
min, cool to 80 °C before addition of Taq DNA polymerase, followed by 18 cycles of 95°C 
for 1 min and 70°C for 3 min with final extension at 72°C for 10 min. 10 pi of the samples 
were run on a 1.5% agarose gel next to standards to confirm the presence of products and to 
estimate the concentration. The samples were extracted with P/C/I and C/I, precipitated and 
resuspended at 0.5 fxg/jnl to form the first difference product (DPI).
2.2.5.2.6 Generation o f  the second difference product (DP 2)
To remove the J-adaptors, 2 pg of the difference product was digested with Dpnll. 200ng of 
the digested difference product was then ligated to N-adaptors using T4 DNA ligase at 14°C. 
This ligation was then diluted to 1.25 ng/pl. 10 pi (12.5 ng) of N-ligated DPI was mixed 
with 20 pi (10 pg) of driver (a driver:tester ratio of 800:1), and the subtraction hybridisation 
procedure carried out as before. Amplification to a second difference product was carried 
out as for the first difference product, except using N-primers in place of J-primers and using
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an annealing temperature of 72°C. After extraction and precipitation the pellets were 
resuspended at 0.5 ptg/ptl in TE to form the DP2.
2.2.5.2.7 Generation o f the third difference product (DP3)
The DP2 was digested, ligated to J adaptors and diluted to 1 ng/pl. Hybridisations were set 
up using driver to tester ratios between 5,000:1 and 40,000:1. The DP3 was generated as 
before, performing the final amplification for 23 cycles.
2.2.5.3 Cloning
2.2.5.3.1 Cloning o f  RDA products
Dpnll digested RDA products were ligated into the pBluescript II KS vector digested with 
BamUl, and used to transform XL 1-Blue MRF’ supercompetent cells.
2.2.5.3.2 Cloning o f Gpr33
Primers were designed against Gpr33 cDNA (NCBI Accession NM 008159). The forward 
primer was engineered to contain a HindiII site (5’ AGA CAA AGC TTT GAG GTA ATT 
ATG GAT TTG ATC AAC TCC 3’) the reverse primer contains an EcoR\ site (5’ GGA 
ACT GAA TTC CAA TTG AAG AAC AGC AAG GAT TTC TTA 3’). Gpr33 was 
amplified from IFN-a/p treated DCs cDNA using Pfu Turbo DNA polymerase (Stratagene), 
digested with Hindlll and EcoR\ and ligated into the pcDNA6/V5-His/ABC vector 
(Invitrogen). The ligated plasmid DNA was used to transform One shot TOP 10 competent 
cells (Invitrogen). Plasmid DNA containing the correct Gpr33 sequence was used to 
transfect various mammalian cell lines including BHK-21. Stable transfectants were 
generated by selection in lOug/ml blasticidin (Invitrogen).
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2.2.53.3 Cloning o f FLAG-Gpr33/CCR7 constructs
The forward primers were engineered to contain a HindlU site (Gpr33) or an EcoRl site 
(CCR7), additional bases were added to allow translation in frame with the N-terminal FLAG 
tag when cloned into the pFLAG-CMV-4 vector (Sigma). Between the Hindill site and the 
start codon of Gpr33 we modified a stop codon to encode glycine, and changed a 
hydrophobic isoleucine to asparagine. The CCR7 reverse primer was engineered to contain 
a BamHl site, whilst a BamHI site exists in Gpr33 shortly after the stop codon. Primers 
sequences were as follows: Gpr33 forward 5’-TTA CTT AAG CTT GGA GGT A AT ATG 
GAT TTG ATC AAC TCC-3’, Gpr33 reverse 5’- GGA ACT GAA TTC CAA TTG AAG 
AAC AGC AAG GAT TTC TTA-3’, CCR7 forward 5’-CTG TGT GAA TTC TTA CAG 
CCC CCA G-3’, CCR7 reverse 5’-CAC ATT AAG GAT CCT GGG AGA GGT C-3’. 
Gpr33 was amplified from previously cloned cDNA in the pcDNA6 vector, CCR7 was 
amplified from CD8+ T cell cDNA. The products were digested and ligated into pFLAG- 
CMV-4 and used to transform competent bacteria. Plasmid DNA containing Gpr33 or 
CCR7 cDNA of the correct sequence was used to transfect Baf/3 cells.
2.2.5.3.4 Vector and Insert Preparation
The vector and PCR product to be cloned were digested with the appropriate restriction 
enzyme(s). If necessary, the vector was treated with calf alkaline phosphatase to prevent the 
ends re-ligating and extracted once with P/C/I. The vector was purified by running on a 1% 
agarose gel and DNA recovered by gel extraction. The digested vector and PCR product 
were then precipitated with 2.5 volumes ethanol and 0.1 volume 3M sodium acetate (pH 5.3).
2.2.5.3.5 Ligation and transformation
Ligations were carried out using T4 DNA ligase (Promega), incubating at room temperature 
for at least 2 hours. 10 -  lOOng of DNA was used to transform XL 1-Blue MRF’ or TOP 10
105
cells following the manufacturer’s protocol (Stratagene/ Invitrogen). The cells were plated 
onto Luria broth (LB)- agar plates containing lOOpg/ml ampicillin (for blue-white colour 
screening a solution containing 2% X-gal and 40mM IPTG was first spread onto the plates), 
and incubated overnight at 37°C. Colonies were screened for the correct inserts by PCR 
using M l3 primers or by restriction digest.
2.2.5.3.6 Preparation o f plasmid DNA
Luria broth containing lOOpg/ml ampicillin was inoculated with a single colony and 
incubated overnight at 37°C , 225 rpm. Plasmid DNA was isolated using QIAgen plasmid 
mini, midi or maxi kits following the manufacturers instructions.
2.2.5.4 Transfection o f mammalian cell lines
2.2.5.4.1 Transfection o f the cell line BHK-21
Cells were cultured in Glasgow MEM media containing 7% FBS, 100 units/ml penicillin, 
lOOpg/ml streptomycin and 10% tryptose phosphate broth. Cells were seeded the day before 
transfection and were 40-80% confluent at the time of transfection. 1 pg of the pcDNA6 
plasmid (Invitrogen) containing the Gpr33 gene or a control plasmid containing the green 
flourescent protein gene were transfected into BHK-21 cells using Effectene (QIAgen) 
according to the manufacturers instructions. BHK-21 cells containing the pcDNA6 plasmid 
were selected by culturing in medium containing lOpg/ml blasticidin.
2.2.5.4.2 Transfection o f the cell line BAF/3
The IL-3 dependent cell line Baf/3 was grown in RPMI1640 containing 10% FBS, 10% 
WEHI-3B (an IL-3 producing cell line) conditioned media. 20pg DNA was used to transfect 
5 x 106 cells by electroparation at 260V, 950pF on a Gene Pulser II (Biorad). 24 hours later 
selection in 1 mg/ml G418 was started to generate stable transfectants.
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2.2.5.5 RT-PCR
Single-stranded cDNA was synthesised using the reverse-iT first strand synthesis kit 
following manufacturer’s instructions (Abgene). To determine expression of Gpr33 in 
various cell lines, PCR was carried out using the following primers: Gpr33 forward 5’-GTT 
TCC TTC TGC CTT TCC-3’, reverse 5’-TCA CTG AGC CAT CTC TCC-3’ and p-actin 
forward, 5’-GCC AAC CGT GAA AAG ATG ACC-3’, reverse 5’-CGT ACT CCT GCT 
TGC TGA TCC-3’.
2.2.5.6 Sequencing
Reactions were carried out using the Big Dye Terminator kit (PE applied biosystems) and T3 
primers, cycling: 90°C for 10 minutes, 25 cycles of 50°C for 5 seconds and 60°C for 4 
minutes. Samples were loaded onto Long Ranger Singel gels (Flowgen) and run on an 
ABI377 automatic sequencer. Alternatively, samples were air-dried and shipped to MWG 
for sequencing.
2.2.5.7 Southern blotting
2.2.5.7.1 Transfer o f DNA to nylon membranes
DNA was separated by agarose gel electrophoresis. The DNA was denatured by soaking the 
gel in 1.5M sodium chloride, 0.5N sodium hydroxide for 45 minutes and then neutralised in 
1M Tris (pH 7.4), 1.5M sodium chloride for 45 minutes. The DNA was transferred onto 
Hybond N nylon membranes (Amersham) by capilliary action in lOx sodium chloride- 
sodium citrate buffer (SSC). After transfer the membrane was rinsed in 6x SSC, dried and 
the DNA fixed by UV irradiation in a UV Stratalinker 2400 (Stratagene).
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2.2.5.7.2 Generation o f DIG labeled probes
PCR was carried out on pBluescript plasmids containing the cloned sequences of interest 
using T3 and T7 primers and the PCR DIG probe synthesis kit (Roche) according to the 
manufacturers instructions.
2.2.5.7.3 Hybridisation and detection o f bound probes
Nylon membranes were pre-hybridised in Rapid-Hyb buffer (Amersham) at 60°C for 30 
minutes, then hybridised for 2.5 hours at 60°C with probes diluted 1:1000 in Rapid-Hyb 
buffer. Membranes were washed twice in 2x SSC, 0.1% SDS at 60°C for five minutes 
followed by two washes in 0.1 x SSC, 0.1%SDS. Membranes were processed using the DIG 
wash and block buffer set (Roche): equilibrated in washing buffer for one minute and then 
blocked for one hour at room temperature. Membranes were incubated for 30 minutes with 
anti-DIG antibody diluted 1:20,000 in blocking solution then washed several times in 
washing buffer. Chemiluminescent detection was by CPD-Star diluted 1:50 in detection 
buffer (Roche). The membranes were exposed to chemiluminescent film for varying 
durations.
2.2.5.8 Western blotting
2.2.5.8.1 Protein lysates
1 x 107 cells were lysed in 1ml of a) RIPA buffer (PBS, 1% v/v NP40, 0.1% (w/v) SDS, 
0.5% (w/v) sodiumdeoxycholate containing 200 pg/ml PMSF (Sigma) and a 1:500 dilution 
of a protease inhibitor cocktail (Sigma) or b) lysis buffer B (50mM Tris pH 7.4, 150 mM 
sodium chloride, ImM EDTA 1% Triton X-100) containing a 1:500 dilution of a protease 
inhibitor cocktail. The samples were rotated at 4°C for at least two hours. Cell debris was 
removed by centrifugation and the supernatants stored at -20°C.
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2.2.5.8.2 Immunoprecipitations
FLAG-tagged proteins from tranfected cells lysed with lysis buffer B were immuno- 
precipitated using the anti-FLAG M2 affinity gel (Sigma) according to the manufacturers 
instructions. The Met-FLAG-BAP control protein was immunoprecipitated in parallel.
2.2.5.8.3 SDS-PAGE and Western Blotting
Samples were separated by denaturing gel electrophoresis and transferred onto a Hybond C 
membrane. The membranes were blocked in TBS-T/10% dried milk powder for 1 hour. 
The membranes were incubated with primary antibody for 2 hours, then secondary 
biotinylated antibody for 1 hour and strepavidin-HRP for one hour, all in TBS-T/1% marvel. 
The membranes were washed 3 times with TBS-T after each step and all steps were done at 
room temperature. The detection was done using an ECL detection kit (Amersham 
pharmacia) and exposure to X-ray film. Detection of FLAG fusion proteins was carried 
using the method detailed by the manufacturers (Sigma) using the anti-FLAG M2 antibody.
2.2.5.9 Real-Time (quantitative)PCR
Probes and primers were designed using Primer Express 1.0 software (PE Applied 
Biosystems). We applied additional rules not included in the software: primers containing 
more than two cytosines or guanines in the five nucleotides at their 3’ end were excluded. 
Probes with an initial 5’ guanine (which would act as a quencher) or containing more 
guanines than cytosines were excluded. The PCR was carried out as a one step reaction 
using the Reverse Transcriptase qPCR kit from Eurogentec. Probes were obtained from 
Sigma-Genosys labeled 5’ with the reporter fluorophore 6-carboxy-fluorescein (FAM) and 3’ 
with the reporter fluorophore 6-carboxy-N,N,N’,N’-tetramethylrhodamine (TAMRA). The 
probes were used at a final concentration of lOOnM, while primer concentrations were
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optimized and were between 0.8 and 1.2pM (Table 2.2). Cycling was carried out on an ABI 
prism 7700 Sequence Detector (PE Applied Biosystems) as follows: cDNA synthesis for 30 
minutes at 48°C, hot GoldStar activation for 10 minutes at 95°C followed by 40 cycles of 15 
seconds at 95°C and 1 minute at 60°C. Quantification of RNA was based on the cycle 
number (Ct) at which the change in level of fluorescence from the reporter dye passed a 
significance threshold. Standard curves were generated using 10-fold dilutions from 10'1 to 
10'5 of total RNA extracted from splenic DCs treated in vitro with type IIFN. To correct for 
differences in RNA between samples and for the efficiency of the reactions the following 
equation was used, where m is the slope of the standard curve and DF is the difference factor:
((40- Ct) x mqeneX)
(m28S x DF)
The DF was calculated by dividing the mean of the 28S Ct for the samples by the mean 28S 
Ct for all samples. Fold changes were calculated in one of two ways, for chapter 3 and 4 the 
following equation was used: (Ct sample -  Ct contr0|)*10
^genex
For chapter 5 fold changes were calculated as the difference in corrected Ct values to the log 
of base 2.
Table 2.2 Taqman primer concentrations and reaction efficiencies
Name Primer concentration (pM ) m (slope o f standard curve)
28S 0.6 3.57
M xl 0.2 3.87
9130002C22Rik 0.8 2.98
AI448571 0.8 4.80
M xl Intron 0.6 3.82
Slfn5 0.2 3.79
Slfn4 0.6 3.26
Gpr33 0.6 4.12
Ms4a4c 0.1 4.62
Ms4a6B 0.2 4.54
IMAGE 4168084 0.6 4.57
Ppicap 0.1 4.20
CCR7 0.6 3.81
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2.2.6 Microarray Analysis
2.2.6.1 Processing o f  samples
2.2.6.1.1 cDNA synthesis
Total RNA was isolated using Trizol reagent. The RNA was quantified and the quality 
checked on an agarose gel. RNA was then purified using a QIAgen RNeasy kit. cDNA 
was synthesized using a cDNA synthesis system (Roche) which includes the oligo [(dT)24 
T7prom] 65 primer (GGCC AGT GAATT GT AAT ACG ACTC ACT AT AGGGA GGCGG 
(T) 2 4  VN). First and second strand synthesis were carried out as described in the 
manufacturers’ protocol.
2.2.6.1.2 cRNA synthesis
Double stranded cDNA was purified using the GeneChip Sample Cleanup Module 
(Affymetrix) before the in vitro transcription reaction. Biotin-labeled cRNA was 
synthesized using the Enzo BioArray High Yield RNA transcript labeling kit. This kit uses 
T7 RNA polymerase which binds the T7 promoter site incorporated during cDNA synthesis. 
The cRNA was purified using the QIAgen GeneChip Sample Cleanup Module and the 
quality and quantity assessed on the Agilent 2100 Bioanalyser.
2.2.6.1.3 Hybridisation and detection o f cRNA transcripts
15 pg of fragmented cRNA was hybridised to the murine U74Av array or the mouse genome 
430 2.0 array (Affymetrix) for 16 hours at 45°C. After hybridisation the transcripts were 
detected by sequential staining with streptavidin phycoerythrin (SAPE), biotinylated, anti- 
streptavidin antibody and a second layer of SAPE using the GeneChip fluidics station 450.
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2.2.6.2 Data Analysis
2.2.6.2.1 Image acquisition
Arrays were scanned on the GeneChip scanner 2000. Scanned arrays were visualised and 
analysed using the Affymetrix Microarray Suite 5.0. The initial step of analysis was 
automatic grid alignment onto the array image for demarcation of probe cells. The software 
uses the hybridisation pattern of the B2 oligo (a positive hybridisation control spiked into the 
hybridisation cocktail) to align the grid. The intensity of signal from individual probe cells 
is then calculated and this information is used to generate an expression analysis file. Each 
transcript is represented on the arrays as a set of probe pairs which consist of a perfect match 
probe and a mismatch probe. Signal intensities from the probe pairs is used to determine the 
overall signal for a given probe set, in addition to a detection call which indicates whether the 
transcript is present or absent.
2.2.6.2.2 Quality control
During the analysis of the array image file, various parameters were checked to monitor the 
quality of the array and sample hybridisation. Initial inspection of the array image was 
carried out to check for irregularities and to verify correct grid alignment. Presence of the 
B2 oligo hybridisation control around the borders of the array was also checked. The 
average background of the arrays was between 40 and 70, and raw noise between 1 and 3, 
both falling within acceptable levels for the scanner type. There were similar levels of 
background and noise in arrays to be compared. The presence of hybridisation controls 
(Genechip Eukaryotic Hybridisation control kit) was used to evaluate the sample 
hybridisation efficiency. RNA sample quality was determined by the 3’ to 5’ ratio of the 
probe sets for actin and GAPDH internal control genes. A high 3’ to 5’ ratio indicates RNA 
degradation or inefficient cDNA or cRNA transcription resulting in truncated transcripts.
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For initial analysis of the arrays global scaling was carried out, which corrects for any 
differences in overall intensity of the arrays due to assay variables such as hybridisation 
efficiency. The scaling factors were also taken into consideration when deciding which 
arrays were suitable for comparison, since large scaling factors (>3 fold) may indicate 
significant assay variability or sample degradation leading to noisier data.
2.2.6.2.3 Gene spring analysis
Data obtained in the Microarray Suite 5.0 was imported into Genespring 7 software (Agilent) 
as metrics text files. The data was normalised as follows: measurements less than 0.01 were 
set to 0.01, per chip normalisation was to the 50th percentile, per gene normalisation was to 
specific samples. With the Genespring software data can be interpreted in a number of 
ways, and this determines how the data is analysed. In our case, we wished to compare 
replicates from one treatment compared to another, therefore the interpretation was set up to 
group the data in this way. The data was then filtered to include only genes which had a 
detection call of present or marginal in at least 2 out of 6 samples. If gene expression is not 
detected in either condition any changes in expression seen would not be real. Secondly we 
filtered out any genes which were not changing in expression by more than 1.5 fold. The 
filtered gene list was then subjected to a parametric statistical test with a p-value cut-off of 
0.05, where the variances were not assumed to be equal.
2.2.6.2.4 Gene clustering
Data normalised in Genespring was exported to Microsoft Excel. The expression data from 
experiments on splenic DCs came from the murine U74Av2 array whereas the data from 
BMDCs came from the murine genome 430 2.0 array. In order to link the data from these 
experiments we used the array comparison files available on the Affymetrix web site to 
identify cases where probe sets from the U74Av2 array could be directly compared to probe
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sets on the 430 2.0 array. The two sets of data were merged in Microsoft Access, which 
generated a file containing all the data from both experiments, including the cases where data 
from either experiment had no corresponding data from the other experiment. This file was 
then transferred back into Excel to make a number of modifications. Firstly, a unique 
identifier was generated by concatenating the U74Av2 array systematic name with the 430 
2.0 array systematic name. The data from each probe set is flagged as present, absent or 
marginal. In the cases where there was a mixture of these flags from the same probe set we 
converted the flag to absent. In Microsoft Access, we then filtered the data so that only 
those probe sets passing the following criteria in at least one of the cell types/timepoints 
tested would remain: the expression must change at least 1.5 fold between control and IFN- 
treated samples, have an associated p-value of less then or equal to 0.05 and be flagged as 
present for the transcripts with higher expression. In Excel, where the expression data was 
changing significantly, the fold change values were transformed into log base 2. Otherwise 
the data was given a value of zero. The data was also colour coded depending on the level 
of expression. The data was then clustered and visualised using the TIGR multi-experiment 
viewer (Saeed et al., 2003) from the Institute of Genomic Research.
2.2.7 ELISAs for detection of mouse cytokines
ELISAs were carried out on supernatants from cultured DCs using Biosource Immunoassay 
kits (IL-ip, IL-6, CCL2, CCL5) or Quantikine kits from R & D systems (CCL4, CCL12, 
CXCL9). These were carried out using the manufacturer’s protocols, absorbance read at 
450nm and subtracted from absorbance at 540nm to correct for optical imperfections in the 
plate. CXCL10 was measured using matched antibody pairs following the manufacturer’s 
instructions (R & D systems).
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2.2.8 Production and screening of monoclonal antibodies
2.2.8.1 Gpr3 3 peptides
2.2.8.1.1 Prediction o f the structure o f Gpr33
A model for the structure of Gpr33 was provided by Darren Flower (Edward Jenner Institute, 
Compton, UK). Briefly, the sequence of the uncharacterised chemokine-like G-protein 
coupled receptor (GPCR) was aligned to other representative GPCR sequences using 
CINEMA (Lord et al., 2002), which gave a one-to-one relationship between the chemokine- 
like GPCR and bovine rhodopsin. This was used to perform homology modelling of the 
chemokine-like GPCR using the structure of bovine rhodopsin, as determined (Palczewski et 
al., 2000), as the template. Homology modelling was undertaken using the modeller system 
(Fiser et al., 2003).
Since the purpose of this exercise was to establish the probable distribution of residues 
between intracellular, extracellular, and transmembrane regions, only initial modelling, 
without subsequent optimisation, was performed. In the absence of extra constraints 
provided by experiment, only those constraints implicit within the process, i.e. those arising 
from residue substitution, were used. Regions of the protein which are extracellular were 
established by visual inspection.
2.2.8.1.2 Peptide synthesis
Peptides were synthesised by Alta Bioscience (University of Birmingham) as octomeric 
multiple antigenic peptides. Eight identical peptide chains were synthesised, and joined to a 
common poly-lysine core peptide. The molecular weight of these peptides, (10kDa-15kDa) is 
sufficient for them to be highly immunogenic without the need to couple to a carrier protein. 
The peptides were purified by dialysis through a 3kDa membrane.
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2.2.8.1.3 Peptide dissolution
A volume of methanol or acetonitrile (50/1 OOpl) was added to lmg of peptide and left to 
stand for 5 -  10 minutes at room temperature. 5 pi of pH modifying reagent was then 
added: either ethanolamine (acidic peptides) or glacial acetic acid (basic peptides). After a 
further 5 -1 0  minute incubation at room temperature, a volume of water equal to that used in 
the initial step was added. The sample was then diluted to an appropriate volume with PBS.
2.2.8.2 Immunisation with Gpr33 peptides
0.5mg of each peptide (Al, A2 and A3) were dissolved into a total volume of 300pl in PBS. 
An emulsion was then made with an equal volume of Titermax Gold Adjuvant (Sigma) and 
used to immunize rats either intraperitoneally or subcutaneously. 19 days later, the rats were 
boosted with the same dose of peptide with Titermax Gold. A final boost consisting of a 
combination of 0.1 mg of each peptide in PBS was given four days prior to sacrifice.
2.18.3 ELISAs
Falcon 3912 plates were coated with lOpg/ml of peptide diluted in carbonate buffer (0.5M 
sodium carbonate, pH 9.6) overnight at room temperature or for two hours at 37°C. Plates 
were washed three times with PBS, 0.05% Tween and blocked with a 4% milk solution in 
PBS for one hour at room temperature (or 45 minutes at 37°C). Plates were washed three 
times before addition of test antibodies. Serial 1:2 dilutions of rat sera were made in PBS, 
1% milk, and added to the plates. Hybridoma supernatants were added to the plates neat. 
After one hour at room temperature a 1:500 dilution of anti-rat IgG -HRP or anti-rat IgG-AP 
in PBS, 1% milk was added, followed by a further one hour incubation. The ELISAs were 
developed using an OPD or pNPP solution (Sigma) and the reactions stopped with 3M 
hydrochloric acid or 3 N sodium hydroxide, with absorbance read at 492nm or 405nm 
respectively.
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2.2.8.4 Cell fusion
Fusion of rat spleen cells with myeloma cells was done as originally described by Galfre et 
al. (Galfre et al., 1979). Cell fusions were carried out by Brenda Jones at the Institute for 
Animal Health, Compton, UK. 1 x 108 spleen cells from the immunized rat were mixed with 
1 x 108 Y3 myeloma cells and centrifuged at 1200 rpm for five minutes. The cell pellet was 
resuspended in 1ml of polyethylene glycol (PEG) 1500 followed by slow addition of 10ml 
RPMI. The cells were centrifuged at 1200 rpm for five minutes and the cell pellet 
resuspended in 48ml RPMI 20% FCS. The cells were aliquoted at 1 ml/well into 48 well 
plates and 1ml of spleen feeder cells (5 x 105/ml) was added. On days one, three, five and 
seven, 1 ml of the cell cultures was removed and 1ml of hypoxanthine, aminopterin and 
thymidine (HAT) selection medium was added. After 10-14 days, clones were assayed for 
production of Gpr33 peptide specific antibodies by ELISA. Positive clones were subcloned 
by limiting dilution to produce monoclonal hybridomas.
2.2.9 Production of Rabbit Polyclonal Antibodies
Polyclonal antibodies were made by Pacific Immunology, California. The antibodies were 
raised against the N-terminal region of Gpr33 by immunising rabbits with a 15 amino acid 
sequence (NSSTHVINVSTSLTN) conjugated to a KLH carrier protein. Gpr33 peptide- 
specific antibodies were isolated from the serum of immunised rabbits by affinity 
purification.
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2.2.10 Calcium flux assay
Baf/3 cells were washed twice in modified HBSS (containing calcium chloride and 
magnesium chloride), 1% BSA, and resuspended at 106 cells/ml. Indo-1 AM was added to 
the cells to give a final concentration of 2.5pg/ml. The cells were then incubated at 30°C in 
the dark for 30 minutes followed by two washes with modified HBSS. Agonists were added 
to the cells to give a final concentration of lpg/ml and calcium mobilization measured on a 
MoFlo cytometer. Once calcium mobilization reached a plateau lOOpl of 25mM EDTA was 
added.
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Chapter 3: Identification of IFN-I-induced genes in splenic DCs by 
Representational Difference Analysis 
3.1 Introduction
Representational difference analysis (RDA) was first developed as a method for analysing 
the differences between complex genomic DNA populations and can be used to identify 
changes such as gene rearrangements, which could be the cause of cancers or inherited 
disease (Lisitsyn et al., 1993). Since we are interested in gene expression we used a 
modification of this technique, cDNA RDA, which identifies differences in levels of mRNA 
between cell populations (Hubank et al., 1994). RDA is a polymerase chain reaction (PCR)- 
based, subtractive hybridization technique used to find genes which are more highly 
expressed in one cell population, the tester population, compared to another, the driver 
(Figure 3.1). cDNA generated from the two cell populations is first digested using a 
restriction enzyme, producing fragments of a relatively homogenous length for efficient 
amplification which can be ligated to adaptor molecules which serve as primer binding sites. 
The enzyme used (DpnII) recognizes a 4bp sequence and yields fragments with an average 
length of 256bp which ensures that the majority of genes will contain at least one amplifiable 
fragment. These amplified cDNA products are then representative of the original mRNA 
population. It is essential to maintain the relative proportions of mRNA species throughout 
the procedure and this achieved by limiting the number of PCR cycles at each stage to keep 
amplification within the linear range. The representative amplicons (representations) are 
then digested again to remove the adaptors before re-ligating new adaptors to the tester 
representation only. The driver and tester populations are hybridized at a ratio of 100:1 to 
compete out sequences that are present in both the driver and tester populations. Any tester
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Figure 3.1 cDNA Representational Difference Analysis
(a) mRNA is isolated from  two cell populations and reverse transcribed into cDNA. The cD N A  is 
digested and ligated to oligonucleotide adaptors which serve as prim ers for PCR am plification to 
generate representations, (b) The adaptors are then rem oved and replaced by new  adaptors on the 
tester cDNA only. A t this stage the cDNA from  the tester and driver populations are hybridised 
together with an excess o f  driver (100:1). Subsequent PCR will result in  the am plification o f  only 
those fragments which rehybridise as tester:tester, and so will represent genes w hich are expressed at 
elevated levels in  the tester population com pared to the driver. This process is then repeated, 
hybridising the difference product to the driver at increasingly higher ratios to produce 2nd and i f  
necessary 3rd difference products. These will contain only differentially expressed genes which can 
then be cloned and sequenced.
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fragments which hybridize to the driver will not be amplified exponentially in subsequent 
PCR reactions as they do not have adaptors at each 5’ end. The ratios of driver to tester are 
delicately balanced as proportions of mRNA species are critical if relative rather than 
absolute differences in gene expression are to be detected. Amplification of the hybridized 
fragments yields the first difference product, which is enriched in differentially expressed 
cDNA fragments but must be subjected to further, more stringent hybridizations before the 
products can be isolated as bands on an agarose gel, cloned and sequenced.
In addition to RDA, several other techniques have been developed for isolating differentially 
expressed genes, for example differential display (DD) has been used very successfully 
(Liang et al., 1992). However this technique has several drawbacks compared to RDA; 
there is a 3’ bias in isolation of gene fragments, it requires the use of radioactive isotopes, 
there is a higher degree of mispriming events during PCR and since there is no subtractive 
step it yields a higher proportion of false positives (Frazer et al., 1997). When isolating cells 
directly from their in vivo environment (as we have done) it is impossible to obtain an 
absolutely pure cell population, and this would not be amenable to analysis by differential 
display.
An important advantage of RDA over other methods is that it is extremely sensitive: genes 
expressed in less than 1% of the tester population can be identified. Secondly, only small 
quantities of starting material are needed. It is possible to carry out RDA on just 104 to 105 
cells and so the technique is suitable for study on FACS sorted lymphocytes. Finally, RDA 
is relatively cheap and uses conventional molecular biology techniques. For these reasons it 
was initially our preferred method for identifying differentially expressed genes.
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cDNA RDA has previously been used to identify gene expression changes induced by 
cytokines in T cell helper clones (Louahed et al., 1999) and differences between B cell 
populations (Frazer et al., 2000). The discovery of DC subsets and their divergent roles in 
immunity has stimulated a search for markers differentially expressed between them. Two 
molecules, CIRE and FIRE, expressed more highly on the CD8a- DC subset than the 
CD8a+ subset were identified by RDA (Caminschi et al., 2001a; Caminschi et al., 2001b). 
Both are cell surface molecules: CIRE, a C-type lectin, shares 57% amino acid identity with 
human DC-SIGN, the receptor for ICAM-2 and ICAM-3, while FIRE shows homology to G- 
protein coupled receptors. Both CIRE and FIRE were found to be downregulated on 
activation and so may be involved during early stages of DC maturation. Tspan-3, another 
mouse DC transmembrane protein, was identified by RDA (Tokoro et al., 2001). In this 
case, RDA was used to compare resting and CD40 activated DCs. As with CIRE and FIRE, 
Tspan-3 expression was downregulated in activated DCs.
We have used RDA to investigate the regulation of gene expression by IFN-I in splenic DCs. 
By identifying changes in levels of gene expression associated with DC activation, we hoped 
to gain insights into the mechanisms by which DCs influence the outcome of immune 
responses. A diverse range of genes were found to be upregulated by IFN-I in splenic DCs, 
from genes encoding transcription factors involved in regulating the IFN genes themselves to 
proteins involved in the anti-viral response and antigen presentation. Several expressed 
sequences of unknown function were also identified.
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3.2 Results
3.2.1 RDA on IFN-I-treated C D llc+ DCs : optimization
RDA was used to test the differences in gene expression between untreated DCs (DC 0) and 
DCs treated with IFN-I (DC IFN). In all RDA experiments the IFN-I used was a 
combination of IFN-a (25%) and IFN-p (75%). 7 xlO6 C D llc+ DCs were isolated from
C57B1/6 mouse spleens by FACS sorting and were cultured for two hours with or without 2 x 
104 U/ml IFN-I. This dose of IFN-I approximates that produced locally during a viral 
infection (Gallucci et al., 1999), which can rapidly reach very high titres. Notably however, 
different viruses induce amounts of IFN-I which can vary over a 10,000 fold range (Marcus 
et al., 1998) and human plasmacytoid DCs can produce in the range of 2 - 64 x 104 U IFN-I 
per 105 cells on viral stimulation (Siegal et al., 1999). Transcription of IFN-induced genes 
occurs rapidly: Mx gene transcription is increased 50-fold only 90 minutes after IFN 
treatment (Staeheli et al., 1986a). We chose to isolate the DCs after a two hour incubation 
as we wished to use conditions which would reveal genes induced at an early stage after IFN- 
I exposure. This would increase the chance of identifying genes directly induced by IFN-I 
and not those induced further downstream.
During the RDA procedure reciprocal subtractions were carried out, that is, we used DC 0 as 
the driver sample and DC IFN as the tester sample in one experiment and vice versa in 
another. This allowed us to test for genes both upregulated and downregulated by IFN-I.
In order to generate sufficient quantities of representative cDNA, 26 cycles of amplification 
of the R-ligated cDNA template was needed. The representations were visualized as a smear 
of DNA fragments on an agarose gel, and ranged between 200bp and 1.2kb in size, as would
be expected (Figure 3.2). After generation of the first difference product (DPI) there were 
no obvious bands in the samples, and both the samples (from the reciprocal subtractions 
either with DC 0 or DC IFN as the tester) appeared very similar. However, the second 
difference product (DP2) had distinct bands in the sample where DC IFN was used as the 
tester (Figure 3.3). In the sample with untreated DCs as the tester, we could detect only a 
very faint smear. To try to eliminate any background and make the banding more distinct 
we generated a second DP2, with increased stringency. However, since this only resulted in 
the bands becoming fainter, we used the initial DP2 for further analysis. Individual bands 
ranging from 300 to 700 bp were isolated from the agarose gel (Figure 3.4), cloned and 
sequenced.
The nucleotide sequences were run through BLAST searches against the NCBI non- 
redundant or mouse EST databases (Table 3.1). Although we were unable to clone the lkb 
band due to insufficient amounts of DNA, we considered this preliminary RDA to be 
successful since several of the genes identified had previously been characterized as IFN- 
inducible. At the time of cloning, three of the inserts (from bands 3, 4 and 6), did not match 
to known genes in the NCBI database and were either uncharacterized, or classed as “similar 
to” known genes. For instance, the product cloned from band 3, expressed sequence 
AI447904, is also known as “similar to interferon activated gene 203 (Ifi203)”. Ifi203 itself 
belongs to a family of IFN induced genes, the Ifi 200 family. Unlike other members of this 
family, Ifi203 has not been shown to be involved in the anti-proliferative effect of type I IFN 
(Gribaudo et al., 1999). The function of Ifi203 and “similar to Ifi203” is currently unknown. 
Verification that these genes were truly differentially expressed and not simply an artifact 
produced by multiple PCR amplifications, was provided by probing a southern blot of 
independently isolated cDNA representations, an example of which is shown in Fig 3.5.
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Figure 3.2: Optimisation o f PCR conditions for generation o f representations
CD1 lc + DCs were isolated from the spleens o f  C57/B16 mice and placed in culture for two hours 
in the presence or absence o f  IFN-I (2 x 104 U/ml). RNA was isolated and RDA perform ed, 
using 2 or 2.5fil o f  the R-ligated samples for the indicated num ber o f  PCR cycles. 0 = cDNA 
from non-treated DCs; IFN = cDNA from IF N -a/p  treated DCs; control = positive control 
cDNA derived from a cell line (EL4); -RT are negative controls where no reverse transcriptase 
was added to the cDNA synthesis reactions.
Figure 3.3: Bands representing differentially expressed genes are apparent in the second  
difference product (DP2) when using DC IFN but not DC 0 as the tester
a, D PI, and b, DP2 for RDA analysing gene expression in IFN -I-treated DCs (subtractive 
hybridisation was carried out at a ratio o f  100:1 and 800:1 driver:tester, repectively). IFN = DC 
IFN used as tester; 0 = DC 0 used as tester. Control = RDA carried out on samples generated 
from an untransfected (driver) and tranfected (tester) cell line and therefore with known 
differences in gene expression, as a positive control. The lower bands represent digested 
adapters. The arrows indicate bands that represent differentially expressed genes in the IFN- 
treated DCs. Only a faint sm ear was seen in the reciprocal subtraction w ith untreated DC as the 
tester.
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Figure 3.4: Strategy for cloning DP2 generated from RDA on C D llc + DCs
a, Subtractive hybridisation was repeated using a ratio o f  4000:1 driver:tester. The bands were 
identical to the initial DP2, only fainter, b, Bands from  the DP2 produced using a ratio o f 
800:1 driventester were separated on an agarose gel at low voltage for several hours. Seven 
bands were excised from the gel and bands 2 - 7  were cloned.
0 IFN
oo 2?
Figure 3.5 Verification of differential gene expression by probing o f Southern blots from  
independently generated cDNA representations. cDNA representations from  splenic DCs 
cultured in media alone or with 2 x 104 U IFN-I w ere blotted onto a m em brane and hybridised 
with a probe specific for the Ifit3 gene fragm ent identified by RDA. Upregulation o f  the 
transcript can clearly be seen in samples treated w ith IFN-c^jS. The probe for Ifit3 also 
recognizes a band o f  smaller size from  which Ifit2 was cloned.
oo 2?
*  *
Ifit3
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Table 3.1 Genes upregulated in IFN-I treated C D llc+ DCs identified by RDA
Band Accession Symbol Gene name Function
1 Not cloned
2 NM 008884 PML Promyelocytic leukemia gene
Controls cell proliferation, 
apoptosis, transcription regulation 
and tumourigenesis
3 NM _ 175026 AI447904 Expressed sequence AI447904 Unknown
4 CV 562282
Similar to G l/S  specific cyclin 
D2 Control o f  cell cycle
5 NM 008332 Ifit2
IFN-induced gene with 
tetratricopeptide repeats 2 Unknown
6
7
N M _010501 
NM 020557
Iflt3
Tyki
IFN-induced gene with 
tetratricopeptide repeats 3 
Thymidylate kinase family, 
LPS inducible member
Unknown
Nucleotide biosynthesis
The genes Ifit2 and Ifit3 (Interferon-induced gene with tetratricopeptide repeats 2 and 3) 
neither of which has a known function, were also identified in these initial RDAs. Ifit2 
(GARG-39, IFI54) and Ifit3 (GARG-49, IRG2) are both glucocorticoid-attenuated response 
genes (GARGs), the majority of which so far identified encode for chemokines and so it is 
possible that Ifit2 and Ifit3 are involved in intercellular communication (Smith et al., 1997). 
Thymidylate kinase catalyses the formation of the DNA precursor dTTP, a function usually 
associated with DNA replication and cell division. The thymidylate kinase family member 
identified here was originally cloned from LPS-activated macrophages (Lee et al., 1995), and 
may be needed during activation due to the rapid synthesis of mitochondrial DNA.
3.2.2 RDA on DC subsets treated with IFN-I
Splenic DC subsets preferentially inhabit different anatomical areas, the CD8+ DCs in the T- 
cell rich areas and the CD8' in the marginal zone (De Smedt et al., 1996; Kelsall et al., 1996; 
Reis e Sousa et al., 1997), which suggests they may affect different aspects of T and B cell 
activation. They express different TLRs and therefore have the ability to respond to
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different pathogens (Iwasaki et al., 2004). They also produce different cytokines in response 
to pathogens, thereby stimulating T cell polarization (Hochrein et al., 2001), and in turn 
require different cytokines to promote this function (Maldonado-Lopez et al., 2001). For 
these reasons, we wanted to test whether the DC subsets would respond differently to IFN-I.
The CD8' subset of DCs expresses the myeloid lineage marker CDllb, whereas the CD8+ 
subset does not. In order to separate these two subsets of DCs we first enriched the CD1 lc+ 
population by positive selection on a MACS column, which facilitates and improves the final 
purity from the following FACS sort on C D llb and C D llc expression (Vremec et al., 
2000)(Fig 3.6). The DCs were cultured for two hours with or without 2 x 104 U/ml IFN-I 
and we proceeded with the RDA, carrying out reciprocal subtractions as before. Again, the 
first difference products appeared as smears with no distinct bands. The second difference 
product appeared as distinct bands where DC IFN was used as tester and only as a smear in 
the samples with DC 0 as tester. After going through a third round of subtractive
hybridization the results were much improved, with several well defined bands detected in
each of the DC IFN samples (Fig 3.7, a and b). A slight background smear persisted.
In each of these RDAs less than ten separate bands representing differentially expressed 
genes were detected. However, we would expect there to be a far greater number of IFN- 
a/p induced genes, since greater than 400 human genes are induced by IFN-I (Der et al., 
1998). It is possible that amplified products from different genes could be of the same size 
and therefore would migrate together on a gel. Therefore, we endeavored to sequence at 
least five separate clones from each band; in some cases up to three different genes were
identified in the same band (Table 3.2). We were again unable to clone three of the
amplified products (Figure 3.7b) due to insufficient quantities of DNA.
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Figure 3.6: Isolation o f C D llb - and C D llb + DC subsets.
DCs were enriched from  splenocytes on a N ycodenz gradient followed by positive selection o f  
C D llc + cells by MACS, a, Purified DCs before cell sort. The sorted DC subsets are b, 
C D llb + DCs (which corresponds to the CD8" DC subset) and c, C D llb "  DCs (which 
corresponds to the CD8+ DC subset)
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aFigure 3.7: Differentially expressed genes in DC subsets treated for two hours and 
C D llc + DCs treated for six hours with IFN-I. (a) and (b) show difference products 
from  RDA for DCs treated for two hours with IFN-I while (c) represents a six hour RDA. 
Bands 1-7 o f  the DP3 were cloned and sequenced for both the CD8* DC RDA (a) and the 
CD8+ DC RDA (b). We were unable to clone the faint bands m arked with *. c, DP3 
from  DCs treated for 6 hours with type I IFN: only two bands were cloned, as we were 
unable to reduce the background smear.
130
Two genes appeared frequently in the sequencing results, namely promyelocytic leukemia 
gene (Pml) and guanylate binding protein 2 (Gbp2). Both of these genes have been 
characterized as IFN induced, although their precise functions are not well understood.
Two of the sequences expressed in CD llb+ DCs matched to ESTs with no functional 
annotation: RIKEN cDNA 9130002C22 (9130002C22Rik) and Expressed Sequence 
AI448571 (AI448571). 9130002C22Rik is a full length cDNA clone whereas AI448571
belongs to a contig of overlapping ESTs (in which we could find no open reading frame) 
which maps close to murine TRAIL gene on chromosome 3.
Table 3.2 Genes upregulated by IFN-I in C D llb+and CDllb' DCs
C D llb + C D llb '
Band Accession Gene Accession Gene
1 NM 008884 Pml NM 008884 Pml
2 NM 008884 Pml NM 008884 Pml
N M _010260 Gbp2
3 N M _010260 Gbp2 NM 021394 N o significant matches (Zbpl)
NM 008884 Pml N M _010846 N o significant matches (M xl)
4 NM 008884 Pml NM  008884 Pml
NM 029000 9130002C22Rik N M _183201 Schlafen 5
5 AI448571 AI448571 NM  008332 Ifit2
N M _010260 Gbp2
6 N M _010501 Ifit3 N M _010501 Ifit3
AI448571 AI448571 NM 008884 Pml
X-actin
7 N M _010501 Ifit3 N M _010501 Ifit3
NM 008884 Pml NM _173754 Usp43
NM 020557 Thymidylate Kinase
Two sequences from the CD1 lb' RDA did not produce any significant matches to sequences 
on the NCBI non redundant or mouse EST databases. At first it appeared that we had 
isolated sequence from novel genes, however we subsequently discovered, by carrying out a
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BLAST search of the Ensemble database, that the sequences are located within the introns of 
Mxl and Zbp. Zbp is a Z-DNA binding protein also known as DLM-1, which is upregulated 
in macrophages activated by LPS or IFN-y (Fu et al., 1999).
Finally, a sequence matching to a gene named Similar to hypothetical protein FLJ34922 
{Homo sapiens) was identified. This gene belonged to a predicted family (Ensemble 
ENSF00000003059) containing 5 members which all contain an ATP/GTP binding-site 
motif. Our cloned sequence shared 98% sequence identity with this gene and 65-67% 
identity with three other members of the family. This region of identity is split into two 
sections from nucleotides 1-58 and 136-154 of our sequence. Nucleotides 1-58 also 
matched human genes which are weakly similar to the Schlafen (Slfn) gene members Slfn3 
and Slfn4. Since this predicted gene family is located directly next to the Schlafen gene 
family on chromosome 11, we thought it possible that they were related. Recently this gene 
has been assigned as Slfn5 (Geserick et al., 2004).
In conclusion, several genes were upregulated in both the C D llb ' and C D llb+ DC subsets, 
namely Pml, Ifit2 and Ifit3. However, Gbp2 upregulation was detected several times in the 
CD1 lb+ DCs but never in the C D llb ' DCs. In these experiments we identified what we 
believed to be only a small subset of the genes upregulated by IFN-I in the two subsets, and 
amongst these, we did not identify any genes which could contribute to different localisation 
or the T cell-polarizing effect of the two subsets.
3.2.3 RDA on DCs treated for 6h with IFN-I
Not surprisingly, many of the genes identified in the RDAs on DCs treated for 2 hours with
IFN-I were involved in the innate anti-viral response common to most cell types. However,
our aim was to isolate genes which were involved in the DCs ability to regulate adaptive
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immune responses. We thought it possible that these genes might be upregulated at a later 
stage of IFN-stimulation. To investigate this we isolated CD1 lc+ DCs and cultured for six 
hours with IFN-I stimulation. Technical difficulties with this RDA meant that we could not 
amplify clear bands, even after a third subtractive hybridization (Fig 3.7c). The presence of 
a slight background smear is likely to have produced some false positives in the sequencing 
results, such as the 18s RNA which is very highly expressed and therefore may not have been 
completely competed out during the subtractions. However, many of the genes sequenced 
were known IFN-induced genes (Table 3.3). In addition to genes identified in RDAs carried 
out on DCs treated for two hours with IFN-I, we found expression of the PI3 kinase y 
regulatory subunit p i01. PI3 kinase I is a key component in signal transduction from 
numerous receptors, including cytokine receptors, TLRs and T and B cell receptors, and 
mediates cell proliferation, survival and migration (Deane et a l, 2004). The association of 
the p i01 regulatory protein with PI3 kinase y is essential for its sensitivity to G-protein 
coupled receptor (GPCR) activation (Stephens et al., 1997). Two transcription factors were 
upregulated at 6h: RelB, a component of the transcription factor NFkB and Irf7, which acts 
in a positive feedback loop by upregulating expression of the IFN-I genes themselves. 
Encouragingly we also saw upregulation of an MHC II gene, which we would expect to see 
as the DCs mature. In this experiment we also identified another member of the Slfn gene 
family Slfn4. The function of several of the genes identified remains elusive and we carried 
out an Interpro search for conserved domains within the amino acid sequences, in an attempt 
to assign a putative function for these genes (Table 3.4). This gave us an indication of type 
of processes these proteins may be involved in. For example, the Myosin 1G protein 
contains myosin domains which play important roles in both cell motility and organelle 
transport.
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Table 3.3 Genes identified by RDA in DCs after 6h IFN-I treatment
Clone No Symbol Function Accession Gene Name
Antigen presentation
B5b, B7a, B8 Antigen presentation BC031711
MHC class II H2-IA-alpha 
gene
Signal transduction
A6
B2
F730038I15Rik
CRHSP-24
Kinase AY 156924 
AK004711
PI3-kinase y regulatory 
subunit p i01 
Homologue of calcium- 
regulated heat stable protein
T ranscription/translation
A5a RelB Transcription factor NM_009046 V-rel oncogene related B
A5b Rpl9 Inferred protein synthesis NM_011292 Ribosomal protein L9
A7 Irf7 Transcription factor NM_016850 IFN regulatory factor 7
B9a Slu7-pending Pre-mRNA splicing AK049178 Step II splicing factor SLU7
B13 18s rRNA HSRRN18S 18s ribosomal RNA
IFN response
A10 Ifit3 NM_010501
IFN induced protein with 
tetratricopeptide repeats 3
B12 Vigl NM_021384 VHSV induced gene
Ion transport
Al Atp5b ATPase BC013253
Beta-Fl ATPase, 
mitochondrial
B3
B5a
Fth
Slc25a3
Iron homeostasis NM 010239 
Mitochondrial substrate carrier BCO18161
Ferritin heavy chain 
Solute carrier family 25, 
member 3
Protein alteration
A ll
B ll
Uspl8
Sat
Protease NM_011909 
NM_009121
Ubiquitin specific protease 18 
Spermidine N 1 -acetyl 
transferase
Nucleotide biosynthesis
B6 Tyki Kinase BC057565
Thymidylate kinase family, 
LPS-inducible member
Thymocyte development
A2b, A3, A8 Slfn4 NM 011410 Schlafen 4
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Table 3.4 Conserved domains present in novel IFN-I induced genes
Clone No Gene Name Accession Interpro/NCBI Domains Interpro
A2a RIKEN cDNA 9530019H02 gene BC056466 Ras GTPase 
Sigma-54 factor,
Small GTP-binding domain
IPR001806
IPR002078
IPR005225
A9a Epididimal secretory protein 
(Niemann-Pick type C2)
AB021289 ML
E1 _DerP2_DerF2
Smart00737
Pfam02221
A12 KIAA0431 protein BC060631 Zinc finger,C2H2 type IPR007087
B7b Similar to RIKEN cDNA 4933437104 gene BC031980 Untranslated
B9b Lymphocyte cytosolic protein 1 BC022943 Actin-binding, actinin-type 
Calponin-like actin binding 
Calcium-binding EF hand
IPR001589
IPR001715
IPR002048
BIO Myosin 1G AK088011 Calmodulin-binding 
Myosin head 
Myosin tail 2
IPR000048 
IPR001609 
IPR010926
3.2.4 Verification of RDA results by Real-time PCR
To confirm that the results of the RDA experiments were true difference products 
corresponding to IFN-I induced genes we carried out real-time PCR. Initially we designed 
probes and primers against the two expressed sequences of unknown function, since we 
believed that these had not previously been identified as IFN-induced genes. These were 
9130002C22Rik and AI448571 identified in the C D llb+ DCs, and the sequence that 
subsequently was found to be an intron of Mxl from the RDA on CD1 lb' DCs. RNA for 
these experiments came from freshly isolated CD1 lc+ splenic DCs that were cultured with or 
without 20,000 U/ml IFN-I for two hours. The results are summarised in figure 3.8, and 
confirmed that both 9130002C22Rik and Mxl were upregulated by IFN-I. However, when 
we tested for expression of these genes in T and B cells, we found that in some cases IFN-I 
enhanced the expression even further than in DCs. This was especially true for AI448751 
which was not significantly upregulated in DCs compared with 12-14 fold in T cells and for 
Mxl (intronic sequence) which was also strongly upregulated in T cells after IFN-I
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□  9130002C22Rik 
■  M xl intron
□  A 1448571
DC CD8+ CD4+ B ce,]s 
T  cells T  cells
Figure 3.8: The expression o f  uncharacterised sequences upregulated in IFN-I 
treated DCs is also elevated in T and B cells follow ing IFN-I stim ulation . RN A
was isolated from  C D llc + DCs, CD8+ and C D 4+ T  cells and B cells w hich had been 
cultured for two hours w ith or w ithout IFN -I (2 x 104 U /m l). E xpression o f  
sequences identified by RD A  were analysed by  real-tim e PC R  and w ere found to be 
ubiquitously upregulated by  type I IFN. In som e cases expression was m ore highly  
upregulated in T and B cells than in DCs. Results are p lo tted  as fold change in 
expression in cells cultured in IFN-I versus m edium  alone, after norm alising test 
m RNA  levels to 28S RNAlevels.
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stimulation. Our original aim was to identify DC-specific genes, however enhanced 
expression in T and B cells does not necessarily rule out an important role in regulating DC- 
specific functions.
Members of the Schlafen (Slfn) gene family have been shown to be differentially expressed 
during the course of T cell development (Schwarz et a l, 1998). Slfn4 expression decreases 
in T cells during progression from the triple negative (CD3’’ CD4‘, CD8') to the single 
positive (either CD8+ or CD4+) stage, yet increases following activation. None of the Slfn 
genes had previously been shown to be expressed in DCs or induced by IFN-I . For these 
reasons we decided to investigate expression of Slfn4 and Slfn5 identified in the six hour 
RDA and the CD8+ DC RDA respectively. Slfn4 was more highly upregulated in DCs 
treated for two hours with IFN-I than in T cells treated for the same time and was down- 
regulated in B cells (Figure 3.9). Slfn5 expression was markedly different, its expression 
increasing by almost 20-fold in T cells treated with IFN-I.
In addition to investigating the effect of IFN-I on the expression of these genes, we made two 
other comparisons. First, we compared expression in DCs, T cells and B cells cultured for 
two hours in medium alone. As shown in figure 3.10, 9130002C22Rik was more highly 
expressed in T cells and B cells than in DCs. Slfn4 and AI448571 were also expressed at 
higher levels in T and B cells than in DCs, although the differences were not as large. By 
contrast Slfn5 expression was lower in T cells than DCs and Mxl intron expression was 
decreased in both T and B cells compared to DCs.
Second, we compared expression of these genes in DCs that had been cultured for two hours 
or six hours in medium alone. Since splenic DCs mature spontaneously when placed in 
culture, we wanted to know whether this process, like IFN-I-induced maturation, was
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□  Slfn5
DC CD8+ 
T cells
CD4* 
T  cells
B ce l ls
Figure 3.9: Com parison o f Slfn4 and Slfn5 expression in IFN -treated DCs, T cells 
and B cells. Real-tim e PCR was carried out for RNA extracted from  DCs, T  and B 
cells cultured in m edium  alone or with 2 xlO 4 U IFN-I. Slfn4 expression w as increased 
the m ost in DCs treated for 2 hours with IFN-I but decreased in B cells. Slfn5 had 
extrem ely elevated expression in T  cells treated with IFN. Results are p lo tted  as fold 
change in expression in IFN -treated cells versus that in the sam e cells cultured for the 
sam e tim e in m edium  alone.
□  9130002C22Rik
■  Mxl intron
■  A1448571
■  Slfn 4
□  Slfn5
CD8+ 
T cells
CD4+ 
T cells
B cells
Figure 3.10: Levels o f expression o f the genes identified in R D A s varies betw een cell 
types. Real-tim e PCR was used to com pare expression o f  the indicated sequences 
using RNA from  DCs cultured in m edium  alone for tw o hours as the reference sam ple 
and RN A from  T cells and B cells also cultured for two hours in m edium  alone as the 
test samples.
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Figure 3.11: Expression o f  A I448571, Slfn4 and Slfn5 are induced by 
culture o f DCs in m edium  alone. Real tim e PCR was used to calculate 
fold changes in levels o f  expression o f  the indicated genes in D Cs cultured 
for six hours in m edium  alone com pared to D C s cultured for two hours in 
m edium  alone.
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associated with upregulation of these genes. In fact, AI448571, Slfn4 and Slfn5 were all 
markedly upregulated in DCs between two and six hours of culture (17-24 fold, Figure 3.11). 
This indicates that expression of these genes is being upregulated as the DCs mature, and that 
IFN-I is accelerating the maturation process.
3.3 Discussion
We have carried out representational difference analysis to investigate differential gene 
expression induced by IFN-I after two hours in splenic C D llc+ DCs, CD8' and CD8+ DC 
subsets and after six hours in splenic CD llc+ DCs. We detected genes which were 
upregulated by IFN-I but none that were downregulated. The majority of genes identified in 
these experiments fell into two broad categories. Firstly, we found genes which had 
previously been characterized as IFN-induced, such as Pml, Gbp2 and the Ifit gene family. 
Secondly, we identified genes and which had not been previously shown to be induced by 
IFN; these genes had little functional characterization such as Slfn4 or were expressed 
sequences representing putative or novel genes with no assigned function.
Identification of genes whose expression is known to be induced by IFN-I confirmed that we 
were identifying true difference products. One of these genes, interferon response factor 7 
(Irf7) which we detected at six hours of IFN-I stimulation, belongs to a family of 
transcription factors which regulate the cellular response to extracellular pathogens 
(Taniguchi et al., 2001). Irf7 was first identified as a protein which bound to the promoter 
of an Epstein Barr gene and was linked to controlling the latency of this virus (Zhang et al.,
1997). It is expressed predominantly in lymphoid tissues as four different isoforms (Zhang 
et al., 1997; Au et al., 1998) and is induced by IFN-a, viral infection and LPS (Au et al.,
1998). IRF7 is a key mediator in the expression of type I IFNs themselves. Translocation
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of IRF7 to the nucleus is dependent on virally-induced phosphorylation, preventing 
inappropriate IFN-I production. Therefore it is not surprising that we did not detect 
induction of the IFN-I genes themselves.
Pml was identified as the gene whose disruption in humans leads to acute promyelocytic 
leukemia (Goddard et a l , 1991) and has since been implicated in multiple cellular functions: 
cell growth, apoptosis, regulation of transcription and viral inhibition (Zhong et al., 2000), 
(Ruggero et al., 2000). Pml expression is regulated by signals of cellular stress such as viral 
infection and heat shock. It is upregulated by both type I and type II IFNs and could 
therefore mediate anti-viral and pro-apoptotic effects of IFN. In support of this, TNF- 
related apoptosis inducing ligand (TRAIL) has recently been identified as a downstream 
transcriptional target of Pml (Crowder et a l , 2004). The multiple functions of Pml seem 
inextricably linked with multiprotein complexes known as nuclear bodies (NBs) with which 
Pml is associated. Pml is necessary for the formation and integrity of NBs to which a wide 
variety of other proteins are also recruited. These include the apoptotic protein Daxx and 
other IFN-induced proteins such as the anti-viral protein Mxl. However, one isoform of 
Pml which is not associated with NBs has recently been shown to be a modulator of TGF-p 
signaling (Lin et al., 2004).
Gbp2 has a role in growth regulation (Gorbacheva et a l , 2002), and belongs to a family of 
guanylate binding proteins (Gbps) which were first identified as some of the most abundantly 
expressed proteins produced after IFN stimulation (Boehm et a l, 1998), and have 
demonstrated anti-viral activity (Anderson et a l, 1999). However, Gbps are more strongly 
up-regulated by IFN y than by IFN-I (Cheng et a l, 1986).
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The relative abundance of Gbps and Pml would likely contribute to their frequent cloning in 
these experiments. Another factor could be that they are preferentially amplified: the Pml 
gene is large, (4.3kb) and contains numerous Dpnll restriction sites which would yield up to 
five different amplifiable fragments in an RDA, depending on the Pml isoform.
Two of the novel sequences, after carrying out a BLAST search of the Ensemble database, 
were found to be located within the intronic sequence of two genes, Z-DNA binding protein 
(Zbp) and Mxl. It is likely that these transcripts were isolated before splicing out of the 
introns had occurred. Zbp (also known as DLM-1) was originally identified as a gene 
upregulated in response to the presence of tumours and is upregulated in macrophages after 
four hours stimulation by IFN-y (Fu et a l , 1999). Mxl is a well known anti-viral whose 
expression is controlled by IFN-I (Staeheli et al., 1986a).
Three further novel genes were upregulated in IFN-I treated DCs. Firstly, 9130002C22Rik,
a full length cDNA clone which encodes a protein sharing 92% amino acid identity with a
recently described protein, very large inducible GTPase-1 (VLIG-1). VLIG-1 is a member
of a new family of IFN-inducible GTPases (Klamp et al., 2003). Second we identified a
sequence known as AI448571 whose function remains unknown. The final novel gene was
known at the time as “similar to hypothetical protein FLJ34922”, located within lOOkb of the
original Slfn gene family on chromosome 11. This gene has recently been redesignated
Slfn5 and is a member of a new subgroup of the Slfn family (Geserick et al., 2004).
Members of this subgroup have a unique C terminus containing motifs present in RNA
helicases. Another member of the Slfn gene family, Slfn4, was upregulated in DCs treated
for six hours with IFN-I. Slfn genes are differentially regulated in thymocyte development
and have been implicated in cell growth control (Schwarz et al., 1998). Expression of many
of the Slfn genes is induced by IFN-y and LPS in bone-marrow derived macrophages,
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although Slfn4 was only observed to be elevated by LPS treatment (Geserick et al., 2004). 
Notably, induction of Slfn genes by LPS was dependent on IFN-I signaling. In addition to 
being induced during LPS or IFN-y induced activation, transcription of Slfn genes was 
upregulated during differentiation of the myeloid cell line, Ml, into macrophage-like cells. 
We found that expression of Slfn4 and Slfn5 were highly elevated in DCs cultured for six 
hours compared to DCs cultured for two hours. Since DCs mature when isolated and placed 
in culture, it is possible that these Slfn genes could also be involved in regulating DC 
maturation.
We tested the expression patterns of these genes, including the Mxl intronic sequence, by 
real-time PCR and found that each of the novel genes were upregulated in DCs, T and B cells 
by IFN-I. With the exception of the Mxl intronic sequence, they were expressed at higher 
levels in untreated T and B cells than in untreated DCs. Therefore it appears that these 
genes do not confer a cell-specific function for DCs and are more likely to serve a more 
general function such as anti-viral activity.
RelB, a component of the transcription factor NF-kB, was upregulated in DCs treated with 
IFN-I for six hours. NF-kB is plays a key role in both the innate and adaptive immune 
responses. By mediating signal transduction from TLRs NF-kB initiates production of 
inflammatory cytokines and prevents apoptosis (Bonizzi et al., 2004). In human monocyte- 
derived DCs, CD40 ligand-induced maturation and APC function is dependent on NF-kB 
(O'Sullivan et al., 2002). Since IFN-I is known to induce CD40 expression by murine DCs 
(Montoya et al., 2002), it could in this way amplify the CD40 ligation signal to further 
enhance DC maturation. RelB also plays an important role in DC differentiation/maturation, 
since RelB knockout mice are deficient in CD8' DCs (Wu et al., 1998).
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Several of the sequences which were isolated belonged to genes which have no known 
function. In an attempt to predict something about the possible function of these genes we 
used a bioinformatics approach. Where translated sequences were available, we carried out 
InterPro and protein BLAST searches which, in some cases, identified domains which hinted 
at their function. The translated sequence of the RIKEN cDNA 9530019H02 gene contained 
a conserved domain belonging to the Ras GTPase superfamily and was most closely related 
to the Rab subfamily of proteins. Rab proteins are involved in many aspects intracellular 
vesicle transport, including different stages of endocytosis, exocytosis and vesicle movement 
between the ER and Golgi (Novick et a l , 1997). The Rab subfamily of proteins is large, 
containing at least 40 members in mammals, likely reflecting the complexity of vesicle 
transport systems and the need for different systems in different cell types. Indeed 
expression of some Rab GTPases is restricted to certain cell types as they carry out specific 
functions only required in those cell types (Stenmark et al., 2001). The ML (MD-2 related 
lipid recognition) domain identified in the epididimal secretory protein (also known as 
Niemann-Pick type C2) is involved in innate immunity (Inohara et al., 2002). This domain 
is present in MD-2 and MD-1 which act as co-factors for TLR4 and RP105 LPS recognition 
respectively (Shimazu et al., 1999; Miyake et al., 2000). The KIAA0431 protein contains 
zinc-finger binding domains which are a common feature of DNA-binding proteins and 
indicate a function as a transcription factor.
The number of genes identified by RDA was limited and had not provided us with any 
promising candidates for conferring an enhanced ability to stimulate secondary immune 
responses. The technique of cDNA RDA does have its limitations and may not be 
appropriate when a large number of differences are expected. Since certain products will be
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preferentially enriched, many differentially expressed genes could be missed. Although 
cDNA RDA is very sensitive and can detect absolute differences between genes that are 
expressed at very low levels it may not detect small (3-5 fold) differences in transcript 
abundance (Hubank et al., 1999). We did not detect a change in expression in co­
stimulatory molecules CD80 or CD86, whose expression at the cell surface is known to be 
induced by type I IFNs. In addition, we did not identify any chemokines or cytokines 
known to be induced by IFN in these experiments, for instance CXCL9, CXCL10 and IL-15. 
Using the technique of RDA, genes which may be expressed at high levels but which do not 
increase more than three-fold after IFN treatment may not be detected. In order to gain a 
more global picture of changes in gene expression after IFN treatment, we decided to use the 
approach of microarray analysis.
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Chapter 4 :
Identification of genes regulated by IFN-I in DCs by microarray analysis 
4,1 Introduction
In recent years, microarrays have been developed as a powerful tool for examining gene 
expression, allowing simultaneous analysis of the expression of thousands of transcripts from 
a biological sample. The completion of genome sequencing projects has meant that arrays 
covering entire genomes can be manufactured, providing a means for truly global gene 
expression analysis. A great deal of valuable data can be obtained through microarray 
experiments, although the enormous volume of data generated means that analysis is difficult 
and time consuming.
Two kinds of array are widely used, cDNA and oligonucleotide arrays, which are 
manufactured and analysed in different ways. cDNA arrays are produced by spotting PCR 
products representing specific genes onto a glass or membrane matrix and fixed by 
ultraviolet irradiation (Duggan et al., 1999). Our experiments were carried out on 
Affymetrix oligonucleotide arrays, which are made by building the oligonucleotides onto the 
array step by step using a combination of photolithography and combinatorial chemistry 
(Pease et a l, 1994). A solid support covered with photoprotected hydroxyls is illuminated 
through a mask which removes the photolabile protecting groups so that a nucleoside 
phosphoramidite can be coupled to the hydroxyl group. Cycles of illumination and coupling 
are repeated, generating a specific set of oligonucleotide probes at known locations on the 
array. This method eliminates the possibility of misidentification of an array feature which 
may occur when dealing with large libraries of cDNA clones.
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Affymetrix arrays use several different oligonucleotides to probe expression of the same gene 
transcript (known as a probe set), thereby reducing any cross-hybridising effects. 
Additionally, each oligonucleotide has a mismatched partner which serves as a control for 
cross-hybridisation and is used for background subtraction. The use of multiple short (25- 
mer) oligonuceotides on the Affymetrix arrays may provide the greatest discrimination 
between related sequences but at the expense of poorer hybridisation efficiency (Hardiman, 
2004). Another difference between the two systems is that whereas samples for comparison 
by Affymetrix arrays are hybridised to separate arrays, samples for comparison on cDNA 
arrays are hybridised to the same array and are distinguished using a two-colour dye system. 
Hybridisation to replicate arrays can be an advantage since the control sample can be 
compared to limitless test samples.
In the last few years several groups have utilised microarrays for the exploration of DC 
function. An early focus of these studies was to identify genes regulated during 
differentiation and maturation of human CD14+ monocytes into immature and mature DCs 
(Lapteva et al., 2001; Le Naour et al., 2001). The validity of this approach was confirmed 
by the identification of genes known to be regulated during differentiation and maturation 
such as genes encoding MHC class II and co-stimulatory molecules and the chemokine 
receptor CCR7. In addition, genes not previously associated with DC maturation were 
identified, including genes encoding cell adhesion molecules and secreted factors.
The response of DCs to different activation stimuli, including CD40L (Tureci et al., 2003), 
pathogens and their components, has also been investigated using microarray technology. 
Distinct subsets of genes were shown to be regulated in human monocyte-derived DCs in 
response to Escherichia coli, Candida albicans and influenza virus (Huang et al., 2001a).
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Similarly, Grannuci et al., have examined the gene expression profile in the mouse DC line 
D1 when driven to maturation by TNF-a or LPS (Granucci et al., 2001b) and over a time 
course of activation by Gram-negative bacteria (Granucci et a l , 2001a). These studies have 
revealed a wide range of genes important in the different stages of DC maturation, from loss 
of phagocytic capability to the efficient stimulation of T and B cells. In addition to giving 
an overall view of the relationship between gene regulation and kinetics of DC maturation, 
these studies have provided fresh insights into DC function. For example IL-2, an essential 
mediator of T cell function, was found to be upregulated in DCs by Gram negative bacteria. 
Further in vitro analysis showed that DC-derived IL-2 was necessary for maximal T cell 
proliferation in a mixed lymphocyte reaction assay (Granucci et al., 2001a). Also using the 
mouse cell line Dl, Trottein et al. found that schistosoma mansoni larvae and their eggs 
elicited markedly different transcriptional responses in DCs, with the eggs preferentially 
inducing inflammatory cytokines, chemokines and IFN response genes (Trottein et al.,
2004). The difference in gene expression profiles was in part due to the autocrine action of 
IFN-P which was produced by egg-stimulated DCs, and could help to explain the different 
immune responses induced by them.
Oligonucleotide arrays have also been used successfully to determine differential gene 
expression between mouse splenic DC subsets (Edwards et al., 2003a), which showed that 
the CD4' and double negative subsets were more similar to each other in gene expression 
profiles than the CD8+ subset. Finally, gene expression analysis has been used to examine 
the effects of uptake of tumour-lysates on murine bone marrow-derived DCs (BMDCs) 
function (Grolleau et al., 2003).
Microarray analysis has also been used to identify type-I IFN regulated genes. In a human 
fibrosarcoma cell line, 94 and 268 genes increased in expression by more than two-fold after
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IFN-a2a and IFN-p stimulation respectively (Der et al., 1998). Since different IFN-a 
subtypes and IFN-P exert themselves in distinct biological ways despite binding to the same 
receptor, data of this type can help to explain the phenomenon. Genes most highly up­
regulated by the type I IFNs included well known interferon-stimulated genes such as MxA, 
MxB, 2-5A synthetase and STAT1. In addition, novel interferon-stimulated genes were 
identified, including genes involved in the apoptotic effect of IFNs.
We wished to obtain a comprehensive profile of genes regulated by IFN-a4 in DCs. To this 
end, we have used oligonucleotide arrays to identify genes differentially expressed in murine 
splenic and BMDCs treated with IFN-a4. Several hundred IFN-regulated genes were 
identified, including known IFN-stimulated genes and genes which we had previously 
identified by RDA. Analysis of the data from splenic DCs revealed several genes with a 
potential influence on DC function, which were chosen for further study. Real-time PCR 
was used to confirm IFN-induced expression of these genes in DCs and to determine their 
pattern of expression in other cell types of the immune system. In addition we confirmed the 
regulation of cytokines and chemokines at the protein level by ELISA.
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4.2 Results
4.2.1 Gene expression in splenic DCs treated with IFN-I
4.2.1.1 Experimental overview
CD1 lc+ DCs were initially isolated by FACS sorting as before. However, we subsequently 
found that we could consistently isolate DCs of high purity (>98% C D llc+) by positive 
selection on consecutive MACS columns (Figure 4.1). Since we could recover more than 
double the number of DCs using this method than by FACS sorting, we used MACS columns 
to purify DCs for the remaining experiments. RNA was isolated from DCs which had been 
cultured either alone or with 2 x 104 units of IFN-a4/ml for two or six at hours 37°C. As an 
indication of the quality of the experiment we assessed the regulation of Mxl by real-time 
PCR. In one case Mxl was not expressed at higher levels in the DCs treated with IFN-a4, 
and therefore these samples were discarded. The cRNA was hybridised to the Affymetrix 
murine genome U74Av2 array, which contains approximately 6000 functionally 
characterised genes and 6000 EST clusters. An example of a scanned array is given in 
figure 4.2. The experiments were carried out in triplicate and analyzed using Genespring 
software.
4.2.1.2 Normalisation and filtering criteria
Normalisation of data was carried out using Genespring 7 software. Differences in the
overall signal intensities between arrays was corrected for by normalisation to the median
value: the signal intensity for each probe set is divided by the median of the signal intensity
for all the probe sets on the array. This step corrects for any differences between the arrays
which are due to assay variability, such as sample concentration, hybridisation or staining
efficiencies. The second normalisation step in Genespring is a per gene normalisation,
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Figure 4.1 Purity o f  splenic DCs isolated by m agnetic bead sorting
Splenic DCs were digested by collagenase/D N ase follow ed by enrichm ent o f  low
density  cells on a N ycoprep density gradient (a). Cells w ere then  stained w ith
C D llc -F IT C  then with anti-FITC m icrobeads and positively selected  on a M A CS
colum n (b). To isolate cells o f  high purity  the cells w ere then isolated on a second
M A CS colum n (c).
Figure 4.2 Section o f a scanned A ffym etrix array
B iotin-labeled cRNA sam ples w ere hybridised to A ffym etrix  arrays and stained w ith 
streptavidin-PE. The arrays were scanned on a G eneC hip scanner 2000. a) an 
enlarged section and b) a further enlarged section o f  a scanned m urine genom e 430  2.0 
array.
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which is used to determine the level of transcript on one array relative to another. This 
normalisation can be done either by comparing the signal value to the median value for the 
probe sets or by normalising to the corresponding probe set in a specified sample. After 
carrying out a normalisation to the median we carried out a sample correlation, which 
revealed that samples processed on the same day were more similar in their expression 
profiles than the replicate samples. As described in section 2.2.6.2.2, the arrays were 
reviewed for various quality control measures. At the six hour timepoint this day to day 
sample variation can be seen in the number of genes whose expression has been detected as 
present (Table 4.1). For these reasons, the per gene normalisation was carried out between 
specific samples. This means that the measurements for the IFN-treated samples were 
normalised to the measurements from the control samples isolated on the same day. 
Following normalisations, the data was filtered so as to only consider those genes which 
were being expressed in at least two out of a total six samples, and which were changing in 
expression by at least 1.5 fold. The filtered gene list was then subjected to a Welch’s t-test, 
a t-test used when the variances between the samples are not assumed to be equal, with a p- 
value cut-off of 0.05.
Table 4.1 Quality control measurements
Sample Name Replicate
number
Q (Noise) Scale
factor
Genes
present
GAPDH B-actin
Untreated 2h 1 2.59 0.828 43.0% 2.04 1.97
2 1.84 0.653 51.5% 1.92 1.51
3 2.75 0.576 49.5% 1.83 1.27
IFN-treated 2h 1 1.97 0.891 45.1% 1.73 1.72
2 1.76 0.548 53.8% 1.9 1.48
3 2.43 0.555 51.4% 2.4 1.45
Untreated 6h 4 2.27 0.922 41.5% 1.88 1.55
5 1.69 3.349 29.2% 2.82 2.83
6 1.78 4.327 27.1% 3.7 2.67
IFN-treated 6h 4 2.1 1.038 37.0% 2 1.62
5 1.59 7.38 22.2% 3.08 2.69
6 1.98 7.464 22.1% 4.18 3.64
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4.2.1.3 Analysis o f differentially expressed genes
The expression of 201 genes changed significantly by at least 1.5 fold after 2h IFN 
stimulation and 270 genes after 6h , of which 48 were common to both (Figure 4.3). Many 
of the genes identified in these experiments were known IFN-induced genes which we had 
also previously identified by RDA, for example Ifit2 and Ifit3, Pml and Gbp2, confirming 
that the results were reliable. By RDA we had identified a thymidylate kinase family 
member known as thymidylate kinase family, LPS-inducible member (Tyki). This gene 
showed the highest fold-increase in expression of any of the genes, and was increased by 
more than 100-fold in the DC IFN sample compared to the untreated control at two hours of 
culture. This high fold change is in part due to the extremely low level of expression in the 
untreated control sample, which was barely detectable. Thymidylate kinase is an essential 
enzyme in the synthesis of dTTP, but it is not clear what role thymidylate kinase family 
members may play in immunity. We identified genes involved in a wide range of functions; 
anti-viral (Mxl), antigen presentation (Tapi), signaling (Statl), transcription factors (Irf7), 
chemokines (CXCL9), cytokines (IL-15), and their receptors (CCR5, IL-6R). Many of the 
genes identified were of unknown function.
Genes which were detected as differentially expressed after two hours (2h) but not after six 
hours (6h) (Table 4.2) included CCR7, which is essential for the migration of maturing DCs 
to the draining lymph node. The signal values from the 6h data show that CCR7 was being 
expressed at high levels by both untreated and IFN-treated DCs at this timepoint, and 
therefore the fold difference between them was lower. It is possible that the expression of 
CCR7 mRNA by the IFN-DC had reached a plateau by six hours. This was true for a 
number of genes, including Ifi204 and Tapi, which were clearly still being maintained at 
elevated levels by IFN at 6h but the fold increase compared to the untreated samples was less
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sDC BM D C
2h 6h 2h 6h
IFN -a Induced
IFN-or Suppressed
Figure 4.3 N um ber o f  genes w hose level o f expression changed by at least 1.5 fold after IFN - 
a 4  treatm ent Samples from CD1 l c + sDCs or BM DCs treated in vitro  in the presence o f  2 x  104 
units IFN-o4 or in media alone were hybridised to Affym etrix murine U 74A v2 or 430  2.0 arrays. 
Data generated from BM DCs is presented here for com pleteness and is discussed in section  
4.2.2. Data was analysed in Genespring 7.2 and changes o f  more than 1.5 fold were determined 
to be significant by W elch’s approximate t-test where p-values were less than or equal to 0.05.
142 129 376137
333 40 245135
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Gene Description
EST EST M 7 9 3 9 7 2
Mx2 Myxovirus resistance 2
Ifi204 interferon activated gene 204
AI447904 ex p ressed  seq u en ce  AI447904
IMS interleukin 15
M s4a6b m em brane-spanning 4-dom ains, subfamily A, m em ber 6B
Trim30 tripartite motif protein 30
Slfnl schlafen 1
AI481105 ex p ressed  seq u en ce  AI481105
LOC236219 ex p re ssed  seq u en ce  LOC236219
Pttg l pituitary tumor-transforming 1
Gbp3 guanylate binding protein 3
Tor3a torsin family 3, m em ber A
Ifi204 interferon activated g en e  204
Gpr33 G protein-coupled receptor 33
Trim21 tripartite motif protein 21
Pml promyelocytic leukemia
T pstl protein-tyrosine sulfotransferase 1
Ifi35 interferon-induced protein 35
Pnp tl potynbonucleotide nucleotidyltransferase 1
EST Mus m usculus transcribed seq u en ces
M s4a6b m em brane-spanning 4-dom ains, subfamily A. m em ber 6B
Sap30  sin3 assoc ia ted  polypeptide
Fndc3a fibronectin type III domain containing 3a
I5204 interferon activated g ene  204
2310005P05Rik RIKEN cDNA 2310005P05 gene
U sp25 Ubiqultin specific protease 25
Ct!a2a cytotoxic T lym phocyte-associated protein 2 alpha
6720480F16Rik RIKEN cDNA 6720480F16 g ene
TnfsflO  (TRAIL) tum or necrosis factor (ligand) superfamily, m em ber 10
EST Mus m usculus transcribed seq u en ces
Adar adenosine d eam inase. RNA-specific
Snx2 sorting nexin 2
S ta tl signal transducer and activator of transcription 1
Ogfr opioid growth factor receptor
Trim21 tripartite motif protein 21
Irf7 interferon regulatory factor 7
Fln29-pending FLN29 gene  product
D 1Ertd622e DNA segm ent. Chr 1, ERATO Doi 622, exp ressed
e tn k l ethanolamina kinase 1
Isgf3g interferon dependen t positive acting transcription factor 3 gam r
Rnf34 ring finger protein 34
Dck deoxycytidine kinase
Adar adenosine deam inase. RNA-specific
1810054D07Rik RIKEN cDNA 1810054D07 gene
Zfp90 zinc finger protein 90
Dck deoxycytidine kinase
Max Max protein
Nmi N-myc (and STAT) interactor
Myd86 myeloid differentiation primary response  g ene  88
9 130427A09Rik RIKEN cDNA 9130427A09 gene
C sprs  HSR; M ouse HSR mRNA, clone pM mHSRc-[1.3.3E.10 and  101
C d k n la  cyclin-dependent kinase inhibitor 1A (P 2 1 )
Fold
Change
2h Signal 6h Signal Affymetrix
Accession
Genbank
Accession
14.1
12.5
8.3
6.3
6.0
5.5
3.7
3.7
3.7 
3.6
3.5
3.5
3.0
2.9
2.7
2.7 
2.6 
2.5
2 4
2.3
2.3
2.3
■  739 1558
200 249
177 420
45 . 107
■  U6 315 . 
65 1554i
236 530
Dtnb dystrobrevln, beta 2.2 22
Anxal annexin A1 2.1 24 63
C d k n la cyclin-dependent kinase inhibitor 1A (F*21) 2.1 165 342
Nedd9 neural precursor cell exp ressed , developm em ally down-regulat 2.1 39 102
Map2k1 m itogen activated protein kinase kinase 1 2.0 158 325
Tom 70a IransJocase of outer mitochondrial membrane 70 homolog A (yeast) 2.0 140 263
Ddx24 DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 2.0 151 297
D530037H12Rik RIKEN cONA D530037H12 gene 2.0 *r:J/.33
Stard3 START dom ain containing 3 2.0 173 348
CcfS chem okine (C-C motif) receptor 5 2.0 22 «
BC004022 cDNA sequence BC004022 2.0 169 336
Fnbp4 formin binding protein 4 2.0 U R
Mov10 Moloney leukem ia virus 10 2.0 212 414
C asp l c a sp a se  1 2.0 123 244
SHI
136 180
345 ||4 1 »  I
583 557
555 636
126 168
326
1180 1570
187 232
319 354
495 490
247 246
440 608
29 34
201 267
171 254
356 510
126 246
112 124
865 1189
1239 1737
a s
323 381
33 K M
375 388
264 384
116 125
25 13
365 396
2M M
171 207
K> 71
178 163
363 413
AI451676 
J03368 
M31419 
AA727023 
U14332 
AI835093 
J03776 
AF099972 
AW 121646 
AA289585 
A F071209 
AW 047476 
AI508931 
M31419 
A F045766 
AA138192 
U33626 
A F038008 
AW 121732 
AW 124271 
AW 048912 
AI504305 
A F075136 
AI132380 
AA960657 
AI838150 
C76988 
X15592 
AW209561 
U37522 
AA267568 
AF052506 
AI842754 
U06924 
AI838195 
L27990 
AV373853 
AW 049897 
AW 047450 
AI853226 
U51992 
AI852555 
X77731 
AW046250 
AA168418 
X79828 
X77731 
M63903 
AF019249 
X51397 
AW 061306 
M55219 
AW 048937 
AA163960 
AJ003007 
M69260 
U09507 
AF009366 
L02526 
AI844034 
U46690 
AI482432 
X82457 
AF022990 
AI413179 
AW 121377 
X52574 
L28095
S ig n a l in te n s ity
I
0-10
10-100
100-250
250-500
500-1000
1000-2000
2000-3000
3000-4000
4000-5000
>5000
Table 4.2 (continued over page) IFN -induced genes in splenic DCs after 2h but not 6h o f  
culture. Sam ples from  CD1 lc + DCs cultured in vitro in the presence o f  2 x 104 U IF N -o4  (IFN) 
or in m edia alone (0) were hybridised to A ffym etrix  m urine U 74A v2 arrays. D ata w ere 
generated from  the m ean o f  three experim ents carried  out on independently  isolated D Cs. D ata 
were analysed in G enespring 7.2 and changes o f  m ore than 1.5 fold w ere determ ined to be 
significant by  W elch ’s approxim ate t-test w here p-values w ere less than or equal to 0.05. 
N orm alised signal intensities were colour coded to indicate the level o f  expression, as show n in 
the key.
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O n e Description
Fold
Change
2h Signal 6h Signal Affym etrix
A ccession
Genbank
A ccession
Insl3 insulin-like 3 1.9
Gnb4 guanine nucleotide binding protein, beta 4 1.9
Ppicap peptidylprolyl isom erase C -associated  protein 1.9
6330442E1 ORik RIKEN cDNA 6330442E10 g ene  1.9
Arhh ras homolog g ene  family, m em ber H 1.9
Sh3bp2 SH3-domain binding protein 2 1.9
4632413K17Rik RIKEN cDNA 4632413K17 gene 1.9
Rfc3 replication factor C (activator 1) 3 1.9
Tnfrsfl a  tumor necrosis factor receptor superfamily, m em ber 1a 1.9
C sp rs  com ponent of Sp100-rs 1.9
Snx2 sorting nexin 2 1.8
E m p1;TM P M .m usculusem p-1 gene. 1.8
Mbd2 methyl-CpG binding dom ain protein 2 1.8
C cng2 cy d in G 2  1.8
5031425D22Rik RIKEN cDNA 5031425D22 g ene  1.8
Ythdfl YTH domain family 1 1.8
A tp6v0a2 A TPase, H+ transporting, lysosom al VO subunit a  isoform 2 1.8
T ap i transporter 1, ATP-binding casse tte , sub-family B(MDR/TAP) 1.8
A nxal annex inA I 1.8
Gyg1 glycogenin 1 1.8
Zfp50 zinc finger protein 50 1.8
Slitl slit homolog 1 (Drosophila) 1.8
Minppl multiple inositol polyphosphate histidine phosphatase  1 1.8
Cr2 com plem ent receptor 2 1.8
Tcf4 transcription factor 4 1.7
D 10W su159e Mus m usculus transcribed seq u en ces  1.7
D 5Bwg0860e DNA segm ent, Chr 5, Brigham & W om en 's G enetics 0860 expi 1.7
H nrpal alternative splicing modulator; RNA-binding protein; Mus m u se  1.7
Klrkl killer cell lectin-like receptor subfamily K, m em ber 1 1.7
Nrp1 neuropllln 1 1.7
Scarb2  scavenger receptor c lass  B, m em ber 2 1.7
S dcbp syndecan  binding protein 1.7
Nono non-POU-domain-containing. octam er binding protein 1.7
Vrk1 vaccinia related kinase 1 1.7
Atp6vOa2 A TPase, H+ transporting, lysosom al VO subunit a  isoform 2 1.7
Evi2 ecotropic viral integration site 2  1.7
Trim25 tripartite motif protein 25 1.7
Golga3 golgl autoantigen, golgin subfamily a, 3 1.7
CD47 CD47 antigen 1.7
Hk2 hexokinase II 1.6
U sp38 ublquitln specific protease 38 1.6
Bcl6 B-cell leukem ia/lym phom a 6 1.6
Cybb cytochrom e b-245, beta polypeptide 1.6
Nfil3 nuclear factor, interleukin 3, regulated 1.6
B130024L21Rik RIKEN cDNA B130024L21 g ene  1.6
5830406C15Rik RIKEN cDNA 5830406C15 gene 1.6
Klrkl killer cell lectin-like receptor subfamily K. m em ber 1 1.6
Scotin scotln gene
P lscrl phospholipid sc ram blase 1
P on3 p a ra o x o n a se 3  1.6
Evt Ena-vasodllator stim ulated phosphoprotein 1.6
2010012F05Rik RIKEN cDNA 2010012F05 gene 1.6
S tag2  strom al antigen 2 1.6
HRP12 heat-responsive protein 12 1.6
S ug tl SGT1, suppressor of G2 allele of SKP1 1.5
C d47 CD47 antigen 1.5
Ankrd17 ankyrin repeat domain 17 1.5
A dam decl ADAM-like, decysin 1 1.5
W ars .W R S  tryptophanyl-tRNA synthetase 1.5
P hxrl per-hexam er repea t g ene  1 1.5
Elf1 E74-like factor 1 1.5
C D200 CD200 antigen 1.5
Auh AU RNA binding proteln/enoyl-coenzyme A hydratase 1.5
C rebbp CREB binding protein 1.5
Usp22 ubiqurtin specific p ro tease 22 1.5
D 730040F13Rlk RIKEN cDNA D730040F13 g ene  1.5
R asd l RAS, dexam ethasone-induced  1 1.5
Snx2 sorting nexin 2  1.5
Ccr7 chem okine (C-C motif) receptor 7 1.5
1.6
1.6
I  218 4111
28 5?
125 229
168 312
74 f. 1358 u? m IM 56
195 345
1 150 1 272
1048 1877 1671 2136
101873_at
47 36
34
mm is®
1077 1806
544 897
270 453
222 366
5 4 |a  107 
422 691
107 178
22 36
213 355
119 184
1793 1234*
29 42
113 173
53 81
35 54
Ife 3*3
109 167
27 41
s s■ a n ia
106 165
22 11
05
165 246
20 ?S
282 310
100 139
1021 1197
381 337
206 265» 60 
426 377
103 173
24 31
21 18
1026 1524 4185 4556
X95603 
M63658 
X67809 
AI844839 
AA739233 
L14543 
AI843949 
AV026570 
X57796 
M55219 
AW 259199 
X98471 
AF072243 
U95826 
AA940352 
AI853542 
AW 049274 
U60020 
AV0O3419 
AW049730 
AI842128 
A W 121695 
AW045481 
M29281 
U16322 
AA409010 
AW 049573 
U65316 
AF054819 
AF079528 
AB008553 
AF077527 
AI316087 
AF080253 
AA881202 
M34896 
D63902 
AB029537 
AI848868 
Y11666 
AI157260 
U41465 
U43384 
U83148 
AV264147 
AW 120767 
AF030313 
AW 123754 
D78354 
L76193 
AV371846 
AI843520 
AI846890 
U50631 
AI838149 
AB012693 
A W 120783 
A J242912 
X69656 
X12809 
U19617 
AF029215 
AI837724 
AA177826 
AW 125800 
A F031164 
AF009246 
AW 259199 
L31580
Signal intensity
0-10
10-100
100-250
250-500
500-1000
1000-2000
2000-3000
3000-4000
4000-5000
>5000
Table 4.2 (continued) IFN-induced genes in splenic DCs after 2h but not 6h o f  culture
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than 1.5 due to high levels of expression in the untreated sample. In contrast, the TNF 
receptor (p55 subunit) mRNA which was induced by IFN-a4 at 2h, was lower at six hours in 
both untreated and IFN-treated samples. At 2h, the majority of differentially expressed 
genes represented those that were induced by IFN-a4, with only 16 genes being suppressed 
(Table 4.3). Most notably, IL-6 receptor expression was lower in IFN-DC. IL-6 is thought 
to maintain DCs in an immature state, and has been shown to inhibit LPS-induced maturation 
of BMDCs (Park et al., 2004b). Therefore, by down-regulating the IL-6 receptor DCs could 
escape this suppression, enabling their maturation.
48 genes showed elevated expression in IFN-treated versus untreated DCs after both 2h and 
6h of culture (Table 4.4). Many genes associated with DC function were induced by IFN at 
both timepoints, including IL-6, CD40 and the chemokines CXCL9 and CXCL10. A non- 
classical MHC class I gene from the TL locus was identified (H2-T10), which is recognised 
by the y8-T cell receptor. Ly6a, a haemopoietic stem cell marker, was expressed at very 
high levels after 6h of IFN-treatment. Ly6a expression is associated with lymphocyte 
activation (Malek et al., 1986), and has been shown to be dramatically induced in T cells by 
IFN-I and to a lesser extent IFN-y (Dumont et al., 1986). Ly6a is expressed constitutively 
on splenic DCs (Izon et al., 1994). Despite intense investigation, the function of Ly6a is still 
unclear, although it may be involved in cell signaling (Malek et al., 1986; Rock et al., 1986) 
and cell adhesion (Bamezai et al., 1995). Several other familiar genes are present in the data 
set, including Tyki and Pml. Another highly expressed gene is Vigl (viral hemorrhagic 
septicemia virus (VHSV) induced gene 1), which we had previously identified as IFN- 
induced by RDA. In mice, DCs have been identified as the main cell population which 
induce Vigl expression in response to vesicular stomatitis virus (VSV) infection and 
pseudorabies virus (PrV) by both IFN-independent and IFN-I-dependent pathways,
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G«n« Description
Fold
Change
2h Signal 
0 IFN
6h Signal Affymetrix
Accession
Genbank
A ccession
Gla; A gs galac tosidase . alpha
C ggbpl CGG triplet rep ea t binding protein 1
Sap18 Sin3-associated  polypeptide 18
Nfkbiz nuclear factor of kappa light polypeptide gene enhancer in B-cells Inhibitor, zeta
Galnt4 polypeptide N -acetylgalactosam inyltransferase 4
St6gall b e ta  galactoside alpha 2,6  sialyltransferase 1
IlSra interleukin 6 receptor, alpha
EST M ouse DNA se q u e n c e  from clone CT7-BM573K1 on  chrom osom e 17
1810029F08Rik RIKEN cDNA 1810029F08 gene
Apoa2 apolipoprotein A-ll
Sec63  SEC63-like (S. cerevisiae)
2310020H20Rik RIKEN cDNA 2310020H 20 gene
A430096B05Rik RIKEN cDNA A430096B05 gene
Elk1 ELK1, m em ber of ETS oncogene family
O rel I origin recognition complex, subunit 1-like (S.cereviaiae)
Dri1 d ead  ringer homolog 1 (Drosophila)
3.1
2.3
2.2
1.5
1.5
102341 at
95574 f at
44 « 161303 at161903 f at
161016 at
94431 at
104268 at
102169 at
161888 r at
99648  a t
99350  at
95645 at
162286 r at
96593 at
92458 at
103496 at
L46651
AI641995
AV054196
AV374591
AA673574
D 16106
X51975
A L078630
AV371196
X 62772
C76102
A I837440
AV373294
X87257
A J003133
U60335
Table 4.3 IFN -suppressed genes in splenic DCs after 2h but not 6h o f  culture.
Legend as in table 4.4 below
G e n e  D e sc r ip tio n
Fold
C h a n g e
S ig n a l
IFN
TDKI thym idylate k in ase  hom ologue 124.2
Ifit2 in terferon -induced  protein with te tra tricopep tide  re p e a ts  2 32 .0
Ifit3; Ifi49 in terferon -induced  protein with te tra tricopep tide re p e a ts  3 26 .0
IfiM interferon-induced  protein with te tra tricopep tide re p e a ts  1 23 .9
Cxcl10 ch em o k in e  (C-X-C motif) ligand 10 20 .6
Ifi47 in terferon  g a m m a  inducible protein 16.5
U sp18 ubiquitln specific  p ro te a se  18 13,8
Tgtp T-cell specific  G T P a se 12.8
Mx1 m yxovirus (influenza virus) re s is ta n c e  1 12.1
Ifl1 in terferon  inducible protein 1 11.5
Ifl203 interferon ac tiva ted  g e n e  20 3 10.9
Dnr12 D iabetic nephropa thy -re la ted  g e n e  1 10.0
Igtp In terferon g a m m a  induced  G T P a se 9.7
Vigl viral h em orrhag ic  sep ticem ia  virus(VHSV) induced g e n e  1 9.2
Igtp Interferon g a m m a  Induced G T P a se 9.2
IL-6 interleukin 6 8.4
Isg20 cDNA fo r in terferon s tim ulated  protein (20kD a) 8.0
Irf7 interferon regulatory  fac to r 7 6.2
Isg15 cDNA fo r interferon stim ulated  protein (15kD a) 5.9
P np p u rine-nuc leoside  p h o sp h o ry la se 4.8
Gbp2 g u an y la te  nucleo tide binding protein 2 4.4
Iflhl Interferon-induced  with h e lic a se  C  dom ain  1 4.3
G 1p2 interferon, a lpha-inducib le  protein 4.1
Daxx F a s -d e a th  dom ain  a s so c ia te d  protein Daxx 4.0
Mad M ax d im erization  protein 4.0
S o c s l s u p p re s s o r  of cy tokine signaling  1 3.7
Ifi205 in terferon ac tiva ted  g e n e  205 3.4
EST EST 3.2
CD40 tum or n ec ro sis  fac to r recep to r superfam ily, m em b er 5 3.2
Slfn2 sch la fen  2 3.0
Fgl2 p recu rso r; M ouse fibnnogen-like protein g e n e , exon  2. 2.9
Cxcl9 ch em o k in e  (C-X-C motif) ligand 9 2 .8
S a m h d l SAM dom ain  and  HD dom ain , 1 2.8
Slfn2 sch la fen  2 2.7
If rg 15 IFN-o re sp o n s iv e  g e n e 2.7
M arch5 M em b ran e -a sso c ia ted  ring finger (C 3H C 4) 5 2.5
Cited2 C bp/p300-in teracting  tran sac tiv a to r 2 2.5
C cr5 C -C  ch em o k in e  re c e p to r  5 2.5
Xdh x an th ine  d eh y d ro g e n a se 2.4
S o cs3 su p p re s s o r  of cytokine signaling 3 2.3
Iif1 interferon regulatory  fac to r 1 2.3
Ly6a lym phocyte an tigen  6 com plex , locus A 2.1
H2-T10 histocom patibility  2, T region locus 10 1.9
Adfp a d ip o se  differentiation re la ted  protein 1.7
Evi2 eco trop ic  viral integration s ite  2 1.6
Bzrp b enzo d iazep in e  recep to r, peripheral 1.6
C cn d l cyclin 01 1.6
Ifitm3 IFN -induced tra n sm e m b ra n e  protein 3 1.5
F o ld
C h a n g e
S ig n a l A ffym etrix
A c c e s s io n
G e n b a n k
A c c e s s io n
662
1669
■ J  11003 
42; 869
95 1827
. S3. - 896 
108 1531
155 1899
1*7 1746
44 |  497 
49 507
29 315
■ ■  426 
248 2199
■ ■  ^
90
275
4 .7  |
2 .5
m m  i m
1905 46 7 5
103066 a t 
103639_at
L32973
U 43085
2.2 1161 25 3 0 9 3 9 5 6  a t U 43086
1.8 1404 24 9 0 1 0 0 981_at U 43084
3.8 800 2266 9 3858  a t M 33266
1.9 1027 2027 1 0 4 750_at M 63630
2 .5 1670 4151 9 5 0 2 4 _ a t A W 047653
2 .0 2111 4230 102906_at L38444
2.2 1516 3378 9 8 4 1 7 _ a t M 21038
1.6 340 560 9 7 4 0 9  a t U 19119
2 .0 149 297 93321 a t A F 022371
2.7 260 722 100880_at AA816121
2 .5 343 856 1 60933_at U 53219
2 .9 1515 4384 104 1 7 7 _ a t AA20 4 5 7 9
2 .0 538 1068 98 410  at A J00 7 9 7 2
3.7 102 416 102218 a t X 54542
2 .8 604 1659 10 3 4 32_at AW 122677
2 .3 985 2240 104669 a t U 73037
2.1 447 933 161511 _ f_a t AV15 2 244
2.6 1396 3659 9 3 2 9 0 _ a t U 35374
3.0 764 23 3 6 104597 at A J0 0 7 9 7 0
1.7 660 fl 1101 103446 a t A A 959954
2 .0 2595 5214 98 8 2 2 _ a t X 56602
1.9 584 1149 96 1 2 5 _ a t A F 1 10520
3.4 94 6 8 8 _ a t X 83106
3.1 92832 at U 88325
1.7 3805 6521 9 4 2 2 4 _ s  a t M 74123
1.8
1.6
1.6
4 K
783
878
756
1271
160799 at 
92962  a t 
92 4 7 2 _ f_ a t
A W 0605 4 9  
M 83312 
A F099973
2 .0 712 1438 9 7 9 4 9 _ a t M 16238
2 .8 1073 2960 101436  a t M 34815
1.9 2187 4 2 2 3 103080  a t U 15635
1.7 1782 3 1 0 0 924 7 1 _ i_ a t A F099973
1.5 557 864 9 3 9 9 7  at A I853475
1.6 905 1429 9 9 6 0 4 _ a t A I848713
2 .9 169 494 1 0 1 973_at Y 15163
2 .8
4.0
2 .6
100
S
260
110
198
161968_f_at 
9 7 9 5 0  a t  
9 2 2 3 2 _ a t
A V 370035
X 75129
U 88328
1.9 843 1573 102401 a t M 21065
2.5 2892 7318 9 3 0 7 8 _ a t X 04653
1.5 995 1514 9 3 8 6 5 _ s_ a t M 35244
2.0 ■  374 757 9 8 5 8 9 _ a t M 93275
1.7 323 544 9 8 0 2 5 _ a t M3 4 896
1.5 312 553 93 042  at D 21207
1.8 1804 2732 94 2 3 2 _ a t A I849928
1.5 2443 3709 160253  a t A W 125390
Table 4.4 IFN -induced genes in splenic DCs after both 2h and 6h culture.
Samples from  CD1 lc" DCs cultured in vitro in the presence o f  2 x 104 U  IFN -o4 (IFN ) or in 
m edia alone (0) were hybridised to A ffym etrix m urine U 74A v2 arrays. D ata w ere generated  
from  the m ean o f  three experim ents carried out on  independently  isolated D Cs. D ata w ere 
analysed in G enespring 7.2 and changes o f  m ore than 1.5 fold w ere determ ined to be 
significant by  W elch’s approxim ate t-test w here p-values w ere less than or equal to 0.05. 
N orm alised signal intensities w ere colour coded to indicate the level o f  expression, as show n 
in the key for table 4.2.
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respectively (Boudinot et al., 2000). The human homologue, cig5, is also induced by IFN-I 
and has been shown to inhibit the replication of human cytomegalovirus (HCMV) (Chin et 
al., 2001).
In contrast to the 2h data, there were more IFN-suppressed genes than IFN-induced genes at 
6h. The genes induced by IFN at 6h but not 2h are listed in table 4.5. These included Ly86 
(also known as MD-1) which is found associated with, and positively regulates the cell 
surface expression of a B cell surface molecule which promotes cell proliferation, RP105, 
(Miyake et al., 1994; Miyake et al., 1998). RP105/Ly86 shares structural similarity to
TLR4/Ly96 and has an important role in the immune response to LPS (Ogata et al., 2000). 
Ly86 is necessary for maximum proliferation of B cells in response to LPS (Nagai et a l, 
2002). RP105/Ly86 expression was originally thought to be restricted to B cells. However
it has recently been shown to be expressed on macrophages and DCs (Divanovic et al.,
2005). In addition it was shown that RP105/Ly86 can interact directly with TLR4/MD-2 
and acted to suppress TLR4 signaling in a transfected cell line. TLR4-induced secretion of 
TNF, IL-12p70 and IL-6 by DCs was increased in RP105-deficient mice, indicating that 
RP105 acts as a negative regulator of TLR4 responses. Therefore this could represent an 
example of how type I IFNs could dampen an inflammatory response.
Interestingly, IL-6 signal transducer expression was suppressed at 6h by IFN-a4 (Table 4.6), 
which represents a second possible mechanism for avoidance of IL-6 regulation, along with 
the downregulation of IL-6 receptor expression seen after 2h.
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G ene N am e G ene  d esc rip tio n  _
Ifng interferon gam m a
ligp-pendmg interferon inducible G T P ase  1
Slfn4 schlafen4 (Slfn4)
ligp-pendmg interferon inducible G T P ase  1
Fcgrl Fc receptor, IgG, high affinity I
ART3 ADP-rtbosyltransferase 3
IMOra interleukin 10 receptor, alpha
Ccl4 chem okine (C-C motif) ligand 4
Inpp5b inositol polyphosphate-5-phosphatase B
P tgs2 prostaglandm -endoperoxide syn thase 2
C nn3 calponin 3. acidic
Inpp5b inositol polyphosphate-5-phosphatase B
Lgals9 lectin, galactose binding, soluble 9
Him interleukin 1 receptor antagonist
Atf3 activating transcnption factor 3
Ch25h cholesterol 25-hydroxylase
Gzmb granzym e B
C 3 com plem ent com ponent 3
Perp  PERP, TP53 apoptosis effector
D nase1l3 deoxyribonuclease 1-like 3
P ttg l pituitary tumor-transforming 1
A nxal annexin A1
Gjb2 g ap  junction m em brane channel protein beta  2
Socs3  sup p resso r of cytokine signalling-3 (SOCS-3)
Caml calcium modulating ligand
Enam  enam elin
A!f3 activating transcription factor 3
C pne4 cytokine inducible SH2-containing protein
Phc2 polyhomeotic-like 2 (Drosophila)
Irf6 interferon regulatory factor 6
Serpm a3g spi2 pro teinase inhibitor
Set secretin
4930422J18Rik RIKEN cDNA 4930422J18 gene
Lag3 lymphocyte-activalion g ene  3
lesbpi interferon co n sen su s seq u en ce  binding protein 1
Lgals9 lectin, galac tose  binding, soluble 9
Mthfr 5,10-m ethylenetetrahydrofolate reductase
Hck hem opoietic cell kinase
Ndr1 N-myc dow nstream  regulated 1
C arhsp l calcium regulated heat stable protein 1
Ccl5 chem okine (C-C motif) ligand 5
Pstp ip l proline-serine-threonine phosphatase-interacting protein 1
Slc30a1 solute carrier family 30 (zinc transporter), m em ber 1
Dnmt2 DNA m elhyltransferase 2
5430432M24Rik RIKEN cONA 5430432M 24 gene
1110014K08Rik RIKEN cDNA 1110014K08 gene
Flnb filamin, beta
Trpm l transien t receptor potential cation channel, subfamily M, m em ber 1
Ly6e Thymic shared  antigen-1 (TSA-1) gene
Rnf4 ring finger protein 4
Nedd8 neural p recursor cell exp ressed , developmentally down-regulated gene 8
Fpr-rs1 formyf peptide receptor, related seq u en ce  1
Cam k4 calcium /calm odulin-dependent protein kinase IV
E330014L15Rik RIKEN cDNA E330014L15 g ene
Prg proteoglycan, secretory granule
2310004l24Rik RIKEN cONA 2310004I24 gene
Arf6 ADP-nbosylation factor 6
Prdxl peroxiredoxin 1
Casp4 c a sp a se  4, apoptosis-related cysteine pro tease
Olfr89 olfactory receptor 89
Kcnm al potassium  large conductance calcium-activated channel. Mol
Genbank
Accession
Atp6v1d A TPase, H+ transporting, V1 subunit D 1.7 664 1121 744
Ly86 lymphocyte antigen 86 1.6 593 968 559 871
G dap10 ganglloside-induced differentiation-associated-protem  10 1.6 170 282 387 609
Ctla2a cytotoxic T lym phocyte-associated protein 2  alpha 1.8 109 181 106 188
Gch GTP cydohydro lase 1 1.6 121 196 278 425
Ppp1r15b protein p h o spha tase  1, regulatory (inhibitor) subunit 15b 1.6 174 284 275
Plac8 placenta-specific 8 1.6 2925 4733 2403 2 7 8 ^
Akr1a4 aldo-keto reduc tase  family 1, m em ber A4 (aldehyde reductase) 1.6 3105 4970 1640 2250
Set
2410002M20Rik
Hat1
IL2R
1200016E24Rik 
4930565N07Rik
trans-golgi network protein 
secretin
RIKEN cDNA 2410002M 20 
histidine am inotransferase 1 
M ouse interleukin 2 receptor 
RIKEN cDNA 1200016E24 g ene  
RIKEN cDNA 4930565N07 gene
Ig V kappa-PCG-4 M ,m usculus Ig Vkappa-PCG-4 g ene  
Krt1-2 keratin com plex 1, acidic, g ene  2
Ung uracll-DNA glycosylase
Npc2 Niem ann Pick type C2
pyp pyrophosphatase
Btg3 B-cell translocation g ene  3
P sm b9 pro teosom e subunit, beta  type 9
C sk  c-src  tyrosine kinase
Atp1b3 A TPase, Na+/K+ transporting, be ta  3 polypeptide
Tap2 transporter 2, ATP-binding casse tte , sub-family B (MDR/TAP)
Rnh1 ribonuclease/angiogenin inhibitor 1
Affymetrix6h Signal 2h Signal
A ccessio nC hange
99334 at K00083
96764 at A J007971
92315 al AF099977
103963 f al AA914345
212 102879 s  al M31314
98924 al Y08027
96525 at L12120
94146 at
94398 s al AF040094
104647 at M88242
160150 f at AW 125626
94399 al AI843172
103335 at J550I 0
564 1444
609 1489 104155 f at U19118
32
75 la -
93  222
104509 at AF059213
102877 al M12302
93497 at K02782
97825 at AI854029
94107 at
101027 s  at386 §275^ 6^  
70  152
113 237
66 p  134
AF069051
93038 f at M69260
98423 al M81445
162206 f at AV3 74868
104529 at U21960
94623 at U82698
104156 r al U19118
66 113 100022 at
92867 al AF060076■■WTfcr 92440 al
102860 al251 I 
703 1368
■■9363fiHm  !30
286 546He 1122I MB 777 
167 311
.*• 4 0c-.
92756 f at ' ' iccC
161013 f at A,1596360
98392 at X98113
98002 at995 1232 M32489
161301 f at AV049898
102360 al AW 214225
93483 at J03023
160464 s  at U60593
96884 at AI847631
98406 at4313 7897 2555 3055 AF065947
103946 at U87814
93938 at U17132
93470 at AF012129
103343 at AI845815
98910 al47Q 
315 463
t t t t  i n  .
AI846118
95637 at AI838592
102251 at At 047714
101487 f at6681 12075 3734 4338 U47737
93782 at A1844517
162180 r AV367714
95770 AF071179
104455 at J 03057
103517 at
94085 at •00400  ■
104334 at AW 060314
100462 at D87903
97758 at6360 1 0927 1497 2097
102905 at Y13089
102583 at A J132195
97759 at U09383
96951 at AI839795
94425 at AB007599
94192 at Y17860
96912 s  at X15591
102313 .09737
95609 at
98092 at AA790307
96888 at AI839814
99144 D50031
92756 r at
104713 at AA863717
97895 f740 1112 AW 125218
101917 at M26271
99849 at3758 4368
431 93779 at -  -v 61002
96975 at • 82 691
97767 at
102792 at U55040
160344 at1024 1377 AB021289
194 416
176 182
■707 94W
188 225
160314 at A 839803
96146 al
93085 al
94046 al U05247
1555 1912 99579 al u- ■:■ >. i
209 296 102873 ai .j,
100621 AI848825
1124■■
633
260
1252
Table 4.5 IFN -induced genes in splenic D C s after 6h but not 2h o f  cu lture Sam ples 
from  CD1 l c + D Cs cultured in vitro in the presence o f  2 x 104 U  IFN -o4 (IFN ) or in m edia 
alone (0) w ere hybridised to A ffym etrix  m urine U 74A v2 arrays. D ata w ere generated 
from  the m ean o f  three experim ents carried  out on independently  iso lated  D Cs. D ata w ere 
analysed in G enespring 7.2 and changes o f  m ore than 1.5 fold w ere determ ined to be 
significant by  W elch ’s approxim ate t-test w here p-values w ere less than or equal to 0.05. 
N orm alised signal intensities w ere colour coded to indicate the level o f  expression, as 
show n in the key for table 4.2.
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G ene description
Fold
Change
6h S ignal 
IFN
2h S ig n a l 
IFN
Affymetrix
Accession
Genbank
Accession
Cct22 chem okine (C-C motif) ligand 22 2.9
S lc39a7 solute carrier family 39  (zinc transporter), m em ber 7 2.7
R ad50 RAD50 homolog 2.7
G us b eta-g lucuronidase 2.6
Spic Spi-C transcription factor 2.6
Igsf4 immunoglobulin superfamily, m em ber 4 2.6
Erh e n h an ce r of rudim entary homolog (Drosophila) 2.5
BC005662 cDNA se q u e n c e  BC005662 2.4
Kctd12 potassium  channel te tram erisation  dom ain containing 12 2.3
Ogt O-linked N -acetylglucosamirre (GlcNAc) transfe rase 2.3
Cd1d1 CD1d1 antigen 2.3
Ugt1a1 U D P-glucuronosyltransferase 1 family, m em ber 1 2.2
1810003N24Rik RIKEN cDNA 1810003N24 g ene 2.2
Fdps farnesyl d iphosphate  syn the tase 2.2
Sf3a1 splicing factor 3a , subunit 1 2.1
A pbblip amyloid b e ta  (A4) precursor protein-binding. B1 interacting protein 2.1
Bub1 budding uninhibited by benzim idazoles 1 homolog 2.1
U2af1 U2 small nuclear ribonudeoprotein auxiliary factor 1 2.1
Taf9 TAF9 RNA polym erase II, TB P-associated  factor 2.1
G sr glutathione red u c ta se  1 2 .0
Fdps farnesyl d iphosphate  syn the tase 2.0
111 b interleukin 1 beta 2.0
T c te ll t-com plex -assoc ia ted -testis-exp ressed  1-like 2.0
Sqle sq u a len e  epoxidase 2.0
2310046H11Rik RIKEN cDNA 2310046H11 g ene 2.0
mf6 ring finger protein (C3H2C3 type) 6 2.0
psm dl p ro teaso m e 26S  subunit. non-A TPase, 1 2.0
Ivnslabp influenza virus NS1A binding protein 2.0
A 430106J12Rik RIKEN cDNA A 430106J12 g en e 1.9
S ca10 spinocerebellar a taxia 10 homolog 1.9
G sto l glutathione S -tran sfe rase  om ega  1 1.9
Adh5 alcohol deh y d ro g en ase  5  (c la ss  III), chi polypeptide 1.9
C at ca ta la se 1.9
Cxcr4 chem okine (C-X-C motif) receptor 4 1.9
Ptm a prothym osin alpha 1.8
6330406L22Rik RIKEN cDNA 6330406122 g ene 1.8
psarl presenilin a sso c ia ted , rhomboid-liko 1.8
Cct8 chaperonin  subunit 8  (theta) 1.8
0610011l04Rik RIKEN cDNA 0610011104 gene 1.8
neat interleukin 6 signal transducer 1.8
Kindi killer cell lectin-like receptor, subfamily D. m em ber 1 1.8
Fnbpl Form in binding protein 1 1.8
Kpna2 karyopherin (importln) a lpha 2 1.8
C dkap l CDK2 (cyclin-dependent kinase 2)-assoc ia ted  protein 1 1.8
1500010B24Rlk RIKEN cDNA 1500010B24 g en e 1.8
1300006C06Rik RIKEN cD N A 1300006C06 gene 1.8
B230365D05Rik RIKEN cDNA B230365D05 g ene 1.8
Anxa3 annexin A3 1.8
Ntanl N -terminal Asn am idase 1.7
Atp6ap1 A T P ase, H + transporting , lysosom al accesso ry  protein 1 1.7
C ops6 C O P 9 (constitutive photom orphogenic) homolog, subunit 6 1.7
Atf1 activating transcription factor 1 1.7
Dock2 dedicator o f cyto-kinesis 2 1.7
2510049l19Rik RIKEN cDNA 2510049119 gene 1.7
Cdc34 cell division cycle 34 homolog 1.7
Up1 lysosom al acid lipase 1 1.7
Rpn1 sim ilar to nbophorin I 1.7
Galt g a lac tose-1 -phosphate  uridyl tran sfe ra se 1.7
1200015A19Rik RIKEN cDNA 1200015A19 g en e 1.7
Stip 1 s tress-induced  phosphoprotein 1 1.7
BC032204 cDNA se q u e n c e  BC032204 1.7
Set SET translocation 1.7
1810044022R ik RIKEN cDNA 1810044022  g ene 1.7
Tm7sf1 M us m usculus transm em brane  7 superfam ily m em ber 1 1.7
Hcfcl host cell factor C1 1.7
Jtb jum ping translocation  breakpoint 1.7
Lta4h leukotriene A4 hydrolase 1.7
Bcat2 branched  chain am ino transferase  2, mitochondrial 1.7
1500 519 365 237
76
132
200
M il
184
77
111 43 527 475
631 245 |  209 193
642 ■  250 935 1190
350 139 632 621
177 74 116 121
187 558 661
61 111 128
25- 216 264
652 291 299 264
116 54 235 214
292 136 149 185
«4 44 126 109
310 146 736 844
25
435
«
233
213 103 257 249
408 199 103 102
225 111 135 144
2386 1174
175 
154 
247 133
137 I
166 90
1017 553
620 337
164 iV 90 
265 146
130 71
495 275
243 135
66 37
339 189
264 147
210 118
231 130
553 , '9 ia  1
51 ■»:
214 123
144
138 
191 199
235 148
155 81
275 163
s  s
118 111
208 224
45  3b
268 304
312 324' 44^ 83
375 406
377 380
330 381 I
63 7b
407 299
19 2245
107 ,
8 0  48
535
189
245
395
162
473
273
84
251
212
202
181
188
267 
441 
171 
478
268 
6 0  
264 
232 
212 
182
299 341
5 2  66
312 331
102310_at 
103371_at 
100459_at 
97538_at 
103454_at 
93604_f_at 
94040_al 
1 6 0 8 9 f a t  
104735_at 
94818_at 
103422_at 
99580_s_at 
9 7237_at 
9 9098_at 
96027_at 
102710_at 
104097_at 
97486_at 
103074_f_at 
160646_at 
160424_f_at 
103486_at 
95056 r_at 
94322_at 
161342_r_at 
104049_at 
9 5483_at 
9 7302_at 
95288_i_at 
99127_at 
9 7819_at 
98625 s_ a t 
160479_at 
102794_at 
100718_at 
100511_at 
96641_at 
160102_at 
96605_al 
94345_at 
93677_at 
103638_at 
92790_at 
98532_at 
93358_at 
97401_ a t 
104315_at 
101393_at 
9 6666_at 
9 4043_at 
99106_at 
100984_at 
103462_at 
97866_at 
9 4048_at 
102123_at 
1 6 1 4 0 0 J_ 3 t 
104616_g_at 
95737_at 
100081_at 
160815_at 
98550_at 
96878_at 
103017_at 
100900_at 
102790_at 
100540_at 
100443_at
AF052505 
AF100956 
U66887 
M19279 
AA182189 
A F061260 
D73368 
AW060889 
AI842065 
A W 047223 
M63695 
U16818 
AI837771 
AW045533 
AW120546 
AF020313 
AF002823 
AA693246 
AI842969 
AI851983 
AI846851 
M15131 
AW 122747 
D 42048 
AV136028 
AW 047134 
A W 123318 
AI854285 
AA189811 
X61506 
AI843119 
M 84147 
M 29394 
Z80112 
X56135 
AI154249 
A W 060674 
Z37164 
AI787183 
AI843709 
A F030311 
AW 046460 
D 55720 
AF011644 
AI836451 
AW124244 
AI846773 
A J001633 
U57692 
AB031290 
AF071315 
M 63725 
AW 122239 
AI842858 
AW 120683 
231689 
AV276050 
M96265 
AW120814 
U27830 
AA709534 
AI854006 
AW048566 
AI060729 
AW 209053 
A B016490 
M63848 
A F031467
Table 4.6 (continued over page) IFN -suppressed  genes in splenic D C s after 6h but not 
2h o f culture. Sam ples from  CD1 l c + D Cs cultured  in vitro in the presence o f  2 x 104 U 
IFN -g4  (IFN ) or in m edia alone (0) w ere hybrid ised  to A ffym etrix  m urine U 74A v2 arrays. 
Data w ere generated  from  the m ean o f  three experim ents carried  out on independently  
isolated DCs. D ata w ere analysed in G enespring 7.2 and changes o f  m ore than 1.5 fold were 
determ ined to be significant by  W elch ’s approxim ate t-test w here p-values w ere less than or 
equal to 0.05. N orm alised  signal intensities w ere colour coded to indicate the level o f  
expression, as show n in the key  for table 4.2.
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Gena description
Tpm1 tropom yosin 1, alpha 1.6
S100a4 S 1 00 calcium binding protein A4 1.6
Eif3s10 eukaryotic translation initiation factor 3, subunit 10 (theta) 1.6
3230402J05RIK RIKEN cDNA 3230402J05  g ene 1.6
Fto fatso 1.6
Matr3 matrin 3 1.6
Cops3 C O P9 (constitutive photom orphogenic) homolog, subunit 3 1.6
1110031 E24Rik RIKEN cDNA 1110031E24 g ene 1.6
Cct5 chaperonin subunit 5  (epsilon) 1.6
Rbbp4 retinoblastom a binding protein 4 1.6
1300010A20Rik RIKEN cDNA 130001OA20 g ene 1.6
3300001G02Rik RIKEN cDNA 3300001G02 g ene 1.6
Adprtl2 ADP-ribosyttransferase (NAD+; poly(ADP-ribose) polymerase>-like 2 1.6
2310066N05Rik RIKEN cDNA 2310066N 05 gene 1.6
2700038L12Rik RIKEN cONA 2700038L12 g ene 1.6
Nde1 n uclear distribution g e n e  E homolog 1 1.6
Adss2 adenylosuccinate  syn the tase  2, non m uscle 1.6
G3bp R as-G T Pase-activating protein SH 3-dom ain binding protein 1.6
W dr13 W O rep ea t dom ain 13 1.6
Mtch2 m itochondrial carrier homolog 2 1.6
2410195B05Rik RIKEN cDNA 2410195B05 g ene 1.6
Srebfl sterol regulatory elem en t binding factor 1 1.6
Ext1 e x o s to se s  (multiple) 1 1.6
Emp3 epithelial m em brane protein 3 1.6
0610009D07Rik RIKEN cDNA 0610009D 07 g ene 1.6
1810009M01 Rik RIKEN cDNA 1810009M01 gene 1.6
2310047l15Rik RIKEN cDNA 2310047115 1.6
txnl2 thioredoxin-like 2 1.6
Apg5l au tophagy 5-like 1.6
H2afz H2A hlstone family, m em ber 2 1.6
0610043B10Rik RIKEN cDNA 0610043B10 gene 1.6
Vcp valosin containing protein 1.6
Cks2 CD C28 protein k inase regulatory subunit 2 1.6
G d c glu tam ate-cysteine ligase. catalytic subunit 1.6
1810012E07Rik RIKEN cDNA 1810012E07 g ene 1.6
Uqcrc2 RIKubiquinol cytochrom e c  reduc tase  core  protein 2 1.6
Ncb5or NADPH cytochrom e B5 oxidoreductase 1.5
selenoprotein selenopro tein 1.5
0 6W su116e EST D 6W su116e 1.5
Mt2 m etallothionien II; M ouse metallothionein II (MT-II) gene . 1.5
Cct7 chaperonin  subunit 7 (eta) 1.5
Rnu22 RNA, U22 sm all nucleolar 1,5
Stk 18 serine/threonine k inase  18 1.5
1110001 M20Rik RIKEN cDNA 1110001M20 g ene 1.5
pdapl PDGFA asso c ia ted  protein 1 1.5
Macfl m icrotubule-actin crosslinking factor 1 1.5
803Q499H02Rik RIKEN cDNA 8030499H 02 g ene 1.5
C apzb capping protein (actin filament) m uscle 2-line, beta 1.5
P sm a l p ro teasom e subunit, a lpha type 1 1.5
C530002L11Rik RIKEN cDNA C 530002L11 g en e 1.5
Dighl d iscs, large homolog 1 1.5
Tiall Tiall cytotoxic granu le -assoc ia ted  RNA binding protein-like 1 1.5
G6pdx glucose-6 -phosphate  d ehydrogenase  X-linked 1.5
Acly ATP citrate lyase 1.5
Sucla2 succinate-C oenzym e A ligase, ADP-forming, b e ta  subunit 1.5
C79802 ex p ressed  se q u e n c e  C79802 1.5
Dstn destrin 1.5
Oat ornithine am inotransferase 1.5
G dpdl glycerophosphodiester p h o sphod ieste rase  dom ain containing 1 1.5
C cndbpl cyclin D-type binding-protein 1 1.5
Cd63 C d63 antigen 1.5
Tcf7 transcription factor 7, T-cell specific 1.5
0dx54 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 1.5
1110033G07Rik RIKEN cDNA 1110033G 07 g ene 1.5
Pygb brain glycogen phosphorylase 1.5
Tebp-pending telom erase  binding protein, p23 1,5
Atp5c1 ATP syn thase . H+ transporting, mitochondrial F1 com plex, g1 1.5
Affymetrix6h S ignal 2h S igna l Genbank
AccessionIFN
" 251 220
Accession
607
«a 98
349 339
53 .81
230 221
840 755
118
89
215 135
406 25336
185 118
163 103
309 194
309 195
359 226
617 390
274 173
433 275
118 9-
1868 1789
308 196
660
132 
61 
107
171 112
,34 88
516 338
176 115
123 81
160532_at 
99051_at 
94250_at 
93203_f_at 
98460_at 
96012_f_at 
99113_at 
98057_at 
93295_at 
92647_at 
104398 a, 
97412_at 
100903_at 
97802_at 
160293_at 
94910_at 
99038_at 
103642_at 
94374_at 
160262_at 
96677_at 
93264_at 
102811_at 
93593_f_at 
95714_at 
97885_at 
97448_at 
102103 f_at 
94225_at 
101954_at 
96615_at 
100710_at 
97527_at 
99649_at 
99655_at 
102000_f_at 
97922_at 
96249_at 
98880_at 
101561_at 
160562_at 
97838_at 
98996_at 
95477_at 
104080_at 
98402_at 
103889_at 
9 5142_s_at 
96892_at 
96710_at 
160849_at 
99947_at 
94966_at 
160207_at 
93501_f_at 
95659_at 
94492_at 
92848_at 
95470_al 
101483_at 
160493_at 
97994_at 
95433_at 
97407_at 
97489_at 
94259_at 
92798 at
M22479 
M36579 
U14172 
AW107463 
A J237917 
AI835367 
AF071313 
A W 121162 
Z 31555 
U35141 
AI846222 
AI843157 
A J007780 
AI850195 
AI839817 
AW120739 
L24554 
AB001927 
AI850378 
AI639901 
AI849566 
AI843895 
X 96639 
U87948 
AI226264 
AB031386 
AI845165 
AI482454 
AI844679 
U70494 
AI840137 
214044 
AA681998 
U85414 
AB025405 
AI842835 
AW 045597 
AW 122105 
AW 124955 
K 02236 
2 31399 
AA684508 
L29480 
AW 125185 
A W 212479 
AI843799 
AI834833 
U10407 
AI836804 
AI854262 
U93309 
U55861 
Z11911 
A W 121639 
AF058955 
AF041476 
A B025406 
X64837 
AI846025 
AI850862 
016432  
AI019193 
AW 049776 
AI848025 
AI846739 
AB024935 
AA870675
Table 4.6 (continued) IFN -suppressed  genes in splenic D C s after 6h but not 2h o f  culture
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4.2.1.4 Identification and analysis o f  genes with potential function in DC mediated 
immune responses
Our original aim was to identify IFN-I regulated genes which enhanced the ability of DCs to 
initiate and sustain an effective adaptive immune response. We hoped to find genes 
encoding cell surface molecules involved in either recognition and uptake of antigen, cell­
cell interactions or cell migration. We were also interested in genes encoding secretory 
factors which could affect the function and/or migration of other cells, thereby influencing 
the type of response elicited.
We identified five genes of unknown function containing domains which suggested a role in 
immune function (Table 4.7). Several of the genes contained transmembrane domains 
indicating cell surface localization, in addition to domains common to other proteins 
involved in the immune response such as a domain found in tumour necrosis family (TNF) 
receptors and CD40. The gene Ppicap encodes a protein which contains the scavenger 
receptor cysteine-rich domain (Chicheportiche et al., 1994), a highly conserved domain 
found in diverse secreted and cell surface proteins. These domains are thought to mediate 
protein-protein interactions and ligand binding (Freeman et al., 1990). Two of the genes 
identified, designated Ms4a4c and Ms4a6b, belong to the membrane-spanning 4A (Ms4a) 
family. This is a large family with members including CD20 and FcsRIp, all of which have 
conserved transmembrane domains and are thought to be components of oligomeric cell 
surface complexes (Liang et al., 2001). Members of this family are expressed in different 
tissues and cell types, and the predicted extracellular domains share little sequence homology 
which suggests they serve multiple diverse roles. Ms4a4c and Ms4a6b are expressed at very 
high levels in the lymphoid organs and at low levels in non-lymphoid organs (Liang et al.,
2001). In addition, Ms4a4c has been shown to be differentially expressed in the DC subsets
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y . Proteins containing domain/
Gene Name Symbol Accession Protein domains Interpro Domain function
G-protein coupled Gpr33 94184_at Rhodopsin-like GPCR family IPR000276 Chemokine receptors
receptor33
IMAGE 4168084 102965_at TNFR/CD27/30/40/9 IPR001368 TNF receptors, CD40, CD2 7,
5 cysteine-rich region C D 30,4-1BB, FAS, 0X 4 0
Membrane-spanning 4 Ms4a4c 98373_at Transmembrane domains 
domains 4a4c
CD20 domain IPR007237 CD20, IgE Fc receptor 0  subunit
Membrane-spanning 4 Ms4a6b 97322_at Transmembrane domains 
domains 4a6b
CD20 domain IPR007237 CD20, IgE Fc receptor fi subunit
Peptidylprolyl Ppicap 97507_at Scavenger receptor domain IPR001190 Macrophage scavenger receptor-1,
isomerase C-associated CD5, CD6, Mac-2, MARCO
protein BTB/POZ domain IPR000210 Dimerisation
Table 4.7 Genes induced by IFN-a4 in sDCs with potential function in DC-mediated immune responses
(Edwards et a l, 2003a). One of the genes chosen for further study was G-protein coupled 
receptor 33 (Gpr33), a putative seven transmembrane protein sharing highest homology with 
chemoattractant receptors (Marchese et al., 1998).
We analysed expression of these genes by real-time PCR in DCs, T and B cells treated in 
vitro with IFN-a4. The results confirmed the microarray data; all genes were expressed at 
higher levels in IFN-treated DCs after both 2h and 6h of culture (Figure 4.4). The level of 
expression for all of the genes was higher in untreated DCs cultured for 6h compared to 2h 
(Figure 4.4b). The majority of the genes were also elevated in T and B cells treated with 
IFN-a4 compared with untreated controls, in some cases to a greater extent than in DCs. 
For example, Ms4a4c mRNA levels were more than 15-fold higher in CD4+ T cells and 
Ppicap mRNA was around 10-fold higher in both T and B cells. We also compared the level 
of gene expression between untreated DCs and non-DCs cultured for 2h. Ms4a6b was 
expressed predominantly in T cells, while Ms4a4c was expressed at higher levels in B cells 
and at lower levels in CD4+ T cells compared to DCs.
Expression of Gpr33 was interesting since the level of mRNA was not elevated by IFN-a4 in 
any cell type other than DCs. In addition, as well as being higher in DCs after 6h of culture, 
expression was lower in untreated T cells. Although expression in B cells was similar to that 
in DCs, it was expressed at a lower level after IFN-a4 treatment.
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Figure 4.4 Levels o f  expression  o f the genes o f  in terest identified  by 
m icroarray varies betw een cell types. R eal-tim e PCR was carried  out for 
RNA extracted  from  D Cs, T  and B cells cultured in m edium  alone o r w ith 2 
xlO 4 U  IFN -I. C D 4+ and C D 8+ T cells and B cells w ere isolated from  the lym ph 
nodes by D ynabead depletion  follow ed by FACS sorting. Cell purities w ere 
>99% . a) R esults are p lotted as fold change in expression in IFN -treated  versus 
untreated  DC. b) R esults are p lo tted  as fold change in expression o f  untreated  
cells com pared to the untreated  DC at 2h.
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4.2.2 Microarray analysis of BMDCs treated with IFN-I
4.2.2.1 Experimental overview
Splenic DCs undergo a ‘spontaneous’ maturation during in vitro culture (Montoya et al.,
2002), possibly due to activation during the isolation procedure. We also noted that the 
splenic DCs rapidly lose viability during culture (discussed later, section 5.2.2.3). These 
factors are likely to complicate gene expression analysis, therefore we decided to compare 
DCs derived from bone marrow cells which may provide a more robust and immature source 
of DCs. We isolated C D llc+ DCs from bone marrow cells cultured for eight days in 
medium containing GM-CSF, followed by a culture of two or six hours in medium alone or 
medium containing 2 x 104 units of IFN-a4. The RNA samples were processed and 
hybridized to Murine Genome 430 2.0 arrays, which contain probe sets for over 39,000 
transcripts. The experiments were carried out in triplicate and analyzed using Genespring 
software. 644 genes were identified as IFN-regulated after 2h IFN-I stimulation and 790 
genes after 6h, of which 169 were common to both (Figure 4.3). The greater number of 
differentially expressed genes identified compared to the splenic DC samples is a reflection 
of the greater number of transcripts present on the arrays.
4.2.2.2 Analysis o f differentially expressed genes
Less than one third of the genes differentially expressed at the 2h timepoint only were 
upregulated by IFN-I (142 out of 475). These are listed in table 4.8; for simplicity, 
transcripts representing ESTs for which limited annotations were available are not shown. 
As expected, IFN-induced genes Ifitl and Ifit2 were identified. These still appear to be 
elevated by IFN-I at 6h but did not pass the fold change cut-off point of 1.5. One gene 
whose expression we had not previously detected as being IFN-induced was Pnp (purine- 
nucleoside phosphorylase) which was highly expressed at both the 2h and 6h timepoints. In
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Description
2h Signal 6h Signal Affymetrix
Accession
Genbank
A ccession
Hit2 interferon-induced protein with tetratricopeptide rep ea ts  2 19.1
Tyki thymidylate kinase family LPS-inducible m em ber 14.2
O a s lb 2 '-5 'o llgoadenylate  sy n the tase  1B 13.7
A cac acetyt-C oenzym e A carboxylase 8.1
Ifltl interferon-induced protein with tetratricopeptide rep ea ts  1 7.6
S o c s l su p p resso r of cytokine signaling 1 7.3
Slc6a14 solute carrier family 6 m em ber 14 4.4
Nt5c3 5 '-nucleotidase. cytosolic III 4.2
Vig1-pending viral hem orrhagic sep ticem ia virusfVHSV) induced gen e  1 4.2
Panx3 pannexin 3 4.1
P ttg l pituitary tum or-transform ing 1 3 .9
Cyp2f2 cytochrom e P450, family 2, subfamily f, polypeptide 2 3 .8
S ta tl signal tran sd u cer and activator of transcription 1 3.5
Slfn3 schlafen 3 3.5
T im eless tim eless homolog (Drosophila) 3.3
Cited2 C bp/p300-interacting transactivator 3.2
S o c s l su p p resso r o f cytokine signaling 1 3.1
Znfn1a2 zinc finger protein, subfamily 1 A, 2  (Helios) 3.0
Pml promyelocytic leakem ia gene 3.0
Klrkl killer cell lectin-like receptor subfam ily K, m em ber 1 3.0
R slcan l regulator of sex-limitation candidate  1 2.8
Nudt11 nudix (nucleoside diphosphate  linked moiety X)-type motif 11 2.8
Trim 34 tripartite motif protein 34 2.8
Xdh xanthine dehydrogenase 2 .7
Hsh2 hem atopoietic SH 2 protein 2.6
T rexl three prime repair exonuclease  1 2.5
Aldh1b1 aldehyde dehydrogenase  1 family, m em ber B1 2.5
Mthfr 5,10-m ethytenetetrahydrofolate reduc tase 2.4
Prkr protein kinase, interferon-inducible double  stranded  RNA d ep en d en t 2.3
Trim25 tripartite motif protein 25 2.2
Trim25 tripartite motif protein 25 2.1
Bace2 beta-site  APP-cleaving enzym e 2 2.1
Pfdn5 prefoldin 5 2.1
Kdr kinase insert dom ain protein receptor 2.1
Galk2 galactokinase 2 2.1
Zfp354b zinc finger protein 354B 2.0
Foxp2 forkhead box P2 1.9
Eya3 ey e s  ab se n t 3 homolog (Drosophila) 1.9
G pr120 G protein-coupled receptor 120 1.9
Mllt2h homolog of hum an MLLT2 unidentified gene 1.8
Lrat lecithin-retinol acy ltransferase 1.8
R s lh retinoschisis 1 homolog (hum an) 1.8
V cam l vascular cell adhesion  m olecule 1 1.8
Pttg l pituitary tum or-transform ing 1 1.8
T m 4sf10 transm em brane  4  superfamily m em ber 10 1.7
G pr44 G protein-coupled receptor 44 1.7
P la2g2a phospholipase A2, group  IIA 1.7
Tin talin 1.7
Mcf2 mcf.2 transform ing seq u en ce 1.7
Prlpc3 prolactin-like protein C 3 1.7
Zc3hav1 zinc finger CCCH type, antiviral 1 1.7
Pnp purine-nucleoside phosphorylase 1.6
N apb N-ethylmaleimide sensitive fusion protein a ttachm en t protein be ta 1.6
Zc3hav1 zinc finger CCCH type, antiviral 1 1.6
W dr20 W D rep ea t dom ain 20 1.6
Rfxank regulatory factor X -associated ankyrin-containing protein 1.6
Epb4.1l1 erythrocyte protein band  4,1-like 1 1.5
Cul4a cullin 4A 1.5
Evl Ena-vasodilator stim ulated phosphoprotein 1.5
C e tn l centrin 1 1.5
F gs fo rssm an  glycolipid synthetase 1.5
T uba-rs1 tubulin a lpha, related seq u en ce  1 1.5
665 1968
n
♦22 1070
20
134 237
87  120
HP 10.
71 108
39 5!
I  2815  3831
■ ■  25 31
31 47
1 418293_at 
1450484_a_at 
1 425119_at 
1444556_at 
1 450783_at 
1450446_a_at 
1420504_at 
1431306_at 
1436058_at 
1456073_s_a t 
1 419620_at 
1448792_a_at 
1440481_at 
1450322_S_at 
1 417586_at 
1 452207_at 
1440047_at 
1 456956_at 
1 456103_at 
1450495 _ a_ a t 
1 438004_at 
1 435061_at 
1421550_a_at 
1424607_a_at 
1 442130_at 
1450672_a_at 
1451260_at 
1434087_at 
1422005_at 
1426415_a_at 
1419879_s_at 
1435581_at 
1422297_at 
1449379_at 
1 438642_at 
1421379_at 
1438231_at 
14 39590_at 
1 439489_at 
1 425640_at 
1421345_at 
1 421085_at 
1 4 5 1314_a_at 
1438390_s_a t 
1449885_at 
1441578_at 
1450128_at 
1422367_al 
1419021_al 
1424387_al 
1428378_at 
1416530_a_a t 
1452444_at 
1431909_at 
1 430004_s_a t 
1425670_at 
1434575_at 
1426060_at 
1440885_at 
1 453881_x_at 
1426148 _ at 
1427832 at
N M J)08332 
AK004595 
BC 012877 
B B223018 
NM _008331 
AB000710 
AF320226 
B G 518810 
BB132493 
AV220875 
N M _013917 
N M _007817 
BB229853 
NM _011409 
NM _011589 
Y15163 
A V237386 
BB291816 
BB667149 
A F039026 
BB324894 
A1853080 
NM _030684 
B C 020078 
B G 091940 
NM _011637 
BC020001 
B G 069750 
M 93567 
AI746456 
AA960166 
BE947462 
NM _027044 
N M _010612 
AV278176 
A F 184112 
BB 376288 
AV273072 
A V025152 
A F074266 
NM _023624 
NM _011302 
L08431 
AV105428 
NM_138751 
BB142123 
N M _011108 
NM _019485 
N M _133197 
A F466150 
AK004770 
B C 003788 
A U 067119 
AK013726 
A K015014 
B C 010971 
BB794965 
B C 007159 
AW546029 
AK015808 
AF292399 
M 19413
Table 4.8 IFN -induced genes in B M D C s after 2h but not 6h o f  cu lture. Sam ples from  
CD1 lc + D Cs cultured in vitro in the presence o f  2 x 104 U  IFN -o4 (IFN ) or in m edia alone (0) 
w ere hybrid ised  to A ffym etrix m urine U 74A v2 arrays. D ata w ere generated  from  the m ean  o f  
three experim ents carried out on independently  iso lated  DCs. D ata w ere analysed  in 
G enespring 7.2 and changes o f  m ore than 1.5 fold w ere determ ined  to be sign ifican t by  
W elch’s approxim ate t-test w here p-values w ere less than  o r equal to 0.05. S ignal in tensities 
w ere co lour coded to indicate the level o f  expression, as show n in the key  for table 4.2.
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humans, a deficiency in Pnp is associated with cellular imunodeficiency, where patients have 
reduced T cell numbers and function (Markert, 1991). Mice carrying Pnp mutations have 
abnormal thymocyte development and splenic leukocytes from these mice have reduced 
numbers of T cells with impaired responses to IL-2 (Snyder et al., 1997).
Many of the genes suppressed by IFN-I at two hours were expressed at low levels, and their 
downregulation may not have a significant impact on biological function (Table 4.9). One 
gene whose expression was greatly reduced is Egr2 (early growth response 2), encoding a 
zinc-finger transcription factor which has been shown to regulate FasL expression 
(Mittelstadt et al., 1999). Recently, it has been reported that Egr2 is necessary for full 
induction of T-cell anergy (Harris et a l , 2004) and is involved in promoting TCR-induced 
negative regulation of T cell activation (Safford et al., 2005). A role for Egr2 in dendritic 
cell function has not been investigated.
169 genes were detected as differentially expressed at both the 2h and 6h timepoints. Where 
enhanced expression was seen at the 2h timepoint (129 genes, table 4.10), expression was 
also increased at 6h. Similarly, genes suppressed at 2h were also suppressed at 6h (40 
genes, table 4.11): no genes were enhanced at one timepoint and suppressed at the other. 
Many of the upregulated genes are commonly associated with DC function, including the 
chemokines CXCL9, CXCL10 and CXCL11, which all act via the CXCR3 receptor that is 
expressed mainly on activated Thl cells (Bonecchi et al., 1998; Sallusto et al., 1998b). The 
relatively low expression of CXCL11 mRNA compared to CXCL10 may reflect its potent 
chemotactic ability, since it induces optimal chemotaxis at concentrations 10 fold lower than 
does CXCL10 (Meyer et al., 2001). Induction of CXCL11 had not been detected in splenic 
DCs, and is represented on the U74Av arrays used in those experiments. In support of 
previous work (Mattei et al., 2001), we saw upregulation of IL-15 and the IL-15 receptor a
169
2h Signal
H13 histocom patibility  13 10.8
M apk7 m itogen -activated  protein k inase  7 7.4
M tssl m e ta s ta s is  su p p re s so r  1 6.2
S lc6a13 so lu te  carrie r family 6 (n eu ro transm itte r transpo rter, GABA), m em ber 13 4.7
Man2t>1 m a n n o s id a se  2, a lp h a  B1 4.7
Brd3 b ro m odom ain  containing 3 3.8
Egr2 eariy  grow th re s p o n s e  2 3.6
P p p 2 r5 a protein p h o sp h a ta se  2 , regulatory subun it B (B56), a lpha  isoform 3.4
Cxcr4 chem o k in e  (C-X-C motif) receptor 4 3.2
H erp u d l hom ocysteine-inducib le , E R  stress-inducib le , ubiquitin-like dom ain  1 2 .6
S h3d3 S H 3 dom ain  protein 3 2 .6
A dora2b ad e n o s in e  A 2b recep to r 2 .5
Slitt2 Slit-like 2  (D rosophila) 2 .5
Ddit3 D N A -dam age inducible transcrip t 3 2 .5
Angptt4 angiopoietin-like 4 2 .5
Pdgfb pla te le t derived  grow th factor, B polypeptide 2 .4
Rpl12 ribosom al pro tein  L12 2.4
S e sn 2 se s tr in  2 2 .4
Egr2 early  grow th re s p o n s e  2 2.4
C a tn a l ca ten in  a lp h a  1 2 .4
Idb3 inhibitor of DNA binding 3 2 .4
M tssl m e ta s ta s is  su p p re s so r  1 2.3
A drb2 adren e rg ic  recep to r, b e ta  2 2 .3
M ap4k4 m itogen -ac tiva ted  protein k inase  k in a se  k inase  k in ase  4 2 .3
G rtp l GH regu la ted  TBC protein 1 2 .3
Gpi1 g lu c o se  p h o sp h a te  iso m e ra se  1 2 .3
Matr3 m atrin  3 2 .3
Trappc5 trafficking pro tein  particle com plex 5 2.2
H spa8 h e a t  sh o ck  protein 8 2.2
Jundm 2 Ju n  d im erization protein 2 2.2
Ier2 im m ed ia te  earty  re s p o n s e  2 2.1
Pgf p lacen ta l g row th  facto r 2.1
Pim 3 proviral in tegration s ite  3 2.1
Lox lysyt o x id ase 2.1
Chic2 cyste ine-rich  hydrophobic  dom ain  2 2.1
Zfp146 zinc  finger pro tein  146 2.1
P h o sp h o l p h o sp h a ta se , o rphan  1 2.1
P e n period hom olog  1 (D rosophila) 2.1
Spic S pF C  transcrip tion  fac to r (Spi-1/PU. 1 related) 2.1
G na11 g u a n in e  nuc leo tide  binding protein, a lp h a  11 2.1
P tger4 p rostag land in  E recep to r 4  (sub type  E P 4) 2.1
0 X lm x41e DNA se g m e n t, C h rX , Im m u n ex 4 1 , e x p re sse d 2 .0
G as5 grow th  a rre s t  specific  5 2 .0
M yo9b m yosin  IXb 2.0
C 130032F 08 hypothetical p ro tein  C 130032F 08 2 .0
114,1 interleukin 4  induced  1 2 .0
Plu1 p utative D N A /chrom atin binding motif 1 2 .0
Axot axotrophin 2 .0
Fosl2 fos-like an tig en  2 1.9
Fgd3 FYVE, R hoG E F  and  PH dom ain  containing 3 1.9
Cdkl2 cy c lin -d ep en d en t k inase-like  2 (C D C 2-related  k in ase) 1.9
Zfp275 Zinc finger p ro tein  275 1.9
N olcl nuc leo la r an d  co lled-body phosphopro te in  1 1.9
Pld2 p h o sp h o lip a se  D2 1.9
Flrt3 fibronectin  leuc ine  rich tra n sm e m b ra n e  protein 3 1.9
Trim 13 tripartite motif p ro tein  13 1.9
G as5 grow th a rre s t  specific 5 1.9
N dst3 N -d eace ty la se /N -su lfo tran sfe ra se  (h e p a ra n  g lucosam inyl) 3 1.9
Flrt3 fibronectin  leuc ine  rich tra n sm e m b ra n e  protein 3 1.9
□ id o l d e a th  inducer-obliterator 1 1.9
Mt1 m etallo th ionein  1 1.8
Brd8 brom odom ain  containing 8 1.8
Kiflb k inesin  family m em b er 1B 1.8
S iat4a sia ly ttran sfe ra se  4A (be ta -g a lac to sid e  a lp h a-2 ,3 -s ia ly tran sfe rase) 1.8
AtplOd A T P ase . C la s s  V, type 10D 1.8
Cblb C a s ita s  B -lineage lym phom a b 1.8
E td n erythroid differentiation regulator 1 1.8
E2f3 E 2F  transcrip tion  fac to r 3 1.8
G sn gelsolin 1.8
Rb1 re tinob lastom a 1 1.8
H bxap hypothetical p rotein H bxap 1.8
Arf2 A D P-ribosytation fac to r 2 1.8
P tger2 prostag land in  E recep to r 2  (sub type  E P 2 ) 1.8
Tm7sf1 tra n sm e m b ra n e  7 supe tfam ily  m em b er 1 1.8
Zfp68 Zinc finger pro tein  68 1.8
Zfp3612 zinc finger pro tein  36, C3H type-like 2 1.7
Affymetrix6h Signal Genbank
Accession Accession
1438456 at
1 418060 a  at NM 011841
1446284 at
1424338 at B C 023117
1436781 at
1436960 at
1427682 a  at X06746
1438914 at AW 741731
1 448710 at □ 87747
1 435626 a  at AI835088
1446023 al A V 024397
1450214 at NM 007413
1455812  x a t
1443897 at BB200603
1 4 17130_s_a t NM 020581
1 450413 at NM 011057
1435655 at B G 807990
1 425139 at BC 005672
1 427683 at X06746
28  32 1436631 at
1 416630 at NM 008321
1440847 at
1437302 at A V 083350
1440609 at BB113015
1439150 x  at
1456909 at B F017016
1436796 at
1448999 at
1431182 at A K004608
1450350 a  at NM 030887
1416442 at NM 010499
1418471 NM 008827
1 437100 x at656
1416121 a t NM 010728
1444018 a t
1422135 at NM 011980
1457063 at2 7 AI447357
1449851 at
81 1 418555 X at NM 011461
1449144 at NM 010301
1 424208 at B C 011193
24 20 1458023 at B G 070379
1436222 al A W 547050
1 438533 at BM 121122
1 434043 a  a t AV286809
1 415926 at NM 053074
1427143 a t B C 019446
100 65 1440966 at BB248730
1437247 at BM 245170
1 433398 a t AKO18025
1457625 s  at
1418397 at B C 0 19962
M B 1450087 a  al NM 0530861417237 al11 1  i NM 008876
1453102 at
1417888 at NM 023233
1 4 2 4843_a_at
1443277 at
5 7 6  310 1429310 at2 1 8  157
18 22
235 196
5 .
7 0  50
9 9  92
20 23
6 2  4 J
94
A K 017456
1437182 at BM 224349
1451612 at
1429526 at AK014475
1451642 at
1441216 at BB024025
1436544 at BBO16769
1443086 at
1452566 at BC021831
1434564 at B Q 176318
1439687 at BM 207947
1428615 at1531 1123 AK008952
1442207 at
1438661 a  a t AV023312
138 68 1449310 at B C 005440
1423164 at
1459979 x a t
1437626 at B B 031791
Table 4.9 (continued  over page) IF N -suppressed  genes in  B M D C s after 2h but not 6h o f  
culture. Sam ples from  CD1 lc + D C s cu ltu red  in vitro in the presence o f  2 x 104 U IFN -o4 
(IFN ) or in m edia alone (0) w ere hybrid ised  to A ffym etrix  m urine U 74A v2 arrays. D ata 
w ere generated  from  the m ean o f  three experim ents carried  out on independently  isolated  
D C s. D ata w ere analysed in G enespring  7.2 and changes o f  m ore than 1.5 fold w ere 
determ ined to be significant b y  W elch ’s approxim ate t-test w here p-values w ere less than  or 
equal to 0.05. N orm alised  signal in tensities w ere co lour coded to indicate the level o f  
expression, as show n in the key  for tab le 4.2.
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Gene Description
Fold
C hange
2h Signal
0 IFN
6h Signal Affymetrix
A ccession
Genbank
A ccession
Zfp397 zinc finger protein 397
Rp!30 ribosom al protein L30
P k n o x l P bx/knotted  1 hom eobox
M G C 57096 hypothetical protein M G C57096 
Trim 2 tripartite motif protein 2
F u s fusion , derived  from  t(12 ;16) m alignant liposarcom a (hum an)
Fbxo32 F-box only protein 32
E s1 0  e s te r a s e  10
M ap4k4 m itogen-activated  protein k inase  k in ase  k inase  k inase  4
S ca2  sp in o ce reb e lla r a tax ia  2  hom olog (hum an)
Cxcl7 chem o k in e  (C-X-C motif) ligand 7
N edd8 n eu ra l p recu rso r cell ex p re ssed , developm entally  dow n-regulated  I
M apk8 m itogen  ac tiva ted  protein k in ase  8
E rd rl erythroid differentiation regu lato r 1
R n p c l RNA-binding region (R N P1, RRM) containing 1
Pou2f1 PO U  dom ain , c la s s  2, transcription facto r 1
U be2i ubiquitin-conjugating en zy m e E2I
G 2 a  G  protein-coupled  recep to r G2A
Skp2 S -p h a s e  k in ase -a sso c ia ted  protein 2  (p45)
M tr3-pending Mtr3 (mRNA tra n sp o rt regulator 3)-hom olog (yeast)
Serp inM  se r in e  (or cyste ine) p ro te in ase  inhibitor, c lad e  H, m em b er 1
Arf2 ADP-ribosytation fac to r 2
D naja3  D naJ (H sp40) hom olog, subfam ily A, m em b er 3
Irf4 in terferon  regulatory  fac to r 4
Trim 27 tripartite  motif protein 27
Btg2 B -cell transloca tion  g e n e  2, anti-proliferative
Nsd1 n u c lea r receptor-b ind ing  SET -dom ain  protein 1
Aldh2 a ld eh y d e  d eh y d ro g e n a se  2 , mitochondrial
Syt13 syn ap to tag m in  13
Ubtf u p s tre a m  binding transcrip tion  factor, RNA p o lym erase  I
O gt O -linked N -ace ty tg lucosam ine  (GlcNAc) tra n s fe ra se
E pha4  E ph rec e p to r  A4
Sfpq splicing facto r pro line/glutam ine rich
Zfp472 zinc  fin g er protein 472
Lsm 10 U7 snR N P -spec ific  Sm -like protein LSM10
Picalm  phosphatldylinositol binding clathrin a ssem b ly  protein
R ps17  ribosom al protein S 17
Cdc37l cell division cycle  37  hom olog (S. cerev isiae)-like
Zfp292 zinc  finger protein 292
Ulk1 Unc-51 like k in a se  1 (C. e leg an s)
Facl2 fatty  acid  C o en zy m e  A ligase, long chain  2
M asp2 m annan-b ind ing  lectin s e r in e  p ro te a se  2
S p a ta1 3  sp e rm a to g e n e s is  a s so c ia te d  13
D usp9 dua l specificity p h o s p h a ta s e  9
Tgfbrl transform ing  grow th factor, be ta  recep to r I
Glb1 g a la c to s id a se . b e ta  1
W ee1 w ee  1 hom olog  (S . pom be)
Perq  1 P E R Q  am ino  ac id  rich, with GYF dom ain  1
G stm l g lu tath ione S - tra n sfe ra se , m u 1
Epm 2aip1 EPM 2A (laforin) in teracting  protein 1
C dca4  cell division cycle a sso c ia te d  4
B3gat1 beta -1 ,3 -g lu cu ro n y ttran sferase  1 (g lu cu ro n o sy ltran sferase  P)
Solh sm all op tic  lobes hom olog (Drosophila)
P d e4 b  p h o sp h o d ie s te ra se  4B, cAMP specific
Il17r interleukin 17 recep to r
Slc38a2  so lu te  e a rn e r  fam ily 38, m em b er 2
C xd1  ch em o k in e  (C-X-C motif) ligand 1
Spred2  sp rou ty  protein with EVH-1 dom ain  2, re la ted  s e q u e n c e
Htf9c H pall tiny frag m en ts  locus 9 c
G filb  grow th fac to r in d ep en d en t 1B
Bcl2l11 BCL2-like 11 (ap o p to sis  facilitator)
G sp tl G1 to  p h a s e  transition  1
Cbx2 chrom obox  hom olog 2  (D rosophila P c  c la ss )
Zfp36l1 zinc finger protein 36, C3H type-like 1
A dora2b a d e n o s in e  A2b recep to r
Pigq phosphatldylinositol glycan, c la ss  Q
Tardbp  TAR DNA binding protein
C dk5r cyclin -dependen t k in ase  5, regulatory subun it (p35)
Siit7  sirtuin 7
Nr4a1 nu c lea r recep to r subfam ily 4 , g roup  A, m em b er 1
Z iprol zinc finger proliferation 1
Trim27 tripartite motif protein 27
Fbs1 fibrosin 1
Spg20 sp as tic  p a rap leg ia  20
Bcl2l11 BCL2-like 11 (ap o p to sis  facilitator)
Im ap38 im m unity-associated  protein
27 22
25 21
31 82 20
11 14 f  11
18
48 54 52
106
2 4  15
128 WttM
102 I I  
107 I TO 
372  242
183 119
2 0 0  131
204 134
168 111
84 , 56
224 150 I
17 12
109 9 5
I  t
I  218 1401
2- “
271 207WtM
2 0 7  22111 to
;
30
237  281
131 102
105 103
85 L.r!.:’?K
141 190
13 16
721 543  ■
141 102s s
389 341
s :
136 137
2  i
50
57
145 102
130 174
83  67
127 95■■■■I
14 35664_at 
1438076_at 
1450172_at 
1457157_at 
1 4 1 7028_a_at 
1455831_at 
1448747_at 
1447724_x_at 
14 4 8 0 50_s_a t 
1433455_at 
1418480_at 
1429180_at 
1437045_at 
1439200_x_at 
14 2 1265_a_at 
14 2 7695_a_at 
1429545_at 
1421755_at 
1437 0 3 3 _ a_ a t 
1435544_at 
1 4 5 0843_a_at 
1 416459_at 
1427894_at 
1421173_at 
1456375_x_at 
1416250_at 
1457464_at 
1437410_at 
1434470_at 
1460 3 0 4 _ a_ a t 
1 425517 _ s_ a t 
1421929_at 
1436898_at 
1 425058_at 
1 417515_at 
1455773_at 
1438502_x_at 
1433574_at 
1436308_at 
1 448370_at 
1 4 5 0 6 43_s_a t 
1436318_at 
1437865_at 
1454737_at 
1420895_at 
1435795_at 
1416773_at 
1423460_at 
1425626_at 
1434105_at 
1 456240_x_at 
1454821_at 
1 427785_x_at 
1422473_at 
1420904_at 
1429593_at 
1 457644_s_a t 
1436892_at 
1448115_at 
1420399_at 
1456005_a_at 
1446550_at 
14 3 4 1 16_at 
1 4 2 2528_a_a t 
1434772_at 
1 4 2 6055_a_a t 
1 4 5 5655_a_a t 
1433451_at 
1434054_at 
1416505_at 
1416370_at 
1 4 48101_s_a t 
1451645_at 
1451520_at 
1456006_at 
1449988 at
A V 342828 
B E447059 
A A409923 
BB 247624 
BB 667078 
B E 985138 
A F441120 
BB324282 
B F450398 
A W 536901 
N M _023785 
A K 017821 
AV345871 
B E686792 
N M _019547 
X 56230 
B I080812 
N M _019925 
B B784099 
B B446614 B1220012 
N M _007477 
A K 012169 
NM _013674 
BB 290427 
B G 965405 
B G 070926 
BB 513627 
BB244585 
BB832806 
B I657000 
B B 706548 
B I738328 
B C 023090 
N M _138721 
B G 797225 
A A030209 
B E824561 
BB315561 
A F 072370 
B I413218 
A V 338665 
AW546433  
A V 295798 
B M 248342 
B E956926 
B C 006852 
B I688428 
J0 3 9 5 2  
A V 276770 
BB329505 
B B 424673 
B C 022685 
A F326555 
NM _008359 
B E 854973 
B B 554288 
BB133520 
NM _008307 
NM _008114 
BB667581 
BB162021 
B I693188 
B B 036959 
B B 795854 
A F030178 
B M 935796 
BB17 7836  
BB342453 
N M _010444 
N M _011757 
N M _009054 
B B 162362 
B B 040507 
BB667581 
NM 008376
Table 4.9 (continued) IF N -suppressed  genes in B M D C s after 2h but not 6h o f  culture
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G ene D escrip tion
Ifttl in te rfe ro n -in d u ced  p ro te in  with te tra trico p ep tid e  re p e a ts  1
C x d 9  c h e m o k in e  (C-X -C  motif) ligand 9
Tyki thym idyiate  k in a se  fam ily L P S -inducib le  m e m b e r
M x2 m yxovirus (in fluenza v irus) re s is ta n c e  2
M s4 a4 c  m e m b ra n e -sp a n n in g  4 -d o m a in s , sub fam ily  A, m e m b e r  4C
ligp -pend ing  in te rfe ron -induc ib le  G T P a s e
Ifit3 in te rfe ro n -in d u ced  p ro tein  with te tra trico p ep tid e  re p e a ts  3
Isg20  in te rfe ro n -stim u la ted  pro tein
T g tp  T -cell sp ec ific  G T P a s e
S a m h d l  SAM  d o m a in  a n d  HD do m ain , 1
S lfn l sch la fe n  1
CxcH  1 ch e m o k in e  (C-X -C  m otif) ligand 11
M s4 a 4 c  m e m b ra n e -sp a n n in g  4 -d o m a in s , sub fam ily  A, m e m b e r  4C
ligp in te rfe ron  inducib le  G T P a s e  1
M xl m yxovirus (in fluenza v irus) r e s is ta n c e  1
Igtp in te rfe ron  g a m m a  in duced  G T P a s e
S e rp in a 3 g  s e r in e  (o r c y s te in e ) p ro te in a se  inhibitor, d a d e  A, m e m b e r 3G
U sp18  ubiquitin sp ec ific  p ro te a s e  18
V igl viral h e m o rrh a g ic  s e p tic e m ia  virus(V H SV ) induced  g e n e  1
Zbp1 Z-DNA binding p ro te in  1
Ifi47 in te rfe ron  g a m m a  inducib le  p ro tein
Ifi1 in te rfe ron  inducib le  p ro tein  1
C x d 9  ch e m o k in e  (C-X -C  motif) ligand 9
Igtp in te rfe ron  g a m m a  in duced  G T P a s e
V igl viral h e m o rrh a g ic  s e p tic e m ia  virus(V H SV ) induced  g e n e  1
1115 in terleuk in  15
Ifi203 in te rfe ron  a d iv a te d  g e n e  2 0 3
O asH  2 '-5 ' o lig o ad en y la te  sy n th e ta se - lik e  1
T rim 21 tripartite  m otif p ro te in  21
Il15ra in terleukin  15  recep to r, a lp h a  chain
S lfn5  sc h la fe n  5
Trim 21 tr ip artite  m otif p ro te in  21
O a s 2  2 '-5 ' o lig o ad en y la te  s y n th e ta s e  2
Lhx2 LIM h o m eo b o x  p ro te in  2
S lfn5 s c h la fe n  5
C D 40  tu m o r n e c ro s is  f a d o r  re c e p to r  superfam ily , m e m b e r  5
P m l prom yelocy tic  leu k em ia
T rim 30 tripartite  m otif p ro te in  30
S lfn4 s c h la fe n  4
M ad M ax d im eriza tion  pro tein
S ta t2  s ig n a l tr a n s d u c e r  a n d  a d iv a to r  o f tran scrip tio n  2
D axx F a s  d e a th  d o m a in -a s so c ia te d  pro tein
Ly6e lym phocy te  an tig en  6  com plex , lo cu s E
M s4 a6 b  m e m b ra n e -sp a n n in g  4 -d o m a in s , sub fam ily  A, m e m b e r  6B
C x d 1 0  ch e m o k in e  (C-X -C  m otif) ligand 10
M ad M ax d im eriza tion  p ro tein
Il15ra in terieukin  15 recep to r, a lp h a  chain
P le c l  p le d in  1
B agl-pending  B a g g re s s iv e  ly m phom a
C ard 4  c a s p a s e  rec ru itm en t d o m a in  4
N at2  N -ac e ty ltra n s fe ra se  2  (ary lam ine N -ace ty ltran sfe ra se )
G bp2  g u a n y la te  n u d e o tid e  binding pro tein  2
P rk r pro tein  k in ase , in terferon -inducib le  d o u b le  s tra n d e d  RNA d e p e n d e n t
C e n ta 2  cen tau rin , a lp h a  2
T a p i  tra n sp o r te r  1, A T P-binding c a s s e t te ,  sub-fam ily  B (M DR/TAP)
R p!4l rib o so m al p ro tein  L41
M s4a6c  m e m b ra n e -sp a n n in g  4 -d o m a in s , sub fam ily  A, m e m b e r  6C
C po  cop ro p o rp h y rin o g en  o x id a se
O a s lg  2 '-5 ' o lig o ad en y la te  s y n th e ta s e  1G
Dtr d ip h th eria  toxin re c e p to r
P o ls  p o ly m e ra se  (DNA d ir e d e d )  s ig m a
T o r3 a  torsin  fam ily 3, m e m b e r  A
Ifrg15-pending in terferon  a lp h a  re sp o n s iv e  g e n e
Lck lym phocy te  p ro tein  ty ro sin e  k in ase
T tr8 toll-like re c e p to r  8
C tla2 a  cy totoxic T  ly m p h o cy te -a sso c ia ted  pro tein  2  a lp h a
C a sp 2  c a s p a s e  2
P lac8  p lacen ta -sp ec ific  8
C h a n g e C h a n g e
I  5 5 3
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481 2 3 5 9 1*3 « m
208 594
114 6 3 38! 524
1234 1257
N377 2892
W m  3 3 0
2 3 8 ’ 2 4 6 2 1
1411
2 9 2 0  4 4 7 6
15 f t  105
1 3 0  826
12 41
124 4 2 0
196 523
2 2 5
1113 223 9
■ 5 9 8  W O509
^■^■697
118 23S
80 233
2 27 4  3674
383
5 9 8  9 5 4
193 555
1676 3434
8
A ffym etrix
A c c e s s io n
1 4 3 5 529_at 
1 41 8 6 5 2 _ at 
1 4 2 2 0 9 5 _ a_ a t 
1 41 9 6 7 6 _ at 
1 4 2 0 6 7 1_x_at 
1 4 1 9042_at 
1 44 9 0 2 5 _ at 
1 4 1 9 5 6 9 _ a_ a t 
1 44 9 0 0 9 _ at 
1 44 4 0 6 4 _ at 
1 41 8 6 1 2 _ at 
1 41 9 6 9 7 _ at 
1 4 5 0 2 9 1_S_at 
1 4 1 9 0 4 3 _ a _ a t 
1 4 5 1 9 0 5 _ a _ a t 
1 4 1 7 7 9 3 _ a t 
142 4 9 2 3 _ at 
1 4 1 8 1 9 1 _ a t 
142 1 0 0 8 _ at 
1 4 1 9 6 0 4 _ a t 
1 4 1 7 2 9 2 _ a t 
141 8 8 2 5 _ at 
1 4 5 6 9 0 7 _ a t 
1 4 1 7 1 4 1 _ a t 
1 4 2 1 0 0 9 _ a t 
1 4 1 8 2 1 9 _ a t 
1 4 5 1 5 6 7 _ a_ a t 
142 4 3 3 9 _ at 
144 8 9 4 0 _ at 
1 4 4 8 6 8 1 _ a t 
1 4 5 8 4 5 8 _ a t 
1 4 1 8 0 7 7 _ a t 
1 4 2 5 0 6 5 _ a t 
1 4 1 8 3 1 7 _ a t 
1 4 4 2 6 4 0 _ a t 
1 4 6 0 4 1 5 _ a _ a t 
1 44 8 7 5 7 _ at 
1 4 1 7 9 6 1 _ a_ a t 
1 42 7 1 0 2 _ at 
1 4 5 5 1 0 4 _ a t 
1 4 2 1 9 1 1_at 
1 4 1 9 0 2 6 _ a t 
1 4 3 9 7 7 3 _ a t 
141 8 8 2 6 _ at 
1 4 1 8 9 3 0 _ a t 
143 4 8 3 0 _ at 
1 4 2 2 3 9 7 _ a_ a t 
145 2 1 7 8 _ at 
1 4 1 6 8 9 7 _ a t 
1 4 5 4 7 3 3 _ a t 
1 4 4 9 9 8 1_a_ a t 
1 4 1 8 2 4 0 _ a t 
142 2 0 0 6 _ at 
1 4 2 5 6 3 9 _ a t 
1 4 1 6 0 1 6 _ a t 
1 4 5 4 6 3 9 _ x _ a t 
14 5 0 2 3 4 _ a t 
1 4 3 1 2 9 6 _ a t 
1 4 2 4 7 7 5 _ a t 
1 4 1 8 3 5 0 _ a t 
1 4 3 8 0 0 3 _ a t 
1 4 5 0 4 5 4 _ a t 
1 4 5 8 3 6 4 _ s_ a t 
1 4 2 5 3 9 6 _ a_ a t 
145 0 2 6 7 _ at 
1 4 5 2 3 5 2 _ a t 
1 4 4 8 1 6 5 _ a t 
145 1 3 3 5  a t
Table 4.10 IFN -induced  genes in B M D C s after both 2h and 6h cu lture.
Sam ples from  CD1 l c + D Cs cu ltu red  in vitro  in the p resence o f  2 x 104 U  IFN -o4 (IFN ) o r in 
m edia alone (0) w ere hybrid ised  to A ffym etrix  m urine U 74A v2 arrays. D ata w ere generated  
from  the m ean o f  three experim ents ca rried  out on  independently  iso lated  D Cs. D ata w ere 
analysed in G enespring  7.2 and changes o f  m ore than  1.5 fold w ere determ ined  to be 
significant by  W elch ’s approxim ate t-test w here p -values w ere less than or equal to 0.05. 
N orm alised  signal in tensities w ere co lour coded  to indicate the level o f  expression, as show n 
in the key for table 4.2..
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Gane Description
H erpudl endoplasm ic reticulum stress-inducible. ubiquitm-like dom ain m em ber 1
Pdgfb platelet denved  growth factor, B polypeptide
A ps adap to r protein with pleckstrin hom ology and  src
Gpr68 G protein-coupled recep to r 68
Ubl4 ubiquitin-like 4
Cnk cytokine inducible kinase
S tk10 serine/threonine k inase 10
Slc39a14 so lu te  e a rn e r family 39 (zinc transporter), m em ber 14
C ebpa  CCA A T/enhancer binding protein (C/EBP), alpha
Eif2ak3 eukaryotic translation initiation factor 2 alpha k inase  3
Rit1 Ras-like without CAAX 1
B u b lb  budding uninhibited by benzim idazoles 1 homolog, be ta  (S- cerevisiae)
R ab40c Rab40c, m em b er RAS on co g en e  family
Ptpre protein tyrosine p h o sp h atase , recep to r type, E
Rnu22 RNA, U22 sm all nucleolar
M adh6 MAD hom olog 6  (Drosophila)
Slco4a1 solute ea rn e r organic  anion transpo rte r family, m em ber 4a1 
P tpre protein tyrosine p h o sp h a ta se , recep to r type, E
Bet11 blocked early  in transport 1 hom olog (S. cerevisiae)-like
Txntd3 thioredoxin red u c ta se  3
IFN
19
Change
92
Signal Affymetrix
A ccession
Genbank
A ccession
1.6
1.7
759  m  
239 137
1448185_at 
1450414_at
NM 022331 
BC023427
1.8
1 7 456 266
1450718_at 
1455000 at
NM 018825 
BB538372
1.6
1.8 2 H
1424539_at 
1434496 at
BI650739
BM947855
1.7 257 148 1417751_at NM _009288
2.0 177 I 90 1427035_at BB399837
1.5 438 286 1418982_at BC011118
1.5 183 119 1449278_at NM 010121
1.7 1428710_at AK018785
2.2 1447363_s_at AU045529
1.6 290 U 183 1424331 at BC027008
1.8 552 307 1418539_a_at NM 011212
1.9 386 206 1433674_a_at BQ177137
1.6 126 : 7? fc 1422771_at A F010133
1.6 115 1 73 1455803_at AV375182
1.7 600 , 359 1418540_a_at U35368
1.7 H M U 5 1 1 1430549_at AV252862
1 8 63 36 1449623 at AM 96535
T able 4.11 IF N -suppressed  genes in B M D C s after both 2h and 6h culture.
Sam ples from  CD1 lc"  D Cs cu ltu red  in vitro in the p resence o f  2 x 104 U  IF N -a4  (IFN ) or in 
m edia alone (0) w ere hybrid ised  to A ffym etrix  m urine 430 2.0 arrays. D ata w ere generated  
from  the m ean o f  three experim ents ca rried  out on  independently  iso lated  D Cs. D ata w ere 
analysed in G enespring  7.2 and changes o f  m ore than 1.5 fold w ere determ ined  to be 
significant by  W e lc h ’s approxim ate t-test w here p -values w ere less than  or equal to 0.05. 
N orm alised  signal in tensities w ere co lour coded to indicate the level o f  expression, as 
show n in the key  for table 4.2.
D escription
6h Signal
0 IFN
2h S ignal
D n ase1 l3 d eo x y rib o n u c lease  1-like 3 25 .3
M s4 a4 b m e m b ra n e -sp a n n in g  4 -d o m a ln s, subfam ily  A, m e m b e r 4B 11.6
Pou3f1 P O U  do m ain , c la s s  3, transcrip tion  fac to r 1 5.4
Tlr3 toll-like re c e p to r  3 5.1
CxcM 1 c h e m o k in e  (C-X-C motif) ligand 11 4.7
lie in terleukin 6 4 .2
T nfsflO tu m o r n e c ro s is  facto r (ligand) superfam ily , m e m b e r  10 4.1
C sp g 2 chondro itin  su lfa te  pro teog lycan  2 4 .0
C sp g 2 chondro itin  su lfa te  pro teog lycan  2 3 .8
C h25h cho le ste ro l 25 -hydroxylase 3.7
16203 in terferon  ac tiva ted  g e n e  203 3.6
c a th e p s in  C c a th e p s in  C 3.3
T nfrsf5 tu m o r n e c ro s is  facto r re c e p to r  superfam ily , m e m b e r  5 3 .3
Fgl2 fibrinogen-like pro tein  2 3.1
T  nfrsf5 tu m o r n e c ro s is  fac to r re c e p to r  superfam ily , m e m b e r 5 3.1
G nb4 g u a n in e  nuc leo tide  binding protein, b e ta  4 2 .9
IA203 in terferon  ac tiva ted  g e n e  203 2 .8
H m gn3 high mobility g roup  n u c leo so m a l binding do m a in  3 2.7
M ov10 M oloney leukem ia  virus 10 2 .6
M ef2c m yocy te  e n h a n c e r  fac to r 2 C 2 .6
G nb4 g u a n in e  nucleo tide binding protein, b e ta  4 2 .6
S lco3a1 so lu te  ca rrie r o rgan ic  an io n  tran sp o rte r  family, m e m b e r 3a1 2.6
R p l35a ribosom al p ro tein  L35a 2.6
F c g rl F c  recep to r, IgG , high affinity I 2 .6
F cg ri F c  recep to r , IgG, high affinity I 2 ,5
Bbx b obby  so x  hom olog (D rosophila) 2.5
T m em 2 tra n sm e m b ra n e  pro tein  2 2.5
D nr12 d iab e tic  nep h ro p a th y -re la ted  g e n e  1 2.4
D m tfl cyclin D binding m yb-like transcrip tion  fac to r 1 2.4
O a s3 2 - 5 'o lig oadeny la te  s y n th e ta s e  3 2.4
Pou3f1 PO U  do m ain , c la s s  3, transcrip tion  facto r 1 2.4
Pdgfrl p la te le t-derived  grow th fac to r receptor-like 2.4
Zbp1 Z-DNA binding protein 1 2.3
G pr86 G pro te in -coup led  rec e p to r  86 2.3
SprecM sp ro u ty  pro tein  with EVH-1 dom ain  1. re la ted  s e q u e n c e 2 .3
Dtr d ip h th eria  toxin recep to r 2.3
A b c b la ATP-binding c a s s e tte ,  sub-fam ily  B (M DR/TAP), m e m b e r 1A 2.3
M ad M ax dim erization  protein 2.3
O asl2 2 '-5 ' o ligoadeny la te  sy n th e ta se -lik e  2 2.3
C d 8 6 C D 86  an tigen 2.3
H m gn3 high m obility g roup  nuc leo so m a l binding d o m a in  3 2.2
Fgf23 fib rob last g row th  facto r 23 2.2
S g cb sa rco g ly can , b e ta  (dy stro p h in -a sso c ia ted  g lycoprotein) 2.2
Itprl inositol 1 ,4 ,5 -trip h o sp h a te  recep to r  1 2.2
P ttg l pituitary tum or-transform ing  1 2.2
Nmi N -m yc (an d  STAT) in te rac to r 2 .2
Pdgfrl p la te le t-derived  grow th fac to r receptor-like 2.2
R p s2 4 rib o so m al pro tein  S 24 2.2
S g c b sa rco g ly can , b e ta  (d y stro p h in -a sso c ia ted  g lycopro tein) 2.2
Ly6a lym phocyte  an tigen  6  com plex , locus A 2.2
Slfn5 sch la fe n  5 2.1
F nbp2 form in binding protein 2 2.1
Zfp318 zinc finger pro tein  318 2.1
Tgfb1i4 transfo rm ing  grow th fac to r b e ta  1 induced  tran sc rip t 4 2.1
Z nfn1a2 z in c  finger protein, subfam ily  1A, 2  (H elios) 2.1
C a sp 3 c a s p a s e  3, ap o p to sis  re la ted  cy ste in e  p ro te a se 2.1
H rasls3 HRA S like su p p re s so r  3 2.1
H2-Bf histocom patibility  2, c o m p lem en t c o m p o n e n t fac to r  B 2.1
Aim1 a b s e n t  in m e lan o m a  1 2.1
Mertk c -m e r p ro to -o n co g en e  ty rosine  k in ase 2.1
1112b in terleukin 12b 2.1
Ripk2 re c e p to r  (T N FR SF)-in teracting  se r in e - th reo n in e  k in a se  2 2.1
Lap3 leuc ine  a m in o p e p tid a se  3 2.1
Z c 3 h d c l zinc  finger C C C H  type  do m a in  contain ing  1 2.1
P n p purin e-n u c leo sid e  p h o sp h o ry la se 2.1
S p re d l sp ro u ty  pro tein  with EVH-1 do m ain  1, re la ted  s e q u e n c e 2.1
Xm1 5 - 3 ' e x o r ib o n u d e a s e  1 2 .0
C 3ar1 co m p lem en t c o m p o n en t 3 a  re c e p to r  1 2 .0
1118rap interleukin 18 recep to r  a c c e s s o ry  pro tein 2 .0
C rsp 9 co fac to r requ ired  for Sp1 transcrip tiona l activation , su b u n it 9 2 .0
H hex hem atopo ietlcally  e x p re s s e d  hom eo b o x 2 .0
G 1p2 in terferon , a lpha-induc ib le  protein 2 .0
A pobec3 apo lipop ro tein  B editing com plex  3 2 .0
T p s tl pro teirr-tyrosine su lfo tran sfe ra se  1 2 .0
A pafl apop to tic  p ro te a se  activating  fac to r 1 2 .0
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S f,
137 261
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187 317
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1 4 2 1 0 5 7 _ a t 
1 4 2 3 4 6 7 _ a t 
1 4 6 0 0 3 8 _ a t 
1 42 2 7 8 2 _ S _ a t 
1 4 1 9 6 9 8 _ a t 
1 4 5 0 2 9 7 _ a t 
1 4 2 0 4 1 2 _ a t 
1 4 2 7 2 5 6 _ a t 
1 4 2 1 6 9 4 _ a _ a t 
1 4 4 9 2 2 7 _ a t 
1 4 2 5 0 0 8 _ a _ a t 
14 3 7 9 3 9 _ S _ a t 
1 4 4 9 4 7 3 _ s_ a t 
1 4 2 1 8 5 4 _ a t 
1 4 3 9 2 2 1 _ s_ a t 
1 4 1 9 4 7 0 _ a t 
1 4 4 8 7 7 5 _ a t 
1 4 3 4 8 7 5 _ a _ a t 
1 4 1 6 3 8 0 _ a t 
1 4 2 1 0 2 8 _ a _ a t 
1 4 1 9 4 6 9 _ a t 
1 4 1 8 0 3 0 _ a t 
1 4 3 6 0 3 2 _ a t 
1 4 3 6 6 2 5 _ a t 
1 4 1 7 8 7 6 _ a t 
1 4 2 2 7 4 1 _ a _ a t 
1 4 5 1 4 5 8 _ a t 
1 4 3 4 3 8 0 _ a t 
1 4 3 9 3 7 6 _ x _ a t 
1 4 2 5 3 7 4 _ a t 
1 4 2 2 0 6 8 _ a t 
14 5 4 8 2 4 _ s_ a t 
1 4 2 9 9 4 7 _ a _ a t 
1 4 2 8 7 0 0 _ a t 
1 4 2 8 7 7 7 _ a t 
1 4 1 8 3 4 9 _ a t 
1 4 1 9 7 5 9 _ a t 
1 4 2 2 0 0 2 _ a t 
1 4 5 3 1 9 6 _ a _ a t 
1 4 4 9 8 5 8 _ a t 
1 4 3 1 7 7 7 _ a _ a t 
1 4 1 6 1 2 4 _ a t 
1 4 1 9 6 6 7 _ a t 
1 4 6 0 2 0 3 _ a t 
1 4 2 4 1 0 5 _ a _ a t 
1 4 2 5 7 1 9 _ a _ a t 
143650T _at 
1 4 5 5 1 9 5 _ a t 
1 4 1 9 6 6 8 _ a t 
1 4 1 7 1 8 5 _ a t 
1 4 5 6 2 8 8 _ a t 
1 4 2 7 9 6 7 _ a t 
1 4 2 5 3 4 7 _ a _ a t 
1 4 5 4 7 5 8 _ a_ a t 
1 4 3 7 5 4 2 _ a t 
1 4 2 6 1 6 5 _ a _ a t 
1 4 5 1 6 1 1 _ a t 
1 4 1 7 3 1 4 _ a t 
1 4 2 6 9 4 2 _ a t 
1 4 2 2 8 6 9 _ a t 
1 4 4 9 4 9 7 _ a t 
1 4 5 0 1 7 3 _ a t 
1 4 5 0 8 6 0 _ a t 
14 2 6 7 7 4 _ a t 
1 4 5 3 2 9 9 _ a_ a t 
1 4 5 2 9 1 1_at 
14 5 0 3 0 8 _ a _ a t 
1 4 4 2 0 8 2 _ a l 
1 4 2 1 2 9 1 _ a t 
1 4 3 0 4 1 9 _ a t 
1 4 2 3 3 1 9 _ a t 
1 4 3 1 5 9 1 _ S _ a t 
1 4 1 7 4 7 0 _ a t 
1 4 2 1 7 3 3 _ a _ a t 
14 5 2 8 7 0  a t
B C 012671 
B B 199001 
B G 065255  
N M _126166 
N M _019494 
N M _031168 
N M _009425 
B I692925 
N M _019389 
N M _009890 
L 14559  
B M 237633 
N M _011611 
N M _008013 
B B 220422  
B I713933 
N M _008328  
AVO18952 
N M _008619  
A I595932 
N M _013531 
B B 3 3 7 160 
B B 201888  
B B 075261 
A F 143181 
A V 255109 
B C 0 19745  
BM 241271 
B B 357590  
A B 067534  
N M _011141 
B B 699957  
A K 008179 
A K 008013 
B G 0 6 0 6 4 6  
N M _010415 
B B 819674 
L 38926  
B Q 03 3 1 3 8  
N M _019388 
A K 002970 
B B 840359  
N M _011890 
N M _010585 
A F069051 
B C 002019  
A W 554551 
B M 119287 
A K 014381 
B C 002070  
B B 134615  
B E 6 5 3 2 9 5  
B B 1685 3 6  
A U 016382 
B B 319935  
D 86352 
B C 024581 
N M _008198 
B M 233292 
N M _008587 
A F128214  
N M _13 8952  
AKO10384 
B M 227980 
A K 008143 
A K 017680 
N M _011916 
B B 333624 
N M _010553 
A K 009549 
A K 014111 
A K 019325 
N M _030255 
N M _013837 
AKO18076
T able 4.12 (continued over page) IFN -induced genes in B M D C s after 6h but not 2h o f  
culture. Sam ples from  CD1 lc + D C s cultured  in vitro in the presence o f  2 x  104 U IF N -a4  
(IFN ) or in m edia alone (0) w ere hybrid ised  to A ffym etrix  m urine 430 2.0 arrays. D ata w ere 
generated  from  the m ean o f  three experim ents carried  out on  independently  isolated DCs. 
D ata w ere analysed in G enespring 7.2 and changes o f  m ore than  1.5 fold w ere determ ined  to 
be significant by  W elch’s approxim ate t-test w here p-values w ere less than  o r equal to 0.05. 
N orm alised  signal intensities w ere colour coded to indicate the level o f  expression , as show n 
in the key  for table 4.2.
1 7 4
G e n e D e s c r ip t io n
6h  S ig n a l 
IFN
2 h  S ig n a l A ffy m etrix
A c c e s s io n
G e n b a n k
A c c e s s io n
O gfr opioid grow th  fac to r  recep to r
K a tn a l k a tan in  p60  (A T P ase-con ta in ing ) su b u n it A1
C yp27a1  cy to ch ro m e  P 4 5 0 , family 27 , subfam ily  a , po lypep tide  1
F a b p 3  fatty  ac id  binding protein 3. m u sc le  an d  h e a r t
T gfb1i4 transfo rm ing  g row th  fac to r b e ta  1 in duced  tran sc rip t 4
S n n  s tan n in
M gat4a  m an n o s id e  a ce ty lg lu co sam in y ltran sfe ra se  4, iso en zy m e  A
Lrp8 low d en s ity  lipoprotein recep to r-re la ted  pro tein  8
P c a f  p 3 0 0 /C B P -a sso c ia te d  facto r
Ptgs2 prostaglandin-endoperoxide synthase 2
P tp n 2  p ro tein  ty ro sin e  p h o s p h a ta s e ,  n o n -re c e p to r  ty p e  2
Z n f2 12 Zinc finger pro tein  212
B ckdhb  b ra n c h e d  ch a in  ke toac id  d e h y d ro g e n a se  E 1 . b e ta  po lypeptide
C ited2  C b p /p 3 00-in te rac ting  tran sac tiv a to r 2
Itprl inositol 1 ,4 ,5 -trip h o sp h ate  re c e p to r  1
S ta t l  s ig n a l t ra n s d u c e r  a n d  activa to r of transcrip tion  1
B cld B -cell C L L /lym phom a 9
S ta t l  s ig n a l t ra n s d u c e r  a n d  ac tiva to r of transcrip tion  1
Pvrl4 poliovirus recep to r-re la ted  4
111 Sbp in terleukin 18 binding protein
T cf4 transcrip tion  fac to r  4
S lam f8  SLAM fam ily m e m b e r  8
S p re d l  sp ro u ty  pro tein  with EVH-1 do m a in  1, re la ted  s e q u e n c e
T gfb1i4 transfo rm ing  grow th  fac to r b e ta  1 in duced  tran sc rip t 4
T rim 26 tripartite  m otif p ro tein  26
D a a m l d ish ev e lled  a s s o c ia te d  ac tiva to r o f m o rp h o g e n e s is  1
S c h ip l s c h w an n o m in  in teracting pro tein  1
Bbx b obby  sox  hom olog  (D rosophila)
T bc1d1 TBC1 d o m ain  family, m e m b e r  1
C klfsf6 ch em o k in e-lik e  fac to r s u p e r  fam ily 6
C cn d 2  cyclin D2
S a m h d l  SAM d o m a in  a n d  HD dom ain , 1
S e m a 4 c  sem a p h o rin  4C
R a p 2 c  R A P2C , m e m b e r  o f RAS o n c o g e n e  family
Fcr13 F c  recep to r-like  3
Ph ip  p leckstrin  h o m ology  dom ain  in teracting  pro tein
G p r1 0 8  G p ro te in -coup led  recep to r  108
S p 1 0 0  n u c le a r  an tig en  S p 1 00
S tx 1 1 syn tax in  11
H d a c l h is to n e  d e a c e ty la s e  1
Il13ra1 in terleukin  13 recep to r, a lp h a  1
C a sp 4  c a s p a s e  4 , a p o p to s is -re la ted  c y s te in e  p ro te a s e
Azi2 5 -azacy tid in e  induced  g e n e  2
X dh x an th in e  d e h y d ro g e n a se
T m e m 2  tr a n s m e m b ra n e  p ro tein  2
U sp 1 2  ubiquitin sp ec ific  p ro te a se  12
G tp a t1 2  g e n e  tra p  PA T 12
Plcl2 p h o sp h o lip a se  C-like 2
l r p 8  low d en s ity  lipoprotein rec e p to r-re la te d  pro tein  8
C yp11a1  cy to ch ro m e  P 4 5 0 , fam ily 11, sub fam ily  a , po lypep tide  1
S ta t2  s ig n a l t ra n s d u c e r  a n d  ac tiva to r of tran scrip tio n  2
Dr1 do w n -reg u ta to r o f transcrip tion  1
P 2ry12  pu rinerg ic  re c e p to r  P2Y, G -p ro te in  co u p led  12
G m p p b  G D P -m a n n o se  p y ro p h o sp h o ry ia se  B
Kitl kit ligand
T  m po thym opoietin
Tcf4 tran scrip tio n  fac to r 4
Upp1 u rid ine p h o sp h o ry la se  1
syn tax in  11 M us m u sc u lu s  tran sc rib ed  s e q u e n c e s
Fgf23  fib rob last g row th  fac to r 23
B far b ifunctional ap o p to s is  reg u la to r
T o r3 a  to rs in  fam ily 3 . m e m b e r  A
Ph ip  p leckstrtn  h om ology  do m ain  in teracting  p ro tein
A rhh r a s  hom olog  g e n e  family, m e m b e r H
Z fp3 l 3  z inc fin g e r p ro te in  313
C s rp l  c y s te in e  a n d  glycine-rich p ro tein  1
S ta t l  s ig n a l t ra n s d u c e r  a n d  ac tiv a to r o f tran sch p tio n  1
E tohd2  e th an o l d e c re a s e d  2
U sp 1 2  ubiquitin sp ec ific  p ro te a se  12
M itd  MAD hom olog  4  interacting  tran scn p tio n  c o ac tiv a to r  1
A tp11b A T P a se , C la s s  VI, type  11B
S lam f7  SLAM fam ily m e m b e r  7
C 3ar1  c o m p le m e n t co m p o n en t 3 a  re c e p to r  1
C cl2  c h e m o k in e  (C -C  motif) ligand 2
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1 4 2 2 5 1 2 _ a_ a t 
1 4 5 0 9 4 9 _ a t 
1 4 1 7 5 9 0 _ a t 
1 4 1 6 0 2 3 _ a t 
I4 5 4 9 7 1 _ x _ a t 
1 4 5 2 7 8 9 _ a t 
1 4 4 4 3 4 7 _ a t 
1 4 4 0 8 8 2 _ a t 
1 4 3 4 0 3 7 _S _at 
. 1 4 1 7 2 6 3 _ a t 
1 4 2 5 1 9 8 _ a t 
1 4 5 1 2 9 2 _ a t 
1 4 2 7 1 5 3 _ a t 
1 4 2 1 2 6 7 _ a _ a t 
1 4 1 7 2 7 9 _ a t 
1 4 2 0 9 1 5 _ a t 
1 4 5 1 5 7 4 _ a t 
1 4 5 0 0 3 4 _ a t 
1 428701 a t
1 42 5 2 9 4  a t
1455244  a t
1 4 4 7 0 1 6 _ a t 
1 4 5 1 1 14_at 
1 4 3 0 1 2 7 _ a _ a t 
1 4 1 8 1 3 1 _ a t 
1 4 3 3 9 2 0 _ a t 
1 4 6 0 4 3 0 _ a t 
1 4 2 5 2 2 5 _ a t 
1 4 3 8 5 3 5 _ a t 
1 4 2 6 0 7 8 _ a _ a t 
I 4 5 i8 2 l_ a _ a t  
1 4 5 3 2 2 8 _ a t 
1 4 4 8 2 4 6 _ a t 
1 4 5 1 7 7 5 _ s_ a t 
1 4 4 9 5 9 1_at 
4 3 1 8 2 2 _ a _ a t 
1 4 5 1 0 0 6 _ a t 
1 4 2 4 7 1 1_at 
1 4 3 4 4 8 3 _ a t 
1 4 3 4 3 0 6 _ a t 
14 2 6 4 5 0 _ a t 
1 4 2 1 4 5 9 _ a _ a t 
1 4 3 9 9 4 7 _ a t 
145040 3 _ a t 
1 4 1 6 0 1 9 _ a t 
4 3 1 7 2 4 _ a _ a t 
1 4 3 9 0 3 0 _ a t 
1 4 1 5 8 5 4 _ a t 
1 4 2 8 9 7 6 _ a t 
1 4 2 4 0 8 9 _ a_ a t 
1 4 4 8 5 6 2 _ a t 
1 4 5 7 7 8 0 _ a t 
1 4 3 4 7 4 5 _ a t 
1 4 2 6 4 9 0 _ a t 
1428660_S _3 t 
14435 2 2 _ S _ at 
1 4 2 9 3 1 9 _ a t 
1 4 2 2 9 5 9 _ s_ a t 
1 4 2 5 8 1 0 _ a _ a t 
1 4 5 0 0 3 3 _ a_ a t 
1 4 3 3 9 1 0 _ a t 
1 4 2 7 4 7 8 _ a t 
1 4 3 3 6 0 6 _ a t 
1 4 5 1 3 8 8 _ a _ a t 
1 4 5 3 4 7 2 _ a _ a t 
1 4 1 9 4 8 2 _ a t 
1 4 2 0 3 8 0  a t
A W 476433  
A K 012319 
N M _024264 
N M _010174 
B B 357514  
A K 012171 
B G 070161 
B B 7 5 0 9 4 0  
A V 094898  
M 94967 
B G 07 6 1 5 2  
B C 0 0 6 6 9 3  
A W 047304  
N M _010828  
N M _008789  
B M 239586 
B C 0 19641 
A W 2 1 4 0 2 9  
A K 004821 
A F 1108 0 3  
A I639846  
B C 0 2 4 5 8 7  
B Q 0 4 4 2 9 0  
A F 2 0 1 2 8 5  
A F 2 3 0 3 9 5  
B B 7 94633  
N M _013928 
A F 4 5 4 9 4 4  
B B 2 56507  
B C 0 2 7 2 4 8  
A K 007904 
N M _018851 
B Q 03 2 8 4 3  
A K 008416 
B C 0 2 7 3 1 0  
B B 523030  
A F 3 7 6 7 2 6  
U 8 3636  
A K 017897 
N M _008228  
S 8 0 9 6 3  
N M _007609  
A K 004992 
A V 286265 
B B 6 6 7 2 2 9  
A W 5 3 9 1 8 9  
B F 3 1 9 0 1 5  
B M 207017  
N M _053073  
C 8 7 5 2 4  
A F 0 8 8 8 6 2  
N M _026106  
A K 013804 
B I410722 
B C 0 1 1 3 2 2  
A K 017463 
U 16321 
N M _009477 
B B 767243  
B Q 175 8 8 0  
A K 013874 
A K 009693 
B M 221262 
B M 243660 
N M _030743 
A F092921 
N M _009283 
B M 208041 
B I558267 
B G 069 2 3 2  
B C 026741 
A K 016183 
B C 003728  
A F 065933
T able 4.12 (continued) IFN -induced genes in B M D C s after 6h but not 2h o f cu lture
175
D escrip tion
Fold
C hange
6h S ignal 2h Signal
0 IFN
Affy m atrix  G enbank
A c cessio n  A c cess io n
Tnk1 ty ro s in e  k in a se , n o n -re c e p to r , 1 1.7
Z fp m l z in c  fin g er pro tein , m ultitype 1 1.7
C d 8 6 C D 8 6  an tig en 1.7
Crkl v-crk s a r c o m a  v iru s  C T 10 o n c o g e n e  hom otog  (av ian H ik e 1.7
Mllt2h h o m olog  o f  h u m a n  MLLT2 unidentified  g e n e 1.7
Lyn Y am ag u ch i s a r c o m a  viral (v -yes-1 ) o n c o g e n e  hom olog 1.7
Ic sb p l in te rfe ron  c o n s e n s u s  s e q u e n c e  b inding p ro tein  1 1.7
Fgf23 fib ro b last g row th  fa c to r  23 1.6
T im e le s s t im e le s s  hom olog  (D rosophila) 1.6
O gfr opioid grow th  fa c to r  recep to r 1.6
F n b p 2 form in  b inding  p ro te in  2 1.6
Tlk2 to u sled -lik e  k in a s e  2 1.6
H o m e rl h o m e r  h o m olog  1 (D rosophila) 1.6
T o r3 a to rs in  fam ily 3, m e m b e r  A 1.6
P rp f4 P R P 4  pre-m R N A  p ro c e ss in g  fac to r 4  hom olog  (y east) 1.6
H o m e rl h o m e r  h o m olog  1 (D rosophila) 1.6
A nkrd17 ankyrin  re p e a t, d o m a in  17 1.6
M p p e l m e ta llo p h o s p h o e s te ra s e  1 1.6
Brd2 b ro m o d o m ain  con ta in ing  2 1.6
Ifi205 in te rfe ron  a c tiv a ted  g e n e  205 1.6
M pv17 M pv17 tra n s g e n e ,  k idney  d is e a s e  m u tan t 1.6
T m o d 3 tropom odu lin  3 1.6
T bc1d1 TBC1 d o m a in  family, m e m b e r  1 1.6
1112 rb2 in terleuk in  12 re c e p to r , b e ta  2 1.6
T m p o thym opoietin 1.6
G lipr2 GLI p a th o g e n e s is - re la te d  2 1.6
C ds1 C D P -diacylg lycero l s y n th a s e  1 1.6
A d ar a d e n o s in e  d e a m in a s e ,  R N A -specific 1.6
Il13ra1 in terleuk in  13  recep to r, a lp h a  1 1.6
C ds1 C D P -d iacy lg lycero l s y n th a s e  1 1.6
M ap4k5 m ito g en -ac tiv a ted  p ro te in  k in a se  k in a se  k in a se  k in a se  5 1.6
Rbl1 re tin o b la s to m a-lik e  1 (p107) 1.6
C a sp S c a s p a s e  8 1.6
L gals9 lectin , g a la c to s e  binding , so lu b le  9 1.6
Bfar b ifunctional a p o p to s is  reg u la to r 1.6
H cph h em o p o ie tic  cell p h o s p h a ta s e 1.6
Nkd1 n a k e d  cu tic le  1 hom olog  (D rosophila) 1.6
R fc3 rep lica tio n  fac to r  C  (ac tiva to r 1) 3 1.6
Insl6 insu lin-like  6 1.6
Ic sb p l in te rfe ron  c o n s e n s u s  s e q u e n c e  b inding p ro tein  1 1.6
N r3c1 n u c le a r  re c e p to r  sub fam ily  3, g ro u p  C , m e m b e r 1 1.6
C p n e 3 c o p in e  III 1.6
R a b 1 9 R A B 19, m e m b e r  R A S o n c o g e n e  fam ily 1.6
H 2-T 10 histocom patib ility  2 . T reg ion  lo cu s 10 1.6
P d k 3 p y ru v a te  d e h y d ro g e n a s e  k in a se , iso e n z y m e  3 1.6
E va ep ithe lia l V-like an tig en 1.6
Kif24 k in esln  fam ily m e m b e r  2 4 1.6
Fgf23 fib ro b la st g row th  fac to r  23 1.6
P fkfb3 6 -p h o sp h o fru c to -2 -k in a se /fru c to se -2 ,6 -b ip h o sp h a ta se  3 1.5
Crif3 cy to k in e  recep to r-lik e  fac to r 3 1.5
D dx24 DEAD (A sp-G lu-A la-A sp) box p o lypep tide  24 1 .5
C cl3 c h e m o k in e  (C -C  m otif) ligand 3 1 .5
R in2 R a s  a n d  R ab  in te rac to r 2 1.5
M gatl m a n n o s id e  ac e ty lg lu c o sa m in y ltra n sfe ra se  1 1.5
Skil SKI-iike 1.5
W h e e l  11 W olf-H irschhom  sy n d ro m e  c a n d id a te  1-like 1 h o m olog  (h u m an ) 1.5
S lc2 5 a1 2 s o lu te  ca rr ie r  fam ily 2 5  (m itochondrial c a rrie r, A ralar), m e m b e r  12 1.5
P c sk 7 p ro p ro te in  c o n v e r ta s e  subtilisin/kexin ty p e  7 1.5
Atm a ta x ia  te la n g ie c ta s ia  m u ta ted  hom olog  (hu m an ) 1 .5
S tx 3 sy n tax in  3 1.5
B pgm 2 ,3 -b is p h o sp h o g ly ce ra te  m u ta s e 1.5
Crkl v-crk s a r c o m a  v iru s  C T 10  o n c o g e n e  hom olog  (av ian)-like 1.5
T c e b 3 tran sc rip tio n  e lo n g a tio n  fac to r  B (S ill), p o lypep tide  3 1.5
F srg 3 fe m a le  s te rile  h o m eo tic -re la ted  g e n e  3 1.5
G olga3 golgi au to a n tig e n , golgin sub fam ily  a .  3 1.5
T 2 b p T raf2  b inding p ro tein 1.5
A tp8a1 A T P a se , am inophospho lip id  tra n sp o rte r  (APLT), c la s s  I, ty p e  8A,1 1.5
Fgfr4 fib ro b la st g row th  fac to r  re c e p to r  4 1.5
S lc7 a2 s o lu te  ca rr ie r  fam ily 7 ,  m e m b e r 2 1.5
C yp1b1 c y to c h ro m e  P 4 5 0 , family 1, sub fam ily  b , po ly p ep tid e  1 1.5
M ina m yc In d u ced  n u c le a r  an tigen 1.5
E dg2 e n d o th e lia l differen tia tion , ly so p h o sp h a tid ic  ac id  G P C R , 2 1.5
P sm b 9 p ro te o s o m e  (p ro so m e , m ac ro p a in ) su b u n it, b e ta  ty p e  9 1.5
Bbx b o b b y  so x  h o m olog  (D rosophila) 1 .5
S  19  3 2 3
117 196 
169 278
3 9
80.
194
3 8
188
3 5
32
378
58
5 3
* 6 3 4
2 9
41
3 3
4 0
491 466
6 16 1006 5 8 6
356
3 0
833
290 
5 !  46
4 8 5  
. 7?
448 
■  56
5 69 9 2 2 416 691
94 156 160 160
259 425 145 232
152 247 130 176
286 463 195 452
3 2 ' V 149 82 108
231 365 204 248
474 7 6 8 440 471
233 370 235 275
480 7 8 3 460 473
1919 3 1 0 6 1258 2 7 1 0
A F 3 0 7 7 4 6
A A 014267
B C 0 1 3 8 0 7
N M _ 007764
B B 5 86268
M 64608
B C 0 0 5 4 5 0
41 44
317 5 0 8 263 264
32 '52 
114 184 
477 765  
178 289 
58 92
3  4  8  * 3
132 161 
421 443 
193 186 
5 6  Ifl 58
324 521 
193 311
120 227 
200 192
5 8  ' i  t E H  
3 6  f  136 
197 309
71 j&MB I 
|  95 128 
209 229
606  9 5 9
1 57 9  2 5 1 0
6 3 9  742  
1412 1749
190 J O B 155 202
6 4 8  1024 5 9 7  5 5 6
2 4  2S
453 7 1 4  
444 681
291 352 
230 358
■ ■
168 259
203 317 |
4 8  6 0
179 157 
121 178
1243 1940 654  1037
98* 5 9 3  
469 7 5 4  
|2 1 5  331
878  1398 
238 363 
378 581
4fi 7S
166 143 
380 435 
303 284
1822 2321 
266 334 
311 415
46 5 6
331 5 8 3  
170 2S6 I 
Cft 8 8  
197 299 
24 3 6  
214 331 
226 343 
32 4 9  
141 212 
■
395 401 
184 189 
55 54 
284 284 
3 9  3 6  
190 220 
275 296 
3 3  3 5  
103 107 
338 5 22
7 t  110 
3 0  ■ 4 8  I
121
71 9 9
162 241 221 ' 232 
4 6  60
762  1160 479 I 6 8 9  
■ ■ ■■ 165 248 1
1 4 2 5 6 3 5 _ a t 
1 4 5 1 0 4 6 _ a t 
1 4 2 0 4 0 4 _ a t 
1 4 2 1 9 5 3 _ a t 
1 4 2 5 6 4 1 _ a t 
1 4 2 5 5 9 8 _ a _ a t 
1 4 1 6 7 1 4 _ a t 
1 4 4 8 2 2 9 _ s_ a t B M 1 1 8 6 7 9  
1 4 1 7 5 8 7 _ a t B M 230269
1 4 2 2 5 1 1 _ a _ a t N M _ 031373  
1 4 3 4 4 0 6 _ a t B Q 1 7 4 4 0 0  
1 4 3 1 8 2 7 _ a _ a t A K 014829  
1 4 3 9 6 6 2 _ a t BM 1 2 4 6 0 9  
1 4 2 1 9 9 8 _ a t A V 290846
1 4 2 9 7 2 4 _ a t B G 9 1 8 5 0 5
1 4 3 7 3 6 3 _ a t B Q 0 4 3 2 3 8
1 4 3 6 7 7 5 _ a _ a t A W 5 5 7 8 2 6  
1 4 4 0 8 8 0 _ a t B I648107
1 4 3 7 2 1 0 _ a _ a t 
1 4 5 2 2 3 1_ x _ a t 
1 4 4 1 0 7 6 _ a t 
1 4 2 3 0 8 9 _ a t 
1 4 1 9 4 4 6 _ a t 
1 4 2 1 6 2 3 _ a t 
1 4 5 2 0 3 6 _ a _ a t A A 153892  
1 4 2 8 4 9 2 _ a t A K 017557
1 4 5 6 1 1 4 _ a t 
1 4 2 5 4 0 5 _ a _ a t 
1 4 2 7 1 6 5  a t
A I506310  
M 74124 
B M 939297  
A K 01 7725  
N M _01 9636  
NM 0 0 8 3 5 4
1 4 2 8 6 8 0 _ a t 
1 4 3 8 7 0 2 _ a t 
1 4 2 4 1 5 6 _ a t 
1 42 4 5 5 2  a t
Bl 152841 
A F 2 9 1 8 7 6  
A A 879826 
A K 014670 
B G 0 7 5 6 9 9  
U 2 7177  
B C 0 0 6 7 3 7
1 4 2 1 2 1 7 _ a _ a t N M _010708  
1 4 2 6 4 8 8 _ a t A V 235863
1 4 6 0 1 8 8 _ a t N M _013545 
1 4 4 0 4 4 6 _ a t B M 021767
1 4 3 2 5 3 8 _ a _ a t A K 013095  
14 1 8 3 4 6  a t NM 0 1 3 7 5 4
1 4 4 8 4 5 2 _ a t 
1 4 2 1 8 6 6 _ a t 
1 4 2 8 5 1 4 _ a t 
1 4 3 0 1 4 8  a t
B G 0 6 9 0 9 5
N M _008173
A K 017651
B M 241400
1 4 4 9 8 7 5 _ s_ a t N M _010395  
1 4 2 6 4 1 0  a t  A V 086243
1 4 1 6 2 3 7 _ a t 
1 4 3 1 9 3 7 _ a t 
1 4 1 6 1 2 3 _ a t 
141 6 4 3 2  a t
N M _007962  
A K 016916  
B M 118679  
NM 133232
146 0 3 3 8  a  a t  B B 1 6 1 2 5 3
1 4 1 5 7 1 3 _ a _ a t 
1 4 1 9 5 6 1 _ a t 
1 4 2 6 3 6 8 _ a t 
1 4 2 3 6 0 9 _ a _ a t 
1 4 2 2 0 5 4 _ a _ a t 
1 4 5 9 9 0 7 _ a _ a t 
1 4 2 8 4 4 0 _ a t 
1 4 1 7 1 8 0 _ a t 
1 4 2 1 2 0 5 _ a t 
1 4 3 4 5 5 9 _ a t 
1 4 1 5 8 6 5 _ s_ a t B C 0 0 4 5 8 9  
1 4 3 6 9 5 0 _ a t A W 541802
1 4 3 4 1 1 7 _ a t 
14 5 0 1 7 8 _ a t 
14 1 9 1 5 9 _ a t 
1 4 2 6 5 0 1 _ a _ a t 
1 4 2 3 5 9 7 _ a t 
1 4 2 7 8 4 6 _ x _ a t 
1 4 5 0 7 0 3 _ a t 
1 4 1 6 6 1 2 _ a t 
1 4 5 1 0 4 2 _ a _ a t A K 013451 
1 4 4 8 6 0 6 _ a t U 70 6 2 2
1 4 5 0 6 9 6 _ a t N M _013585  
1 4 3 0 8 2 0  a  a t B C 0 2 4 4 4 9
U 4 6690  
N M _011337  
A K 014548  
B B 205495  
U 3 6 2 0 3  
B I658695  
A K 019150  
N M _008794  
NM 0 0 7 4 9 9  
A W 5 3 6 4 1 5
A V 264059 
N M _054054 
D 78 2 7 0  
B B 277065  
B B 3 03874  
A F 1 2 7 1 4 0  
B F 5 3 3 5 0 9  
NM 0 0 9 9 9 4
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6h Signal 2h Signal
Gene Description Chant
Maff v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) 2.4
Rragd Ras-nelated GTP binding D 2.3
Gaint9 polypeptide N-acetytgalactosaminyltransferase 9 2.3
Ing3 inhibitor of growth family, member 3 2.2
Txnrd3 thioredoxin reductase 3 2.2
Tcergl transcription elongation regulator 1 (CA150) 2.1
H2afx H2A histone family, member X 2.1
Fasn fatty acid synthase 2.1
Cyhrl cysteine and histidine rich 1 2.0
Epm2aip1 EPM2A (laforin) interacting protein 1 2.0
TgfbM transforming growth factor, beta receptor I 2.0
Sprrl7 small proline rich-like 7 2.0
Smt3h1 SMT3 (supressor of mif two, 3) homolog 1 (S. cerevisiae) 2.0
Ell elongation factor RNA polymerase II 2.0
Klhl2 kelch-like 2, Mayven (Drosophila) 2.0
Zdhhc7 zinc finger, DHHC domain containing 7 1.9
Bub 1b budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) 1.9
Cerk ceramide kinase 1.9
Ampd3 AMP deaminase 3 1.9
Il6ra interleukin 6 receptor, alpha 1.9
Mbp myelin basic protein 1.9
Tfap4 transcription factor AP-4 (activating enhancer-binding protein 4) 19
Cdk4 cyclin-dependent kinase 4 1.9
Trim37 tripartite motif protein 37 1.9
Hist2h2bb histone 2. H2bb 1.8
Cnr2 cannabinoid receptor 2 (macrophage) 1.8
Dapkl death associated protein kinase 1 1.8
Ube3a ubiquitin protein ligase E3A 1.8
Fcmd Fukuyama type congenital muscular dystrophy homolog (human) 1.8
Ssa2 Sjogren syndrome antigen A2 1.8
Cd97 CD97 antigen 1.8
Polh polymerase (DNA directed), eta (RAD 30 related) 18
Gdc glutamate-cysteine ligase. catalytic subunit 1.8
Arhf ras homolog gene family, member f (in filopodia) 1.8
C76746 expressed sequence C76746 1.8
Sca7 spinocerebellar ataxia 7 homolog (human) 1.8
Zfp99 putative zinc finger protein 99 sequence 1.8
Glell GLE1 RNA export mediator-like (yeast 1.8
Eno2 enolase 2, gamma neuronal 1.8
Tex292 testis expressed gene 292 1.8
Skp2 S-phase kinase-associated protein 2 (p45) 1.8
Rora RAR-related orphan receptor alpha 1.8
Ahr aryl-hydrocarbon receptor 1.8
Fbxo5 F-box only protein 5 1.8
Tcfe2a transcription factor E2a 1.7
Ptovl prostate tumor over expressed gene 1 1.7
Srd5a2l steroid 5 alpha-reductase 2-like 1.7
Akap8 A kinase (PRKA) anchor protein 8 1.7
R e d piectin 1 1.7
Gys3 glycogen synthase 3, brain 1.7
Mtssl metastasis suppressor 1 1.7
Tardbp TAR DNA binding protein 1.7
Spata13 spermatogenesis associated 13 1.7
GTP binding protein 3 GTP binding protein 3 1.7
Sox 7 SRV-box containing gene 7 1.7
LrrcS leucine-nch repeat-containing 5 1 7
Fnbpl formin binding protein 1 1.7
Cdadcl cytidine and dCMP deaminase domain containing 1 1.7
Acvrll activin A receptor, type ll-like 1 17
Fgfrlop Fgfrl oncogene partner 17
Orm1 orosomucoid 1 1.7
Cdr2 cerebellar degeneration-related 2 17
Rad23a RAD23a homolog 1.7
Pcm1 pericentriolar material 1 1.7
Ormdl3 ORM1-like 3 (S. cerevisiae) 1.7
Galnt6 polypeptide N-acetylgalactosaminyltransferase 6 17
Affymetrix
Accession
Genbank
Accession
TO 47
S 2
173 
257  178
447 218
16 10
33I W
24 11HH” i#Ti
240  173
S N i i
1056 607
111 
219  115
1418936_at 
1434909_at 
1434055_at 
1422806_x_at 
1423869_s_at 
1450100_a_at 
1416746_at 
1423828_at 
1451153_a_at 
1434106_al 
1420894_at 
1420332_x_at 
1417033_at 
1460643_at 
1426978_at 
1438876_at 
1416961_at 
1434034_at 
1422573_at 
1452416_at 
1425263_a_at 
1418187_at 
1422440_at 
1436393_a_at 
1447854_s_at 
1450476_at 
1427358_a_at 
1445727_at 
1435801_at 
1436533_at 
1418394_a_al 
1420988_at 
1424296_at 
1441510_at 
1428391_al 
1442186_at 
1452610_at 
1440719_at 
1418829_a_at 
1423884_al 
1460247_a_at 
1420583_a_al 
1422631_at 
1429499_at 
1426297_at 
1416945_at 
1439241_x__at 
1450983_at 
1437554_at 
1416737_at 
1434036_at 
1423723_s_at 
1434958_at 
1450980_al 
1416564_at 
1433506_at 
1451806_at 
1439105_at 
1435825_at 
1428919_at 
1451054_at 
1417430_at 
1417619_at 
1418525_at 
1419450_at 
1434399 at
BC022952 
BF462770 
BB048942 
BB020556 
AF349659 
AW046403 
NM_010436 
A Fl27033 
BC025112 
BB175879 
025540 
NM_027137 
AF296657 
BC024894 
AW682368 
BB667355 
NM_009773 
B1905090 
D85596 
X53802 
L07508 
NM_031182 
NM~009870 
BG065227 
AV127319 
NM_009924 
BC026671 
BB166188 
AV365405 
AV232359 
NM_011925 
AB037184 
BC019374 
BB157359 
AK004767 
BE945939 
AK009842 
AV251087 
NM_013509 
BC027399 
NM_013787 
NM_013646 
NM^013464 
AK011820 
AF352579 
NM_133949 
BB825787 
BG069776 
BM232239 
NM_008195 
AV024771 
BC012873 
BG075163 
BM207274 
NM_011446 
BB315861 
BC003867 
BE200391 
BG969012 
BB667817 
BE628912 
NM_007672 
NM_026320 
BG088656 
NM_025661 
AV231866
Table 4.13 (continued over page) IFN -suppressed  genes in B M D C s after 6h but not 2h  
o f culture. Sam ples from  CD1 lc + D Cs cultured  in vitro in the p resence o f  2 x 104 U  IFN - 
aA (IFN ) or in m edia alone (0) w ere hybrid ised  to A ffym etrix  m urine 430 2.0 arrays. D ata 
w ere generated  from  the m ean o f  three experim ents carried  out on independently  iso lated  
DCs. D ata w ere analysed in G enespring 7.2 and changes o f  m ore than 1.5 fold w ere 
determ ined to be significant by W elch ’s approxim ate t-test w here p-values w ere less than  or 
equal to 0.05. N orm alised signal intensities w ere co lour coded  to indicate the level o f  
expression, as show n in the key  for table 4.2.
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6h Signal 2h Signal
Gene Description Chant
Mki67ip Mki67 (FHA domain) interacting nucleolar phosphoprotein 1.7
Rps6ka2 ribosomal protein S6 kinase, polypeptide 2 1.7
Lpinl lipin 1 1.7
Erccl excision repair cross-complementing rodent repair deficiency, group 1 1.7
Osbpl3 oxysterol binding protein-like 3 1.7
Rnu22 RNA. U22 small nucleolar 1.6
Tnrc15 trinucleotide repeat containing 15 1.6
Crebl cAMP response element binding protein (Crebl) 1.6
Sfrs2 splicing factor, arginme/serine-nch 2 (SC-35) 1.6
Gas7 growth arrest specific 7 1.6
Ms4a1 membrane-spanning 4-domains, subfamily A. member 1 1.6
Msh6 mutS homolog 6 (E. coli) 1.6
Syncrip synaptotagmin binding, cytoplasmic RNA interacting protein 1.6
Golgbl golgi autoantigen, golgin subfamily b, macrogolgin 1 1.6
Sh3glbl SH3-domain GRB2-like B1 (endophilin) 1.6
Hoxal homeo box A1 16
Pitpnb phosphotidylinositol transfer protein, beta 1.6
Uchrp ubiquintin c-terminal hydrolase related polypeptide 1.6
Pdcd4 programmed cell death 4 1.6
Duspl 9 dual specificity phosphatase 19 1.8
Slc6a12 solute earner family 6 (neurotransmitter transporter, betaine/GABA),12 1.6
Nudt6 nudix (nucleoside diphosphate linked moiety X)-type motif 6 1.6
Jtv1 JTV1 gene 1.6
Mrps18b mitochondrial ribosomal protein S18B 1.6
Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 1.6
DnajblO DnaJ (Hsp40) homolog. subfamily B, member 10 1.6
Lpinl lipin 1 1.6
Kpnbl karyopherm (importin) beta 1 1.6
Siva Cd27 binding protein (Hindu God of destruction) 1.6
Rai14 retinoic acid induced 14 1.8
Abcel ATP-bindmg cassette, sub-family E (OABP), member 1 16
Erdrl erythroid differentiation regulator 1 1.6
Pdxk pyridoxal (pyndoxine, vitamin B6) kinase 1.6
Syncrip synaptotagmin binding, cytoplasmic RNA interacting protein 1.8
Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 1.6
Me2 malic enzyme 2, NAD(+)-dependent, mitochondrial 1.6
Hs1bp3 HS1 binding protein 3 1.6
Ibsp integrin binding sialoprotein 1.6
Solh small optic lobes homolog (Drosophila) 1.6
zinc finger protein s11-6 zinc finger protein s11-6 1.6
Tbrg4 transforming growth factor beta regulated gene 4 1.6
Rassf3 Ras association (RalGDS/AF-6) domain family 3 1.8
Mtssl metastasis suppressor 1 1.6
Solh small optic lobes homolog (Drosophila) 1.5
Cent cydin F 1.5
Acpp acid phosphatase, prostate 1.5
Sec14l1 SEC14-like 1 (S cerevisiae) 1.5
Thrap3 thyroid hormone receptor associated protein 3 1.5
additional sex combs like additional sex combs like 1 1.5
11411 interleukin 4 induced 1 1.5
Atf4 activating transcription factor 4 1.5
Arhgef16 Rho guanine nucleotide exchange factor (GEF) 16 1.5
integrin beta 3 integrin beta 3 1.5
Acpp acid phosphatase, prostate 1.5
Agpat4 1-acylglycerol-3-phosphale O-acyttransferase 1 1.5
Tef thyrotroph embryonic factor 1.5
Rassf3 Ras association (RalGDS/AF-6) domain family 3 1.5
Dgkd diacytglycerol kinase, delta 1.5
Ccnbl cyclin B1 1.5
Mafg v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) 1.5
Unc119 unc-119 homolog (C elegans) 1.5
Cdca3 cell division cycle associated 3 1.5
Zrf2 zuotin related factor 2 1.5
Txnl thioredoxin-like 1.5
Hps4 Hermansky-Pudlak syndrome 4 homolog (human) 1.5
ItgalO integrin, alpha 10 1.5
62 3?
2* *2
142 88
74 47
SB S4
163 r.
177 
336 
267 172iso W*
372
Affymetrix
Accession
1424001_at 
1441311_at 
1426516_a_at 
1430138_at 
1428484_at 
1433675_at 
1461397_at 
1421583_at 
1452439_s_at 
1417859_at 
1450912_at 
1416915_at 
1450743_s_at 
1435032_at 
1434916_at 
1420565_at 
1420307_a_at 
1448230_at 
1456393_at 
1426447_at 
1449382_at 
1424510_at 
1424151_at 
1451164_a_at 
1434184_s_at 
1448657_a_at 
1418288_at 
1416925_al 
1418377_a_at 
1417400_at 
1416015_s_at 
1427820_at 
1427930_at 
1422769_at 
1422615_at 
1428572_at 
1433843_at 
1417485_at 
1434416 a_at 
1434355 at 
1448796_s_at 
1448546_at 
1424826_s_at 
1434417_at 
1422513lat 
1441975_at 
1451908_a_at 
1452125_at 
1435077_at 
1438917_x at 
1448135_at 
1438178 x_at 
1455257_al 
1453943_a_at 
1436640_x_at 
1424175_at 
1417015~at 
1433564_at 
1416076_at 
1448916_at 
1418123 at 
1452040_a_at 
1417657_s_at 
1437906_x_at 
1448629 at 
1440235~at
O enbank
Accession
AY030275 
BG063083 
AK014526 
AW987309 
AK004768 
BQ177137 
BC027137 
AF448508 
AF250135 
NM_008088 
BB236617 
U42190 
BG920261 
BM213299 
AV377318 
NM_010449 
BG975479 
NM_009462 
AI642124 
AK009187 
NM_133661 
BC027267 
BC026972 
BC021752 
BQ175905 
NM_020266 
NM_015763 
NM_008379 
NM~013929 
AF274866 
NM_015751 
BC021831 
BG063905 
BG920261 
NM_008696 
BF730769 
AW541327 
L20232 
BB022975 
BB159201 
BB768873 
BC011511 
AA250031 
BB022975 
NM_007634 
BB008092 
BC005766 
BG075035 
BE956516 
AW240611 
M94087 
BB368056 
AV352983 
AK020693 
BE994529 
BC017689 
NM_138956 
BB422487 
X58708 
BC002092 
BC001990 
B1081061 
NM_009584 
AV106191 
NM_138646 
BB"l51146
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chain. Three members of the membrane-spanning 4-domain family of proteins, two of 
which whose expression we had investigated by real-time PCR in splenic DCs, were also 
induced by IFN-a in BMDCs.
A large number of genes (376) were induced by IFN-I at the 6h timepoint but not the 2h 
timepoint (Table 4.12). This was the only condition in which IL-12p40 mRNA was detected 
as IFN-induced, and was expressed at relatively low levels. Similarly this is the only 
condition where CD86 was significantly upregulated by IFN-a4. In addition to detecting 
dramatic enhancement of CCL2 (MCP-1) and CCL3 (MIP-la), known be induced during DC 
maturation (Sallusto et al., 1999b), we detected a gene named chemokine-like factor super 
family 6 and a putative cytokine receptor named cytokine receptor-like factor 3 which may 
merit further investigation. Genes which were suppressed at 6h but not at 2h are shown in 
table 4.13.
It should be noted that, several of the genes listed were also upregulated at the 2h timepoint, 
for example Pnp which was discussed earlier. This is because differential expression has 
been detected by different probe sets. Therefore they have not been grouped together in the 
list containing genes differentially regulated at both 2h and 6h.
4.2.3 Comparison of gene expression in splenic DCs and BMDCs
4.2.3.1 Merging and clustering o f  splenic DC and BMDC data
Since we had used different versions of microarrays to analyse gene expression in splenic 
DCs (sDCs) and BMDCs, it was impossible to do a direct comparison using probe set 
identification numbers. Therefore, in order to make comparisons between the two data sets 
it was necessary to make an independent analysis. The data was normalised in Genespring 
as described previously. Following this, the entire data sets were exported and the sDC and
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BMDC data sets merged using data comparison files provided by the array manufacturer 
(Affymetrix). We only used the data present in the “best match” comparison files, which are 
matched based on a stringent set of parameters that includes the percentage identity between 
the representative sequences and the amount of overlap between the target sequences chosen 
for probe selection. Where probe sets existed in the 430 2.0 array but did not match to probe 
sets in the U74Av2 array, or vice versa, the data was retained for separate analysis.
The data were then filtered on the following criteria: the change in expression for a gene 
must be greater 1.5 fold in at least one of the conditions, and have an associated p-value of 
less than 0.05 in the paired t-test. In addition, the gene must be detected as present (i.e. 
being expressed) in all three replicates in the condition displaying higher expression. 
Following this, the data were visualised using the TIGR multiple-experiment viewer 
(TMEV)(Saeed et al., 2003). The data were clustered using a hierarchical method, which 
was done purely for visualisation purposes and was not intended to infer functional 
relationships within groups of genes.
More than 1000 genes were differentially expressed in at least one of the conditions tested 
(figure 4.5a). Of these, more than half of those found in the BMDCs (430 2.0 array) had no 
corresponding probe set for the sDC data (U74Av2 array), which was expected. However 
437 genes whose expression changed more than 1.5 fold were represented on both arrays 
(Figure 4.5b). Of these, 17 genes were enhanced by IFN-a in all four conditions, which 
included the usual suspects: CXCL9, CXCL10, Tyki, Mxl and known IFN-induced genes. 
48 genes were enhanced in at least three of the conditions. However, many of the induced 
genes were detected in only one of the conditions. Of the suppressed genes, only one was 
common to both sDCs and BMDCs, which was CXCR4.
180
-4 +4
Fold change
F igure 4.5 C om parison  o f  genes regulated  by IF N -o4  in sD C s and B M D C s. D ata w ere 
norm alised  in G enespring 7.2, and w ere generated  from  the m ean o f  three experim ents carried  
out on independently  isolated D Cs. sD C and B M D C  data sets w ere exported  and m erged  and 
genes w hich  did not change in expression  by  at least 1.5 fold w ith an  associa ted  t-test p -values 
o f  less than  or equal to 0.05 in at least one condition w ere filtered  out. a) C om parison  o f  
p robe sets (w here IFN -regulation  w as detected  in at least one condition) from  sD C  and 
B M D C  data sets, b) D ata w as clustered  using TM EV . C hange in expression  level is 
indicated  by  green colouring (suppressed) or red  colouring (induced).
4.2.3.2 Functional classification
The genes were classified into various categories depending on their biological function or 
the biological or molecular function inferred by gene ontology information available on the 
Affymetrix database (Table 4.14). There may be some overlap between the categories, for 
instance many of the transcription factors are likely to play roles in regulation of cell cycle 
and apoptosis, such as Pml. Additionally, molecules involved in signal transduction may 
also act as transcription factors, such as STATl.
Table 4.14 Classification of IFN-regulated genes
C ategory Num ber o f genes
Classical ISGs 41
Cytokine receptors 10
Migration and adhesion molecules 23
Cell surface expressed 77
Secreted (cytokines and chemokines) 21
Regulation o f  transcription 106
Cell cycle, growth and apoptosis 69
Signaling molecules 75
Protein synthesis and regulation 66
Ion transport 33
Nucleotide synthesis and DNA replication 40
Actin modelling and cytokinesis 15
ESTs 279
Unclassified 332
4.2.3.2.1 Classical ISGs
As would be expected, many known IFN-induced genes were identified in both the sDCs and 
the BMDCs, and included several anti-viral genes (Figure 4.5c). In general, these genes 
were most strongly induced at the 2h timepoint, but it should be noted that the transcription 
level of these genes in the 6h untreated controls was high. It is possible that these genes are 
being induced by endogenous IFN-I produced by the DCs. A group of genes was induced at
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F igure 4 .5c C om parison  o f  expression  o f  classical ISG s in sD C s and B M D C s.
D ata w ere norm alised  in G enespring  7.2, and w ere generated  from  the m ean  o f  three 
experim ents carried  out on  independently  iso lated  D Cs. sD C and B M D C  data sets 
w ere exported  and m erged, and filtered  to include on ly  genes w hose expression  
changed  by  at least 1.5 fold (p=<0.05) in at least one condition . D ata w as clustered  
using TM EV . C hange in expression  level is ind icated  by  green  colouring  
(suppressed) or red colouring (induced). S ignal in tensities for the control sam ples 
w ere co lour coded to indicate the level o f  expression, as show n in the key.
1 8 3
2h in sDCs but not BMDCs. Again, mRNA expression was high in the BMDC untreated 
controls where enhanced gene expression was not detected.
4.2.3.2.2 Cytokine receptors
This group of genes includes the a-chains of the IL-15 receptor (IFN-enhanced) and IL-6 
receptor (IFN-suppressed) which were discussed previously. Notably, enhanced expression 
of the IL-13 receptor a l (IL-13Ral) was detected by three different probe sets on the 430 2.0 
array (Figure 4.5d). The U74Av array does contain two probe sets representing IL-13Ral, 
but neither of these probe sets could be compared to probe sets on the 430 2.0 array. This 
enhancement is interesting, since there is data indicating that a soluble form of IL-13Ral 
promotes IgG2a and IgG2b production by B cells in the germinal centres (Poudrier et al., 
1999). In addition, IL-13 can replace IL-4 in the generation of DCs from peripheral blood 
mononuclear cells (Morse et al., 1999).
4.2.3.2.3 Migration and adhesion molecules
In this group of genes whose function is associated with cell migration and adhesion, none 
were enhanced in both splenic and BMDC data sets (Figure 4.5e). In sDCs there was 
enhanced expression of both CCR5 and CCR7 at 2h of IFN-stimulation. Upregulation of 
CCR7 is expected, since maturing DCs need to express this receptor in order to migrate to 
the LN. CCR5 upregulation was unexpected however, since it has previously been shown 
that after LPS-maturation of human DCs, CCR5 mRNA levels remained stable whilst cell 
surface expression was lost (Sallusto et al., 1998c). Also unexpected was the 
downregulation of CXCR4, which is again in contrast to results shown in human LPS- 
matured DCs which strongly upregulate CXCR4 mRNA (Sallusto et al., 1998c). However, 
the upregulation of CXCR4 mRNA was not reflected in expression on the cell surface, which 
was not detectable in mature DCs.
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In addition to chemokine receptors, adhesion molecules are essential for DC migration. One 
cell adhesion molecule identified here, Integrin a4 (also known as very late antigen 4, VLA- 
4), which was induced by IFN in BMDCs, is essential for lymphocyte migration across high 
endothelial venules and into inflamed tissues (Steeber et al., 2005). Some of the genes 
identified have roles in adhesion in non-immune cells such as retinoschisis 1, which is 
thought to mediate interactions between cells of the eye (Reid et al., 2003) but has not been 
implicated in DC function.
Another gene upregulated by IFN in sDCs but not BMDCs included peptidylprolyl isomerase 
C-associated protein/lectin (Ppicap) whose expression we had investigated by real-time PCR 
and whose human homologue is thought to mediate cell adhesion and migration through its 
ligand MAC-2/galectin-3. Although we did not detect upregulation in BMDCs, the 
expression of this gene is highly elevated in untreated BMDCs.
4.2.3.23 Cell surface molecules
In addition to the cell surface molecules already discussed, DCs express numerous receptors 
which mediate their activation, such as CD40, here seen upregulated in all conditions except 
after 2h in BMDCs (Figure 4.5f). Several TLRs were enhanced by IFN-I in BMDCs: TLR3, 
TLR7, and TLR8. TLR3 recognises dsRNA, whilst TLR7 and TLR8 recognise viral ssRNA 
(Takeda et al., 2005). Therefore, this may represent a mechanism which allows DCs to 
respond correctly to the pathogen, since the presence of type-I IFNs indicate viral infection. 
None of the probe sets for these TLRs are directly comparable to probe sets on the U74Av 
array; indeed only TLR3 is represented at all on these arrays.
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Figure 4 .5 f C om parison  o f  IF N -a4  regulated expression  o f  genes encod ing
cell surface m olecules in sD C s and B M D C s Legend  as in figure 4 .2 .3 .1c
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Another cell surface molecule, lymphocyte activation gene 3 (LAG-3) which was induced 
only in splenic DCs at the 6h timepoint, is more commonly associated with T cells. 
Interactions between MHC class II molecules on APCs and LAG-3 expressed on T cells 
inhibits T cell activation. However LAG-3-MHC class II interactions activate the APC and 
stimulate IFN-y and IL-12 production (Triebel, 2003).
4.2.3.2.4 Secreted molecules
The majority of genes for secreted molecules enhanced by IFN-a4 are cytokines and 
chemokines (Figure 4.5g). We identified genes encoding the DC effector cytokines IL-15, 
IL-6 and IL-12p40. IL-1 p was suppressed at 6h in sDCs, whilst IL-1 receptor antagonist
(IL-IRn) was enhanced. This dual regulation may confer a type-1 polarizing signal on the 
DCs, since IL-IRn, which inhibits IL-1 function, has been shown to promote a type-1 
antibody response and cytokine production profile (Lin et al., 2002). Enhancement of IL- 
IRn is consistent with previous studies on LPS-treated murine D1 cells (Granucci et al., 
2001b), although in this case IL-1 P was also enhanced. In contrast, IL-18 binding protein , 
which inhibits the action of the Thl promoting cytokine IL-18 (Novick et al., 1999), was 
induced in the BMDCs at 6h. However the level of expression of IL-18 binding protein was 
low compared to IL-IRn.
In general, the chemokine genes induced by IFN-a4 are associated with a Thl-type response.
CXCL9, CXCL10 and CXCL11 all act through the same receptor CXCR3, which is
primarily expressed by activated Thl cells (Bonecchi et al., 1998; Sallusto et al., 1998b).
CCL4 and CCL5, enhanced in sDCs at 6h, are also thought to have Thl inducing properties,
although CCL2, which was induced in BMDCs at 6h, promotes Th2 effector cell
development (Luther et al., 2001). sDCs also strongly suppressed CCL22 expression in
response to IFN-a at the 6h timepoint. This chemokine directs the migration of Th2 cells via
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CCR4 (Zlotnik et a l , 2000). Both CCL1 and CCL7 were suppressed by BMDCs at 6h. 
CCL1 and CCL7 are agonists for CCR8 and CCR3 respectively, which are also expressed on 
Th2 cells (Sallusto et a l , 1998a; Colantonio et al., 2002).
A gene encoding a chemokine-like factor (chemokine-like factor superfamily 6, CKLF6) was 
identified in BMDCs. The human homologue of CKLF6 was identified along with other 
members of this family using an in silico approach through its sequence similarity with the 
original member of this family, chemokine-like factorl, which contains a CC motif and has 
chemotactic properties (Han et a l, 2003).
4.2.3.2.5 Regulation o f transcription
A large number of genes encoding transcription factors were induced by IFN-I (figure 4.5h). 
Among these, the most easily identifiable were the interferon regulatory factors (IRFs), of 
which IRF7 and IRF1 were identified in both sDCs and BMDCs.
4.2.3.2.6 Signaling (Figure 4.5i)
Few genes involved in cell signaling were commonly regulated in sDCs and BMDCs. One 
of these, STATI (signal transducer and activator of transcription 1) mediates signaling from 
the IFN-I receptor which involves its dimerisation with STAT2 (induced in BMDCs). 
Members of the SOCS (suppressor of cytokine signaling) family of proteins, were also 
induced by IFN-I. Whereas SOCS-1 was induced in both DC types, SOCS-3 upregulation 
was only detected in sDCs. Both SOCS-1 and SOCS-3 are known to be induced by many 
types of stimuli including interleukins, IFN-a and IFN-y in addition to TLR ligands LPS and 
CpG DNA (Fujimoto et al., 2003). SOCS-1 and -3 regulate complex negative-feedback 
mechanisms since they can inhibit multiple cytokine receptor signal transduction pathways.
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4.2.3.2.7 Cell growth/cell cycle/apoptosis
Many genes with putative roles in either cell cycle, differentiation or cell death were 
differentially expressed (figure 4.5j). A number of genes were regulated similarly in sDCs 
and BMDCs. These included Fas death domain associated protein (Daxx), a signaling 
molecule associated with the Fas receptor (Yang et al., 1997). IFN-a enhances the 
expression and nuclear translocation of Daxx where it associates with nuclear bodies and 
induces cell cycle arrest and apoptosis (Gongora et al., 2001). As previously discussed, 
Pml, whose expression was also induced by IFN is an essential component of nuclear bodies 
and also mediates apoptosis.
Lectin, galactose binding, soluble 9/ Galectin-9 (Lgals9/Gal-9) was induced after 6h in both 
types of DC. Lgals9 functions as a proapoptotic factor for many cell types including 
thymocytes and activated T cells (Wada et al., 1997; Kashio et al., 2003). In addition 
Lgals9 acts as a chemotactic factor for eosinophils (Hirashima, 1999).
4.2.3.2.8 Protein synthesis and regulation
This group includes genes with a range of functions in the regulation of proteins including 
their translation, such as ribosomal proteins, folding (chaperonin subunits) and their 
transport, for example sorting nexin 2 (figure 4.5k). Several genes in this group are involved 
in protein ubiquitination or encode proteases which act on ubiquitinated proteins. A known 
IFN- stimulated gene, ubiquitin specific protease 18 (Uspl8), which was induced by IFN at 
both timepoints and DC type, regulates signaling through the JAK-STAT pathway. This 
gene was also identified by RDA. It acts by unconjugating the IFN-stimulated protein 
ISG15, a ubiquitin-like protein, from other intracellular proteins. Since cells lacking Uspl8 
are hypersensitive to type I IFN, it is thought to act as a negative regulator of IFN-signaling 
(Malakhova et a l, 2003).
193
Fold change
-4 +4
-  ** &£1 J2 Cl
( 1  KU
u  o  
«  «  m  cq
0-50
50-100
100-250
250-500
500-1000
1000-2000
2000-3000
3000-4000
4000-5000
>5000
I
s c h l  a f c n  1
p  i t u  i t ;  a r y  t  u m o i " t r  a n s £ o t m  i n g  1 
F a s  d c A t l \  d o w * m - * 3 s o c i * t e d  p r o t e i n  
p r o m y e l  o c y t  i c  l e u k e m i a
" t i u n o r  n e c r o s i s  f a c t o r  ( l i g a n d )  s u p e r f a m i l y ,  m e m b e r  1 0  ( T r a i l ) "
" c a s p a s e  4.. a p o p t o s  i s - r  e l  a t e d  c y s t e i n e  p r o t e a s e "
" l e c t i n ,  g a l  a c t  o s  e  b  i n d  i n g , s o l  u b  1 e  9 " 
a n n e x  i n  A l  
c y c l i n  D1
e c o t r o p  i c  v i r a l  i n t e g r a t i o n  s i t e  2 
s c h l a f e n  2 
s c h l a f e n  2 
c a s p a s e  1
" n e u r a l  p r e c u r s o r  c e l l  e x p r e s s e d /  d e v e l  o p m e n t  a l  l y  d o v n - r e g u l  a t  e d  g e n e  9 "  
c y c l  i n * d e p e n d e n t  k i n a s e  i n h i b i t o r  1A ( P 2 1 )  
a n n e x  i n  A l
c y c l  i n - d e p e n d e n t  k i n a s e  i n h i b i t o r  1A < PC1) 
s t r o m a l  a n t i g e n  2 
s c o t  i n  g e n e
e c o t r o p  i c  v i r a l  i n t e g r a t i o n  s i t e  2 
c y c l  i n  G2
h o m o l o g  o f  h u m a n  MLLTC u n i d e n t i f i e d  g e n e  
a p o p t o t i c  p r o t e a s e  a c t i v a t i n g  f a c t o r  1  
m y e l o c y t o m a t o s i s  o n c o g e n e  
c - m e r  p r o t o - o n c o g e n e  t y r o s i n e  k i n a s e  
c a s p a s e  8
r e t i n o b l a s t o m a - 1 i k e  1  ( p l 0 7 )
v - c r k  s a r c o m a  v i r u s  C T 1 0  o n c o g e n e  h o m o l o g  • a v i a n ) - l i k e  
U - m y c  d o w n s t r e a m  r e g u l a t e d  2 
c a s p a s e  2
c e l l  d i v i s i o n  c y c l e  a s s o c i a t e d  5
t r i p a r t i t e  m o t i f  p r o t e i n  1 3
p l a c e n t a l  g r o v t h  f a c t o r
g r o v t h  a r r e s t  s p e c i f i c  5
g r o v t h  a r r e s t  s p e c i f i c  5
h o s t  c e l l  f a c t o r  C l
r  e t  i n o b 1 a s t  o m a  b  i n d  i n g  p  r  o t  e i n  4
c e l l  d i v i s i o n  c y c l e  3 4  h o m o l o g  » 3 .  c e r e v i s i a e )
CDK2 ( c y c l i n - d e p e n d e n t  k i n a s e  2 ) - a s s o c i a t e d  p r o t e i n  1  
CDCCC p r o t e i n  k i n a s e  r e g u l a t o r y  s u b u n i t  2
T i a l l  c y t o t o x i c  g r a n u l e - a s s o c i a t e d  PJIA b i n d i n g  i > r o t e  i n - 1  i k e  1
c a s p a s e  r e c r u i t m e n t  d o m a i n  4  
s c h l a f e n  1  
s c h l a f e n  3
p r o m y e l o c y t i c  l e u k e m i a  
f i b r o b l a s t  g r o v t h  f a c t o r  2 3 
p i t u i t a r y  t u m o r - t r a n s f o z m i n g  1
" c a s p a s e  3 /  a p o p t o s i s  r e l a t e d  c y s t e i n e  p r o t e a s e "  
c y c l i n  D2 
c y c l i n  DC
b i f u n c t i o n a l  a p o p t o s i s  r e g u l a t o r  
f i b r o b l a s t  g r o v t h  f a c t o r  2 3 
s e r u n v ' g l u c o c o r t i c o i d  r e g u l a t e d  k i n a s e  3 
Y a m a g u c h i  s a r c o m a  v i r a l  ( v - y e s - 1 )  o n c o g e n e  h o m o l o g  
t  o u s 1 e  d - 1 i k  e  k  i n a s  e  2 < Ar a b  i d o p  s i s )  
f i b r o b l a s t  g r o v t h  f a c t o r  2 3 
c y c l i n  D 1
b i f u n c t i o n a l  a p o p t o s i s  r e g u l a t o r  
c y c l i n  DC
" p l a t e l e t  d e r i v e d  g r o v t h  f a c t o r ,
" p l a t e l e t  d e r i v e d  g r o v t h  f a c t o r ,  
g r o v t h  a r r e s t  s p e c i f i c  5 
b r o m o d o m a i n  c o n t a i n i n g  8 
h e a t  s h o c k  7 0 k D  p r o t e i n  8 
c y t o k i n e  i n d u c i b l e  k i n a s e  
s i r t u i n  7
6-1 t o  p h a s e  t r a n s i t i o n  1
B C L 2 - 1  i k e  1 1  i a p o p t o s i s  f a c i l i t a t o r )
B C L C - 1 i k e  1 1  ( a p o p t o s i s  f a c i l i t a t o r )
" B - c e l l  t r  a n s i  o c a t  i o n  g e n e  2 ,  a n t i - p r o l i f e r a t i v e "  
3 - p h a s e  k i n a s e - a s s o c i a t e d  p r o t e i n  2 ( p 4 5 )
" b u d d i n g  u n i n h i b i t e d  b y  b e n i i m i d a i o l e s  1  h o m o l o g ,  b e t a  
c e l l  d i v i s i o n  c y c l e  3 7  h o m o l o g  < 3 .  c e r e v i s i a e ) - 1  i k e  
c e l l  d i v i s i o n  c y c l e  a s s o c i a t e d  4
B p o l y p e p t i d e "  
B p  o 1 y p e p t  i  d e  "
Figure 4.5j C om parison  o f  IFN-o:4 regulated  exp ression  o f  genes encod ing
m olecules involved in cell cycle , grow th  and apoptosis in sD C s and B M D C s
Legend as in figure 4 .2.3.1c
194
Fold change
-4 +4
A A
A A Cl '-u
C 1
u o
o u Q
Q Q S sn n CQ CQ
>> 0-50
U) 50-100100-250£ 250-500
c 500-1000
1000-2000
03 2000-3000
O) 3000-4000
CO 4000-5000>5000
u b i q u i t i n  s p e c i f i c  p r o t e a s e  JL8 
U b i q u i t i n  s p e c i f i c  p i o t e i s e  2 5  
s o r t i n g  n e x i n  2 
“t o c s i n  f a m i l y  3 ,  m e m b e r  A"
e u k a r y o t i c  t r a n s l a t i o n  i n i t i a t i o n  f a c t o r  2 a l p h a  k i n a s e  3 
u b  i q u i t  i n - 1  i k e  4
“h o m o c y s t e  i n e - i n d u e  i b l  e ,  E R  s t r e s s - i n d u e  i b l  e , u b  i q u i t  i n - 1 i k e  d o m a i n  1 “ 
k a r y o p h e r i n  ( i m p o r t i n )  a l p h a  2 
c h a p  e r o n  i n  s u b u n i t  8  ( t h e t a )
“ e u k a r y o t i c  t r a n s l a t i o n  i n i t i a t i o n  f a c t o r  1 A ,  "V-l  i n k e d "  
m i t o c h o n d r i a l  c a r r i e r  h o m o l o g  2 ( C .  e l e g a n s )  
l e u k o t r i e n e  A4  h y d r o l a s e  
c h a p  e  r  o n  i n  s u b u n  i t  5  ( e p s i l o n )
“ e u k a r y o t i c  t r a n s l a t i o n  i n i t i a t i o n  f a c t o r  2 ,  s u b u n i t  1 0  ( t h e t a ) ” 
c h a p e r o n i n  s u b u n i t  7  ( e t a )
“p r o t e a s o m e  ( p r o s o m e ,  m a c r o p a i n )  s u b u n i t ,  a l p h a  t y p e  4 “ 
m i t c h o n d r i a l  r i b o s o m a l  p r o t e i n  3 7  
u b  i q u i t  i n - a c t  i v a t  i n g  e n t y m e  E 1 - 1  i k e  
t r y p t o p h a n y l  - t R IT A  s y n t h e t a s e
“p r o t c o s o m e  <p r o s o m e ,  m a c r o p a i n )  s u b u n i t ,  b e t a  t y p e  S " 
u b i q u i t i n  s p e c i f i c  p r o t e a s e  2 2
" S & T 1 ,  s u p p r e s s o r  o f  &2 a l l e l e  o f  3 K P 1  ( 3 .  c e r e v i s i a e ) "  
t r y p t o p h a n y l - t P J T A  s y n t h e t a s e
" p r o t e a s o m e  ( p r o s o m e ,  m a c r o p a i n )  2 f S  s u b u n i t ,  n o n ~ A T P a s e ,  1 “ 
s o r t i n g  n e x i n  2 
s o r t i n g  n e x i n  2 
s o r t i n g  n e x i n  2
u b i q u i t i n  s p e c i f i c  p r o t e a s e  20
“h o m o c y s t e  i n e - i n d u e  i b l  e ,  EP. s t r e s s -  i n d u e  i b l  e  ,  u b  i q u i t  i n - 1  i k e  d o m a i n  1 “
r i b o s o m a l  p r o t e i n  L 1 2
r i b o s o m a l  p r o t e i n  L 3 0
v a c u o l a r  p r o t e i n  s o r t i n g  1 8  ( y e a s t )
A D P - r  i b o s y l  a t  i o n  f a c t o r  £ 
r i b o s o m a l  p r o t e i n  3 1 7  
t r i p a r t i t e  m o t i f  p r o t e i n  3 4  
IB R  d o m a i n  c o n t a i n i n g  2 
I B R  d o m a i n  c o n t a i n i n g  2 
p e r o x i s o m e  b i o g e n e s i s  f a c t o r  2 t  
U b i q u i t i n  s p e c i f i c  p r o t e a s e  25  
r i b o s o m a l  p r o t e i n  L 4 1
“p o l y  < A D P - r  i b o s e ) p o l y m e r a s e  f a m i l y ,  m e m b e r  S “ 
p r o t e i n  p h o s p h a t a s e  l k  ( P P 2 C  d o m a i n  c o n t a i n i n g )
“t o r s  i n  f a m i l y  3 ,  m e m b e r  A" 
r i n g  f i n g e r  p r o t e i n  3 1  
u b  i  q u  i t  i n - a c t  i  v a t  i n g  e n s y m e  E l - l i k e  
c  a t h e p  s  i n  C
" h i s t o c o m p a t i b i l i t y  2 ,  c o m p l e m e n t  c o m p o n e n t  f a c t o r  B "  
b e t a - s i t e  APP c l e a v i n g  e n s y m e  
U b i q u i t i n  s p e c i f i c  p r o t e a s e  2 5  
l e u c i n e  a m i n o p e p t i d a s e  3
k a t a n i n  p £ 0  ( A T P a s e - c o n t a i n i n g )  s u b u n i t  A l
r i b o s o m a l  p r o t e i n  3 2 4
t r i p a r t i t e  m o t i f  p r o t e i n  3 4
t r i p a r t i t e  m o t i f  p r o t e i n  2ff
t r y p t o p h a n y l - t R U A  s y n t h e t a s e
u b i q u i t i n  s p e c i f i c  p r o t e a s e  1 2
u b  i q u i t  i n - a c t  i v a t  i n g  e n s y m e  E l - l i k e
s y n t  a x  i n  1 1
“p y r u v a t e  d e h y d r o g e n a s e  k i n a s e ,  i s o e n s y m e  3 “ 
t r i p a r t i t e  m o t i f  p r o t e i n  3 4  
1 c u p  a x  i n  
c  a t h e p  s i n  C
u b i q u i t i n  s p e c i f i c  p r o t e a s e  1 2  
" t  o  r  s  i n  f  am i 1y  3 ,  m e m b e r  A "
“ C0 X 1 5  h o m o l o g ,  c y t o c h r o m e  c  o x i d a s e  a s s e m b l y  p r o t e i n  ( y e a s t ) "
Figure 4.5k Comparison of IFN-a4 regulated expression of genes 
encoding molecules involved in protein regulation in sDCs and BMDCs
Legend as in figure 4.2.3.1c
1 9 5
We also identified a protease which digests proteins for presentation by MHC II molecules, 
cathepsin C. Three subunits of the proteasome were also differentially regulated. The 
proteosome is involved in the degradation of ubiquitin-conjugated proteins and is also 
important in generating peptides for MHC class I presentation (Groettrup et a l, 1996). IFN- 
y induces expression of three alternative proteasome subunits, which replace subunits which 
are constitutively expressed. This “immunoproteasome” is thought to be more efficient at 
supplying peptides for antigen presentation, but may only be required for the processing of 
certain viral antigens (Groettrup et al., 1996). We identified one of these alternative 
subunits, proteasome subunit beta type 9 (Lmp2), as being induced after 6h of IFN-a4 
treatment in sDCs. This subunit has previously been shown to be up-regulated during DC 
maturation (Macagno et al., 1999).
4.2.4 Identification of novel genes identified by RDA in the microarray data
For comparison of the two methods of identifying differentially expressed genes, we
attempted to locate the novel IFN-induced genes identified by RDA in the data generated by
microarray analysis. We had already noted several genes identified by RDA appearing in
the microarray data: Pml, Gbp2, Vigl, Uspl8 and Schlafen family members. However, it
was more difficult to locate the uncharacterised genes. Identified in the initial RDA on
CD1 lc+ DCs, the gene with NCBI accession NM_ 175026 was enhanced 8-fold in sDCs at 2h
in the microarray data and was also enhanced in BMDCs at both 2h and 6h. Another gene of
unknown function identified by RDA in DCs at 6h of IFN-I stimulation, known as epididimal
secretory protein (Table 3.4), was of interest due to a domain present in proteins which bind
TLRs. Reflecting the RDA, this gene’s expression was not found to be enhanced by IFN-I
in sDCs after 2h, but was enhanced 1.5 fold at 6h (Table 4.5, NCBI Accession AB021289,
this gene is also known as Niemann Pick type C2). Other genes identified by RDA were not
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detected in the microarray analysis due to either failure to pass statistical criteria or because 
they were not represented on the U74Av2 arrays. Although all the genes were represented 
on the Murine 430 2.0 arrays, these data were from BMDCs and did not appear to correspond 
to data from the RDA which had been derived from sDCs. Again, this highlights the 
apparent difference in the responses of sDCs and BMDCs to IFN-I.
4.2.5 Analysis of cytokines released by in vitro cultured DCs
Expression of mRNA for several cytokines was differentially regulated by IFN-a4 (Figure 
4.6). To test whether regulation of these genes at the mRNA level was reflected at the level 
of protein expression we measured the levels of these cytokines produced by in vitro cultured 
DCs. Supernatants from splenic DCs or BMDCs cultured for 2h -  24h in media alone or 
containing 2 xlO4 units/ml IFN-a4, were assayed for the presence of cytokines by ELISA.
In general, regulation of cytokines secreted by DCs in response to IFN-a4 correlated with the 
mRNA expression data. Overall, the levels of cytokines produced by the BMDCs were 
higher than from splenic DCs (Figure 4.6). This could be explained by the cell size; since 
BMDCs are larger than splenic DCs they may have a higher capacity for cytokine 
production. However, this is unlikely to account for the large difference seen for some 
cytokines (CXCL10), or for the two cases where expression could not be detected in splenic 
DCs (CCL2 and CCL12).
Lower levels of IL-1 p mRNA were detected after 6h IFN treatment of splenic DCs compared 
to untreated controls. At the same time, expression of IL-1 receptor agonist (IL-IRn) 
mRNA was upregulated. We could not detect any change in the level of secreted IL-ip, 
although its function may be blocked by increased levels of IL-IRn. Due to reagent 
unavailability we could not test the levels of IL-IRn by ELISA. IL-6 expression was
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markedly enhanced by IFN-a4 and the pattern of expression was similar in splenic and 
BMDCs. However, levels were at least 20-fold less in splenic DCs.
IL-12 p40 levels steadily accumulated in both the sDC and BMDC cultures up to 24 hours. 
It was not clear whether the presence of exogenous IFN-I had an effect on IL-12 p40 
expression, although it appeared that IL-12 p40 was slightly suppressed by IFN-I in sDCs, 
whilst being enhanced in BMDCs.
Of the CC-chemokines tested, CCL2 and CCL12 were expressed by BMDCs but not detected 
in the supernatants of sDCs. Secretion by BMDCs increased after IFN-a4 treatment, 
markedly so for CCL12. CCL4 was also expressed with a differing pattern between splenic 
and BMDCs: in splenic DCs expression was low and constant, while in BMDCs levels were 
highly elevated at 2h and steadily decreased to barely detectable levels by 24h. The level of 
CCL5 was comparatively low, increased to a small extent with IFN-treatment, and was 
similar in splenic and BMDCs. The reason for the disappearance of CCL4, and the low 
levels of CCL5 observed, may be that they are binding to their receptor, CCR5 expressed on 
the surface of the DCs. Therefore they would not be detected by ELISA.
The most striking results were seen in BMDC CXCL10 levels, which were almost 10-fold 
higher in the IFN-treated DCs compared to untreated at the 4h timepoint. The level of 
BMDC CXCL10 was extremely high compared to splenic DC derived CXCL10 and all other 
cytokines tested, reaching a maximum level of 17ng/ml at 6h. It has previously been shown 
that IFN-a2 treatment of human monocyte-derived DCs induces high amounts of CXCL10 
production (Padovan et al., 2002; Lande et a l , 2003). After 24h of culture, the level of 
CXCL10 in BMDCs cultures was severely demised, while in splenic DC cultures the level of
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CXCL10 was maintained. CXCL9 expression by BMDCs was a fraction of CXCL10, 
reaching a maximum of 300pg/ml in 6h IFN-treated samples.
4.3 Discussion
We have used microarrays to identify genes whose expression in DCs is regulated by IFN- 
a4. In addition to previously reported IFN-induced and DC maturation-induced genes, we 
have identified novel genes with potential roles in DC function. IFN-induced upregulation 
of several of the genes, which encode putative cell surface molecules, was verified by 
quantitative PCR. Of particular interest was a gene encoding a chemokine receptor-like 
molecule, Gpr33, which was induced by IFN-a4 in DCs but not T or B cells, and is the 
subject of chapter 5.
Previous studies using microarrays to analyse gene expression in DCs activated by
maturation stimuli have used either in v//ro-derived human DCs or the mouse DC cell line
Dl. The maturation stimuli used in these studies were either pathogens or their components,
which act via TLRs, and whose actions are at least partly dependent on type-I IFNs. We
have investigated the expression of IFN-a4 induced genes in ex-vivo splenic DCs and DCs
generated in vitro from bone marrow cells (BMDCs). The use of sDCs allows investigation
on “real” DCs rather than in vitro derived DCs which are unlikely to behave in exactly the
same manner as DCs would in vivo. However, sDCs are activated by mechanical
manipulation, and do not survive prolonged periods in culture, thereby complicating their
analysis. For these reasons we also chose to investigate BMDCs which are more robust in
vitro. These DCs are likely to represent DCs developing from a myeloid lineage, since they
are differentiated in the presence of GM-CSF and may differ from DCs differentiated in vivo
which do not require GM-CSF for their development (Ni et al., 2001; Gilliet et a l, 2002).
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However these cells display the characteristics of DCs in their expression of cell surface 
markers, including high levels of MHC II, and their ability to induce proliferation in the 
MLR (Inaba et a l, 1992; Lutz et a l , 1999). The BMDCs can be further matured by TNF-a 
or LPS (Inaba et al., 1992; Lutz et a l, 1999) and type I IFNs contribute to their full 
maturation (Montoya et a l, 2002).
Analysis of microarray data was performed in two different ways, and was initially carried 
out using Genespring software. A total of 471 and 1265 IFN-regulated genes were identified 
in sDCs and BMDCs respectively. This large discrepancy in the number of differentially 
regulated genes is most likely due to the number of transcripts present on the arrays used. 
The fold change cut-off point we chose for identification of differentially expressed genes 
was 1.5 fold. Commonly, a fold change cut-off of 2 is used in gene expression studies of 
this type. However we believed that this may exclude many interesting genes which are 
expressed at high levels in the control samples. In these cases the fold change may be low, 
but the absolute level of transcript may have increased a significant amount. An example of 
this is CCR7, essential for migration of maturing DCs to the lymph nodes and known to be 
induced by IFN-I in DCs (Parlato et a l, 2001). We found relatively high levels of CCR7 
mRNA in untreated sDCs, which increased by 1.5 fold after IFN-a4 treatment.
We carried out expression analysis of genes from sDCs on U74Av2 arrays (representing 
12,000 transcripts) and from BMDCs on 430 2.0 arrays (representing 39,000 transcripts). 
We chose to use the 430 2.0 arrays for analysis of the BMDCs samples since they provided 
comprehensive coverage of the mouse genome on single arrays but had not been available 
when carrying out the analysis on sDCs samples. However, since the probe sets for these 
arrays were designed on updated sequence information from the Unigene database they 
cannot be directly compared to probe sets present on the U74Av2 arrays. We attempted to
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overcome this problem using Affymetrix conversion files which allowed us to compare at 
least part of the information from the two data sets. The majority of probe sets on the 
U74Av2 array which represented genes differentially expressed in sDCs were comparable to 
probe sets on the 430 2.0 arrays (437 out of 492). However it was apparent that the majority 
of differentially expressed genes were not commonly regulated in both sDCs and BMDCs. 
Strikingly, only one IFN-suppressed gene (CXCR4) was detected in both sDC and BMDC 
data sets. Those genes which were consistently induced in both sDCs and BMDCs (87 in 
total) included CXCL9 and CXCL10, in addition to many known IFN-stimulated genes.
In an attempt to obtain an overall picture of how IFN-induced gene expression could affect 
DC function, we grouped the differentially expressed genes into functional categories. Since 
control of DC migration is important for vaccination strategies, we were particularly 
interested in this group of genes. DOCK2 (Dedicator of cytokinesis 2) is a scaffold protein 
necessary for efficient migration of lymphocytes in response to chemokines. However, its 
suppression in sDCs may not affect their migration since migration defects in DOCK2 
deficient mice appear to be lymphocyte specific (Reif et al., 2002). More surprising 
perhaps, is the enhancement of the FI 1 receptor seen in BMDCs at 6h. FI 1 receptor has 
been shown to be expressed on the surface of BMDCs but did not increase after maturation 
with TNF-a. Furthermore, F ll receptor deficient mice displayed enhanced trafficking of 
DCs from the skin to the lymph nodes (Cera et al., 2004), therefore we would not expect this 
receptor to be induced during DC maturation.
Peptidylprolyl isomerase C-associated protein (Ppicap, also known as cyclophilin C 
associated protein and galactosidase binding, soluble, 3 binding protein, Lgals3bp) a gene 
upregulated in sDCs after 2h IFN-I stimulation, has a potential role in cell adhesion and 
migration. Ppicap was identified on the basis of its ability to bind the peptidylprolyl
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isomarase cyclophilin C (Friedman et a l , 1993), and was independently isolated as a cell 
surface antigen present on mouse macrophages (Chicheportiche et a l , 1994), but was 
subsequently shown to be a secreted protein (Trahey et a l, 1999). Ppicap was proposed to 
be the mouse homologue of human MAC-2 binding protein (hMAC-2BP) (Chicheportiche et 
a l, 1994), which has been shown to mediate cell adhesion through interactions with its 
ligand, MAC-2/Galectin-3 (Inohara et a l, 1996). MAC-2 /Galectin-3, is a secreted molecule 
which modulates various aspects of immunity, acting as a chemoattractant to monocytes and 
macrophages, and mediating DC interactions with naive lymphocytes, thereby facilitating 
antigen presentation (Rabinovich et a l, 2002). However, Ppicap and hMAC-2BP appear to 
be functionally distinct since Ppicap does not bind MAC-2 and hMAC-2BP does not bind 
cyclophilin C (Jalkanen et a l, 2001). Alternative to a role in adhesion or migration, Ppicap 
appears to modulate host responses to endotoxins by regulating levels of proinflammatory 
cytokines (Trahey et a l, 1999).
DCs are known to rapidly produce inflammatory chemokines in response to inflammatory 
stimuli (Sallusto et a l, 1999b). This is likely to serve two functions: recruitment of 
monocytes and immature DCs to the site of inflammation and downregulation of cognate 
receptors on maturing DCs permitting their migration away from the inflamed tissue. CCL4 
(MIP-lp) is an inflammatory chemokine which is expressed by most mature haematopoietic 
cells, including LPS-stimulated monoctyes and activated T cells, B cells and NK cells, and is 
important in the recruitment of T cells, B cells and immature DCs to the site of infection 
(Menten et a l, 2002). Additionally, CCL4 acts as a chemoattractant for NK cells and 
increases their cytolytic ability (Menten et a l, 2002). CCL4 signals through CCR5 which in 
humans is expressed on memory but not nai've T cells, and on Thl but not Th2 cells 
(Loetscher et a l, 1998). In human dendritic cells CCL4 has been shown to be induced by
204
LPS, TNF-a and CD40L (Sallusto et al., 1999b), with expression peaking at between six and 
twelve hours of stimulation. We saw an increase in CCL4 levels after IFN-a4 treatment in 
both sDCs and BMDCs. Concentrations of CCL4 in the supernatants from sDCs were 
sustained up to 24h, whereas levels in the BMDCs cultures peaked at 2h and steadily 
declined thereafter. Perhaps this difference could be explained by differing cell surface 
CCR5 expression, that is if BMDCs express higher levels of CCR5 they may internalise 
CCL4 more rapidly. As previously mentioned, production of CCL4 and CCL5 are thought 
to be important in mediating downregulation of CCR5 from the cell surface, which is rapidly 
internalised in maturing DCs (Sallusto et a l , 1999b).
CCL5 like CCL4 is an agonist for CCR5, in addition to CCR1, CCR3 and CCR4. CCL5 
mediates the trafficking of T cells, monocytes, basophils, eosinophils, NK cells and DCs. At 
high concentrations CCL5 can induce T-cell proliferation or apoptosis, and the release of 
pro-inflammatory cytokines such as IL-2, IL-5, IFN-y and CCL4 (Appay et al., 2001). 
Again, we saw steady levels of CCL5 in cultures of sDCs but in BMDCs supernatants levels 
had begun to fall by 24h. This is in contrast to results in LPS-treated monocyte derived DCs 
where levels of CCL5 continued to rise at 24h (Sallusto et al., 1999b). Notably, though, 
LPS-treatment is also known to down-regulate CCR5 on monocyte-derived DCs (Sallusto et 
a l, 1998c).
We also detected a downregulation of CXCR1 expression after IFN-a4 treatment, which is 
consistent with the phenotype of mature DCs (Sallusto et al., 1998c). In accordance with 
recent observations (Lande et a l, 2003) we saw upregulation of CXCL9 and CXCL10 in 
IFN-a4 treated DCs. In addition to their importance in mediating migration of T cells, these 
chemokines also function as mediators of T cell responses, and have been shown to enhance
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T cell proliferation and IFN-y production (Whiting et al., 2004). However, in disagreement 
with previous reports we also saw IFN-suppression of CXCR4 (Sallusto et al., 1998c).
Type-I IFNs act on all cell types to induce the expression of anti-viral factors. Therefore a 
large number of the genes identified in this study represent genes involved in anti-viral 
defense and are not specifically involved in DC function. A database aimed at listing and 
classifying all IFN-stimulated genes has been constructed and includes data from a human 
fibrosarcoma cell line (de Veer et al., 2001). Many of the genes identified in our 
experiments are present in this IFN-stimulated gene database, which may indicate a DC non­
specific role for these genes in immunity. However genes such as IL-15, an important 
mediator of DC function, are also listed in this database, therefore we cannot rule out the 
importance of genes simply due to their upregulation by IFN-I in unrelated systems.
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Chapter 5 : Characterisation of Gpr33
5.1 Introduction
Essential to DC function is their ability to migrate in response to chemotactic factors. 
Immature DCs express receptors for inflammatory chemokines such as CXCR1, CCR1, 
CCR2 and CCR5, as well as receptors for bacterial and complement chemoattractants 
(Sallusto et a l , 2000). This enables rapid movement of DCs to sites of infection for uptake 
of antigen. At the site of infection, DCs are exposed to maturation stimuli, triggering a 
reprogramming of DC function. This reprogramming includes a switch in chemokine 
receptor expression enabling the DCs to respond to a different set of chemokines which 
direct their migration to the lymph nodes.
Chemokine receptors belong to a large family of cell surface receptors, the G-protein- 
coupled receptors (GPCRs). GPCRs are integral membrane proteins containing seven 
transmembrane domains which send signals to the cell through trimeric G proteins (Baldwin, 
1994). The human formyl-peptide receptor (FPR), and its variants FPR-like 1 and FPR-like 
2 (FPRL1 and FPRL2) also belong to the GPCR family, and like chemokine receptors, 
mediate cell migration (Le et a l , 2002). Since these receptors were originally thought to 
bind solely to N-formyl peptides, which are derived from bacterial and mitochondrial 
proteins, it followed that these receptors could be involved in directing cells towards sites of 
bacterial infection or tissue damage. It is now known that a wide variety of non-formylated 
peptides are also recognised by the FPRs (Le et a l , 2002). These peptides are both 
pathogen-derived (HIV) and host-derived, such as an annexin 1 peptide. Commonly, the 
host-derived peptides are associated with disease; for instance, one agonist for FPRL1 is a
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prion peptide. In the mouse, at least six formyl peptide receptor genes exist, of which three 
encode proteins orthologous to either FPR or FPRL1 and bind a similar variety of ligands to 
their human counterparts.
G-protein coupled receptor 33 (Gpr33) is an orphan GPCR which shares highest amino acid 
identity to another orphan GPCR, Gpr32, chemokine-like receptor 1 (CMKLR1), and the 
formyl-peptide receptors (Marchese et a l, 1998). Human FPR is expressed in immature 
myeloid DCs but is downregulated on DC maturation (Yang et a l, 2000), and FPRL1 is 
downregulated even as DC precursors differentiate into immature DCs (Yang et a l, 2001). 
FPRL1 expression is maintained in macrophages which implies an involvement in innate 
host defense rather than adaptive responses. However FPRL2 expression is maintained on 
DCs after maturation, suggesting a role in trafficking of both immature DCs to the site of 
infection, and mature DCs to the lymphoid organs for antigen presentation to T cells (Yang et 
al, 2002). We have shown that Gpr33 mRNA is expressed at higher levels in DCs treated 
with IFN-I than in untreated DCs, which suggests that it may be involved in regulating the 
movement of mature DCs.
To gain an insight into the function of Gpr33, we used real-time PCR to analyse expression 
in DC subsets and other immune cells. In addition, we attempted to generate monoclonal 
and polyclonal antibodies against Gpr33 that would allow us to study expression at the 
protein level and investigate how this is regulated by stimulation with IFN-I. At the same 
time we produced Gpr33 transfected cell lines for the initial purpose of testing the antibodies 
and secondly, for screening possible ligands of this receptor.
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5.2 Results
5.2.1 Analysis of Gpr33 expression by real-time PCR
5.2.1.1 Expression o f Gpr33 in subsets o f  DCs treated with IFN-I
DC subsets reside in distinct anatomical locations and differ in their responses to chemokines 
(Pulendran et al., 1997; Iwasaki et al., 2000). Therefore we investigated whether Gpr33 was 
differentially expressed in subsets of DCs. We isolated the CD4+CD8\ CD4'CD8+, CD4‘ 
CD8' subsets (these will be referred to as C D llchlgh since pDCs express intermediate levels 
of CD 11c) and pDCs from the spleen by depleting lymphocytes and granulocytes followed 
by MACS sorting. The DCs were treated in vitro for two hours with IFN-a4. The results of 
real-time PCR analysis showed that only the CD4+ CD8' subset showed a small increase (1.8 
fold) in Gpr33 expression after IFN-I treatment (data not shown). We reasoned that, since 
isolation of the subsets was lengthy and required many manipulations, that the DCs were 
being activated and maturing rapidly during the two hour incubation period, even without 
IFN-I stimulus. Therefore to avoid culturing the DCs we decided to treat the DCs with IFN- 
a4 in vivo. We also altered the isolation method to sort CD1 lchlgh subsets by FACS to avoid 
excessive cell manipulations. Mice were injected intravenously (i.v) with IFN-a4 and 
sacrificed after 30 minutes. The CD1 lchlgh DCs and pDCs were isolated from the spleen by 
MACS, the three CD1 lchlgh subsets were sorted on expression of CD4 and CD8 by FACS.
First, we compared expression of Gpr33 between control and IFN-treated DCs. 
Upregulation of Gpr33 in CD1 lchlgh DC subsets treated with IFN-a4 varied between five and 
twenty fold (Figure 5.1a). The data did not indicate that any one subset preferentially 
upregulated Gpr33 expression, as the mean fold changes for each, which ranged from eight to
209
a 25-]
20 H
aa>
ro 15
s zO
19 10
o
5 -
Total CD4< CD8* DN pDC
CD11c+
b
100,
CD 80
O)c
CD 60
S I
o 40
■O
o
LL 20
0
-20
C D 4+
Control DCs
DN C D 8+
10Q
80
60
40
20
0
-20
pDCs C D 4+
IFN-treated DCs
DN CD8^ pDCs
CD11c+ CD11C 1
Figure 5.1 Expression o f  G pr33 in subsets o f  D Cs treated w ith IF N -a4
M ice were injected i.v. with 1 x  105 units IF N -a4  or PBS, 30 m inutes later m ice w ere sacrificed 
and the DCs isolated from  the spleen. C D l l c + D Cs and pD C s w ere isolated by M A CS, D C 
subsets w ere sorted by FACS. D N  represents the double negative CD4 C D 8 ' subset. Cell 
purities were >90% . RNA was isolated and expression o f  G pr33 analysed by  real-tim e PCR. a) 
Results are plotted as fold change in expression in cells from  IFN -treated m ice versus control, 
b) R esults are plotted as fold change in expression com pared to the CD 1 l c +C D 4+C D 8‘ subset 
(therefore values for CD4+C D 8' D Cs are alw ays equal to 1 ie no change in expression). D ata 
is from  three independent experim ents, except pDCs, for w hich only tw o experim ents were 
carried out.
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eleven fold, were not significantly different. Expression of Gpr33 changed comparably in 
pDCs, with an average increase of 12 fold in IFN-treated compared to control pDCs.
Although treatment with IFN-a4 upregulated Gpr33 expression to a similar extent in all DC 
subsets, we were interested to know whether levels of Gpr33 expression differed between the 
subsets. We compared expression of Gpr33 mRNA in subsets of DCs from the control mice 
and from the IFN-treated mice independently. Among C D llchlgh cells in untreated mice, 
expression of Gpr33 was lowest in the CD4+CD8' subset, and was on average five fold 
higher in the CD4 CD8' subset. However, much higher expression was detected in the CD4‘ 
CD8+ subset, with levels of more than 40 times that in the CD4+CD8' subset (Figure 5.1b). 
Expression of Gpr33 in pDCs was equivalent to that in CD4+CD8' DCs. Very similar results 
were obtained when DC subsets from IFN-treated mice were compared. Therefore, although 
IFN-treatment increases Gpr33 expression by approximately ten fold in each DC subset, this 
equates to an enormous increase in Gpr33 levels in the CD4'CD8+ subset. If compared to 
levels of expression in the control CD4+CD8* subset, CD4'CD8+ cells express 500 fold more 
Gpr33 mRNA.
5.2.1.2 Expression o f Gpr33 over a time course o f  in vitro DC culture
Expression of Gpr33 was measured by real-time PCR in splenic C D llc+ DCs which had 
been cultured with or without 2 x 104 U/ml IFN-I for two, four of six hours. Consistent with 
the results of microarray analysis, the results showed higher expression of Gpr33 mRNA in 
IFN-treated DCs at the two hour time point, but not at the later time points (Figure 5.2). 
Expression of Gpr33 in the untreated DCs was stable over time, whereas expression in the 
IFN-treated DCs was downregulated after four hours, and returned to the level of expression 
in the untreated DCs by six hours of culture.
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Figure 5.2 Expression o f  G pr33 over a tim ecourse o f  IFN -treatm ent in splenic DCs
CD1 lc + D Cs isolated from  spleens by  M A CS w ere cultured in vitro in m edia alone (0) 
or w ith 2 x 104 U IFN -a4/m l (IFN ) for the indicated tim es. Cell purities were >85% . 
RN A  was isolated and expression o f  G pr33 analysed by  real-tim e PCR. a) Results are 
p lo tted  as fold change in expression in IFN -treated versus untreated D Cs. b) Results 
are plo tted  as fold change in expression com pared to the untreated D Cs at 2h (therefore 
value for untreated DCs at 2h  equals 1 ie no change in expression). D ata is from  tw o 
independent experiments.
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5.2.1.3 Expression o f Gpr33 in lymphocytes and macrophages treated in vivo with IFN-I
Next, we tested whether expression of Gpr33 was restricted to DCs, and whether expression 
in other cell types could also be upregulated by IFN-a4. Mice were injected i.v. with IFN- 
a4 or PBS and sacrificed 30 minutes later. T and B cells were isolated from both the spleen 
and the lymph nodes. We also tested for expression in peritoneal macrophages and NK 
cells. Again, we first compared expression of Gpr33 mRNA between cells isolated from 
IFN-treated and control mice. Gpr33 expression was not regulated to a significant degree by 
IFN-a4 in any of the cell types tested (Figure 5.3). Gpr33 was consistently upregulated in B 
cells isolated from the lymph nodes, but only to a small degree (2 fold), which is not 
meaningful in real time PCR assays. Data from the NK cells was ambiguous as Gpr33 
appeared to be upregulated in one experiment but downregulated in the other.
We then compared expression of Gpr33 in these cell types to expression in DCs. We used 
the CD4+CD8' DC subset for the comparison, since this subset had the lowest expression. 
None of the lymphocytes isolated from control mice expressed Gpr33 at different levels to 
the CD4+CD8' DC subset, except in macrophages, where expression of Gpr33 was around 
five fold lower (Figure 5.4). When cells from IFN-treated mice were compared, a relative 
decrease in Gpr33 expression was observed, reflecting the failure of non-DCs to upregulate 
expression. This was especially true in macrophages where expression was around 40 fold 
lower than that in CD4+CD8' DCs. Expression in B cells was four to six fold lower and in 
CD8+ T cells eight fold lower. Expression was more variable in CD4+ T cells but on average 
was between six and ten fold less than that in CD4+CD8' DCs.
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Figure 5.3 Regulation o f  G pr33 by IFN -I in cells o f the im m une system
M ice w ere injected i.v. w ith 1 x  105 units IFN -o4 or PBS, and sacrificed 30 minutes 
later. C D 4+ and C D 8+ T  cells and B cells w ere isolated from  both  the spleen and the 
lym ph nodes (LN) by D ynabead depletion follow ed by M ACS. N atural killer cells 
(NK ) w ere isolated from  the spleen by M A CS follow ed by  FACS sorting. Peritoneal 
m acrophages (M P) were sorted by  FACS. Cell purities w ere >90% . RN A  was isolated 
and expression o f  Gpr33 analysed by real-tim e PCR. Results from  two independent 
experim ents are plotted as fold change in expression in cells from  IFN -treated mice 
versus control.
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Figure 5.4 Expression o f G pr33 in cells o f the im m une system  com pared  
to expression in DCs M ice w ere injected i.v. w ith 1 x  105 units IFN -o4 or 
PBS, and sacrificed 30 m inutes later. C D 4+ and CD 8+ T  cells and B cells 
w ere isolated from  both the spleen and the lym ph nodes (LN ) by D ynabead 
depletion follow ed by  M A CS. N atural killer cells (NK) w ere isolated from  
the spleen by M ACS follow ed by FACS. Peritoneal m acrophages (M P) were 
sorted by FACS. Cell purities w ere >90% . RN A  was isolated and expression 
o f  Gpr33 analysed by real-tim e PCR. Results are plotted as fold change in 
expression in cells as indicated versus CD 4+C D 8' DCs. D ata is from  two 
independent experim ents.
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5.2.2 Generation of monoclonal Abs against Gpr33
5.2.2.1 Secondary structure prediction o f Gpr33
In order to generate monoclonal antibodies, we wished to immunise rats with peptide 
sequences representing a predicted extracellular region of Gpr33. Gpr33 is a putative G- 
protein-coupled receptor (GPCR) containing seven predicted transmembrane domains 
(Figure 5.5) (Marchese et al., 1998). To confirm this, we generated a model of Gpr33 by 
aligning it to the sequence of bovine rhodopsin, a GPCR for which the crystal structure has 
been determined (Palczewski et al., 2000). The predicted extracellular, transmembrane and 
intracellular regions in our model closely matched the model predicted by Marchese et al., 
with slight variations in the positions of the transmembrane domains. Three overlapping 
peptides of 15 amino acids in length, which span an extracellular loop region of the protein 
were chosen (Figure 5.6). The positioning of transmembrane domains in the Marchese 
model would allow for the formation of a disulphide bond between conserved cysteine 
residues in the first and second extracellular loops, a common feature of GPCRs (Murphy, 
1994). Therefore, the peptides were also selected to avoid this residue. Since the N- 
terminal extracellular portion contained putative N-glycosylation sites, which could interfere 
with antibody recognition, we chose not to immunise with peptides with this amino acid 
sequence.
5.2.2.2 Immunisations and screening o f hybridomas
A combination of the three overlapping peptides (named A l, A2 and A3), synthesized as 
multiple antigenic peptides, was used to immunize rats either intraperitoneally (i.p.) or 
subcutaneously (s.c.). After 15 days the rat serum was tested for production of peptide 
specific antibodies. The rat injected i.p. produced the best response against the Al peptide 
and a weaker response to the A2 peptide. We did not detect any antibodies specific for the
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Figure 5.5 Alignment of the deduced amino acid sequence of Gpr32 with related GPCRs, including Gpr33
Adapted from M archese et al., 1998. Amino acids identical with the receptor encoded by Gpr32 are boxed and shaded. Potentially, a di­
sulphide bond exists between cysteine residues marked *. The region used for immunisation for generation o f  monoclonal is marked by 
the red line. The conserved acidic-arginine-aromatic triplet is marked by the blue line.
Transmembrane 1
M D L I N S S T H V I N V S T S L T N S T G V P  T P A P K T I  I A A S L F M A F I  I G V I S N G L Y L W M L Q F K M
Transmembrane 2 Transmembrane 3
Q R T V N T L L F F H L I L S Y F I S T L I L P F M A T S F L Q D N H W V F G S V L C K A F N S T L S V S M F A S V F
Transmembrane 4
F L S A I S V A R Y Y  LI  L H P V W S Q Q H R T P H W A S R I A L Q I W I S A T I L S I P Y L V  F R T T H D D H K G
A1
A3
Transmembrane 5
R I K C Q N N Y I V S T D W E S K E H Q T L G Q W I H A A
A2
C F V G R F L L G  F L L P F L V I  I F C Y K R V A T K M
Transmembrane 6 Transmembrane 7
K E K G L F  < S S K P F K V M V T A V I S F F V C W M P Y H V H S G L V L T K  S Q P L P L H L T L G L A V V T I S F
N T V V S P V L Y L  F T G E N F K V F K K S I L A L F N S T F S D I S S T E R T Q T L N S E T E I
Region used to generate monoclonal antibodies 
Region used to generate polyclonal antibodies
C=C
n h :
Intracellullar
COOH
Figure 5.6 Design o f  peptides for generation o f  anti-G pr33 antibodies
a, Three overlapping peptides (A l , A2 and A 3) spanning an extracellu lar loop betw een 
transm em brane dom ains four and five w ere chosen for the im m unisation o f  rats. Residues in 
blue are those w hich differ in the rat hom ologue (XP_234113). A dditionally, polyclonal 
antibodies w ere raised against the N -term inal region. Residues in bo ld  type are extracellular. 
A sparagine residues m arked * are putative glycosylation sites, b, Schem atic representation 
o f  G pr33 structure, show ing the putative extracellular loop against w hich we attem pted to 
raise m onoclonal antibodies (residues m arked in red), potential N -linked glycosylation sites 
and di-sulphide bond (C=C).
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Gpr33 peptides from the rat immunized s.c. (Figure 5.7). Both rats were then boosted i.p. on 
day 18 with the same combination of three peptides. Five weeks after the initial 
immunization, the sera of the rat initially immunized i.p. contained elevated levels of 
antibody specific for the Al and A2 peptides. This rat was given a final immunization of 
peptides four days prior to sacrifice and fusion of splenic and myeloma cells. Hybridomas 
were generated and maintained by B.Jones at the Institute for Animal Health. The rat 
initially immunized s.c. did not produce an antibody response against any of the peptides. 
Supernatants from the hybridomas created were screened for production of antibody against 
immunising peptides by ELISA. Three of the hybridomas gave positive results in the 
ELISA against the A2 peptide, one of which also gave a weak signal against the Al peptide. 
Monoclonal hybridomas were produced from these by limiting dilution.
5.2.23 FACS staining o f  DCs by hybridoma supernatant
Preliminary FACS staining was carried out on CD1 lc+ DCs using rat serum collected on day 
35 of the immunization schedule, however there was a large degree of non-specific staining 
which made detection of any specific binding impossible. Next, we tested supernatants 
obtained from the polyclonal hybridomas which had bound peptide in the ELISAs, for their 
ability to bind DCs treated in vivo with IFN-a4. Mice were injected with IFN-a4 or PBS 
alone and 12 hours later C D llc+ DCs were isolated. After IFN-treatment, the hybridoma 
clone LF7 appeared to stain a small subset of DCs (Figure 5.8).
Since we identified Gpr33 in DCs treated in vitro, it was possible that expression of this 
molecule was more efficiently induced in vitro. Therefore we isolated DCs and treated them 
in vitro with IFN-a4 for three, four or six hours. We noted that during the incubation a large 
proportion of the cells were dying; the number of cells in the live cell gate was reduced from
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Figure 5.7 Sera from  the rat im m unised intraperitoneally  contained  
antibodies against the A l and A2 G pr33 peptides Serum  taken from  rats 
initially im m unised subcutaneously (SC) or in traperitoneally  (IP), and thereafter 
im m unised IP w ere tested for their ability  to b ind the three im m unising peptides, 
A l ,  A2 and A3 by  ELISA.
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Figure 5.8 The LF7 hybridom a supernatant stains a subset o f  C D l lc + DCs 
treated in vivo w ith IFN -I M ice w ere in jected  i.v. w ith 1 x 105 units IF N -a4  or 
PBS alone. 12 hours later C D l l c + D Cs w ere isolated from  the spleen by  M ACS 
sorting. Cells w ere stained using either a rat anti-C D 86 antibody or the Gpr33 
hybridom a supernatants, follow ed by  an  anti-rat PE conjugated antibody.
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70% when cells were kept on ice to 25% or less after six hours of incubation at 37°C (Figure 
5.9). Again, using the LF7 polyclonal hybridoma supernatant, we detected a small 
proportion of positive cells in the live gate, although there was no detectable increase after 
IFN-a4 treatment (Figure 5.10a). We also tested supernatant from LF7 monoclonal 
hybridomas with similar results. In addition, the LG 10 and OA7 supernatants produced 
some staining but not to the same extent as the LF7 supernatant.
However, when analysis was focused on cells with the forward/side scatter characteristics of 
dying cells, there was a large population of cells staining positively with the LF7 
supernatants (Figure 5.10b). Staining with the LG10 supernatant was also brighter in this 
population of cells. This was in direct contrast to CD86 expression which was markedly 
lower in the population of dying cells: 20% were CD86 positive compared to 60% of live 
DCs. Staining with the negative control supernatant, BF2, and the OA7 supernatant was 
unchanged. To study this further, thymocytes were cultured overnight at 37°C to induce cell 
death. The results showed that the antibody from the LF7 hybridoma stained a population of 
dead or dying cells (Figure 5.11).
Since BMDCs survive for longer periods in culture, we also attempted to stain BMDCs using 
the LF7 hybridoma supernatant. BMDCs were cultured for 4 or 24 hours alone or in the 
presence of IFN-a4. A small population of cells was stained by the LF7 hybridoma 
supernatant after four hours of culture but this was not increased by IFN-a4 treatment or 
blocked by addition of Gpr33 peptides (Figure 5.12). Again, the staining was much more 
pronounced in dead/dying cells. The same was true after 24 hours where the majority of 
LF7 stained cells were dying and the staining was not affected by the addition of the Gpr33 
peptides. Therefore, it appeared that the interaction between the monoclonal LF7 antibody 
and dead cells was a non-specific one.
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Figure 5.9 DCs cultured at 37°C lose viability over time
C D llc + DCs were isolated, and either stored on ice or cultured at 37°C for the 
indicated times in media alone or in the presence o f  2 x  104 units IFN-a4/m l. The 
region R1 contains live cells, cells in the region R2 are dead/dying. These cells were 
untreated, but a similar effect w as seen  with IFN-treated cells.
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Figure 5.10a (continued over page) Stain ing o f  in vitro-treated  splenic D C s by 
the G pr33 hybridom a supernatants CD1 lc + D Cs w ere isolated from  the spleen 
by  M A C S sorting and either stored on ice or cu ltured  at 37°C for the indicated 
tim es in m edia alone or in  the presence o f  2 x  10s units IFN -o4/m l. Cells w ere 
stained using either a rat anti-C D 86 antibody or the G pr33 hybridom a 
supernatants, follow ed by  an anti-rat PE conjugated  antibody. BF2 is a G pr33 
hybridom a w hich tested  negative by  ELISA . C ells w ere gated  on the live gate R1 
(Figure 5.9).
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Figure 5.10a (continued) Staining o f  in v itro-treated  splenic DCs by the G pr33  
hybridom a supernatants
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Figure 5.10b (continued over page) Staining o f  in vitro-treated  splenic D Cs by the 
G pr33 hybridom a supernatants CD1 lc + DCs were isolated from the spleen by M ACS  
sorting and either stored on ice or cultured at 37°C for the indicated times in media alone 
or in the presence o f  2 x 105 units IFN-a4/m l. Cells were stained using either a rat anti- 
CD86 antibody or the Gpr33 hybridoma supernatants, follow ed by an anti-rat PE 
conjugated antibody. BF2 is a Gpr33 hybridoma which tested negative by ELISA. Cells 
were gated on the region R2 (figure 5.9), cells with forward/side scatter characteristics o f  
dying cells.
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Figure 5.11 The LF7 supernatant stains a population o f  dead or dying thym ocytes
Thym ocytes were cultured overnight to produce a population o f  dead or dying cells. 
Cells w ere stained with the LF7 supernatant or the negative control supernatant, BF2, 
follow ed by an anti-rat IgG, FITC conjugated antibody, in addition to PI staining.
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Figure 5.12 LF7 hybridom a supernatant binds non-specifically to dying  
B M D Cs BM DCs w ere cultured in vitro with or w ithout 2 x 104 U  IFN -a4 
for 4 hours (A  + B) or 24 hours (C ). BM DCs w ere harvested  and stained for 
expression o f  CD 11c and Gpr33. W here indicated, we attem pted to block 
binding o f  the LF7 supernatant by addition o f  the Gpr33 peptides A l ,  A2 and 
A3 (each at 20/yg/ml). A, Live cell gate, B, D ead cell gate and C BM DC s 
harvested at 24 hours were additionally  stained w ith PI to detect dead cells.
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5.2.2.4 Screening o f hybridoma supernatants using a Gpr33 transfected cell line 
Since any staining seen on DCs could be due to non-specific binding, or binding of the 
antibody to cell surface molecules other than Gpr33, we tested whether the Gpr33 hybridoma 
supernatants could detect Gpr33 on the surface of transfected cells. Full-length Gpr33 
cDNA was cloned into the mammalian expression vector pcDNA6. To choose a target cell 
for transfection, we first determined whether various cell lines expressed Gpr33 
endogenously. We isolated the RNA from several cell lines and screened by RT-PCR for 
Gpr33 mRNA. We could not detect Gpr33 mRNA expression in any of the cell lines tested. 
Transfection into BHK-21 cells was the most successful, and these were grown in selective 
media to obtain stable transfectants. Expression of Gpr33 mRNA in the transfected BHK-21 
cells was confirmed by quantitative PCR.
The Gpr33 transfected cells were used to screen hybridoma supernatants which had bound 
peptide in the ELISAs. This included a number of hybridoma supernatants which had given 
a relatively weak signal compared to the stronger signal from the LF7, OA7 and LG 10 
supernatants. A comparison between untransfected and transfected BHK-21 revealed that 
the hybridoma supernatants LF7, OA7 and LG 10, were staining a dying cell population (PI 
positive) in both cases (Figure 5.13). No specific staining of viable cells was detected.
Since we used linear peptides to immunise the rats, it was also possible that the monoclonal 
antibodies were not recognizing the protein in its native form. To test this, we ran Gpr33 
transfected cell lysates on a denaturing SDS-PAGE gel and probed the blot with the Gpr33 
monoclonal antibody. No bands were detected (data not shown).
Taken together, these data indicated that the antibodies raised by immunization with Gpr33 
peptides did not bind to Gpr33 protein. However, although we tested for Gpr33 mRNA
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Figure 5.13 Screening of Gpr33 hybridoma supernatants by FACS staining of transfected 
cells (Figure continued over page) Supernatants from hybridomas were used to stain BHK-21 
cells which had been stably transfected with Gpr33 (Gpr33) and compared with staining of 
untransfected cells (UT).
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Figure 5.13 (continued) Screening of Gpr33 hybridoma supernatants by FACS staining 
of transfected cells
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expression in the transfected BHK-21 cells, it was impossible to know whether the mRNA 
was being translated into protein, or whether the Gpr33 protein was being correctly trafficked 
to the cell surface.
5.2.3 Generation of a FLAG-Gpr33 fusion protein
5.2.3.1 Cloning and expression o f a FLAG-Gpr33 fusion protein
To generate a model in which we could verify Gpr33 expression at the cell surface 
independently of the specificity of our anti-Gpr33 monoclonal antibodies, we cloned the 
Gpr33 cDNA into the expression vector pFLAG-CMV4, which contains an N-terminal 
FLAG marker. Transfected cells expressing the FLAG -Gpr33 fusion protein could then be 
detected using an anti-FLAG antibody. As a positive control, murine CCR7 was cloned in 
parallel into the same vector. The murine pre-B cell line Baf/3 was transfected and grown in 
selective media to obtain stable transfectants. Expression of Gpr33 was confirmed by real­
time PCR. Gpr33 mRNA was detected in untransfected cells, but was expressed at levels 
600 fold higher in transfected cells. CCR7 was also expressed endogenously, but 
unfortunately, we could detect no difference in expression in the transfected cells.
5.2.3.2 FACS analysis o f FLAG-Gpr33 transfected cells
We could not detect cell surface expression of the FLAG-Gpr33 fusion protein in stably 
transfected Baf/3 cells using the anti-FLAG M2 antibody (Figure 5.14). A small population 
of cells stained positively with the anti-FLAG M2 antibody but this was true even for the 
untransfected cells. This suggests that the M2 antibody is cross-reacting with a protein 
expressed by the Baf/3 cells.
Additionally, intracellular staining was carried out to test whether the fusion protein was 
being expressed in the cytoplasm. In this case there was a dramatic shift in staining in both
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Figure 5.14 Staining o f  FLA G -G pr33 transfectants by the anti-FLA G  M 2 
antibody Baf73 cells w hich were either untransfected (UT), transfected by  the 
pFLA G -C M V -4 vector alone (pFLA G 4), or w ith the pFLA G -CM V -4-G pr33 construct 
(pFLA G 4-G pr33) were stained w ith the M 2 anti-FLA G  antibody a) Cell surface 
staining b) Intracellular staining.
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the untransfected and Gpr33 transfected cells, again this strongly indicates that the M2 
antibody is cross-reacting with an unrelated protein.
5.2.3.3 Western blot o f  FLAG-tagged Gpr33
Lysates from untransfected cells and from cells transfected with the FLAG-Gpr33 fusion 
construct, were subjected to SDS-PAGE separation and detected by Western blot using an 
anti-FLAG antibody. In addition, we immunoprecipitated FLAG-tagged protein from the 
transfected cells. As shown in figure 5.15 the anti-FLAG antibody recognised a protein of 
approximately 40kDa in size, which is close to the predicted size of GPCRs. However, this 
protein also exists in the untransfected cells, so we must conclude that this antibody is cross­
reacting with a protein expressed in the BAF/3 cell line.
5.2.4 Gpr33 ligand screening
Although Gpr33 protein expression could not be detected in the transfected cell lines, 
transfection had been successful, since Gpr33 mRNA was being expressed. Therefore, we 
screened a panel of peptides for their ability to induce a calcium flux in Gpr33 transfected 
cells. The peptides and proteins chosen for screening were known agonists for receptors 
with the highest homology to Gpr33 (Marchese et al., 1998)(Table 5.1). The majority of the 
agonists were identified as ligands for human receptors, but at least two, amyloid p protein 
and temporin A (TA), have been shown to act on mouse FPR2 (mFPR2), the homologue for 
human FPRL1. We detected a calcium flux in cells treated with the MMK-1 peptide. 
However, this flux was apparent in both untransfected and transfected cells (Figure 5.16). 
No calcium flux was detected for any of the other peptides tested. Therefore we were unable 
to identify a ligand for Gpr33 amongst the panel of peptides screened.
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Figure 5.15 Im m unoblot o f  FLA G -G pr33 transfected cells
Proteins from  Baf/3 cells, untransfected or tranfected  w ith the FLA G - 
G pr33 contruct w ere detected  on a W estern b lo t using the anti-FLA G  
M 2 antibody. The sam ples w ere either cell lysates o r proteins 
im m unoprecipitated from  the lysates using anti-FLA G  M 2 antibody. 
The FLA G -BA P pro tein  is a control w ith a size o f  49 kDa.
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o f  flourescence at 330 nm to 398 nm. Ionom ycin (lono), w hich is known to induce a 
clacium  flux in all cell types, was used a positive control.
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Table 5.1 Peptides and proteins screened in calcium flux assay
Peptide Sequence Receptor Reference
A5 SLLWLTCRPWEAM FPRL1 (Klein eta l. ,  1998)
Annexin 1 (A cl-25) Ac-AMVSEFLKQAWFIEN
EEQEYVQTVK
FPR, FPRL1, 
FPRL2
(Ernst et al. , 2004)
HIV-derived F EGSDTITLPCRIKQFINMWQE FPRL1 (Deng et a l ,  1999)
HIV-derived T20 Ac-YTSLIHSLIEESQNQQEKN  
EQELLELDK W A SL WNWF -NH2
FPR (Su e ta l . ,  1999)
HIV-derived V3 RIHIGPGRAFYTTKN FPRL1 (Shen et al. , 2000)
Humanin MAPRGFSCLLLLTSEIDLPVKRRA FPRL1 (Ying et al., 2004)
I4G10-C FLPIIASLLGKLL-NH2 FPRL1 (Chen et al., 2004)
I4S10-C FLPIIASLLSKLL-NH2 FPRL1 (Chen et al. , 2004)
MMK-1 LESIFRSLLFRVM FPRL1 (Klein et al., 1998)
Rana-6 FISAIASMLGKFL-NH2 FPRL1 (Chen et al., 2004)
TIP FLPIVGKLLSGLL-NH2 Unknown (Chen et al., 2004)
TA FLPLIGRVLSGIL-NH2 FPRL1, mFPR2 (Chen et al., 2004)
W WKYMVm FPR, FPRL1, 
FPRL2
(Le et al., 1999) 
(Christophe et al., 2001)
Amyloid P protein DAEFGHDSGFEVRHQKLVFFAED  
V GSNKG AIIGLM V GG V VIA
FPRL1, mFPR2 (Tiffany et al., 2001)
Prion protein (106- KTNMKHM AGAAAAGAVVGGLG FPRL1 (Le et al., 2001c)
126)
Chemerin (human) NCBI: Y14838 CMKLR1 (Meder et al., 2003; 
Wittamer et al., 2003)
Chemerin (mouse) NCBI: NP 082128 CMKLR1 (Meder et al., 2003; 
Wittamer et al., 2003)
fMLF Formyl-MLF FPR (Le et al., 2001a)
5.2.5 Generation of polyclonal antibodies against Gpr33
The peptide sequences which we used to immunise mice for production of monoclonal 
antibodies spanned a predicted extracellular loop of Gpr33. However, it is impossible to 
predict the conformation of this region, and the native protein could be folded in such a way 
that this region is not accessible to an antibody or is not recognised by an antibody raised 
against linear peptides. Therefore, we decided to raise antibodies against another site in 
Gpr33, the N-terminal region (Figure 5.6). Although this portion of the molecule contains 
potential N-glycosylation sites, it might adopt a more linear structure in vivo. Polyclonal 
antibodies were raised against this region by conjugating the N-terminal 15 amino acids to a 
carrier protein and immunising rabbits.
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Figure 5.17 Staining o f FLA G -G pr33 transfectants w ith polyclonal anti-G pr33
Baf/3 cells which were either untransfected (UT), transfected by the pFLA G -C M V - 
4 vector alone (pFLAG4), or w ith the pFLA G -C M V -4-G pr33 construct (pFLA G 4- 
G pr33) were stained with the rabbit polyclonal anti-Gpr33 antibody a) Cell surface 
staining b) Intracellular staining.
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5.2.5.1 FACS staining with the polyclonal anti-Gpr33 antibody
Using the polyclonal anti-Gpr33 antibody, we attempted to detect both cell surface and 
intracellularly expressed Gpr33 protein in FLAG-Gpr33 transfected cells (Figure 5.17). As 
shown, the proportion of cells which appeared to be Gpr33 positive in the FLAG-Gpr33 
transfected cells was similar to that in untransfected or control transfected cells, and was not 
above the background seen with the isotype control. In addition, we could not detect Gpr33 
expression by cell surface and intracellular staining on splenic DCs which had been treated 
either in vivo or in vitro with IFN-a4 (data not shown).
5.3 Discussion
We initially identified Gpr33 as a gene which was upregulated after two hours of IFN-a4 
treatment in splenic DCs. Further analysis by real-time PCR revealed that Gpr33 is 
expressed in all DC subsets and is upregulated by IFN-a4 to a similar extent in each. 
However, the CD4'CD8+ subset expressed Gpr33 at a level substantially higher than the 
CD4+CD8' or double negative DC subsets. The differential ability to prime T cell responses 
observed by CD8+ and CD8' DC subsets may depend to some extent, on their tissue 
distribution and migratory properties. Indeed, DC subsets are distributed in distinct 
anatomical locations in both the spleen (Pulendran et al., 1997) and the Peyer’s patch 
(Iwasaki et al., 2000). In the spleen, CD8+ DCs are concentrated in the T cell rich PALS, 
whereas CD8* DCs are found in the marginal zone (Pulendran et al., 1997). Similarly, in the 
Peyer’s patch, CD8' DCs are positioned for antigen capture in the subepithelial dome, with 
the CD8+ DCs residing in the T-cell rich interfollicular region. This difference in location 
could be attributed to expression of CCR6 by CD8' DCs and their ability to migrate towards 
CCL20/MIP-3a (Iwasaki et al., 2000).
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CD8+ and CD8' DCs subsets also appear to have different capacities for migration in vivo. 
In experiments where DCs were injected into the footpad of mice, only CD8' DCs were 
detectable in the draining lymph node after 22-24 hours (Ruedl et a l , 1999; Smith et al.,
1999). Drake et al. (Drake et al., 2001), showed that although both subsets could migrate to 
the draining LN after s.c. injection, it was the CD8' subset that preferentially did so. In a 
more recent study, only CD8+ DCs which had been matured were seen to traffic to the 
draining LN, but again with lower efficiency than CD8" DCs (Colvin et al., 2004b). This 
apparent difference in LN homing ability could be attributed to a lower capacity to migrate in 
response to CCL19 and CCL21 seen in vitro, even though no difference in chemokine 
receptor expression between the subsets could be detected . The route of administration is 
also important, since both mature DC subsets localised in the T cell areas of the spleen after 
i.v. injection. The impaired ability of CD8+ DCs to reach the LN after s.c injection may be 
due to a lack of expression of adhesion molecules which would prevent crossing of 
endothelial cells into lymphatic vessels. In mice, CD8' DCs express higher levels of the 
adhesion molecule CD1 lb. However, this does not appear to mediate in vitro transmigration 
of epithelial cells in response to CCR7 ligands (Colvin et a l, 2004a). Alternatively, 
expression of as yet unidentified chemokine receptors could represent a mechanism for 
retention of CD8+ DCs in the peripheral tissues. Gpr33 represents a candidate which could 
confer the different migratory properties of CD8+ DCs.
Gpr33 shares 35% amino acid identity with chemokine-like receptor 1 (CMKLR1, formerly 
Chem23, Dez) (Marchese et al., 1998), which is expressed by pDCs in human blood (Zabel 
et al., 2005). CMKLR1 mediates migration to a proteolytically regulated chemoattractant, 
chemerin, activated during blood coagulation, suggesting a role for CMKLR1 in attracting
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pDCs to sites of tissue damage. In contrast to CMKLR1 expression, Gpr33 expression was 
much lower on pDCs than on the CD8+ DCs. In addition, treatment of Gpr33 transfected 
cells with chemerin did not induce a calcium flux, and so Gpr33 and CMKLR1 appear to 
have different ligand specificities. Therefore the function of the two receptors may not be 
closely related.
To gain further insight into the function of Gpr33, we investigated mRNA expression in 
other cells of the immune system. Expression of Gpr33 mRNA in lymphocytes was 
comparable to the untreated CD4+CD8‘ DCs, with no detectable regulation by IFN-a4. 
Expression of Gpr33 was lower in macrophages than in CD4+CD8' DCs which suggests that 
the role of Gpr33 is not to mediate migration of phagocytic cells to sites of infection, as is 
thought to be the case for formyl peptide receptors (Le et al., 2002). However it may be of 
interest to test for expression in neutrophils, which are also known to respond to N- 
formylated peptides (Schiffmann et a l , 1975).
To characterise cell surface expression of Gpr33, we attempted to raise antibodies against it. 
First, we generated rat monoclonal antibodies against the 2nd putative extracellular loop by 
immunisation with three overlapping peptides. Although we isolated hybridomas which 
produced antibodies against the immunising peptides, they did not appear to detect native 
protein expressed on a transfected cell line or on IFN-a4-treated DCs. There are problems 
inherent with this approach. Firstly, the amino acid sequence of rat Gpr33 is similar in 
sequence to mouse Gpr33, with only three amino acids differing over the 26 amino acid 
sequence chosen for the immunisations (Figure 5.6). The immunising peptides Al and A2 
contained all three of these amino acid changes, whereas the A3 peptide only contained one 
amino acid difference, which could explain why the rats did not mount a response to this 
peptide. Secondly, since the immunisations were with linear peptides, and our initial
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screening method selected antibodies specific for the linear peptides, we may have isolated 
hybridomas which were not specific for the native conformation of this extracellular loop of 
Gpr33. Unfortunately, since the isotype of the three monoclonal antibodies generated was 
IgM, they would be of relatively low affinity and may have worked in the ELISA due to the 
presence of multiple antigens which would bind the pentameric structure more efficiently. It 
is likely that these antibodies would not recognise cell surface-expressed Gpr33 as 
efficiently. To test whether the antibodies could detect Gpr33 in a denatured form, we 
carried out Western blotting of transfected cell lines. Since this was unsuccessful, it was 
impossible to determine whether the antibodies were not specific for Gpr33 or whether 
Gpr33 mRNA in the transfected cells was not being translated. A lack of correlation 
between mRNA expression and cell surface expression of chemokine receptors has 
previously been reported (Sallusto et al., 1998c).
We tried to overcome these problems in two ways, firstly, we attempted to clone Gpr33 in 
frame with an expression tag in order to verify expression on the surface of transfected cells. 
We could not detect cell surface or intracellular expression by FACS or by Western blot, 
which suggested that the Gpr33 mRNA was not being translated. However, if the N- 
terminus of Gpr33 is glycosylated this could interfere with binding to the FLAG tag. In 
addition, we have cloned Gpr33 with the initiating methionine still present. Since the FLAG 
tag is short, the start codon is only 40 base pairs from the Gpr33 start codon. In this case the 
ribosome may have a preference to initiate translation at the second methionine which would 
prevent translation of the FLAG-Gpr33 fusion protein.
Secondly, we had antibodies raised against the N-terminal region of Gpr33. We initially 
chose to avoid this region due to the presence of three potential N-glycosylation sites, which 
would interfere with antibody binding. However, antibodies against chemokine receptors
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are commonly raised against this region, and antibodies against CMKLR1 were generated in 
this way (Zabel et al., 2005). It must be noted though, that unlike Gpr33, the N-terminal 
region of CMKLR1 does not contain any N-glycosylation sites.
The final stage of the characterisation of Gpr33 was to determine the ligand. To do this we 
screened a panel of ligands for their ability to induce a calcium flux in Gpr33 transfected 
cells. We chose a panel of ligands which were already known to be agonists for CMKRL1 
and the formyl peptide receptors. However, it is difficult to predict the nature of the ligand 
when the closest relatives share such low homology (35%). Indeed, neither chemerin, the 
CMKRL1 ligand, or any of the formyl peptide receptor ligands induced a calcium flux in 
Gpr33 transfected cells, although again, we have to accept the possibility that Gpr33 protein 
was not expressed in the transfected cells.
Gpr33 contains conserved residues which indicate that it is a functional GPCR. A conserved 
acidic-arginine-aromatic triplet present at the N-terminal end of the second cytoplasmic loop 
has been suggested to interact with G-proteins (Attwood et al., 1991). Although Gpr33 does 
not contain the initial acidic residue, the arginine and aromatic tyrosine are present (Figure 
5.5). In addition, the C-terminal region contains several threonine and serine residues, 
which are potential phosphorylation sites in desensitised receptors (Murphy, 1994). 
However, without the identification of a functional ligand, Gpr33 remains an orphan GPCR.
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Chapter 6: Final Discussion
DCs have been described as ‘nature's adjuvant’, since during an infection they facilitate the 
proliferation of naive antigen-specific T cells. This unique property makes them prime 
candidates for the development of new vaccination strategies. In order to manipulate DCs so 
that they can be used to develop effective vaccines, a detailed knowledge of their biology is 
required. One aspect of DC biology which requires particular attention is their migration, 
both to sites of infection for efficient uptake of antigen, and to the secondary lymphoid 
tissues where they can interact with T cells. Secondly, it is vital to determine how stimuli 
from pathogens and the host affect DC maturation and how they influence the type of 
response elicited by the DCs. In addition, a knowledge of the molecular mechanisms by 
which DCs exert their immunogenic function may aid the development of efficient vaccines.
Early studies in the mouse showed that antigen- or gene-loaded DCs could induce immunity 
in vivo (Inaba et al., 1990; Somasse et a l , 1992) and that DCs loaded with tumour antigens 
could induce anti-tumour immunity (Gilboa et al., 1998). Ex vivo generated, antigen-loaded 
DCs have been used as vaccines in patients with cancer (Davis et a l , 2003) and chronic HIV 
infection (Lu et a l , 2004). However, antigen-loaded immature DCs can induce tolerance 
(Fu et a l , 1996) and the antigen presenting DC subset can also influence the outcome of the 
immune response (Maldonado-Lopez et a l , 1999; Pulendran et a l, 1999). Therefore, these 
factors must be considered in DC-based vaccine design.
Currently, DNA vaccines which directly manipulate DCs in vivo are being developed. 
These vaccines work by using a combination of plasmids which encode proteins to both 
recruit and activate DCs, along with the plasmid encoding the specific antigen. For 
example, in one study co-vaccination with plasmids encoding CCL3 (M IP-la) and fms-like
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tyrosine kinase 3 (Flt3L) enhanced IFN-y production by T cells specific for the antigen 
encoded by a co-injected plasmid (Sumida et a l, 2004). In this case CCL3 acts by recruiting 
immature DCs expressing the receptor CCR5, to the site of vaccination. Once there, they 
are activated by Flt3L, which also expands DC numbers. Therefore, this increases the 
number of DCs taking up antigen and the likelihood that these DCs will mature and migrate 
to the LN.
DC maturation is a complex process, which has evolved to facilitate 1) efficient processing 
and presentation of antigens which have been captured at sites of infection, 2) transport of the 
antigens to sites where they can be recognised by antigen-specific naive T cells and 3) 
delivery of antigen together with signals which instruct T cells on the type of response to be 
elicited (Banchereau et a l, 2000). DC maturation must therefore be tightly regulated to 
avoid the initiation of inappropriate immune responses. DC maturation can be triggered 
directly by pathogen components, or indirectly by ‘danger signals’ such as inflammatory 
cytokines (Matzinger, 2002; Medzhitov et a l, 2002). Indeed the presence of different 
cytokines during maturation of DCs in vitro influences how they function in the adaptive 
immune response. For example DCs differentiated in the presence of IL-4 are less efficient 
at inducing CTL priming than DCs differentiated in the presence of IL-15 (Mohamadzadeh et 
a l, 2001). Therefore careful consideration must be taken in how DCs to be used for 
vaccination are generated in vitro.
DCs matured in the presence of IFN-a strongly promote a Thl response (Santini et a l,
2000), which is vital in anti-viral and anti-tumour immunity. IFN-a has been used in
combination with poly(I:C) and a type-1 polarising cytokine cocktail (TNF-a/IL-lf3/IFN-y)
to generate mature type-1-polarised DCs in a serum-free medium (Mailliard et a l, 2004). In
addition to exhibiting the phenotypic and migrational characteristics of mature DCs, these
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DCs had the ability to produce IL-12 after CD40L stimulation, making them superior 
inducers of antigen-specific CTLs. To identify the mechanisms by which IFN-I is able to 
enhance the maturation and function of DCs, we have investigated genes regulated by IFN-I 
in splenic and BM-derived DCs.
6.1 Identification of genes induced in DCs by IFN-I using RDA
By using the technique of RDA we hoped to rapidly and economically identify IFN-induced 
genes associated with DC function, since this technique requires only basic laboratory 
equipment and relatively inexpensive molecular biology reagents. This initial approach 
proved valuable, since in addition to identifying several known IFN-induced genes we also 
succeeded in identifying transcribed products representing novel ISGs.
Initially, RDA was used to identify genes regulated by IFN-I after a two hour culture of total 
splenic DCs or DCs separated into the CD1 lb+ (CD8‘) and CD1 lb‘ (CD8+) DC subsets. To 
verify that the novel genes or sequences identified were induced by IFN-I we either probed a 
southern blot or carried out quantitative PCR on independently generated samples. 
Although we found novel sequences or genes which were exclusively upregulated by IFN-I 
in either DC subset we did not exclude the possibility that this was due to day to day 
experimental variation. This is possible, since none of the novel sequences detected in the 
RDA on sorted DC subsets were detected in the RDA on total DCs, and conversely the novel 
sequences identified in total DCs were not detected in either DC subset. Therefore it is not 
clear whether these differences truly reflect differences between the subsets or experimental 
variation. This could be determined by carrying out Q-PCR using RNA isolated from sorted 
DC subsets.
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In addition we carried out an RDA to identify genes differentially regulated after six hours of 
culture in the presence of IFN-I. This RDA yielded promising results since in addition to 
identification of an MHC class II gene, which is consistent with a mature DC phenotype, we 
identified a number of genes which had not previously been shown to be IFN-induced such 
as the pi 01 regulatory subunit of PI 3-kinase. Several genes with unknown function were 
also identified at the six hour timepoint, and we extended the characterisation of these genes 
by searching for functional domains in their amino acid sequence. The genes were found to 
contain domains which are present in proteins involved in nucleic acid binding, intracellular 
protein transport and pathogen recognition. Although these proteins did not enter the 
original remit of this study they may be of interest in DC biology. In particular, the 
Niemann-Pick type C2 (Npc2) protein, which we also detected by microarray analysis after 
six hours IFN-I treatment may merit further investigation. Npc2 contains the ML (MD-2- 
related lipid recognition) domain found in proteins which act as cofactors for cell surface 
recognition of LPS (Inohara et a l, 2002). A second ML domain containing protein, known 
as MD-1 or Ly86, was also found to be induced by IFN-I in splenic DC after six hours of 
culture using microarray analysis. However, a specific function cannot be inferred simply 
by the presence of an ML domain since these domains may also be involved in host lipid 
recognition and metabolism (Inohara et a l, 2002). Another gene identified in this 
experiment encodes lymphocyte cytosolic protein (LPL), also known as plastin-2, which 
plays an important role in control of bacterial infections (Chen et a l , 2003). LPL-deficient 
mice cannot generate an adhesion-dependent respiratory burst in response to integrin ligands. 
LPL is an actin crosslinking protein, however it does not control integrin-dependent 
phagocytosis, adhesion or migration. Instead it is thought that actin remodelling by LPL 
provides a scaffold needed for the cells to assemble the integrin-initiated signaling pathway 
(Chen et a l, 2003).
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As expected, a number of genes identified were known ISGs involved in the anti-viral 
response and apoptosis, such as Gbp2 and Pml. In fact, the pleiotropic nature of IFN-I may 
impede this type of experiment, since it means that the proportion of identified genes 
involved specifically in regulating DC function is likely to be low. One way to differentiate 
between ubiquitously expressed ISGs and those whose expression is restricted to DCs is to 
cross-check with public databases of known ISGs such as that of de Veer et al (de Veer et a l ,
2001). However the data available in this resource is somewhat limited. Therefore 
quantitative PCR to detect expression of genes in other cells of the immune system was used 
to determine the expression of unknown ISGs, several of which were also highly upregulated 
by IFN-I in T and B cells. It may also be useful to test for expression of these genes in non- 
immune cells.
Although the RDA experiments had been successful, the data was restricted to only a subset 
of genes induced by IFN-I. This was in part due to the preferential amplification of certain 
genes, particularly at the two hour timepoint where many of the cloned difference products 
represented the genes Gbp2 and Pml. This could possibly have been resolved by competing 
these genes out by spiking the driver samples with the Gbp2 and Pml sequences. Indeed, 
where a large number of differences are expected between two samples, iterative RDA can 
be carried out, where the products of an initial RDA are amplified and added to the driver in 
a subsequent experiment. This prevents the amplification of previously identified products 
and allows the amplification of a different set of difference products (Frazer et al., 1997).
6.2 DC activation
Our aim was to identify genes regulated directly by IFN-I signaling in DCs. This 
necessitates their culture in vitro, rather than in vivo treatment where the IFN-I could act
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indirectly through other cell types which in turn could interact with DCs to influence their 
function. Even in vitro however, cytokines produced by the DCs, such as IL-15, can act in 
an autocrine fashion to further induce their maturation (Mattei et al., 2001). A further 
complication of using an in vitro culture system is that isolation and culture of murine DCs is 
known to induce their maturation. For example, DCs isolated from the spleen are known to 
be activated by adhesion to plastic (Ossevoort et al., 1992) and DCs from the adherent or low 
density fraction of the spleen have been shown to strongly upregulate CD86 expression after 
overnight culture (Inaba et al., 1994). This upregulation was not due to contaminating LPS, 
since DCs from the LPS-nonresponder strain C3H/HeJ also had elevated levels of CD86 after 
overnight culture. In addition, Langerhans cells cultured in vitro mature into DCs with 
potent immunostimulatory capacity (Schuler et al., 1985). GM-CSF, which is produced by 
many cells including the keratinocytes of the skin (Witmer-Pack et al., 1987), and IL-1 have 
been shown to mediate Langerhans cell maturation (Witmer-Pack et al., 1987; Heufler et al., 
1988). It is possible that during tissue dissociation these cytokines are released in sufficient 
quantities to activate the DCs. Alternatively, it has been suggested that inhibition of DC 
maturation could occur in vivo, and removing them from this environment may trigger 
maturation (Reis e Sousa, 2004).
The mechanical manipulations involved in DC isolation may trigger DC maturation. 
Dissociation of BM-derived DCs and transfer to fresh plates for overnight culture has been 
shown to result in maturation equivalent to that induced by LPS (Gallucci et al., 1999). In 
addition, recent experiments showed that induction of a calcium flux in one DC, triggered by 
only the touch of a micropipette tip, was transmitted in a matter of seconds via connecting 
structures known as tunneling nanotubules to surrounding DCs (Watkins et al., 2005). The 
transmitted calcium flux was enough to induce veil extension in DCs similar to that seen with
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direct LPS stimulation. This highlights the sensitivity of DCs to mechanical stimulation and 
the concept that DC maturation can be triggered by disrupting interactions with the 
surrounding cells in situ. This would complicate the analysis of gene expression, since if the 
DCs are maturing in culture medium alone this may lessen the differences seen in IFN- 
treated DCs.
The ‘spontaneous’ maturation of splenic DCs during culture has been demonstrated 
(Montoya et al., 2002). In this case the DC maturation was shown to be partially dependent 
on the autocrine action of IFN-I, since addition of anti-IFN-I inhibited up-regulation of 
CD40, CD86 and MHC class I. Indeed, this could explain the upregulation of several of the 
novel ISGs identified by RDA during culture in the absence of exogenous IFN-I. Production 
of IFN-I by the DCs also potentially reduces the number of IFN-induced genes identified. 
However, although both splenic and BM-derived DCs produce IFN-I, these levels are 
extremely low (8-16 units/106 DCs) (Montoya et al., 2002) compared to the levels in our 
culture conditions where exogenous IFN-I was added (4000 units/106 DCs).
6.3 Global analysis of gene expression in IFN-I stimulated DCs
Using microarray analysis we identified more than one thousand genes and expressed 
sequences whose expression was upregulated by IFN-I in either splenic or BM-derived DCs. 
These genes fall into one of several groups. Firstly we found known IFN-induced genes 
whose function is unlikely to be specifically linked with the function of DCs. Of these, 
some have well defined roles. For example, Mxl is a prototypical anti-viral gene, whilst the 
function of others, like the Ifit genes is less clear. Second we found genes which have 
previously been shown to be induced by IFN-I in DCs such as IL-15, CXCL9 and CXCL10, 
and play important roles in DC biology. These types of genes act as useful markers to
251
indicate that the experiments are working correctly. In fact, before carrying out microarray 
analysis we tested for Mxl upregulation in IFN-I treated samples by quantitative PCR.
The number of ESTs identified in these experiments is extremely high, with just under 25% 
of all differentially regulated sequences being ESTs. These sequences represent a large 
number of genes with the potential for shaping the immune response directed by DCs. 
However when little or no functional characterisation is available for these sequences it is 
challenging to determine which, if any encode proteins important for mature DC function. 
One way would be to use a circumstantial approach, that is, to test whether a certain gene's 
expression pattern coincides with that of other genes known to be involved in a specific 
process. This clustering technique is widely used when dealing with microarray data, but is 
only feasible where multiple timepoints and/or stimuli have been tested. In addition, this 
type of study may be more amenable to a population of cells which have been generated in 
culture and therefore are more homogenous in their stage of maturation (Granucci et a l , 
2001b). Also, since many aspects of DC maturation are likely to be occurring 
simultaneously, it may not be possible to link genes to particular processes simply by 
examining the timing of their expression.
Another approach for determining the function of ESTs is to carry out systematic searches 
using the advanced bioinformatics tools now publicly available on the world-wide web. In 
this respect, the Netaffx web resource (Affymetrix) is extremely useful since many of the 
ESTs have been annotated with information such as the conserved protein domains present 
and known homology with other proteins. However, attempting to extract functional 
information on ESTs in this manner is extremely time consuming and may not always yield 
meaningful results. As more information becomes available on databases such as Netaffx, 
the analysis of microarray data will be greatly facilitated.
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As discussed, the wide reaching effects of IFN-I may hinder the identification of genes 
associated with DC function. Ideally, parallel experiments to identify IFN-I induced genes 
in cells unrelated to the immune system could have been carried out. The IFN-regulated 
genes identified could then easily be subtracted from the data from DCs to generate a list of 
DC-specific IFN-I induced genes.
When analysing the expression of mRNA it must be taken into consideration that changes in 
mRNA levels may not necessarily ‘translate’ into a significant change in the level of protein 
sufficient for a functional consequence. For example, expression of mRNA for certain 
chemokine receptors, as has been shown for CCR1, CCR2, CCR5 and the IL-8 receptor, does 
not always correlate with cell surface expression or a functional response (Sozzani et al., 
1997; Sallusto et al., 1998c). Therefore it is important to verify protein levels by other 
means such as ELISA, which we have used to quantitate levels of several cytokines and 
chemokines identified. Related to this issue is the matter of determining the fold change in 
mRNA levels that are considered to be significant. Genes whose expression increases by a 
high fold change may initially appear interesting but might not always be the most 
significant, for example if they are expressed at very low levels. Similarly the abundance of 
a transcript cannot generally be considered as a factor in determining a gene's importance 
since certain proteins, for example secreted proteins, may be required in much larger 
quantities than others, such as cell surface receptors. Finally, a small increase in the level of 
mRNA may result in the expression of protein such that a certain threshold is reached, 
allowing a functional response. Similarly a small change in protein may affect the ratio of 
subunits which make up for example, a cytokine, which could allow a functional form to 
predominate.
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In addition to known DC ISGs, we also identified novel IFN-I regulated genes which could 
play important roles in DC function. These included genes with known function, such as the 
IL-6 receptor and the IL-6 receptor signal transducer, which were both suppressed by IFN-I. 
The large number of genes identified encoded proteins with diverse molecular functions from 
transcription to cell adhesion, and which control many cell processes such as cell cycle and 
cell migration. Although it may be difficult to extrapolate how each of these genes may 
influence DC function, the data help to provide an overall picture of the properties IFN-I 
treatment confers on DCs. For example, we detected upregulation of several TLRs in 
BMDCs after IFN-I treatment; in particular, TLRs which are known to bind viral components 
were identified. Therefore, stimulation with IFN-I appears to promote the expression of 
molecules for detection of viruses which may be necessary for their full maturation or 
development into Thl promoting DCs. IFN-I also increased expression of MyD88 in 
splenic DCs, which mediates signal transduction from all TLRs. As would be expected, the 
cytokine and chemokine production by IFN-I treated DCs would strongly promote a Thl 
profile.
In addition, these studies provide a wealth of data for future studies and several genes 
identified may merit further investigation. One of these, chemokine-like factor super family 
6 was induced after six hours of IFN-I treatment in BMDCs. It would be interesting to test 
whether this protein has chemotactic activity towards T or B cells.
6.4 Gpr33
From the microarray data, we chose to investigate a gene which we believed could be 
involved in the migration of murine DCs, Gpr33, that was upregulated after two hours of 
IFN-I stimulation in splenic DCs. In addition to acting as a chemoattractant receptor, it is
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also possible that Gpr33 acts as a pattern recognition receptor (PRR). Formyl peptide 
receptors (FPRs), of which FPRL1, FPR1 and FPRL2 share 31-33% amino acid identity with 
Gpr33, are known to bind molecules derived from pathogens, as well as molecules from 
damaged host cells and abnormal self proteins which are associated with disease (Le et a l , 
2002). Binding of FPRs activates phagocytes, increasing cell migration, phagocytosis and 
release of proinflammatory cytokines (Le et al., 2001a). Therefore these receptors appear to 
act as PRRs which alert cells to the presence of danger.
DCs are known to express FPRs and migrate in response to various of their agonists (Sozzani 
et a l , 1995), however whether they also mediate DC activation signals is unclear. This is 
perhaps not unlikely, since CCR5, also a GPCR involved in cell migration can send 
maturation signals to DCs. One ligand for CCR5, CCL5 has been shown to induce DC 
activation, as measured by the release of inflammatory chemokines after stimulation (Fischer 
et a l , 2001). In addition, ligation of CCR5 has been shown to mediate IL-12 production by 
DCs after stimulation with the Toxoplasma gondii extract, STag (Aliberti et a l , 2000). 
Therefore this chemokine receptor has the dual function of recruiting DCs to sites of 
infection and inducing their activation. It is possible that activation of DCs may occur 
through other GPCRs such as Gpr33.
Importantly however, FPR signaling is known to be responsible for the heterologous de­
sensitization of various chemokine receptors including CCR5. Activation of FPRL1 by the 
HIV-1 gpl20 F peptide or the synthetic peptide WKYMVm results in downregulation of 
CCR5 and CXCR4 (Deng et a l , 1999; Le et a l , 2001b; Li et a l , 2001). LXA4, a ligand for 
FPRL1 which is induced by STag, also down-modulates CCR5, and results in “DC paralysis” 
where DCs can no longer produce IL-12 on re-stimulation by STag (Aliberti et a l , 2002). In 
fact there is considerable evidence demonstrating the suppression of IL-12 production by
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FPR signaling (Braun et a l,  2001), which could prevent excessive and potentially damaging 
IL-12 production. An inability to produce IL-12 during culture with CD4+ T cells has been 
shown to be associated with final maturation of DCs even though these DCs induced T cell 
IFN-y production (Kalinski et a l, 1999b). Although sharing homology with FPRs, it is 
likely that Gpr33 binds distinct ligands and may be linked to different signaling pathways 
which could potentially produce the opposite outcome, such as suppression of IL-10 
production. Finally, heterologous desensitization of CCR5 may be important for migration 
of DCs out of infected tissue, since downregulation of CCR5 has been shown during DC 
maturation (Sallusto et a l, 1998c).
Although the gene encoding Gpr33 in humans is a pseudogene, since it contains a stop codon 
at nucleotide position 418 of the open reading frame, there may be a functional homologue 
present in humans which carries out a similar function. If Gpr33 does recognise pathogen 
components, the loss of Gpr33 in humans may be explained by differences in evolutionary 
pressure exerted by different organisms which invade mice and humans. This is seen in the 
FPR family, since three FPR genes exist in the mouse for which there are no human 
counterparts suggesting the gene cluster has undergone differential expansion and therefore 
functional divergence of the encoded receptors (Le et a l, 2001a). Similarly, in the TLR 
family, TLR 11 is functional in the mouse whereas the presence of a stop codon prevents 
TLR11 production in humans (Zhang et a l, 2004). Conversely, TLR10 is functional in 
humans but not mice (Takeda et a l, 2005). There could be two reasons for this, firstly it 
could be that the two TLRs have redundant functions and were therefore disposable. 
Alternatively they may have specificity for a pathogen component that is no longer relevant 
to the organism, in which case mutations preventing its function would not be 
disadvantageous.
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We have demonstrated the potential of microarray analysis for identifying genes relevant to 
DC biology and therefore their application in DC-based vaccination. However we have also 
highlighted difficulties in the characterisation of interesting genes. The approach we took 
was to screen differentially expressed genes by identifying conserved protein domains or 
homology to functionally characterised proteins. This provides an indication as to the novel 
protein's function, which is essential for the design of experiments for their characterisation. 
The discovery of an IFN-I induced GPCR related to chemoattractant receptors provided a 
promising candidate for several reasons. It should be expressed at the cell surface and 
therefore antibodies against it could be raised. Although the ligand binding site for Gpr33 is 
not known, it was also possible that the antibodies raised would block the ligand binding site 
and therefore be useful in functional assays. Finally, the nature of the protein also made it 
possible for us to carry out ligand screening, which if successful could have been tested in 
migration assays. Future studies could be directed at secreted molecules which could be 
produced and tested for their function on other immune cells or on DCs themselves.
In conclusion, we have generated a large volume of data regarding the regulation of gene 
expression by IFN-I in DCs and have demonstrated the possibility of utilising this data to 
relate gene expression to the behaviour of DCs. Overall, the microarray data provides 
information on the processes triggered during activation of DCs by IFN-I. Translating 
expression data into functional properties, and identification of genes crucial for immunity 
induced by DCs remains a challenge for the future.
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